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Abstract	
West	Nile	virus	(WNV)	is	a	neuroinvasive	pathogen	transmitted	by	mosquitoes	and	is	one	of	 the	 most	 widespread	 members	 of	 the	 Flaviviridae	 family.	 In	 some	 2%	 of	 infected	individuals,	 infection	 can	 progress	 to	 acute	 lethal	 encephalitis	 associated	with	 a	 severe	immunopathological	response.	Current	treatments	are	symptomatic	only	and	no	approved	vaccine	 exists	 for	 humans.	 Thus,	 research	 and	 design	 of	 viable	 treatment	 strategies	targeting	 the	 pathological	 immune	 response	 in	 this	 disease	 are	 critical.	 Furthermore,	understanding	 the	mechanism	of	 immunopathogenesis	and	development	of	 the	adaptive	immune	response	to	WNV	is	essential	to	elucidate	how	the	virus	is	eventually	eradicated.	Very	 little	 is	 known	 about	 the	 local	 draining	 lymph	node	 response	 to	WNV	encephalitis	and,	until	 recently,	 the	exact	 lymphatic	drainage	pathway	 in	 the	CNS	has	been	relatively	unknown.	We	investigated	the	local	responses	of	the	draining	lymph	nodes	of	the	CNS,	the	cervical	 lymph	 nodes,	 as	 well	 as	 the	 non-draining	 inguinal	 and	 mesenteric	 nodes,	following	 intranasal	 infection	 with	 WNV.	 The	 role	 of	 the	 draining	 lymph	 nodes	 in	 the	development	 of	 an	 adaptive	 immune	 response	 during	 viral	 infection	 is	 well	 known,	however,	 the	extent	to	which	the	“non-draining”	 lymph	nodes	contribute	to	the	adaptive	immune	 response	 against	 a	 CNS	 viral	 infection	 has	 not	 been	 studied.	 In	 our	model,	 the	significant	 expansion	 of	 leukocyte	 numbers	 in	 the	 cervical	 lymph	 node,	 in	 response	 to	WNV	 infection	of	 the	CNS,	demonstrates	 its	 involvement	 in	 the	 immune	 reaction	 to	CNS	viral	infection.	Dendritic	cell	subsets	in	the	cervical	lymph	node	increase	significantly	from	d5p.i.,	 likely	 contributing	 to	 the	 significant	 B	 and	 T	 cell	 clonal	 expansion	 seen	 in	 these	nodes.	Although	a	certain	proportion	of	leukocyte	expansion	in	the	cervical	node	is	due	to	proliferation	of	cells	in	situ,	 leukocytes	are	clearly	recruited	from	other	lymphoid	organs.	Indeed,	during	WNV	infection,	distinct	changes	also	occur	in	the	mesenteric	and	inguinal	lymph	nodes.	In	contrast	to	the	significant	expansion	of	lymphocytes	in	the	cervical	lymph	node,	the	inguinal	and	mesenteric	nodes	show	a	reduction	of	up	to	50%	in	CD4+	and	CD8+	
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T	 cell	populations.	We	hypothesise	 that	 these	T	 cells	preferentially	home	 to	 the	 cervical	lymph	 node,	 contributing	 to	 T	 cell	 populations	 and	 forming	 part	 of	 the	 effector	 cell	population	 in	 the	adaptive	 immune	response	 to	WNV	 in	 the	CNS.	Tracking	of	peripheral	node	 leukocytes	 also	 suggested	 that	B	 cell	 recruitment	 to	 the	 CNS-draining	 lymph	node	was	 increased	 during	 WNV	 infection.	 Furthermore,	 significant	 upregulation	 of	 Ly6C	expression	occurs	in	both	the	draining	and	non-draining	lymph	nodes,	in	direct	response	to	inflammation	in	the	CNS.	Further	characterisation	of	the	inflammatory	response	in	the	draining	and	non-draining	lymph	nodes	will	determine	the	kinetics	of	emigration	of	T	and	B	cells	from	the	non-draining	lymph	nodes	and	their	specific	contribution	to	the	anti-viral	immune	response.		Although	there	is	significant	infiltration	of	 lymphocyte	subsets	into	the	CNS	of	mice	with	WNV	 encephalitis,	 these	 cells	 only	 form	 some	 30%	 of	 the	 total	 leukocyte	 infiltrate,	whereas	 Ly6Chi	 inflammatory	 monocytes	 can	 contribute	 up	 to	 50%.	 Indeed,	 the	recruitment	 of	 pathogenic	 Ly6Chi	inflammatory	 monocytes	 to	 the	 CNS	 is	 a	 hallmark	 of	WNV	 encephalitis,	 as	 this	 subset	 has	 been	 shown	 to	 be	 the	 primary	 contributor	 to	 the	lethal	 immunopathology	 seen	 in	 WNV	 encephalitis.	 We	 have	 recently	 shown	 that	intravenous	administration	of	immune-modifying	microparticles	(IMP)	results	in	a	halving	of	the	numbers	of	Ly6Chi	monocytes	infiltrating	the	brain	and	improves	survival	by	up	to	60%	 in	 a	mouse	model	 of	 intranasal	WNV	 infection.	 These	 cells	 are	 sequestered	with	 a	significant	proportion	of	 IMP+	cells	 observed	within	 the	 splenic	marginal	 zone.	 Since	 the	marginal	 zone	 macrophages	 phagocytose	 apoptosing	 cells	 and	 other	 particulate	 debris,	including	nanoparticles,	we	hypothesised	that	the	spleen,	in	particular	the	marginal	zone	macrophages,	may	be	crucial	for	the	efficacy	of	IMP	treatment.		Surgical	 removal	 of	 the	 spleen	 or	 specific	 depletion	 of	 splenic	 macrophages	 using	clodronate-encapsulated	 liposomes	 resulted	 in	 a	 similar	 decrease	 in	 Ly6Chi	 monocyte	numbers	in	the	CNS	compared	to	IMP	treatment,	but	did	not	result	in	increased	survival.		
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In	splenectomised	mice,	however,	IMP	treatment	resulted	in	a	further	reduction	in	Ly6Chi	monocyte	 numbers,	 and	 while	 not	 significant,	 this	 resulted	 in	 some	 improvement	 in	survival.	In	 clodronate-depleted	 animals,	 in	 which	 marginal	 zone	 macrophages	 are	 completely	ablated,	IMP	treatment	also	improved	survival,	with	reduced	Ly6Chi	monocyte	infiltration	into	 the	 brain.	 However,	 IMP	 treatment	 was	 still	 most	 effective	 in	 mice	 with	 an	 intact	spleen	 that	 received	 no	 clodronate	 treatment.	 These	 data	 demonstrate	 that,	 neither	 the	spleen	 as	 a	 whole,	 nor	 the	 marginal	 zone	 macrophages,	 are	 critical	 for	 successful	 IMP	treatment,	but	the	absence	of	these	components	nevertheless	reduce	IMP	efficacy.	These	data	highlight	the	fact	that	not	all	methods	of	Ly6Chi	 inflammatory	monocyte	modulation	are	equal	and	suggests	that,	compared	to	clodronate	and	splenectomy-mediated	reduction	in	 Ly6Chi	 monocytes,	 IMP	 treatment	 reduced	 this	 inflammatory	 monocyte	 subset	specifically	 and	 with	 minimal	 impact	 on	 other	 components	 of	 the	 immune	 system,	maintaining	 the	 ability	 to	 eradicate	 viral	 infection	 and	 promote	 survival.	 By	 further	characterising	key	differences	between	 these	models	we	have	elucidated	a	 little	 further,	the	mechanism	behind	IMP	treatment	and	expanded	our	understanding	of	the	secondary	lymphoid	organs	in	the	immune	response	to	WNV	encephalitis.	
	 	
	 viii	
Abbreviations	
ACE	 	 angiotensin-converting	enzyme	APC	 	 antigen	presenting	cell	BBB	 	 blood	brain	barrier	BrdU	 	 Bromodeoxyuridine	CLN	 	 cervical	lymph	node	CFSE	 	 Carboxyfluorescein	Succinimidyl	Ester	CNS	 	 central	nervous	system	CSF	 	 cerebrospinal	fluid	CTL	 	 cytotoxic	T	lymphocyte	DC	 	 dendritic	cell	DENV	 	 dengue	virus	DRG	 	 dorsal	root	ganglion	DNA	 	 deoxyribonucleic	acid	DLN	 	 draining	lymph	node	EAE	 	 experimental	autoimmune	encephalomyelitis	EDTA	 	 ethylenediamineetraacetic	acid	ER	 	 endoplasmic	reticulum	FACS	 	 fluorescence-activated	cell	sorting	FCS	 	 foetal	calf	serum	FRC	 	 fibroblastic	reticular	cell	FSC-A	 	 forward	scatter-area	FSC-H	 	 forward	scatter-height	HEV	 	 high	endothelial	venule	ICAM	 	 intracellular	adhesion	molecule	IFN	 	 interferon	
	 ix	
IHC	 	 immunohistochemistry	i.c.	 	 intracranial	i.n.	 	 intranasal	i.p.	 	 intraperitoneal	i.v.	 	 intravenous	IL	 	 interleukin	ILN	 	 inguinal	lymph	node	IMP	 	 immune-modifying	microparticles	ISG	 	 interferon	stimulatory	genes	JEV	 	 Japanese	encephalitis	virus	KO	 	 knockout	LC	 	 Langerhans	cells	mAb	 	 monoclonal	antibody	MDM	 	 monocyte-derived	macrophages	MHC	 	 major	histocompatibility	complex	MI	 	 myocardial	infarction	MLN	 	 mesenteric	lymph	node	MMP	 	 matrix	metalloproteinases	MST	 	 mean	survival	time	MVEV	 	 Murray	Valley	encephalitis	virus	MZM	 	 marginal	zone	macrophages	NK	cell		 natural	killer	cell	NKT	cell	 natural	killer	T	cell	NO	 	 nitric	oxide	NOS	 	 nitric	oxide	synthase	PALS	 	 peri-arteriolar	lymphoid	sheath	PBS	 	 phosphate-buffered	saline	
	 x	
PCR	 	 polymerase	chain	reaction	pDC	 	 plasmacytoid	DC	PFU	 	 plaque-forming	unit	p.i.	 	 post	infection	PLN		 	 popliteal	lymph	node	PMN	 	 polymorphonuclear	cells	PNS	 	 peripheral	nervous	system	PRR	 	 pattern	recognition	receptor	RBC	 	 red	blood	cell	RLR	 	 RIG-I-like	receptor	RNA	 	 ribonucleic	acid	ROS	 	 reactive	oxygen	species	RT	 	 room	temperature	S1P1	 	 sphingosine-1	phosphate	receptor-1	SCS	 	 subcapsular	sinus	SSC-A	 	 side	scatter-area	TBEV	 	 tick-borne	encephalitis	virus	TBST	 	 Tris-buffered	saline	with	Tween-20	TJP	 	 tight	junction	proteins	TLR	 	 Toll-like	receptor	TNF	 	 Tumor	necrosis	factor	Treg	 	 regulatory	T	cell	VCAM	 	 vascular	cell	adhesion	molecule		WNV	 	 West	Nile	virus	WT	 	 wild	type	 	
	 xi	
Table	of	contents	
Declaration	...............................................................................................................................	i	
Acknowledgements	..............................................................................................................	ii	
Publications	and	presentations	......................................................................................	iii	
Abstract	.....................................................................................................................................	v	
Abbreviations	.....................................................................................................................	viii	
Table	of	contents	.................................................................................................................	xi	
1.	 Chapter	1	Introduction	...............................................................................................	1	
1.1.	 West	Nile	virus	...................................................................................................................	1	1.1.1.	 General	introduction	................................................................................................................	1	1.1.2.	 WNV	infection:	Virus	entry	and	initial	spread	..............................................................	3	1.1.3.	 WNV	infection:	Entry	into	the	CNS	....................................................................................	6	1.1.4.	 WNV	infection:	Effects	on	the	CNS	..................................................................................	10	
1.2.	 Flavivirus	pathogenesis:	Immunopathology	versus	viral	contribution	........	12	1.2.1.	 Viral	contribution	...................................................................................................................	12	1.2.2.	 Immune	contribution	............................................................................................................	14	1.2.2.1.	Resident	cells	............................................................................................................................................	15	1.2.2.2.	Infiltrating	cells	........................................................................................................................................	19	1.2.2.2.1.	Myeloid	subsets	..............................................................................................................................	20	1.2.2.2.2.	Lymphoid	subsets	..........................................................................................................................	23	
1.3.	 Secondary	lymphoid	organs	........................................................................................	27	1.3.1.	 Lymph	nodes	............................................................................................................................	27	1.3.1.1.	Architecture	..............................................................................................................................................	29	1.3.1.2.	Leukocyte	subsets	of	the	lymph	node	............................................................................................	33	
	 xii	
1.3.1.3.	Leukocyte	homing	and	trafficking	to	the	lymph	node	............................................................	40	1.3.1.4.	Leukocyte	exit	from	the	lymph	node	.............................................................................................	43	1.3.2.	 Antigen	presentation	in	the	CNS	......................................................................................	44	1.3.3.	 The	Spleen	.................................................................................................................................	46	
1.4.	 Immunomodulatory	treatment	of	flavivirus	infection	.......................................	48	1.4.1.	 Background	and	past	treatment	......................................................................................	48	1.4.1.1.	Vaccines	......................................................................................................................................................	49	1.4.1.2.	Antiviral	therapies	..................................................................................................................................	50	1.4.1.3.	Neutralising	Antibody	treatment	.....................................................................................................	51	1.4.2.	 Current	effective	treatments	and	Immune-modifying	microparticles	............	53	
1.5.	 Objectives	of	this	research	...........................................................................................	55	
2.	 Materials	and	methods	.............................................................................................	56	
2.1.	 Materials	............................................................................................................................	56	2.1.1.	 Virus	.............................................................................................................................................	56	2.1.2.	 Mice	..............................................................................................................................................	56	2.1.3.	 Buffers,	solutions	and	anaesthetic	..................................................................................	56	2.1.4.	 TaqMan	primer	and	probe	sequences	...........................................................................	59	
2.2.	 Methods	..............................................................................................................................	60	2.2.1.	 West	Nile	virus	propagation	..............................................................................................	60	2.2.2.	 West	Nile	virus	Plaque	assay	.............................................................................................	60	2.2.3.	 WNV	infection	..........................................................................................................................	61	2.2.4.	 Animal	monitoring	and	clinical	scoring	........................................................................	62	2.2.5.	 Tissue	dissection,	collection	and	processing	..............................................................	62	2.2.5.1.	Leukocyte	isolation	................................................................................................................................	62	2.2.5.1.1.	Blood	...................................................................................................................................................	63	2.2.5.1.2.	Brain	....................................................................................................................................................	63	2.2.5.1.3.	Bone	marrow	...................................................................................................................................	63	
	 xiii	
2.2.5.1.4.	Spleen	..................................................................................................................................................	64	2.2.5.1.5.	Lymph	nodes	...................................................................................................................................	64	2.2.5.2.	Organ	collection	for	PCR	......................................................................................................................	64	2.2.5.3.	Organ	collection	for	immunohistochemistry	(IHC)	.................................................................	65	2.2.6.	 Administration	of	immune-modifying	microparticles,	Enalapril	and	BrdU	.	65	2.2.6.1.	IMP	................................................................................................................................................................	65	2.2.6.2.	Clodronate	liposomes	...........................................................................................................................	66	2.2.6.3.	Bromodeoxyuridine	(BrdU)	administration	...............................................................................	66	2.2.6.4.	Enalapril	administration	.....................................................................................................................	66	2.2.7.	 Surgery	and	adoptive	transfer	..........................................................................................	67	2.2.7.1.	Surgical	removal	of	the	spleen	..........................................................................................................	67	2.2.7.2.	Dye	injection	and	Adoptive	transfer	experiments	...................................................................	68	2.2.7.2.1.	Footpad	injection	of	PKH26	......................................................................................................	68	2.2.7.2.2.	Adoptive	transfer	of	leukocytes	..............................................................................................	68	2.2.8.	 Flow	cytometry	.......................................................................................................................	69	2.2.8.1.	Cell	surface	staining	...............................................................................................................................	69	2.2.8.2.	Intracellular	staining	.............................................................................................................................	70	2.2.8.3.	Sample	acquisition	and	analysis	......................................................................................................	70	2.2.9.	 RT	PCR	.........................................................................................................................................	71	2.2.9.1.	RNA	extraction	.........................................................................................................................................	71	2.2.9.2.	cDNA	.............................................................................................................................................................	72	2.2.9.3.	Taqman	PCR	..............................................................................................................................................	72	2.2.9.4.	Gel	electrophoresis	and	quantitative	PCR	...................................................................................	73	2.2.10.	 Immunohistochemistry	.......................................................................................................	73	2.2.11.	 Whole	blood	phagocytosis	assay	.....................................................................................	74	
2.3.	 Statistical	analysis	...........................................................................................................	75	
3.	 Chapter	3	The	role	of	the	draining	and	non-draining	lymph	nodes	
following	lethal	WNV	infection	......................................................................................	76	
	 xiv	
3.1.	 Introduction	......................................................................................................................	76	
3.2.	 Results	.................................................................................................................................	77	3.2.1.	 Leukocyte	population	dynamics	in	the	cervical,	inguinal	and	mesenteric	lymph	nodes	following	lethal	WNV	infection	................................................................................	77	3.2.1.1.	T	cells	...........................................................................................................................................................	79	3.2.1.2.	B,	NK	and	NKT	cells	................................................................................................................................	80	3.2.1.3.	Monocytes	and	neutrophils	................................................................................................................	81	3.2.1.4.	Dendritic	cell	populations	...................................................................................................................	81	3.2.2.	 Changes	in	cell	surface	marker	expression	associated	with	inflammation	in	the	draining	and	non-draining	lymph	nodes	during	WNV	encephalitis	............................	83	3.2.3.	 Proliferation	of	leukocyte	subsets	in	the	draining	and	non-draining	lymph	nodes	during	WNV	encephalitis	..........................................................................................................	88	3.2.4.	 Viral	presence	in	the	CNS,	draining	and	non-draining	lymph	nodes	...............	91	3.2.5.	 Distribution	of	cells	from	a	peripheral	node	to	the	draining	CLN	following	lethal	WNV	infection	.................................................................................................................................	92	3.2.5.1.	Footpad	injection	and	subsequent	distribution	of	PKH26	...................................................	92	3.2.5.2.	Number	and	percentage	of	PKH26+	cells	in	the	ispi-	and	contralateral	PLN,	ILN	and	CLN	of	mock-	versus	WNV-infected	mice	.....................................................................................................	94	3.2.5.3.	Adoptive	transfer	of	CD45.1	and	CFSE	stained	lymph	node	cells	......................................	99	
3.3.	 Discussion	.......................................................................................................................	100	
4.	 CHAPTER	4	Spleen,	WNV	infection	and	IMP	treatment	..............................	109	
4.1.	 Introduction	...................................................................................................................	109	
4.2.	 Results	..............................................................................................................................	110	4.2.1.	 Leukocyte	dynamics	in	the	spleen	following	lethal	WNV	infection	...............	110	4.2.2.	 Changes	in	cell-surface	marker	expression	in	various	leukocyte	subsets	of	the	spleen	following	lethal	WNV	infection	....................................................................................	112	
	 xv	
4.2.3.	 Proliferation	of	leukocyte	subsets	in	the	spleen	following	lethal	WNV	infection	113	4.2.4.	 WNV	infection	and	CNS	infiltration	in	the	absence	of	the	spleen	....................	114	4.2.4.1.	Leukocyte	infiltration	........................................................................................................................	114	4.2.4.2.	Percentages	............................................................................................................................................	115	4.2.4.3.	Weight	loss	of	normal	and	splenectomised	mice	following	lethal	WNV	infection	..	116	4.2.4.4.	Survival	of	normal	and	splenectomised	mice	following	infection	with	a	sublethal	dose	of	WNV	...........................................................................................................................................................	117	4.2.5.	 The	development	of	immunity	in	splenectomised	mice	.....................................	117	4.2.6.	 Cellularity	of	the	bone	marrow	of	splenectomised	versus	normal	mice	following	lethal	WNV	infection	..........................................................................................................	118	4.2.7.	 Cellularity	of	the	lymph	nodes	of	splenectomised	versus	normal	mice	following	lethal	WNV	infection	..........................................................................................................	120	4.2.8.	 Cellularity	of	the	blood	of	splenectomised	versus	normal	mice	following	lethal	WNV	infection	...............................................................................................................................	121	4.2.9.	 IMP	treatment	of	normal	and	splenectomised	mice	following	lethal	WNV	infection	122	4.2.9.1.	Modulation	of	CNS	leukocyte	populations	of	normal	mice	following	lethal	WNV	infection	and	treatment	with	IMP	................................................................................................................	122	4.2.9.2.	Survival	of	splenectomised	versus	normal	mice	following	infection	with	sublethal	dose	of	WNV	and	IMP	treatment	..................................................................................................................	124	4.2.9.3.	The	location	of	IMP	and	IMP-containing	cells	in	the	absence	of	the	spleen	...............	125	4.2.10.	 The	potential	role	of	the	spleen	as	a	splenic	reservoir	for	monocytes	infiltrating	the	WNV-infected	CNS:	the	action	of	ACE	inhibitors.	.......................................	126	4.2.10.1.	Leukocyte	infiltration	into	the	CNS	following	Enalapril	treatment	............................	126	4.2.10.2.	Leukocyte	numbers	of	the	spleen	following	Enalapril	treatment	...............................	127	4.2.10.3.	Clinical	symptoms	and	weight	loss	of	mice	following	lethal	WNV	infection	and	Enalapril	treatment	............................................................................................................................................	128	
	 xvi	
4.2.10.4.	Survival	outcome	following	Enalapril	treatment	of	mice	infected	with	a	sublethal	dose	of	WNV	...........................................................................................................................................................	128	4.2.11.	 Locating	IMP+	cells	in	the	WNV-infected	spleen-Adoptive	transfer	of	spleen	cells,	MARCO	and	apoptosis	................................................................................................................	129	
4.3.	 Discussion	.......................................................................................................................	130	
5.	 Chapter	5	Depletion	of	circulatory	and	splenic	resident	macrophages-
WNV	infection	and	IMP	treatment	.............................................................................	139	
5.1.	 Introduction	...................................................................................................................	139	
5.2.	 Results	..............................................................................................................................	140	5.2.1.	 Clodronate	depletion	and	WNV	infection	..................................................................	140	5.2.2.	 CNS	leukocyte	infiltration	in	the	CNS	of	WNV-infected	mice	following	CLO	depletion	......................................................................................................................................................	141	5.2.3.	 Clinical	outcome	of	WNV-infected	mice	following	clodronate	depletion	....	144	5.2.3.1.	Leukocyte	numbers	in	the	spleen	following	CLO-depletion	of	WNV-infected	mice145	5.2.4.	 Leukocyte	numbers	in	the	bone	marrow	following	CLO-depletion	of	WNV-infected	mice	..............................................................................................................................................	147	5.2.5.	 Therapeutic	efficacy	of	IMP	following	clodronate	depletion	of	WNV-infected	mice	 147	5.2.6.	 Distribution	of	IMP+	leukocytes	in	the	CNS	of	WNV-infected	mice	following	clodronate	depletion	..............................................................................................................................	149	5.2.7.	 Splenic	IMP+	leukocyte	content	of	WNV-infected	mice	following	clodronate	depletion	......................................................................................................................................................	150	5.2.8.	 IMP+	leukocyte	content	in	the	bone	marrow	of	WNV-infected	mice	following	clodronate	depletion	..............................................................................................................................	153	5.2.9.	 Long-term	outcome	of	clodronate	depletion	and	IMP	treatment	of	WNV-infected	mice	..............................................................................................................................................	154	
5.3.	 Discussion	.......................................................................................................................	154	
	 xvii	
6.	 Chapter	6	General	discussion	..............................................................................	159	
6.1.	 Role	of	the	draining	and	non-draining	lymph	nodes	during	WNV	
encephalitis	.................................................................................................................................	159	
6.2.	 Role	of	the	spleen	in	the	primary	immune	response	to	WNV	encephalitis
	 161	
6.3.	 The	role	of	the	spleen	in	the	development	of	immunity	against	lethal	WNV	
infection	........................................................................................................................................	163	
6.4.	 Role	of	the	spleen	and	the	marginal	zone	macrophages	in	IMP	treatment
	 164	
6.5.	 Modulation	of	circulatory	and	resident	macrophages	during	WNV	
encephalitis	.................................................................................................................................	165	
6.6.	 Conclusion	......................................................................................................................	166	
7.	 References	..................................................................................................................	168	
8.	 Appendix	.....................................................................................................................	200	
	 1	
1. Chapter	1	Introduction	
1.1. West	Nile	virus	
1.1.1. General	introduction	
West	Nile	 virus	 (WNV),	 a	 single-stranded	RNA	virus,	 belongs	 to	 the	 Flaviridae	 family	 of	viruses,	 representatives	 of	 which	 are	 found	 on	 all	 inhabited	 continents	 (Hayes	 2001).	WNV	consists	of	Lineage	I,	II	and	III	isolates	and	was	first	discovered	in	1937	in	the	West	Nile	region	of	Uganda	(K.	C.	Smithburn	et	al.	1940).	It	belongs	to	the	Japanese	encephalitis	serocomplex,	 as	 do	 other	 medically	 important	 neurotropic	 flaviviruses	 such	 as	 Murray	Valley	encephalitis	virus	(MVEV),	found	in	Australia,	Saint	Louis	encephalitis	virus	(SLEV),	in	 North	 America	 and	 Japanese	 encephalitis	 virus	 (JEV),	 in	 Asia	 and	 the	 subcontinent	(Calisher	et	al.	1989;	Poidinger	et	al.	1996).	WNV	is	geographically	the	most	widespread	of	these,	being	found	in	Africa,	the	Middle	East,	Europe,	the	Americas	and	Western	Asia.		Most	flaviviruses	are	arthropod-borne,	i.e.,	transmitted	by	mosquitoes	or	ticks,	with	birds	generally	serving	as	amplifying	hosts	in	an	enzootic	cycle.	In	general,	humans	are	regarded	as	incidental	hosts,	since	they	do	not	appear	to	develop	high	enough	viral	titres	to	infect	potential	 arthropod	 vectors	 (Mackenzie	 et	 al.	 2004;	 Goldblum	 et	 al.	 1957;	Hayes	 2001).	Rare	 cases	 of	 viral	 transmission	 via	 organ	 transplant,	 blood	 transfusion	 and	 in	 utero	transmission	have	also	been	documented	(Iwamoto	et	al.	2003;	Bode	et	al.	2006;	Lindsey	et	al.	2009;	Moreland	et	al.	2014;	Rhee	et	al.	2011).		While	the	majority	of	WNV	infections	are	subclinical,	some	20%	of	 individuals	develop	a	mild	febrile	illness.	The	most	severe	form	of	WNV	infection	is	seen	with	the	development	of	 encephalitis	 and/or	meningitis,	 which	 occurs	 in	 less	 than	 2%	 of	 infected	 individuals	and,	when	not	 fatal,	 can	 leave	patients	with	 severe	 lifelong	neurological	 sequelae.	 Initial	
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diagnosis	of	WNV	infection	is	based	on	clinical	symptoms	and	early	infection	is	confirmed	by	the	presence	of	virus-specific	IgM	in	the	cerebrospinal	fluid	(CSF)	or	serum	of	patients.	Symptoms	of	WNV	encephalitis	can	include	altered	mental	state,	malaise,	myalgia,	ocular	manifestations,	 nausea,	 headache	 and	 fever	 (Rhee	 et	 al.	 2011;	 Mostashari	 et	 al.	 2001;	Petersen	and	Marfin	2002;	Haley	et	al.	2003).	Ocular	manifestations	of	WNV	encephalitis	generally	 present	 as	 chorioretinitis	 and	may	 include	 blurry	 vision,	 floaters	 and	 in	 some	cases	vision	loss.	Although	disease	in	the	eye	is	usually	self-limiting,	patients	may	be	left	with	persistent	chorioretinal	scars	(Moreland	et	al.	2014;	Myers	et	al.	2005;	Beardsley	and	McCannel	2012).		WNV	 spread	 throughout	 North	 America	 in	 less	 than	 10	 years	 and	 subsequently	 into	Canada	and	South	America,	 following	an	outbreak	of	virulent	Lineage-I	strain	 in	1999	 in	New	York	City.	 It	 is	 now	 the	most	 common	 cause	 of	 viral	meningoencephalitis	 in	North	America,	seemingly	supplanting	SLEV	(Lanciotti	et	al.	1999;	Shieh	et	al.	2000;	Schweitzer	et	 al.	 2006).	 Indeed,	 a	 diagnosis	 of	WNV	 encephalitis	 is	made	 in	 approximately	 60%	 of	patients	presenting	with	seropositive	neuroinvasive	disease	(Samuel	and	Diamond	2009).	The	 young,	 immunocompromised	 and	 elderly	 are	 at	 highest	 risk	 of	 developing	encephalitis	(Weiss	et	al.	2001;	Iwamoto	et	al.	2003;	Guarner	et	al.	2004;	Bode	et	al.	2006;	Khairallah	 et	 al.	 2007;	 Lindsey	 et	 al.	 2009)	 and	 recent	 estimates	 indicate	 that	 up	 to	 3-million	 individuals	were	 infected	with	WNV	 in	 the	 USA	 between	 1999-2010	with	 up	 to	1100	fatal	cases	(Petersen	et	al.	2013).		Various	factors	impact	on	the	increasing	spread	of	arboviruses,	including,	climate	change	and	 geographic	 factors	 like	 the	 expansion	 of	 vector	 habitat.	 While	 the	 difficulty	 of	restricting	the	migration	of	amplifying	avian	hosts	make	these	viruses	virtually	impossible	to	eradicate	(Schweitzer	et	al.	2006).	Despite	considerable	effort,	 the	only	successful	 live	attenuated	vaccine	available	for	humans	in	this	serogroup	is	for	JEV,	while	treatment	for	all	other	flavivirus	encephalitides	remains	supportive.			
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1.1.2. WNV	infection:	Virus	entry	and	initial	spread	
Initial	 infection	 occurs	 when	 an	 infected	 mosquito	 injects	 saliva,	 containing	 WNV,	cutaneously	during	feeding.	It	 is	 likely	that	saliva	is	 locally	immunosuppressive,	allowing	an	 initial	 viral	 replicative	 advantage	 (Schneider	 et	 al.	 2006;	 Schneider	 et	 al.	 2010).	 The	first	 immune	 components	 to	 encounter	 the	 virus	 are	 Langherhans	 cells	 (LC),	 dermal	dendritic	cells	(DC),	which	can	self-renew	during	steady-state	conditions	and	are	present	from	embryonic	development	(Merad	et	al.	2008).	As	antigen-presenting	cells	(APC),	both	dermal	DC	and	LC	can	migrate	to	the	draining	lymph	node	(DLN)	to	stimulate	T	cells	and,	when	depleted,	are	 locally	renewed	from	Ly6Clo	myeloid	precursors	 in	the	bone	marrow	(Steinman	 1991;	 Davison	 and	 King	 2011).	 Virus	 may	 infect	 LC,	 which	 then	 change	sequentially	 into	 migratory	 and	 antigen-presenting	 phenotypes	 (Johnston	 et	 al.	 2000).	Although	active	replication	of	WNV	in	LC	or	DC	has	not	been	shown	in	vivo,	it	does	occur	in	other	 flavivirus	 infections	 (Ho	 et	 al.	 2001).	 LC	 maturation	 into	 a	 migratory	 phenotype	occurs,	 accompanied	 by	 increased	 expression	 of	 cell	 surface	 adhesion	 molecules	 major	histocompatibility	 class-I	 and	 -II	 (MHC),	 CD45	 and	 costimulatory	 molecules	 like	 CD80,	which	are	 involved	 in	T	 cell	 activation	 (Johnston	et	 al.	 1996).	The	prevailing	 chemokine	milieu	induced	by	live	virus	mediates	LC	migration	to	the	DLN	in	an	accelerated	manner	(Johnston	 et	 al.	 2000).	 Cytokines	 such	 as	 IL1-β	 have	 been	 identified	 as	 crucial	 for	 the	emigration	 of	 LC	 from	 the	 epidermis	 to	 the	 DLN	 (Byrne	 et	 al.	 2001),	 where	 evidence	suggests	 that	 these	 LC	 pass	 antigen	 to	 CD8α+	 DC,	 arguing	 for	 a	 series	 of	 collaborative	interactions	 between	 initiating	 elements	 of	 the	 antiviral	 immune	 response	 (Allan	 et	 al.	2003;	Hildner	et	al.	2008;	Kissenpfennig	et	al.	2005).			Viral	 presence	 in	 the	 lymph	 node	 is	 accompanied	 by	 increased	 CCL2	 expression.	 Also	known	 as	monocyte	 chemoattractant-1	 (MCP-1),	 CCL2	 attracts	 bone	marrow	monocyte-derived	macrophages	 (MDM)	 to	areas	of	 infection.	These	MDM	rapidly	become	TNF	and	
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nitric	oxide	(NO)-producing	cells	known	as	TipDC	in	the	DLN,	which	may	contribute	to	the	initiation	of	the	type-1	immune	response	by	inducing	higher	IFN-γ	production	from	local	T	cells,	 compared	 to	other	DC	subsets	 (Davison	and	King	2011).	 Importantly,	 there	 is	 also	significant	 CCL2	 production	 by	 infected	 cells	 in	 the	 skin.	 In	 a	 dermal	 model	 of	 WNV	infection,	 CCL2	 recruited	 large	 numbers	 of	 MDM	 from	 the	 blood.	 These	 subsequently	surrounded	 the	 infected	 focus,	 becoming	 DC	 within	 24h	 of	 arrival.	 Adoptive	 transfer	studies	showed	Ly6Clo	MDM	migrating	to	the	 infectious	 focus	 in	the	skin,	went	on	to	the	DLN,	whereas	Ly6Chi	MDM	homing	to	the	focus	of	infection,	remained	there	in	this	model	(Davison	and	King	2011).			The	initial	innate	antiviral	immune	response	to	WNV	is	triggered	by	the	products	of	viral	replication,	such	as	extra-	and	intracellular	double-stranded	RNA	and	single-stranded	viral	RNA,	detected	by	Toll-	and	RIG-I-like	receptors,	respectively	(TLR	and	RLR)	(Wang	et	al.	2004).	 Collectively	 known	 as	 pattern	 recognition	 receptors	 (PRR),	 the	 ensuing	 result	 of	stimulation	 of	 these	 receptors	 is	 a	 downstream	 cascade	 of	 events,	 starting	 with	 the	activation	 of	 latent	 transcription	 factors	 responsible	 for	 initiating	 the	 reaction	 of	WNV-responsive	genes,	 the	 interferon	 stimulatory	genes	 (ISG)	 (Fredericksen	et	 al.	 2008).	The	result	 is	 a	 vigorous	 inflammatory	 response	 directed	 against	 WNV-infected	 cells	 and	mediated	 by	 several	 proinflammatory	 cytokines	 and	 chemokines	 (Wacher	 et	 al.	 2007).	The	RLR	group	of	PRR	consists	of	RIG-I	and	MDA-5	and	 it	 is	 the	cooperative	 function	of	these	receptors	that	maintains	the	innate	immune	response.		The	balance	of	immune	activation	versus	suppression	forms	a	critical	part	of	PRR	function.	The	adaptor	molecule	 IPS-I	plays	 a	 crucial	 regulatory	 role	 in	 flaviviral	 infection	and	has	been	identified	as	the	converging	point	of	the	RLR.	In	vitro,	the	disruption	of	IPS-I	led	to	a	reduced	 ISG	 response	 and	 in	vivo	its	 signalling	 has	 been	 shown	 to	 greatly	 influence	 the	control	 of	 WNV	 tropism,	 replication	 and	 central	 nervous	 system	 (CNS)	 invasion	(Fredericksen	 et	 al.	 2008;	 Suthar	 et	 al.	 2010).	 In	 vivo,	 the	 regulatory	 role	 of	 IPS-I	 is	
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highlighted	by	the	fact	that	in	its	absence	mice	displayed	considerable	neuropathology	due	to	 abnormal	 levels	 of	 innate	 and	 humoral	 immune	 products	 (Suthar	 et	 al.	 2010).	 In	contrast,	 adaptor	molecules	 such	 as	Myd88,	 which	 functions	 independently	 of	 RLR	 and	IPS-1,	are	critical	for	viral	control	and	leukocyte	trafficking	to	the	CNS.	Reduced	leukocyte	migration	 to	 the	 CNS	 in	 Myd88	 knockout	 (KO)	 mice	 led	 to	 increased	 viral	 load	 and	lethality.	 Similarly,	 WNV	 infection	 of	 TLR-7	 KO	 mice	 showed	 increased	 viremia	 and	susceptibility	 to	 disease,	 due	 to	 decreased	 levels	 of	 chemokines	 such	 as	 IL-23	 impeding	macrophage	recruitment	to	the	CNS	(Town	et	al.	2009;	Szretter	et	al.	2010).		The	actions	of	cytokines,	induced	by	PRR,	are	also	critical	for	the	initiation	of	the	adaptive	immune	response.	Acutely	viremic	human	donors	presented	with	substantial	increases	in	serum	 levels	 of	 IFN-γ	 and	 -α,	 as	 well	 as	 IFN-stimulated	 CXCL10	 and	 CCL2.	 This	upregulation	 occurred	 before	 IgM	 seroconversion	 and	 might	 be	 involved	 in	 the	 initial	management	 of	 acute	 viremia.	 Furthermore,	 upregulation	 of	 IL-4	 occurred	 during	 the	same	time	frame,	implicating	IL-4	in	immunoregulation	and	involvement	of	early	humoral	adaptive	immunity	(Tobler	et	al.	2008).			WNV	infection	of	various	cell	lines	leads	to	an	upregulation	of	cellular	adhesion	molecules	either	directly	or	co-modulated	through	the	action	of	cytokines	(Shen	et	al.	1995;	Shen	et	al.	 1997;	 Arnold	 et	 al.	 2004).	 These	 adhesion	 molecules	 include	 MHC-I	 and	 –II,	intracellular	adhesion	molecule	(ICAM),	vascular	cellular	adhesion	molecule	(VCAM)	and	E-selectin	(King	and	Kesson	1988;	Argall	et	al.	1991;	Shen	et	al.	1997;	Verma	et	al.	2009).	The	increase	in	MHC-I	in	mouse	embryonic	fibroblasts	is	independent	of	TNF	(Cheng	et	al.	2004a)	and	can	be	induced	by	two	signalling	pathways,	namely	type-I	IFN-dependent	and	-independent	 pathways,	with	 the	 IFN-independent	 pathway	 relying	 on	 the	 activation	 of	the	transcription	factor	NF-κB	(King	and	Kesson	1988;	Kesson	and	King	2001;	Cheng	et	al.	2004b).	 This	 is	mirrored	 in	 the	 infection	of	 human	 skin	 fibroblasts	with	WNV,	 in	which	human	 leukocyte	 antigen,	 the	human	analogue	of	MHC-I,	 is	 upregulated	 in	 a	 type-I	 IFN-
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dependent,	 as	 well	 as	 independent	 manner	 (Arnold	 et	 al.	 2004).	 It	 is	 of	 interest	 to	understand	 how	 these	 changes	 in	 MHC	 expression	 influence	 the	 outcomes	 of	 innate	immune	interactions,	such	as	with	natural	killer	(NK)	cells,	and/or	the	ultimate	affinities	of	later	adaptive	cytotoxic	T	cell	responses.	
1.1.3. WNV	infection:	Entry	into	the	CNS	
Virus	 undoubtedly	 spreads	 from	 the	 lymphatic	 system	 to	 the	 bloodstream,	 resulting	 in	infection	of	peripheral	organs,	including	the	CNS,	where	neurons	are	the	main	target	(Xiao	et	 al.	 2001;	 Shrestha	 et	 al.	 2003;	 Cheeran	 et	 al.	 2005;	 Samuel	 and	Diamond	 2009).	 The	factors	influencing	this	phase	of	virus	spread	are	poorly	defined.	Moreover,	how	the	virus	gains	 access	 to	 the	 CNS	 is	 unclear,	 with	 evidence	 of	 both	 direct	 and	 indirect	 modes	 of	infection	across	the	blood	brain	barrier	(BBB)	(Wang	et	al.	2004).	Several	hypotheses	exist	of	how	viral	entry	into	the	CNS	occurs,	including	1)	direct	infection	of	the	CNS	by	virus;	2)	the	 “Trojan	 horse”	 theory	 of	 undetected	 viral	 infection	 through	 a	 carrier	 cell,	 usually	argued	to	be	a	monocyte,	and	3)	retrograde	axonal	transport.		Some	evidence	favours	direct	viral	access	into	the	CNS	via	BBB	breakdown,	however,	BBB	breakdown	is	quite	variable	in	flavivirus	infection	(Liu	et	al.	2008;	Verma	et	al.	2010;	Getts	et	al.	2008).	IFN-λ	was	shown	to	be	protective	against	WNV	by	inducing	the	tightening	of	the	 BBB.	 Ifnlr	 KO	mice,	which	 lack	 the	 IFN-λ	 receptor,	 showed	 increased	BBB	 leakiness	and	 viral	 burden	 in	 the	 CNS	 during	 WNV	 infection.	 Indeed,	 IFN-λ	 may	 preserve	 BBB	integrity	 by	 maintaining	 junctional	 integrity,	 thereby	 reducing	 viral	 access	 to	 neurons	(Lazear	 et	 al.	 2015).	 Although	 certain	 TLR	 play	 a	 protective	 role	 during	WNV	 infection	(Daffis	et	al.	2008),	they	have	also	been	implicated	in	aiding	WNV	infection	into	the	CNS	by	compromising	 the	BBB.	TLR-3	KO	mice	have	 significantly	 lower	 viral	 levels	 in	 the	brain	and	 less	 BBB	 leakiness	 compared	 to	wild	 type	mice	 (WT),	which	 coincided	with	 higher	viral	 load	 in	 the	periphery,	 possibly	 as	 a	 result	 of	 reduced	TNF	production	 (Wang	 et	 al.	
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2004).	Primary	human	macrophages	 isolated	 from	 ‘young’	 individuals	 (20-36	years	old)	showed	a	marked	reduction	 in	TLR-3	 levels	during	WNV	infection,	compared	to	 ‘elderly’	donors	(>55	years	old).	TLR-3	levels	are	controlled	by	a	signal	transducer	and	activator	of	transcription-1	(STAT1)-mediated	pathway,	which	in	turn	is	inhibited	by	WNV	envelope-protein.	The	elevated	TLR-3	expression	 in	macrophages	of	 the	elderly	was	accompanied	by	 increased	 levels	 of	 inflammatory	 cytokines	 such	 as	 TNF,	 suggesting	 that	 TLR-3	may	play	a	role	in	the	increased	susceptibility	of	elderly	individuals	to	WNV	encephalitis	(Kong	et	 al.	 2008).	 Despite	 this,	 more	 recent	 in	 vivo	 studies	 with	 TLR-3	 KO	 mice	 showed	increased	susceptibility	to	infection	with	higher	viral	titres	in	the	CNS	(Daffis	et	al.	2008).	The	 discrepancies	 in	 these	 experiments	 not	 only	 highlight	 the	 different	 outcomes	 of	 in	
vitro	versus	in	vivo,	and	murine	versus	human	studies,	but	also	the	use	of	different	isolates	of	 virus.	 Furthermore,	 it	 may	 also	 bear	 upon	 the	 use	 of	 KO	 mice	 as	 a	 model	 for	 virus	infection.		Astrocytes,	 non-neuronal	 support	 cells	 of	 the	 CNS,	 are	 susceptible	 to	WNV	 infection	 in	
vitro	 (Liu	 et	 al.	 1988;	 Cheeran	 et	 al.	 2005;	 Verma	 et	 al.	 2010).	 In	 addition	 to	 the	upregulation	 of	 MHC-I	 and	 –II	 and	 adhesion	 molecules,	 WNV	 infection	 of	 astrocytes	induces	 the	 production	 of	matrix	metalloproteinases	 (MMP),	 capable	 of	 degrading	 tight	junction	proteins	 (TJP)	such	as	ZO-1	and	claudin-1,	 crucial	 structural	components	of	 the	BBB	(Verma	et	al.	2010).	Although	the	combined	actions	of	proteins	like	MMP	and	TLR	in	response	 to	 WNV	 infection	 might	 impact	 the	 barrier	 function	 of	 TJP,	 leading	 to	 BBB	breakdown,	this	notion	requires	an	existing	viral	presence	in	the	CNS,	making	it	unlikely	to	 be	 the	 initial	method	 of	 viral	 entry.	Mice	 and	 hamsters	 infected	with	WNV	 exhibited	signs	 of	 BBB	 leakiness,	 however	 this	 coincided	 with	 animals	 succumbing	 to	 the	 virus,	suggesting	 that	CNS	 infection	preceded	 the	degradation	of	 the	BBB	 (Morrey	 et	 al.	 2006;	Morrey	 et	 al.	 2008).	 Furthermore,	 the	 significant	 BBB	 disruption	 present	 in	 an	 in	 vivo	model	of	WNV	infection	occurred	after	virus	was	first	detected	in	the	CNS,	correlating	with	
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peak	 viral	 titres.	 There	 was	 a	 concomitant	 decrease	 in	 several	 TJP	 (claudin-1,	 ZO-1,	occludin)	 and	 adherens	 junction	 proteins	 (β-catenin,	 VE-cadherin),	 possibly	 as	 a	 direct	result	 of	 the	 inflammatory	 actions	 of	 increased	MMP.	 It	 is	 likely	 that	 high	 rates	 of	 viral	replication	contributed	to	BBB	disruption	and	although	this	was	not	the	primary	route	of	CNS	 infection,	 it	 likely	 facilitated	 leukocyte	 immigration	 and	 further	 access	 of	 virus	 into	the	CNS	in	this	model	(Roe	et	al.	2012).	WNV	infection	of	endothelial	and	epithelial	cells	induced	 the	 endocytosis	 of	 the	 TJP	 claudin-1,	 leading	 to	 the	 microtubule-dependent	transport	to	a	lysosome	and	subsequent	degradation	of	this	protein,	elucidating	a	possible	mechanism	by	which	virus	mediates	BBB	degradation	(Xu	et	al.	2012).		Alternatively,	virus	may	 infect	 the	CNS	directly	by	crossing	 the	BBB	 through	endothelial	trancytosis	 or	 endothelial	 infection.	 Entry	 of	 JEV	 is	 thought	 to	 occur	 by	 endothelial	transcytosis	of	virus	 (German	et	al.	2006).	However,	despite	 the	susceptibility	of	human	endothelial	 cells	 to	WNV	 in	vitro	 (Shen	et	al.	1997),	 there	are	 few	reports	of	 endothelial	infection	in	vivo	by	flaviviruses.		Another	 hypothesis	 for	 viral	 entry	 into	 the	 CNS	 is	 the	 “Trojan	 horse”	 scenario	 in	which	transmission	 of	 virus	 into	 the	 brain	 is	 mediated	 by	 haematogenous	 entry	 of	 infected	monocytes	or	other	infiltrating	leukocytes.	Indeed,	macrophages	and	monocytes	(and	to	a	lesser	extent	CD4+	lymphocytes)	are	highly	susceptible	to	WNV	infection	in	vitro	(Cardosa	et	 al.	 1986;	 Garcia-Tapia	 et	 al.	 2006;	 Rios	 et	 al.	 2006;	 Yeung	 et	 al.	 2012)	 and	 the	subsequent	upregulation	of	adhesion	molecules	like	E-selectin,	VCAM-1	and	ICAM-1	could	undoubtedly	support	the	extravasation	of	leukocytes	to	brain	(Shen	et	al.	1997;	Getts	et	al.	2012).	 In	 primary	 human	 brain	microvascular	 endothelial	 cells,	 VCAM-1	 and	 E-selectin	upregulation	 is	 induced	when	viral	 replication	peaks	 (Verma	et	al.	2009).	Together	with	BBB	breakdown	and	 the	 influence	of	TLR,	 these	adhesion	molecules	 could	 contribute	 to	the	infiltration	of	infected	leukocytes	into	the	CNS	(Getts	et	al.	2012).	Interestingly,	studies	have	shown	that	polymorphonuclear	cells	(PMN),	like	neutrophils,	exhibited	much	higher	
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viral	loads	than	macrophages.	These	cells	are	recruited	by	CXCL1	and	-2	during	the	early	stages	of	WNV	infection.	Depleting	this	subset	prior	to	WNV	infection	resulted	in	delayed	mortality	and	reduced	viral	 levels,	 implicating	PMN	as	possible	reservoirs	 for	early	viral	replication	 and	 dissemination	 during	 WNV	 infection	 (Bai	 et	 al.	 2010).	 However,	 it	 is	unlikely	 that	 neutrophils	 are	 the	 primary	 carrier	 of	 WNV	 to	 neurons	 as	 they	 only	contribute	 up	 to	 ~3%	 of	 the	 CNS	 leukocyte	 infiltrate	 (Hickey	 et	 al.	 1991;	 Terry	 2012).		Additionally,	 leukocyte-independent	migration	 of	WNV	 directly	 across	 an	 intact	 in	vitro	BBB	model	has	been	reported	(Verma	et	al.	2009).			Lastly,	there	is	good	evidence	for	retrograde	nerve	spread	of	the	virus	from	the	periphery	to	 the	CNS	(Engle	and	Diamond	2003;	Getts	et	al.	2007).	Herpes	simplex	and	Rabies	are	examples	of	viruses	capable	of	infecting	peripheral	nerve	components,	utilising	retrograde	axonal	 transport	 to	 enter	 the	 neurons	 (Finke	 and	 Conzelmann	 2005;	 McGraw	 and	Friedman	2009).	WNV	can	spread	between	neuronal	and	non-neuronal	cell	cultures	 in	a	retrograde	and	anterograde	manner	but	requires	an	intact	axon.	Viral	particles	assemble	in	 axons	 and	 are	 subsequently	 released	 extracellularly.	 If	 the	 sciatic	 nerve	 of	 golden	hamsters	 is	 transected	 above	 the	 site	 of	 infection,	 animals	 develop	 a	 systemic	 infection	with	less	severe	clinical	signs	normally	associated	with	CNS	invasion	(Samuel	et	al.	2007).	Treatment	 of	 mice	 with	 nocodazole,	 a	 microtubule	 inhibitor	 blocking	 axonal	 transport,	prior	to	inoculation,	delayed	virus	infection	of	the	CNS	by	6	days	(Hunsperger	and	Roehrig	2009).	Evidence	for	a	similar	manner	of	viral	dissemination	exists	in	the	footpad	model	of	infection	 that	 is	designed	 to	mimic	 the	 skin	 route	of	 infection	with	WNV	via	a	mosquito	bite.	Here,	 infection	occurs	 in	the	subcutaneous	 layer	of	 the	skin,	which	 is	 innervated	by	the	 sensory	 fibres	 of	 the	 dorsal	 root	 ganglion	 (DRG)	 of	 the	 peripheral	 nervous	 system	(PNS).	Both	the	PNS	(in	vitro)	and	the	DRG	(in	vivo)	have	been	shown	to	be	susceptible	to	WNV	 infection,	 identifying	 this	 as	 a	 possible	 pathway	 of	 retrograde	 axonal	 transport	(Hunsperger	 and	 Roehrig	 2005;	 Hunsperger	 and	 Roehrig	 2006).	 Our	 intranasal	 (i.n.)	
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model	of	WNV	infection	involves	infection	of	the	olfactory	nerve	and	results	in	direct	CNS	infection	 with	 rostral	 to	 caudal	 spread	 via	 neurons	 only,	 which	 further	 supports	retrograde	spread	of	virus	between	neural	connections	in	the	CNS	(Getts	et	al.	2007;	Getts	et	al.	2008).	Although	most	of	the	data	supports	initial	CNS	viral	entry	via	retrograde	axonal	transport,	it	 is	 likely	that	more	than	one	of	these	pathways	are	involved,	and	additional	studies	are	required	 to	demonstrate	 the	primary	and	secondary	routes	of	WNV	 infection	of	 the	CNS	and	induction	of	lethal	WNV	encephalitis	conclusively.	
1.1.4. WNV	infection:	Effects	on	the	CNS	
Whilst	 astrocytes,	 oligodendrocytes	 and	microglia	 are	 permissible	 for	WNV	 infection	 in	
vitro	(King,	Unpublished)	 (Liu	 et	 al.	 1988;	Argall	 et	 al.	 1991),	 neurons	 are	 evidently	 the	main	viral	target	(Shrestha	et	al.	2003;	Cheeran	et	al.	2005)	with	only	one	report	of	glial	cell	infection	in	vivo	(He	et	al.	2009).	One	of	the	responses	to	viral	infection	of	glial	cells	in	
vitro	is	the	production	of	chemoattractants	like	CCL5	and	CXCL10	(Cheeran	et	al.	2005).	In	humans,	viral	antigen	is	found	in	the	cytoplasm	of	neurons	and	neuronal	processes,	often	associated	with	the	presence	of	microglial	nodules	(Guarner	et	al.	2004).	Viral	entry	into	the	 neuron	 occurs	 after	 a	 short	 latent	 period	 with	 the	 attachment	 of	 virus	 to	 plasma	membrane	 and	 subsequent	 entry	 by	 clathrin-mediated	 endocytosis,	 resulting	 in	 the	formation	 of	 endosomes	 and	 lysosomes.	 A	 pH-dependent	 fusion	 mechanism	 expels	 the	nucleoplasmid	and	virus	into	the	cell	cytoplasm,	which	is	then	assumed	to	replicate	in	the	endoplasmic	 reticulum	(ER)	 (Chu	and	Ng	2004).	The	majority	of	animal	models	of	WNV	infection	show	detectable	virus	replicating	exclusively	within	neurons	in	the	CNS	between	day-3	and	-6	post-infection	(p.i.),	a	behaviour	distinguishing	it	from	the	encephalitic	DNA	viruses	 (Steele	 et	 al.	 2000;	 Xiao	 et	 al.	 2001;	 Shrestha	 et	 al.	 2003;	 Brehin	 et	 al.	 2008).	Following	peripheral	inoculation	of	the	footpad,	WNV	replicated	in	lymphoid	tissues	with	
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increased	 viral	 load	 in	 the	 CNS	 culminating	 in	 the	 onset	 of	 encephalitis	 (Brehin	 et	 al.	2008).	 Importantly,	 as	 with	 humans,	 neuroinvasion	 can	 occur	 in	 animals	 that	 do	 not	succumb	to	infection	(Hunsperger	and	Roehrig	2006;	Appler	et	al.	2010).	Certain	locations	in	the	CNS,	like	the	brainstem,	become	infected	as	early	as	48-hours	post-infection,	before	the	peak	of	viremia	and	symptoms	are	present.	There	are	also	indications	that	virus	can	be	cleared,	 only	 to	 be	 followed	by	 re-emergence	 of	 the	 virus	 to	 that	 area	 (Hunsperger	 and	Roehrig	 2006).	 Whether	 this	 is	 recrudescence	 of	 the	 virus	 in	 the	 same	 cells	 infected	initially	 or	 infection	 of	 new	 cells	 close	 by	 is	 unknown.	 The	 brain	 structures	 most	susceptible	 to	virus	and	developing	 the	highest	viral	 titres	 in	 the	murine	model	of	WNV	infection	are	 the	cortex,	hippocampus,	brainstem	and	spinal	cord,	with	humans	showing	involvement	 of	 the	 brainstem	 and	 anterior	 horn	 of	 the	 spinal	 cord	 (Xiao	 et	 al.	 2001;	Hunsperger	and	Roehrig	2006;	Sejvar	et	al.	2003;	Guarner	et	al.	2004).		Encephalitis,	 the	 inflammatory	 involvement	 of	 the	 CNS	 parenchyma,	 occurs	 due	 to	 the	damage	 resulting	 from	 excessive	 virus	 replication	 and/or	 an	 over-exuberant	 immune	response,	 which	 leads	 to	 potentially	 fatal	 outcomes.	 Distinguishing	 between	 viral-	 and	immune-mediated	pathology	in	the	CNS	is	complicated	by	the	increased	presence	of	both	viral	antigen	and	leukocytes	 in	areas	of	neuronal	apoptosis	and	degeneration	(Xiao	et	al.	2001;	 Shrestha	 et	 al.	 2003;	 Brehin	 et	 al.	 2008).	Microglial	 nodules,	 perivascular	 cuffing,	principally	 comprised	 of	 infiltrating	macrophages	 and	 T	 cells,	 and	 in	 advanced	 disease,	neuronal	 loss,	 are	 common	 neuro-histopathological	 and	 immuno-histochemical	 findings	(Steele	et	al.	2000;	Guarner	et	al.	2004;	Petzold	et	al.	2010).	Ultimately,	clinical	symptoms	develop	as	a	result	of	a	combination	of	viral	infection	and	the	inflammatory	milieu.	In	mice	these	 include	 limbic	 seizures,	 with	 animals	 succumbing	 to	 disease	 soon	 after	 seizures	develop.	 	 IFN-γ	 is	a	key	 factor	 in	seizure	development,	as	 IFN-γ	KO	mice	do	not	develop	seizures.	 Suppression	of	 seizures	 in	WT	mice	 extends	 survival	by	 several	days,	 allowing	viral	growth	to	 increase	~10-fold	 in	 the	CNS,	 indicating	that	viral	replication	may	play	a	smaller	role	in	lethal	pathology	than	previously	thought	(Getts	et	al.	2007).	The	following	
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section	 (1.2.)	 considers	 the	 contributions	 of	 viral	 infection	 and	 leukocyte	 infiltration	 to	pathology	in	lethal	WNV	encephalitis.			
1.2. Flavivirus	 pathogenesis:	 Immunopathology	 versus	 viral	
contribution	
	Two	main	 hypotheses	 exist	 as	 to	 the	main	 cause	 of	 flaviviral-induced	 pathology	 in	 the	CNS,	 namely,	 direct	 viral	 induction	 of	 apoptosis	 in	 neurons	 or	 immune-mediated	pathology.	The	immune	system	is	clearly	involved	in	detrimental	responses	against	self	in	autoimmune	 scenarios,	 but	 has	 only	 recently	 been	 implicated	 in	 a	 range	 of	 diseases	previously	 not	 thought	 to	 be	 autoimmune	 related,	 such	 as	 viral	 infection,	 myocardial	infarction	(MI)	and	colitis	(Getts	et	al.	2014).	The	extent	to	which	an	overactive	 immune	response	 can	 drive	 pathology	 in	 viral	 diseases	 is	 only	 now	 becoming	 clear	 and	 this	knowledge	provides	exciting	opportunities	for	development	of	novel	and	potentially	 life-saving	 therapies.	 Although	 several	 cell	 types	 are	 permissible	 for	 flavivirus	 infection	 in	
vitro	(Cheeran	et	al.	2005;	van	Marle	et	al.	2007;	Dutta	et	al.	2010),	CNS	neurons	remain	the	principle	target	for	most	flaviviral	infections	in	mammals	(Desprès	et	al.	1996;	Shieh	et	al.	 2000;	 Cantile	 et	 al.	 2001;	 Getts	 et	 al.	 2007).	 Neurons	 have	 extremely	 limited	regenerating	 capacity	 and	 exhibit	 higher	 rates	 of	 apoptosis	 compared	 to	 other	 CNS	 cell	types,	 with	 flavivirus	 infection	 (van	 Marle	 et	 al.	 2007).	 Whether	 this	 virus-induced	apoptosis	is	sufficient	to	induce	lethality	remains	to	be	elucidated.	
1.2.1. Viral	contribution	
The	 permissiveness	 of	 various	 cell	 types	 to	 WNV	 in	 vitro	 and	 their	 subsequent	 virus-induced	 apoptosis	 forms	 the	 basis	 for	 the	 hypothesis	 of	 virus-mediated	 disease	progression	 (Jan	 et	 al.	 2000;	 Shrestha	 et	 al.	 2003).	 Examples	 include	 the	 concentration-	and	time-dependent	manner	in	which	JEV	promotes	apoptosis	of	human	medullablastoma	
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cells,	 with	 administration	 of	 isolated	 viral	 protein	 also	 inducing	 caspase-3	 activation,	leading	to	mitochondrial-mediated	apoptosis	(Yang	et	al.	2009).	The	caspase	cascade	has	also	 been	 implicated	 in	 mitochondrial-mediated	 apoptosis	 and	 generation	 of	 reactive	oxygen	species	(ROS)	in	JEV-	and	WNV-infected	neuronal	cell	 lines	(Chu	2003;	Lin	2004;	Tsao	et	al.	2008).	Similarly,	apoptosis	has	been	shown	in	neuronal	cell	lines	infected	with	dengue	virus	(DENV)	and	JEV	and	it	is	clear	that	accumulation	of	viral	proteins	in	cells	can	ultimately	lead	to	cell	death	(Desprès	et	al.	1996;	Jan	et	al.	2000;	Prikhod	et	al.	2002).	This	provides	 evidence	 that	 even	 isolated	 viral	 components	 can	 act	 as	 potent	 inducers	 of	apoptosis	in	neural	cells	in	the	absence	of	exogenous	immune	effects.	
In	vivo	evidence	for	virus	induced	cell	death	has	also	been	shown	convincingly	in	several	murine	models	 of	 flavivirus	 infection.	 Intramuscular	 injection	 of	 WNV	 capsid	 protein	resulted	in	apoptosis	as	a	consequence	of	the	disruption	of	mitochondrial	transmembrane	potential	 and	 caspase-9	and	 -3	 activation	 (Yang	et	 al.	 2002).	Moreover	 intracranial	 (i.c.)	infection	of	neonatal	mice	with	DENV	 induced	neuronal	apoptosis	concentrated	 in	areas	with	high	 levels	of	virus	 replication.	However,	 the	minimal	 signs	of	 inflammation	 in	 this	model	could	be	attributed	to	the	immature	immune	response	and	thus	cannot	exclude	the	possibility	that	inflammation	plays	a	role	in	DENV	pathogenesis	in	the	adult	CNS	(Desprès	et	al.	1998).	In	a	hamster	model	of	WNV	infection,	neuronal	degradation	occurred	prior	to	major	 perivascular	 infiltrate	 and	microglial	 nodule	 formation	 (Xiao	 et	 al.	 2001).	 On	 the	other	hand,	abrogation	of	macrophage	migration	 inhibitory	 factor	by	antibody	blockade,	or	 TLR-3	 deletion	 by	 gene	 inactivation	 in	 the	 form	 of	 TLR	 KO	 mice,	 both	 resulted	 in	decreased	 viremia	 and	 mortality	 rates	 following	WNV	 infection.	 However,	 whether	 the	improved	clinical	outcome	was	attributable	to	decreased	viral	titres	is	hard	to	determine,	as	this	occurred	in	conjunction	with	a	significant	reduction	in	leukocyte	infiltration	(Wang	et	al.	2004;	Arjona	et	al.	2007).			
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It	 remains	 difficult	 to	 determine	 if	 neurological	 symptoms	 occur	 as	 a	 result	 of	 virus-induced	apoptosis	or	are	mediated	by	inflammation	occurring	as	a	secondary	response	to	virus-induced	 neuronal	 stress.	 While	 flavivirus	 infection	 clearly	 induces	 cell	 death	 in	several	 neuronal	 cell	 lines,	 evidence	 for	 virus-induced	 neuronal	 degeneration	 in	 vivo	occurring	 independently	 of	 inflammation	 is	 scarce.	 In	 contrast,	 the	 contribution	 of	 the	inflammatory	milieu	in	the	CNS	during	flavivirus	encephalitis	is	well	established	in	animal	models	and	will	be	discussed	in	the	following	section.			
1.2.2. Immune	contribution	
The	 pathogenic	 nature	 of	 the	 immune	 system	 has	 long	 been	 recognised,	 however	 the	extent	 to	 which	 an	 over-reactive	 immune	 response	 contributes	 to	 pathology	 in	 viral	infection	 is	 only	 now	 becoming	 evident	 (Camenga	 and	Nathanson	 1975).	 High	 levels	 of	inflammatory	mediators	 such	as	TNF,	 IL-8,	 IL-6,	NO	and	CCL5	 (RANTES)	 in	 the	CSF	and	serum	 of	 JEV-infected	 patients	were	 associated	with	 a	 fatal	 outcome,	whereas	 high	 IgM	levels	correlated	with	survival	 (Ravi	et	al.	1997;	Winter	et	al.	2004).	Generally,	 flaviviral	encephalitis	 in	 mammals	 is	 characterised	 by	 neuronal	 damage	 occurring	 along	 with	significant	 infiltration	of	 inflammatory	 leukocytes,	 including	monocytes,	T	 cells,	NK	cells	and	 neutrophils,	 with	 accompanying	 activation	 of	 CNS-resident	 cells	 (microgliosis	 and	astrogliosis)	and	the	concomitant	release	of	pro-	and	anti-inflammatory	mediators	(Shieh	et	al.	2000;	Singh	et	al.	2000;	Cantile	et	al.	2001;	van	Marle	et	al.	2007;	Chen	et	al.	2010;	Petzold	et	al.	2010).	Mounting	evidence	suggests	that	this	cascade	of	events	triggered	by	viral	 infection	 is	 responsible	 for	 the	 development	 of	 WNV	 encephalitis.	 Several	publications	 from	 our	 laboratory	 have	 demonstrated	 that	 infiltrating	 inflammatory	monocytes,	rather	than	virus,	are	the	main	contributors	to	lethal	encephalitis	during	WNV	infection	 (Getts	 et	 al.	 2008;	 Terry	 et	 al.	 2012;	 Getts	 et	 al.	 2014).	 However,	 along	 with	infiltrating	 leukocytes,	 there	 is	 also	 evidence	 for	 CNS-resident	 cells	 such	 as	 neurons,	
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astrocytes	and	microglia,	contributing	to	immunopathology	directly	and	indirectly.	These	are	represented	in	Figure	1.1.	
1.2.2.1. Resident	cells	
Neurons	
Although	the	effect	of	inflammatory	mediators,	derived	from	infiltrating	cells,	on	neuronal	death	is	widely	accepted,	it	is	likely	that	neurons	themselves	at	least	partially	contribute	to	the	pathogenesis	of	disease.	Pro-inflammatory	mediators	such	as	CXCL10,	TNF,	 IL-1β,	 -6	and	 -8,	 released	 by	 infected	 neurons	 may	 contribute	 directly	 by	 inducing	 apoptosis	 of	neighbouring	neurons.	Indeed,	antibody-mediated	neutralisation	of	neuronal	TNF	and	IL-1β	 decreased	 apoptosis	 of	 neighbouring	 WNV-infected	 neurons.	 Indirectly,	 neuron-derived	 cytokines	 also	 induced	 the	 activation	 of	 astrocytes,	 which	 too	 have	 been	implicated	 in	 pathogenesis	 of	 disease	 (van	 Marle	 et	 al.	 2007;	 Kumar	 et	 al.	 2010).	Moreover,	 neurons	 of	 WNV-infected	 mice	 produce	 significant	 amounts	 of	 the	chemoattractant	CCL2,	responsible	for	the	recruitment	of	pathogenic	Ly6Chi	inflammatory	monocytes	(Figure	1.1)	 (Getts	et	al.	2008).	Thus,	virus	 infection	and	replication	not	only	has	 a	 cytopathic	 effect	 on	neurons,	 but	 also	 triggers	 an	 “exogenous”	 immunopathogenic	response.		Inhibition	of	viral	entry	in	TLR3	KO	mice	and	reduction	of	subsequent	neuronal	infection	improved	resistance	of	mice	to	WNV	infection,	which	coincided	with	reduction	in	inflammatory	responses	and	concurrent	neurodegeneration	(Wang	et	al.	2004).	Neuronal	contribution	 to	WNV	encephalitis	may	be	 limited	but	 in	an	extended	disease	course	any	additional	inflammatory	stimulus	may	aid	in	tipping	the	balance	of	the	immune	response	from	protective	to	pathogenic.	
Figure	1.1	Immunopathology	of	WNV	infection	
		Figure	1.1	 illustrates	 the	 immunopathology	of	WNV	 infection	of	 the	CNS.	 	WNV-infected	neurons	 (green	 section)	 secrete	 CCL2	 which	 results	 in	 the	 recruitment	 of	 CCR2+	Ly6Chi	inflammatory	 monocytes	 from	 the	 bone	 marrow	 (blue	 section)	 into	 the	 bloodstream.	Upon	 reaching	 the	 bloodstream	 (red	 section)	 the	 CCR2/CCL2–axis	 drives	 migration	 of	CCR2+	Ly6Chi	 inflammatory	 monocytes	 to	 the	 BBB	 where	 receptor/ligand	 interactions	between	 ICAM-1/LFA-1	 and	 VCAM-1/VLA-4	 facilitate	 the	 entry	 of	 pathogenic	 Ly6Chi	inflammatory	monocytes	 into	 the	 infected	 CNS.	 Ly6Chi	 inflammatory	monocytes	 release	NO	in	the	CNS.	Furthermore,	infected	neurons	release	IL-1β	and	TNF,	which	activate	CNS-resident	cells	such	as	astrocytes	and	resting	microglia.	Activated	microglia	can	release	NO,	compounding	 the	 detrimental	 effect	 of	 the	 Ly6Chi	 inflammatory	 monocyte-derived	 NO,	whereas	activated	astrocytes	may	also	release	CCL2,	resulting	in	additional	recruitment	of	Ly6Chi	inflammatory	monocytes.			 	
Figure 1.1 Immunopathology of  WNV infection
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Astrocytes	
Astrocytes,	 the	 main	 glial	 cell	 in	 the	 CNS,	 play	 a	 crucial	 supportive	 role	 during	homeostasis.	Their	intimate	anatomical	and	functional	relationship	with	neurons	and	their	synapses,	as	well	as	 their	ability	 to	produce	various	 inflammatory	mediators	 to	 regulate	the	 surrounding	 CNS	milieu	 in	 a	 neuro-stimulatory	 or	 –inhibitory	manner,	makes	 them	ideal	candidates	to	contribute	to	neuronal	pathology	during	WNV	encephalitis	(Song	et	al.	2002;	Barkho	et	 al.	 2009).	Although	evidence	 exists	 for	direct	 infection	of	 astrocytes	by	flaviviruses	 in	 vitro	 (Cheeran	 et	 al.	 2005;	 Das	 et	 al.	 2008;	 van	 Marle	 et	 al.	 2007),	 it	 is	unlikely	that	activation	of	this	subset	occurs	as	a	result	of	infection	by	live	replicating	virus	and	 they	 are	 more	 likely	 activated	 by	 cytokines	 such	 as	 IL-1β	 and	 TNF,	 released	 by	infected	 neurons	 (Kumar	 et	 al.	 2010)	 (Figure	 1.1.).	 JEV-	 and	WNV-induced	 astrogliosis	results	in	the	secretion	of	several	pro-inflammatory	mediators	such	as	CXCL10,	CCL2,	IL-1β	and	CCL5	(Lieberman	et	al.	1989;	Cheeran	et	al.	2005;	van	Marle	et	al.	2007;	Das	et	al.	2008;	 Swarup	 et	 al.	 2008;	 Chen	 et	 al.	 2010),	 although	 the	 extent	 to	which	 these	 factors	contribute	 to	 pathology	 remains	 to	 be	 elucidated.	 Furthermore,	 IL-6	 is	 significantly	upregulated	in	WNV	encephalitis	and	its	production	by	astrocytes	has	been	implicated	in	enhancing	 the	 inflammatory	 immune	 response	 and	 subsequent	 pathology	 during	autoimmune	 disease,	 such	 as	 experimental	 autoimmune	 encephalomyelitis	 (EAE),	 a	mouse	model	of	multiple	sclerosis	(Getts	et	al.	2007;	Quintana	et	al.	2009).			The	 IL-1	 family	of	pro-inflammatory	cytokines	has	been	 implicated	as	a	crucial	 factor	 in	the	 pathogenesis	 of	 acute	 and	 chronic	 neurodegenerative	 diseases,	 such	 as	 Alzheimer’s	and	stroke	(Reviewed	(Griffin	2006)	(Allan	et	al.	2005).	The	production	of	both	IL-18	and	IL-1β	by	astrocytes	increase	during	in	vitro	and	in	vivo	JEV	infection	of	neurons.	Although	IL-1β	 stimulates	 neurogenesis	 in	 steady	 state,	 during	 JEV	 infection	 these	 cytokines	activate	 glial	 cells,	 inducing	 pro-inflammatory	 cytokine	 release,	 and	 also	 increase	 their	
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own	 production	 via	 an	 autocrine-feedback	 loop.	 Indeed,	 the	 dysregulated	 production	 of	these	factors	all	results	in	apoptosis	of	neuronal	cells	(Barkho	et	al.	2009;	Das	et	al.	2008).	In	 contrast,	 the	 protective	 role	 of	 IL-1β-mediated	 astrocyte	 activation	 has	 also	 been	shown,	 as	 this	 inhibited	 neuronal	 apoptosis	 at	 certain	 concentrations.	 Furthermore,	studies	 show	 that	 the	 duration	 of	 astrogliosis	 i.e.	 chronic	 versus	 acute,	 may	 dictate	whether	 the	 reaction	 is	 beneficial,	 further	 highlighting	 the	 dual	 neuro-protective	 or	pathogenic	role	that	immune	cells	can	play	(Sticozzi	et	al.	2013;	Okada	et	al.	2006).		Similar	to	neurons,	activated	astrocytes	produce	CCL2,	which	may	indirectly	contribute	to	pathogenesis	 by	 recruiting	 large	 numbers	 of	 inflammatory	 monocytes.	 As	 the	 main	cellular	source	of	CCL2,	astrocytes	are	responsible	for	initiating	the	inflammatory	immune	response	during	the	acute	stages	of	a	spinal	cord	injury.	CCL2	expression	is	mediated	via	the	Myd88/IL-1R1	signalling	pathway	and	recruits	significant	numbers	of	neutrophils	and	inflammatory	monocytes	to	the	site	of	 injury,	which	have	been	reported	to	contribute	to	secondary	tissue	loss	in	this	model	(Pineau	et	al.	2010).	Moreover,	astrocyte	production	of	CXCL10	 has	 been	 implicated	 in	 the	 neuropathology	 of	 human-	 and	 simian	immunodeficiency	virus	(HIV	and	SIV)	(Sui	et	al.	2004;	van	Marle	et	al.	2007),	a	possible	mechanism	 being	 the	 binding	 of	 CXCL10	 to	 its	 cognate	 receptor,	 CXCR3,	 inducing	 Ca2+	release	from	the	ER.	Uptake	of	elevated	Ca2+	by	mitochondria	can	result	in	mitochondrial	membrane	permeabilisation	and	cytochrome	c	 release,	which	 induces	a	 caspase-cascade	ultimately	 resulting	 in	 neuronal	 apoptosis	 (Sui	 et	 al.	 2006).	 Human	 brain	 cortical	astrocytes	also	produce	MMP	that	may	play	a	role	BBB	disruption,	further	contributing	to	immune	infiltration	and	subsequent	immunopathology	(Verma	et	al.	2010).	Ultimately,	the	inflammatory	mediators	 released	by	astrocytes	upon	activation	may	 increase	 the	 risk	of	neurodegeneration	 by	 amplifying	 the	 existing	 pathogenic	 immune	 response	 in	 a	 similar	manner	to	neurons.		
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Microglia	
Although	the	inflammatory	products	of	virus-activated	astrocytes	can	induce	neuronal	cell	death,	 this	 effect	 is	 much	 more	 pronounced	 in	 studies	 using	 microglia,	 the	 resident	immune	 cells	 of	 the	 CNS	 (Das	 et	 al.	 2008;	 Chen	 et	 al.	 2010).	Microglia	 function	 as	 local	phagocytes	 and,	 upon	 activation,	 express	 similar	 cell	 surface	markers	 and	 inflammatory	mediators	 to	 circulatory	macrophages.	 These	 cells	 replenish	 themselves	 from	 an	 in	situ	population	 that	originates	 from	 the	yolk	 sac	and	 is	established	 in	 the	brain	during	early	embryogenesis.	(Olson	and	Miller	2004;	Ginhoux	et	al.	2010).	Differential	CD45	and	Ly6C	expression	distinguishes	microglia	from	immigrant	macrophages.		Thus,	 resident	 microglia	 express	 CD45loCD11b+Ly6C-,	 activated/infiltrating	 microglia	become	 CD45intCD11b+Ly6Cint,	 whereas	 recently	 immigrant	 macrophages	 are	CD45hiCD11b+Ly6Chi	(Sedgwick	et	al.	1991;	Getts	et	al.	2008).	While	microglia	undoubtedly	play	 a	 neuroprotective	 role,	 several	 studies	 have	 reported	 a	 correlation	 between	inflammatory	 mediators	 produced	 by	 activated	 microglia	 and	 neuronal	 damage	 during	flavivirus	infections.		Although	 microglia	 can	 be	 infected	 by	 flaviviruses	 in	 vitro,	 viral	 replication	 is	 not	supported	 (Cheeran	 et	 al.	 2005),	 but	 the	 presence	 of	 pathogen	 induces	 activation	 and	secretion	of	various	pro-inflammatory	mediators.	These	include	cytokines	(TNF,	IL-1β,	IL-6,	 IFN-γ),	 chemokines	 (CCL5,	 CCL2),	 inducible	 nitric	 oxide	 synthase	 (iNOS),	cyclooxygenase-2	 (Cox-2)	and	ROS	 (Wang	et	al.	2004;	Ghoshal	et	al.	2007;	Swarup	et	al.	2008;	 Chen	 et	 al.	 2010),	 several	 of	 which	 have	 neurotoxic	 potential	 (Chen	 et	 al.	 2010)	(Figure	 1.1).	 Furthermore,	 activated	 microglia	 lose	 their	 resting	 dendritic	 phenotype,	developing	 a	 motile	 amoeboid	 morphology	 and	 histologically,	 can	 be	 seen	 surrounding	infected	neurons,	forming	microglial	nodules	soon	after	infection	(King	and	Kesson	2003;	Getts	et	al.	2008).	
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Microglial	 activation	 occurs	 prior	 to	 immune	 lymphocyte	 infiltration	 in	 the	 brain	 and	 is	likely	 an	 indirect	 consequence	 of	 neuronal	 viral	 infection	 (Getts	 et	 al.	 2008).	 Although	direct	viral	activation	of	microglia	is	possible	in	vitro	(Chen	et	al.	2010),	evidence	suggests	that	 inflammatory	mediator	 release	 from	 infected	 neurons	 is	 the	main	 activator	 of	 glial	cells	 in	 vivo.	 TNFR-1-associated	 death	 domain	 (TRADD)	 was	 identified	 as	 a	 crucial	mediator	 of	 neuronal	 death	 during	 JEV	 infection.	 Inhibition	 of	 TRADD	 synthesis	 with	small-interfering	 RNA	 reduced	 neuronal	 apoptosis,	 leading	 to	 decreased	 microglial	activation	and	concomitant	 inflammatory	mediator	production	and	 leukocyte	 infiltration	(Swarup	et	al.	2008).	TNF,	IL-18	and	IFN-γ	can	inhibit	the	proliferation	of	neural	precursor	cells	(Liu	et	al.	2005)	and	 IFN-γ	 increased	 the	 rate	 of	 apoptotic	 cell	 death	 but	 this	 effect	 could	 be	 partially	inhibited	 by	TNF	 at	 certain	 concentrations	 (Ben-Hur	 et	 al.	 2003).	 Conversely,	 in	 a	WNV	model	of	infection,	TNF	and	IL-6	directly	mediated	bystander	damage	to	neurons	(Wang	et	al.	2004)	and	raised	TNF	levels	were	associated	with	mortality	in	tick-borne	encephalitis	virus	 (TBEV)	 infection	 (Hayasaka	 et	 al.	 2009),	 emphasising	 that	 multiple	 variables	 are	involved	in	determining	the	effect	of	pro-inflammatory	mediators.	Inhibition	of	Cox-2	and	NOS-2	 in	a	 JEV	model	of	 infection	significantly	reduced	neuronal	death	 (Das	et	al.	2011)	and	aminoguanidine-mediated	 inhibition	of	NO	had	a	significant	protective	effect	during	WNV	 infection	 (Getts	 et	 al.	 2012).	 However,	 CNS-resident	 cells	 are	 clearly	 not	 the	 only	source	 of	 these	 mediators	 and	 the	 significant	 infiltration	 of	 soluble	 factor-secreting	leukocytes	 from	 the	 circulation	 also	 contributes	 to	 pathology	 in	 the	 brain	 in	 WNV	encephalitis.	
1.2.2.2. Infiltrating	cells	
As	discussed	in	the	previous	section,	it	 is	evident	that	flavivirus	infection	of	neurons	and	subsequent	apoptosis	results	in	the	release	of	a	range	of	chemotactic	mediators,	as	well	as	
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the	 activation	 of	 astrocytes	 and	 microglia.	 The	 joint	 action	 of	 activated	 resident	 CNS	populations	leads	to	significant	leukocyte	infiltration	into	the	CNS,	a	hallmark	of	flaviviral	encephalitis	(Shrestha	et	al.	2003).	CCL2	is	known	to	play	a	crucial	role	in	the	recruitment	of	MDM,	however	IL-23	has	also	been	implicated	in	this	process	(Getts	et	al.	2008;	Town	et	al.	2009;	Lim	et	al.	2011).	Significant	infiltration	of	neutrophils	and	mononuclear	cells,	like	macrophages	and	T	cells	occurs	in	humans,	as	well	as	experimental	animal	models	during	flavivirus	 infection.	 Infiltrating	 leukocytes	 are	 often	 concentrated	 in	 the	 most	 severely	affected	areas	of	the	CNS	and	have	been	associated	with	fatal	disease	outcome	(Singh	et	al.	2000;	 Kelley	 et	 al.	 2003).	 Although	 these	 cells	 are	 crucial	 for	 viral	 clearance,	 they	 have	been	implicated	as	the	main	drivers	of	immunopathology	and	cause	of	clinical	symptoms	in	 flaviviral	 encephalitis.	 	DENV-infected	mice	with	meningoencephalitis	 display	distinct	behavioural	changes	occurring	at	the	peak	of	leukocyte	infiltration	into	the	CNS,	(Amaral	et	al.	2011)	and	work	from	our	laboratory	has	linked	specific	infiltrating	leukocyte	subsets	as	 key	 mediators	 in	 the	 development	 of	 clinical	 symptoms	 and	 lethality	 during	 WNV	infection.		
1.2.2.2.1. Myeloid	subsets	
Monocytes	and	Macrophages	Monocytes,	specifically	Ly6Chi	inflammatory	monocytes,	have	been	established	as	the	main	contributors	of	immunopathology	in	our	i.n.	model	of	WNV	encephalitis.	Adoptive	transfer	studies	have	identified	the	bone	marrow	as	a	major	source	for	these	cells,	but	there	is	also	evidence	for	a	splenic	supply	of	Ly6Chi	inflammatory	monocytes	(Swirski	et	al.	2009;	Getts	et	al.	2008).	Mice	and	humans	have	analogous	monocyte	subsets	identified	as	two	distinct	populations	 based	 on	 differential	 cell	 surface	 marker	 expression.	 Murine	 patrolling	monocytes	 (non-classical)	 are	 CCR2loCX3CR1hi	 and	 Ly6Clo/-,	 with	 a	 CD14loCD16hi	expressing	 human	 counterpart.	 Inflammatory	 monocytes	 (classical)	 are	 defined	 as	Ly6ChiCCR2hiCX3CR1lo/int	 in	 mice	 and	 CD14hiCD16lo	 in	 humans	 (Geissmann	 et	 al.	 2003;	
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Sunderkotter	 et	 al.	 2004).	 Inflammatory	 conditions	 result	 in	 the	 differentiation	 of	circulatory	monocytes	 into	either	 inflammatory	macrophages	or	DC	once	 they	 reach	 the	focus	 of	 inflammation.	 The	 factors	 determining	 the	 fate	 of	 circulatory	 monocytes	 are	complex	 and	 not	 well	 understood.	 However,	 evidence	 suggests	 that	 the	 inflammatory	milieu	 present	 in	 viral	 infection	 of	 the	 CNS	 supports	 monocyte-to-macrophage	differentiation	 (Uchide	 et	 al.	 2002).	 Activated	macrophages	 have	 been	 implicated	 in	 the	pathology	of	 several	neurotropic	diseases	 like	Theiler’s	encephalomyelitis	virus	 (TMEV),	neurotropic	mouse	hepatitis	virus	(MHV),	TBEV	and	WNV	(Bennett	et	al.	2003;	Gelpi	et	al.	2005;	Gelpi	et	al.	2006;	Templeton	et	al.	2008;	Howe	et	al.	2012;	Bowen	and	Olson	2013;	Cusick	 et	 al.	 2013).	 In	 contrast,	DC	 are	 a	major	 driver	 of	 autoimmune-mediated	disease	such	as	EAE	(McMahon	et	al.	2005;	Zhu	et	al.	2007;	King	et	al.	2009).			The	 expression	 of	 ICAM-1	 and	 VCAM-1,	 the	 ligands	 for	 LFA-1	 and	 VLA-4	 respectively,	increases	 substantially	 in	 the	CNS	 (Getts	 et	 al.	 2012)	with	WNV	 infection	and	 studies	of	WNV-infected	human	umbilical	vein	endothelial	cells	(HUVEC)	showed	pro-inflammatory	cytokines	further	amplified	VCAM-1	expression.	This	suggests	that	the	combined	action	of	infection	and	cytokine-induced	upregulation	could	facilitate	leukocyte	infiltration	into	the	CNS	(Shen	et	al.	1997).	The	high	level	of	CCL2	produced	in	the	CNS	during	WNV	infection	is	 responsible	 monocyte	 recruitment	 from	 the	 bone	 marrow.	 Neutralisation	 of	 CCL2	resulted	in	significant	reduction	in	inflammatory	macrophages	in	the	brain,	accompanied	by	 prolonged	 survival	 and	 improved	 clinical	 symptoms	 of	WNV-infected	mice.	 As	 there	was	no	reduction	 in	viral	 titre,	 the	amelioration	of	disease	was	directly	attributed	to	 the	significant	decrease	in	inflammatory	monocyte	populations	in	the	CNS	(Getts	et	al.	2008).	Although	 T	 cells	 form	 a	 substantial	 proportion	 of	 the	 leukocyte	 infiltrate	 during	 WNV	encephalitis,	almost	50%	of	 leukocytes	 infiltrating	the	brain	are	Ly6Chi	MDM.	 Infiltration	occurred	 mainly	 via	 the	 integrin,	 VLA-4,	 on	 these	 cells,	 with	 a	 number	 of	 these	macrophages	producing	NO,	a	potent	mediator	of	neuronal	pathology	(Figure	1.1)	(Getts	
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et	al.	2012).	 In	addition,	adoptive	transfer	experiments	with	Ly6Chi	monocytes	show	that	some	 of	 this	 subset	 can	 differentiate	 into	 activated	 microglia,	 adding	 to	 the	 resident	population	(Getts	et	al.	2008).			JEV-activated	macrophages	are	capable	of	producing	several	neurotoxic	and	chemotactic	inflammatory	mediators	such	as	IL-12,	CCL2,	TNF,	IFN-γ,	NO,	ROS	and	Cox-2	(Nazmi	et	al.	2011).	 Inflammatory	 macrophages	 in	 a	 DENV	 model	 of	 infection	 produced	 significant	levels	of	IFN-γ-dependent	NOS-2.	Indeed,	high	NOS-2	levels	were	associated	with	disease	lethality,	 as	 NOS-2	 KO	mice	 exhibited	 improved	 survival	 outcome	 compared	 to	WT	 (de	Souza	et	al.	2013).	In	contrast,	NO	production	plays	a	crucial	antiviral	role	against	DENV	and	 JEV,	 whilst	 IFN-γ-mediated	 NOS-2	 expression	 and	 NO	 production	 were	 critical	 for	survival	in	a	mouse-adapted	DENV-3	infection	(Costa	et	al.	2012;	Neves-Souza	et	al.	2005;	Saxena	 et	 al.	 2000;	 Saxena	 et	 al.	 2001).	 Interestingly,	 in	 human	DENV	 infection,	 low	NO	levels	were	associated	with	poor	outcome	and	development	of	a	haemorrhagic	form	of	the	disease,	 compared	 to	 patients	 with	 elevated	 NO	 (Valero	 et	 al.	 2002).	 However,	discrepancies	in	studies	with	DENV	infection	in	animal	models	due	to	the	use	of	different	viral	 strains	 make	 definitive	 conclusions	 difficult.	 Ultimately,	 it	 is	 likely	 that	 the	concentration	 and	 duration	 of	 NO	 and	 other	 MDM-derived	 inflammatory	 mediators	present	in	the	CNS	determines	whether	it	exerts	a	protective	or	pathogenic	role.		
Neutrophils	
Neutrophils	 (Ly6G+CD11bhi	SSChi)	 are	members	 of	 the	 granulocyte	 family,	which	 include	basophils	and	eosinophils,	and	contribute	up	to	3%	of	the	inflammatory	infiltrate	during	WNV	 encephalitis	 (Getts	 et	 al.	 2012).	 IL-1,	 CXCL2	 and	 TNF	 have	 been	 implicated	 in	 the	recruitment	 of	 neutrophils	 to	 the	CNS	 (McColl	 et	 al.	 2007)	 and	 the	 accumulation	of	 this	subset	has	been	associated	with	increased	levels	of	several	inflammatory	mediators	such	as	 IFN-γ,	 TNF,	 CCL2,	 CCL5,	 CXCL1,	 CXCL2	 and	 iNOS	 (Andrews	 et	 al.	 1999;	 Amaral	 et	 al.	
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2011).	 High	 neutrophil	 numbers	 and	 concomitant	 IL-8	 production	 have	 been	 linked	 to	severe	 forms	 of	 disease	 in	 JEV-infected	 patients	 (Singh	 et	 al.	 2000)	 and	 neutrophils	contribute	significantly	to	the	lethality	of	 lymphocytic	choriomeningitis	virus	infection	in	mice	 (Kim	et	al.	2009).	 Inhibition	of	neutrophil-derived	NO	 increased	 the	mean	survival	time	 (MST)	 of	mice	 during	 flavivirus	 infection.	 However,	 complete	 neutrophil	 depletion	was	more	effective,	suggesting	that	neutrophil-mediated	pathology	was	not	limited	to	NO,	but	due	to	the	combined	action	of	neutrophil-derived	inflammatory	products	(Andrews	et	al.	 1999;	Kreil	 and	Eibl	 1996;	Getts	 et	 al.	 2012).	 In	 contrast,	 neutrophils	have	 also	been	shown	to	have	a	protective	role	in	WNV,	highlighting	the	dual	role	these	innate	cells	may	play	in	flavivirus	infection	(Bai	et	al.	2010).	
Dendritic	cells	
Infiltrating	myeloid	cells	can	differentiate	either	 into	DC	or	macrophages	 in	the	 inflamed	CNS.	Their	 differentiation	 into	DC	occurs	 in	EAE,	 and	 exacerbates	 disease	by	 facilitating	the	ongoing	presentation	of	antigen	within	the	CNS.	However,	this	does	not	seem	to	occur	to	any	significant	degree	 in	WNV	and	 there	are	very	 few,	 if	 any,	DC	subsets	 in	 the	brain	parenchyma	 following	 i.n.	 lethal	 WNV	 infection.	 This	 is	 presumably	 due	 to	 an	inflammatory	milieu,	which	favours	the	differentiation	of	the	majority	of	infiltrating	Ly6Chi	monocytes	 into	 macrophages,	 in	 contrast	 to	 EAE.	 The	 requirement	 of	 DC	 in	 antigen	presentation	 in	 CNS	 infection	 must	 remain	 with	 the	 DLN	 of	 the	 inflammatory	 focus,	marking	out	 the	cervical	 lymph	nodes	 for	 likely	 involvement	 in	 the	 immune	response	 to	WNV	in	the	i.n.	model.		
1.2.2.2.2. Lymphoid	subsets	
CD8+	T	cells	
CD8+	cytotoxic	T	cells	are	the	primary	antiviral	effector	cell	of	the	adaptive	response	and	
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form	a	significant	part	of	the	inflammatory	infiltrate	during	viral	infection.	Indeed,	in	our	model	 of	 WNV	 encephalitis	 this	 subset	 contributes	 ~10-15%	 of	 the	 inflammatory	infiltrate.	 CD8+	T	 cells	 are	 activated	 by	 the	 recognition	 of	 cognate	 antigen	 presented	 by	MHC-I	 on	 virus-infected	 host	 CD8+	 DC,	 generally	 in	 the	 DLN.	 On	 recognition	 of	 infected	cells,	activated	CD8+	T	cells	release	perforin	and	granzymes,	which	induce	the	apoptosis	of	infected	cells.	However,	whilst	crucial	for	viral	clearance,	these	cells	may	contribute	to	the	damage	 of	 bystander	 cells	 (Liu	 et	 al.	 1989;	 Luna	 et	 al.	 2002;	 Shrestha	 et	 al.	 2006b).	Paradoxically,	 flavivirus	 infection	 induces	 MHC-I	 expression	 on	 infected	 cells,	 thereby	increasing	CD8+	T	cell	specific	recognition	and	cytolysis	(Liu	et	al.	1989;	King	and	Kesson	1988;	Douglas	et	al.	1994;	Kesson	et	al.	2002)		
	T	cells	expressing	chemokine	receptor	CXCR3	are	recruited	in	a	region-specific	manner	by	increased	 expression	 of	 the	 ligands	 CXCL10,	 CXCL11	 and	 CXCL9,	 secreted	 by	 activated	astrocytes	and	microglia	(Glass	et	al.	2005;	Muller	et	al.	2007;	Zhang	et	al.	2008).	TNF	has	also	 been	 implicated	 in	 the	 recruitment	 of	 anti-viral	 CD8+	 T	 cells	 during	WNV	 infection	(Shrestha	 et	 al.	 2008).	 WNV-infected	 mice	 deficient	 in	 CD8+	 T	 cells,	 and	 mice	 with	impaired	 CD8+	 T	 cell	 migration,	 due	 to	 loss	 of	 the	 CXCR3	 receptor,	 exhibit	 increased	mortality	rates,	confirming	the	protective	role	of	anti-viral	T	cells	during	viral	encephalitis	(Zhang	et	al.	2008;	Wang	et	al.	2003;	Wang	et	al.	2006;	Brien	et	al.	2008.)	In	contrast,	high-dose	 WNV	 infection	 of	 mice	 deficient	 in	 CD8+	 T	 cells	 resulted	 in	 improved	 survival	indicating	that	this	subset	may	contribute	to	pathology	at	a	certain	threshold	(Wang	et	al.	2003).	Evidently,	at	 lower	viral	doses,	CD8+	T	cells	are	able	 to	efficiently	clear	 the	virus,	whereas	 high-dose	 infection	 may	 recruit	 larger	 numbers	 of	 CD8+	 T	 cells	 and	 other	leukocytes,	resulting	in	immune-mediated	pathology.	This	was	also	evident	in	the	transfer	of	 virus-specific	 CD8+	T	 cells	 in	mice	 infected	with	 respiratory	 syncytial	 virus.	 Although	CD8+	T	cells	cleared	the	virus,	there	was	a	direct	correlation	between	the	number	of	T	cells	transferred	 and	 severity	 of	 respiratory	 distress	 (Cannon	 et	 al.	 1988).	 Granzyme	 B-
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producing	CD8+	T	 cells	were	 associated	with	 apoptosing	neurons	 in	TBEV	 infection	 and	CD8+	T	 cells	 have	been	 identified	 as	 key	players	 in	 the	pathology	of	TBEV	and	DENV	 in	clinical	and	experimental	conditions	(Kurane	et	al.	1991;	An	et	al.	2004;	Ruzek	et	al.	2011;	Gelpi	 et	 al.	 2006).	 Gene	 deletion	 of	 granzyme	 and	 FasL	 in	mice	 with	MVEV	 resulted	 in	higher	 survival	 rates,	 indicating	 that	 these	 factors	 contribute	 to	 CD8+	 T	 cell-mediated	immunopathology	(Luna	et	al.	2002).			The	 relationship	 between	protection	 and	pathology	 by	T	 cells	 is	 further	 complicated	 by	the	 involvement	 of	 other	 infiltrating	 subsets.	 In	 our	 i.n.	model	 of	WNV	 encephalitis,	 the	depletion	 of	 CD8+	 T	 cells	 did	 not	 increase	 survival,	 in	 contrast	 to	 an	 interventional	reduction	 in	monocyte	populations.	However,	 these	populations	evidently	modulate	one	another	as	a	significant	reduction,	but	by	no	means	ablation,	of	T	cell	numbers	occurred	alongside	the	decrease	in	monocyte	numbers,	caused	by	VLA-4	antibody	blockade	or	IMP	infusion	(Getts	et	al.	2012;	Getts	et	al.	2014;	Terry	2012).	Thus,	T	cells	may,	in	concert	with	the	 action	 of	 monocytes,	 contribute	 to	 the	 pathology	 seen	 in	 the	 WNV-infected	 CNS.	Nevertheless,	 irrespective	of	 the	extent	to	which	they	contribute	to	 immunopathology	 in	this	 model,	 T	 cells	 remain	 crucial	 for	 viral	 clearance	 and	 development	 of	 protective	immunity.		
CD4+	T	cells	
CD4+	T	cells,	or	helper	cells,	form	15-20%	of	the	inflammatory	infiltrate	in	the	i.n.	model	of	WNV	encephalitis.	Important	functions	of	this	subset	pertinent	to	the	antiviral	responses	include	 enhancing	 the	 activation	 of	 CD8+	 T	 cells	 and	 class	 switching	 of	 B	 cells,	 As	with	CD8+	 T	 cells,	 CXCR3	 plays	 a	major	 role	 in	 the	 recruitment	 of	 CD4+	T	 cells	 (Muller	 et	 al.	2007).	 CD4+	 T	 cells	 were	 found	 to	 play	 a	 protective	 role	 in	 TBEV	 infection,	 although	secretion	of	pro-inflammatory	cytokines	such	as	 IFN-γ	also	 influenced	 the	production	of	‘macrophage-like’	 cells,	 raising	 the	 possibility	 of	 an	 indirect	 contribution	 to	 the	
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immunopathogenic	response	(Ruzek	et	al.	2009).	 Indeed,	CD4+	T	cell	production	of	IFN-γ	was	found	to	be	crucial	for	Ly6C+	monocyte	function	and	activation	in	a	peripheral	model	of	 Toxoplasma	 gondii	 infection	 (Cohen	 et	 al.	 2013).	 CD4+	 T	 cells	 are	 also	 critical	 for	survival	 during	 WNV	 infection,	 as	 mice	 deficient	 in,	 or	 depleted	 of,	 CD4+	 T	 cells	 were	unable	to	clear	virus	efficiently	and	ultimately	succumbed	to	infection	(Sitati	and	Diamond	2006).	In	addition,	CD4+	T	cells	may	play	a	role	in	specific	lysis	of	infected	cells,	as	shown	with	 the	 transfer	of	CD4+	T	cells	 into	WNV-infected	RAG	KO	(deficient	 in	both	CD4+	and	CD8+	T	cells)	mice.	In	this	model	CD4+	T	cells	alone	sufficiently	cleared	virus	by	specifically	lysing	infected	cells	in	a	perforin	and	FasL-dependent	manner,	which	resulted	in	increased	survival	(Brien	et	al.	2008).	
NK	cells	
NK	 cells	 are	 present	 in	 significant	 numbers	 in	 the	 WNV-infected	 brain,	 constituting	approximately	10%	of	 the	 leukocyte	 infiltrate	 (Terry	2012).	 These	 cells	 are	 able	 to	 lyse	abnormal	 cells,	 e.g.	 virus-infected	 cells,	 independently	 of	 APC-mediated	 stimulation.	 NK	cells	 are	 capable	 of	 destroying	 WNV-infected	 cells	 when	 stimulated	 artificially	 in	 vitro	(Mullbacher	and	King	1989;	Zhang	et	al.	2010;	Hershkovitz	et	al.	2009)	and	the	production	of	 IFN-γ	 by	 NK	 cells	 has	 been	 implicated	 in	 the	 regulation	 of	 monocyte-to-DC	differentiation	in	peripheral	Toxoplasma	gondii	infection	(Goldszmid	et	al.	2012;	Cohen	et	al.	2013).	However,	the	depletion	of	NK	cells	during	WNV	and	DENV	infection	did	not	have	any	effect	on	 survival	or	viral	 load,	 indicating	 that	 this	 subset	 is	not	 crucial	 in	 resolving	these	 infections	 (Shrestha	 et	 al.	 2006a;	 Walsh	 et	 al.	 2008;	 Yoshida	 et	 al.	 2012).	 WNV	infection	of	non-human	primates,	too,	showed	a	marked	increase	in	the	CD56dimCD16bright	NK	 cell	 population	 in	 the	 bloodstream,	 compared	 to	 other	 lymphocyte	 populations	(Verstrepen	 et	 al.	 2014).	 Despite	 this	 information,	 an	 understanding	 of	 the	 role	 for	 NK	cells	 in	 the	 innate	 response	against	WNV	 infection	 remains	elusive,	 especially	 in	 light	of	the	 fact	 that	WNV	 infection	not	only	recruits	significant	numbers	of	NK	cells	 to	 the	CNS,	
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but	 also	 induces	 the	 upregulation	 of	 MHC-I	 on	 infected	 cells,	 which	 is	 associated	 with	reduced	NK	cell	recognition	of	infected	targets.		
B	cells		
Compared	 to	 other	 leukocyte	 subsets,	 B	 cells	 form	 only	 a	 small	 percentage	 of	 the	 total	leukocyte	 population	 in	 the	 CNS	 during	 i.n.	WNV	 infection.	 Nevertheless,	 there	 is	 some	evidence	of	B	cell	 infiltration	 into	 the	CNS	during	 flaviviral	 infection	(Brehin	et	al.	2008;	Maximova	et	al.	2009)	and	antibody	production	is	certainly	crucial	for	systemic	protection	against	WNV	 infection	 (Diamond	et	al.	2003).	They	will	be	 further	discussed	 in	 the	next	section	as	part	of	the	secondary	lymphoid	organ	response	to	viral	infection.	
1.3. Secondary	lymphoid	organs	
The	secondary	lymphoid	organs,	namely	the	lymph	nodes	and	spleen,	play	a	crucial	role	in	mounting	 an	 effective	 immune	 response	 against	 invading	 pathogens.	 These	 organs	 are	closely	associated	with	 the	 lymphatics	and	blood	stream	and	are	distributed	 throughout	the	body,	 allowing	continuous	 tissue	 fluid	equilibration,	 as	well	 as	 sampling	of	 antigens.	The	highly	organised	architecture	 is	a	defining	characteristic	of	 the	 secondary	 lymphoid	organs	 that	 facilitates	and	maximises	 the	 likelihood	of	 antigen	encounter	by	an	antigen-specific	lymphocyte.		
1.3.1. Lymph	nodes	
The	draining	lymph	nodes	or	DLN	are	the	first	lymph	nodes	to	encounter	antigen	drained	from	a	 local	area	of	 infection.	Anatomically,	 lymphatic	drainage	occurs	 to	specific	 lymph	nodes	located	closest	to	the	area	of	infection.	Antigen-presentation	will	result	in	activation	and	 proliferation	 of	 cells	 in	 these	 first-line	 draining	 nodes,	 whereas	 lymph	 nodes	distributed	further	away	or	not	in	direct	line	of	drainage	via	the	lymphatic	vessels	may	not	
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be	 exposed	 to	 antigen.	 Thus	 in	 these	 non-draining	 lymph	 nodes	 resident	 or	 immigrant	cells	are	unlikely	 to	undergo	clonal	expansion	 in	response	to	 infection.	The	 initial	 innate	immune	 response	 triggers	 one	of	 two	 reactions	 in	 the	DLN,	 i.e.	 the	 initiation	of	 an	 anti-microbial	 adaptive	 immune	 response	 during	 viral	 or	 bacterial	 infections	 or	 the	presentation	of	self-antigen	leading	to	either	the	continued	tolerance	or	the	activation	of	an	autoimmune	response.	In	addition	to	the	development	of	antigen-specific	cells	that	will	migrate	 to	 the	 inflammatory	 focus,	 the	 lymph	 node	 components	 have	 to	 minimise	 or	prevent	 local	 infection	 and	 subsequent	 trans-nodal	 spread	 of	 pathogen.	 Indeed,	 the	control	of	 lymph-borne	 infections	 is	 crucial,	 as	 the	 lymphatic	 system	has	open	access	 to	the	 vascular	 compartment	 and	 thus	 to	 nearly	 the	 whole	 body.	 Lymph,	 containing	cytokines,	 chemokines	 and	 antigen,	 free	 or	 loaded	 on	 APC,	 collected	 from	 the	 local	catchment	 area,	 enters	 the	 lymph	 node	 via	 the	 afferent	 lymphatic	 vessel,	 allowing	 the	lymphocytes	in	the	lymph	node	to	sample	concentrated	antigen.	Filtered	lymph	then	exits	via	the	efferent	lymphatic	vessel.	In	addition,	cells	like	fibroblastic	reticular	cells	(FRC)	are	able	to	transport	 lymph	fluid	components	with	a	molecular	weight	of	 less	than	70kDa	to	the	 high	 endothelial	 venule	 (HEV).	 Lymph	 flow	 throughout	 the	 lymph	 node	 occurs	 in	 a	directionally	 controlled	manner,	 as	 lymph	does	 not	 freely	 diffuse	 throughout	 the	 lymph	node	but	 travels	 from	afferent	 lymphatics	 to	 the	subcapsular	sinus.	 It	 then	traverses	 the	node	via	 the	 trabecular	 sinuses	ending	 in	 the	medullary	 sinuses,	which	 fuse	 to	 form	 the	efferent	lymphatics,	allowing	egress	of	lymph	from	the	lymph	node	hilum.	Ultimately,	if	no	antigen	recognition	occurs	by	naïve	cells,	 lymph	enriched	with	 lymphocytes	exits	via	the	efferent	lymphatic	vessel,	ultimately	returning	to	circulation	via	the	thoracic	duct	(Batista	and	 Harwood	 2009;	 von	 Andrian	 and	 Mempel	 2003;	 Willard-Mack	 2006).	 The	 blood	supplies	lymph	nodes	with	essential	nutrition	and	oxygen	required	for	the	maintenance	of	homeostatic	 as	well	 as	 inflammatory	 functions.	Moreover,	 the	opposing	directionality	of	blood	 and	 lymph	 flow	 orchestrates	 the	 increased	 probability	 of	 meeting	 of	 incoming	antigen	 and	 cognate	 immune	 cells.	 The	 continuous	 drainage	 of	 interstitial	 fluid	 via	 the	
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lymphatics	 is	 crucial	 for	 maintaining	 fluid	 equilibrium	 throughout	 the	 body,	 as	 the	occurrence	 of	 lymphedema	 after	 lymphadenectomy	 or	 the	 blockage	 of	 the	 lymphatics	attests.	
1.3.1.1. Architecture	
An	illustration	of	 the	general	 lymph	node	architecture	 is	shown	in	 figure	1.2.	The	 lymph	node	 comprises	 of	 various	 immune	 cells	 contained	 within	 a	 highly	 organised	 tissue	structure.	 Each	 node	 is	 composed	 of	 several	 functional	 units	 called	 lymphoid	 lobules,	encompassed	 by	 a	 collagenous	 capsule	 surrounding	 the	 lymph	 node.	 The	 capsule	 is	bordered	 by	 a	 space	 known	 as	 the	 subcapsular	 sinus	 (SCS),	 which	 contains	 the	 SCS	macrophages	 and	 allows	 the	 movement	 of	 lymph	 deeper	 into	 the	 node	 (Batista	 and	Harwood	2009).	These	sinuses	also	communicate	with	the	cortical	and	deeper	medullary	sinuses,	 thus	 facilitating	 the	efficient	movement	of	 fluid	and	 irrelevant	 cells	 towards	 the	next	lymph	node	in	the	chain.		The	whole	 node	 is	 filled	with	 FRC	 that	 form	 the	 reticular	meshwork	 in	 and	 around	 the	lobules.	 In	addition	to	supplying	structural	support,	 the	soluble	mediators	present	 in	the	FRC	facilitate	the	movement	of	lymphocytes	and	other	immune	cells	throughout	the	node	(Moe	1963;	Gretz	et	al.	1996;	Okada	et	al.	2002).	Histologically,	each	lobule	has	an	apical	cortex	and	a	medulla	at	the	hilum	of	the	node.	The	cortex	is	further	subcompartmentalised	into	 the	superficial	and	deep	cortex,	 the	 latter	of	which	 is	also	known	as	 the	paracortex,	each	with	very	specific	roles	and	cell	types.			The	 vascular	 supply	 of	 the	 lymph	 node,	 much	 like	 the	 anatomy	 of	 the	 lymph	 nodes	themselves,	is	variable.	There	is	abundant	interspecies	variation	in	the	entry-point	of	the	blood	 supply,	 with	 differences	 also	 occurring	 between	 nodes	 of	 the	 same	 animal.	Generally,	arteries	enter	through	the	hilum	but	may	have	other	points	of	entry,	such	as	the	
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capsule,	 as	not	 all	 nodes	have	 an	 identifiable	hilum.	 In	 addition,	 there	 is	 also	 significant	internodal	variability	in	the	number	of	arteries	entering	a	single	node.	Arteries	entering	at	the	 hilum,	 branch	 into	 the	 medulla	 within	 the	 medullary	 cords,	 forming	 arterioles	 and	capillaries	penetrating	deeper	into	the	node,	reaching	the	cortex	in	the	paracortical	cords,	as	well	as	the	capsule.	The	capillaries	form	a	network	throughout	the	node,	supplying	the	deep	 and	 superficial	 cortex.	 Some	 small	 cortical	 capillaries	 connect	with	 the	HEV	 in	 the	paracortex,	 which	 in	 turn	 fuse	 and	 become	 larger	 HEV	 as	 they	 exit	 the	 cortex	 via	 the	paracortical	 and	 medullary	 cords.	 At	 the	 cortico-medullary	 junction	 the	 HEV	 become	medullary	 veins,	 exiting	 the	 lymph	node	 as	 2-3	 hilar	 veins	 (Semeraro	 and	Davies	 1986;	Belz	and	Heath	1995;	Okada	et	al.	2002).		
Paracortex	
The	paracortex	or	deep	 cortex	 is	 also	known	as	 the	T	 cell	 area,	due	 the	abundance	of	T	cells	there	and	is	situated	between	the	medulla	and	superficial	cortex.	It	 is	arranged	into	paracortical	 cords,	 originating	 in	 the	 B	 cell	 follicles	 and	 ending	 as	 they	 merge	 into	 the	medullary	 cords	 in	 the	 medulla.	 The	 paracortical	 cords	 are	 bordered	 by	 lymph-filled	cortical	 sinuses	 that	 communicate	 with	 the	 medullary	 sinuses.	 The	 medullary	 and	paracortical	 cords	 are	 distinguishable	 from	 the	 sinuses	 by	 the	 dense	 cellularity	 and	presence	 of	 arterioles	 and	 venules,	 compared	 to	 the	 lymph	 filled	 sinuses.	 (Belisle	 and	Saintemarie	1981;	Okada	et	al.	2002).	 In	addition	 to	numerous	T	cells,	 the	paracortex	 is	also	home	to	large	numbers	of	APC.	This	is	where	DC	primarily	present	antigen	to	cognate	T	 cells	 in	 order	 to	 initiate	 the	 cell-mediated	 immune	 response.	 The	 paracortex	 is	 also	home	 to	 the	 HEV,	 generally	 situated	 at	 the	 centre	 of	 each	 paracortical	 cord	 and	surrounded	 by	 concentric	 layers	 of	 FRC.	 Named	 after	 its	 characteristically	 “high”	cuboidally-shaped	 endothelial	 cells,	 HEV	 are	 found	 in	 all	 secondary	 lymphoid	 organs,	except	the	spleen,	and	facilitate	the	recruitment	of	naïve	lymphocytes	from	the	blood	into	
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the	lymph	node	in	response	to	inflammation	(Batista	and	Harwood	2009;	von	Andrian	and	Mempel	2003;	Willard-Mack	2006).	
Superficial	cortex	
The	 superficial	 cortex	 is	 known	 as	 the	 B	 cell	 area	 and	 consists	 of	 primary	 follicles,	containing	 mostly	 B	 cells,	 with	 some	 DC	 (follicular	 DC)	 and	 follicular	 T	 helper	 cells.		Follicular	DC,	expressing	high	levels	of	ICAM	and	VCAM	are	distinct	from	classical	DC	and	are	 thought	 to	 have	 a	 mesenchymal	 rather	 than	 hematopoietic	 origin.	 The	 superficial	cortex	is	situated	in	the	outermost	part	of	the	lymph	node	and	is	crucial	for	the	initiation	of	 humoral	 immunity	 to	 T	 cell-dependent	 antigens	 and	 the	 development	 of	 long-term	plasma	 cells	 (Batista	 and	 Harwood	 2009).	 Historically,	 B	 cells	 activated	 by	 T	 cell-dependent	 antigen	 challenge,	were	 thought	 to	have	one	of	 two	 fates.	 They	would	 either	migrate	 to	 extrafollicular	 areas,	 becoming	 antibody-producing	 plasma	 cells,	 or	 develop	into	 the	 germinal	 centres;	 composed	 of	 highly	 proliferating	 B	 cells	 (Allen	 et	 al.	 2007).	Functionally	 divided	 into	 a	 light	 and	 dark	 zone,	 the	 structure	 of	 the	 germinal	 centre	optimises	 the	 likelihood	 of	 rare	 B	 cells	 interacting	with	 their	 cognate	 antigen.	 The	 light	zone	is	situated	proximal	to	the	lymph	node	capsule,	in	close	association	with	follicular	DC	and	 the	 adjacent	 dark	 zone	 is	 located	 deeper	 in	 the	 lymph	 node.	 B	 cells	move	 between	these	 zones	 when	 they	 undergo	 affinity	 maturation	 in	 the	 germinal	 centre,	 a	 complex	process	 involving	 the	 somatic	mutation	 and	 selection	of	B	 cells	with	 the	highest	 affinity	(Schwickert	 et	 al.	 2007).	 Typically,	 antigen-specific	 B	 cells	 form	 the	 dark	 zone	 of	 the	germinal	centre,	as	they	become	rapidly	proliferating	centroblasts.	Centroblasts	give	rise	to	centrocytes	that	migrate	to	the	 light	zone	and	subsequently	undergo	selection	as	they	are	exposed	to	 follicular	DC	and	T	 follicular	helper	cells	 (Allen	et	al.	2007;	Willard-Mack	2006).	However,	new	research	applying	real	time	imaging	shows	that	the	process	is	much	more	 dynamic	 and	 complicated	 than	 previously	 described.	 Indeed,	 the	 germinal	 centre	
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was	 found	 to	 be	 an	 open	 structure	 with	 bi-directional	 migration	 between	 the	 zones	occurring	freely	(Schwickert	et	al.	2007).		Naïve	B	cells	in	the	light	zone	acquire	antigen	from	follicular	DC,	subsequently	processing	and	presenting	it	to	the	T	follicular	helper	cells.	If	B	cells	successfully	present	antigen	they	return	 to	 the	 dark	 zone,	 proliferating	 and	 differentiating	 into	 plasma	 cells	 capable	 of	secreting	 specific	 antibodies	 against	 invading	 pathogen	 (Meyer-Hermann	 et	 al.	 2012).	Another	 distinction	 from	 the	 classic	 scenario	 is	 that	 the	 so-called	 centroblasts	 and	centrocytes	are	a	much	more	homogenous	population	of	cells	than	previously	thought.	In	fact,	 the	 B	 cell	 populations	 of	 the	 two	 zones	 in	 humans	 and	mice	 are	 likely	 to	 have	 the	same	 subset	 up-	 or	 downregulating	 specific	 markers	 such	 as	 CD83	 or	 CXCR4	 as	 they	mature	or	become	activated.	Dark	 zone	 cells	 express	CD83loCXCR4hi,	whereas	 light	 zone	cells	 are	 CD83hiCXCR4lo.	Analysis	 has	 also	 revealed	 that	 the	 genes	 of	 these	 subsets	 are	highly	conserved	between	mice	and	humans	(Victora	et	al.	2012).		
Medulla	
The	medulla,	situated	near	the	lymph	node	hilum,	forms	the	innermost	part	of	the	lymph	node	and	is	organised	into	medullary	cords,	containing	vasculature,	and	sinuses	lined	with	endothelial	cells.	It	is	home	to	B	and	T	cells	with	some	macrophages	and	DC,	however	its	function	is	still	poorly	understood	(von	Andrian	and	Mempel	2003;	Batista	and	Harwood	2009).	 Lymph	 flow	 enters	 via	 the	 afferent	 lymphatic	 vessel	 into	 the	 SCS,	 subsequently	spreading	through	the	trabecular	sinuses	to	the	medullary	sinuses	where	it	finally	exits	via	the	 efferent	 lymphatic	 vessel.	 Throughout	 this	 process,	 DC	 and	 macrophages	 sample	lymph	and	remove	debris	whilst	processing	antigenic	material	for	presentation	to	B	and	T	cells	 (von	Andrian	and	Mempel	2003).	The	medullary	 sinuses	possess	mainly	medullary	sinus	 macrophages	 with	 a	 few	 other	 leukocytes	 dispersed	 throughout,	 whereas	 the	medullary	cords	consists	of	predominantly	plasma	cells	and	macrophages	(Steer	and	Foot	1987).	 The	 sinus-lining	 macrophages	 separate	 the	 medullary	 sinuses	 from	 the	 cords,	
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which	 are	 continuous	 with	 the	 cortex.	 Macrophages	 in	 the	 medullary	 cords	 are	 an	important	 source	 of	 IL-6	 and	 APRIL,	 a	 proliferation	 inducing	 ligand,	 promoting	 the	differentiation	and	maturation	of	antibody-secreting	plasma	cells	(Mohr	et	al.	2009).	Cells	emigrating	from	the	lymph	node	are	hypothesised	to	exit	mainly	via	the	medullary	sinus,	which	can	occur	directly	from	the	SCS,	but	also	from	the	paracortex	via	the	trabecular	and	paracortical	sinuses	(Soderstrom	and	Stenstrom	1969;	Grigorova	et	al.	2009;	Nossal	et	al.	1968).		
1.3.1.2. Leukocyte	subsets	of	the	lymph	node	
B	lymphocytes	
B	 cells	 classically	 form	 part	 of	 the	 adaptive	 immune	 response	 as	 drivers	 of	 humoral	immunity	 and,	 in	 the	 lymph	node,	 are	mainly	 concentrated	 in	 the	 follicles.	Naïve	B	 cells	express	IgD	and	IgM.	Once	activated	with	a	cognate	antigen,	the	IgD	is	downregulated	and	proliferation	 is	 stimulated	 (activated/transitional	 B	 cells).	 The	 primary	 extrafollicular	response	 is	 the	secretion	of	mainly	 low-affinity	 IgM.	Proliferating	B	cells	give	rise	 to	 the	germinal	 centres	 in	 the	 follicles	with	 subsequent	 class-switching	 of	 B	 cells	 occurring	 in	conjunction	 with	 the	 downregulation	 of	 IgM	 and	 induction	 of	 high	 affinity	 IgG	 and	 IgA	expression	and	secretion.	Immature	B	cells	are	also	identified	by	their	expression	of	CD38	and,	ultimately,	B	cells	can	differentiate	into	antibody–secreting	plasma	cells,	identified	as	CD19+/-CD138+,	 with	 terminally	 differentiated	 plasma	 cells	 identified	 by	 their	 positive	expression	of	CD93	(Metcalf	and	Griffin	2011;	Banchereau	et	al.	1994).	Certain	 viruses	 are	 capable	 of	 inducing	 the	 early	 activation	 of	 B	 cells,	 prior	 to	 the	generation	 of	 specific	 IgG.	 This	 function	 may	 aid	 in	 the	 induction	 of	 memory	 B	 cell	populations	 and	 also	 in	 the	 subsequent	 retention	 of	 cells	 in	 the	 lymph	 node.	 This	 early	activation	is	dependent	on	IFN-α/β	but	is	T	cell-independent	(Purtha	et	al.	2008).	Indeed,	during	infection,	B	cells	can	play	a	significant	role	in	viral	clearance,	as	T	cell-independent	
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B	 cell	 activation	occurs	 in	 the	mesenteric	 lymph	node	 (MLN)	during	 rotavirus	 infection,	consequently	facilitating	the	removal	of	virus	(Blutt	et	al.	2002).		In	 addition	 to	 the	 role	 in	 humoral	 responses,	 B	 cells	 also	 contribute	 to	 the	 adaptive	response	as	potent	APC.	Immune	complexes	displayed	by	SCS	macrophages	are	captured	by	their	cognate	B	cells,	which	in	turn	present	these	to	T	cells.	B	cells	can	also	bind	antigen	through	 complement	 receptors	 and	 transport	 antigen	 to	 the	 follicular	 DC	 (Phan	 et	 al.	2007;	Gonzalez	et	al.	2010).		
T	lymphocytes	
T	 cells	 in	 the	 paracortex	 become	 activated	 through	 the	 interaction	 with	 their	 cognate	antigen,	presented	by	either	B	cells	or	DC.	Naïve	T	cells,	arriving	from	the	bloodstream	and	exposed	 to	 cognate	 antigen	 can	have	one	of	 two	 fates.	 Firstly,	 they	 can	become	 tolerant	and	live	or	they	are	deleted	in	order	to	avoid	the	development	of	autoimmunity.	Secondly,	they	 can	 mount	 an	 effector	 response	 in	 the	 form	 of	 a	 cytotoxic	 T	 cell	 and	 T	 helper	response.	 Effector	 T	 cells	 thus	 generated	 will	 home	 to	 peripheral	 tissues	 and	 the	inflammatory	focus,	after	which	they	may	become	memory	T	cells,	whereas	central	T	cells	will	 recirculate	 in	 the	 lymph	 node	 (von	 Andrian	 and	 Mempel	 2003).	 Multi-photon	microscopy	 shows	T	 lymphocytes	moving	 through	 the	 lymph	node	 in	a	 random	manner	picking	 up	 antigen.	 Once	 a	 CD4+	 T	 cell	 encounters	 antigen,	 it	 upregulates	 CXCR5	expression	 and	 downregulates	 expression	 of	 CCR7.	 CXCL13	 then	 attracts	 these	 CXCR5+	cells,	causing	the	CD4+	T	cell	to	disengage	from	the	T	cell	area	and	migrate	towards	the	B	cell	follicles	(von	Andrian	and	Mempel	2003).			During	viral	 infection	 the	DLN	play	an	essential	 role	 in	mounting	a	CD8+	cytotoxic	T	cell	response.	 The	 CD8+	 T	 cell	 numbers	 in	 the	 draining	 mediastinal	 lymph	 node	 increased	during	 i.p.	 LCMV	 infection	 whilst	 the	 non-draining	 lymph	 nodes	 decreased	 in	 T	 cell	numbers	(Olson	et	al.	2012).		The	involvement	of	the	non-draining	or	distal	lymph	nodes	
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during	inflammation	is	also	evident	by	the	presence	of	proliferative	CD8+	and	CD4+	T	cells	in	 the	 non-draining	 lymph	 node	 of	 mice	 immunised	 i.n.	 with	 Streptococcus	 gordonii	(Ciabattini	 et	 al.	 2010).	 In	 addition,	 antigen-primed	 T	 cells	 were	 present	 in	 the	 distal	lymph	 node	 of	mice	 immunised	with	OVA.	 The	 authors	 hypothesised	 that	 the	 source	 of	proliferative	 T	 cells	 in	 the	 non-draining	 nodes	 was	 due	 to	 the	 dissemination	 of	 T	 cells	primed	at	the	site	of	immunisation	i.e.	the	nose.	Antibody-blocking	experiments	indicated	that	this	process	was	highly	dependent	on	CD62L	and	α4β7	integrin	expression	(Ciabattini	et	al.	2011).	Regulatory	T	cells	(Tregs)	also	increase	significantly	in	the	DLN	during	WNV	infection	and	play	an	important	role	in	the	generation	of	the	memory	T	cells,	which	are	in	the	first	line	of	response	to	reinfection	(Graham	et	al.	2014).	Furthermore,	asymptomatic	individuals	 with	 WNV	 has	 lower	 Treg	 frequencies	 in	 their	 peripheral	 blood	 than	 their	symptomatic	 counterparts,	 speculated	 to	 be	 due	 to	 the	 ability	 of	 Tregs	 to	downregulate	the	 pathogenic	 immune	 response	 and	 therefore	 the	 bystander	 damage	 (Lanteri	 et	 al.	2009).	
Macrophages	
The	macrophages	of	the	lymph	node	are	defined	according	to	their	location;	the	main	two	subsets	are	the	medullary	and	the	SCS	macrophages,	both	of	which	capture	lymph-borne	antigens.	SCS	macrophages	are	identified	by	CD169	expression	and,	as	the	name	suggests,	can	be	found	in	the	subcapsular	sinus	of	the	lymph	node.	These	macrophages	are	situated	in	 close	association	with	 the	 cortical	 and	medullary	 sinuses,	 allowing	direct	 sampling	of	antigen	draining	 from	 the	 tissue	 and	present	 in	 the	 lymph	 fluid.	Although	 this	 subset	 is	less	 phagocytic	 than	 their	 medullary	 counterparts,	 they	 still	 perform	 a	 crucial	 APC	function,	 and	 during	 viral	 infection,	 play	 a	 role	 in	 preventing	 viral	 dissemination	 and	systemic	 spread	 (Junt	 et	 al.	 2007;	 Kastenmuller	 et	 al.	 2012).	 Additionally,	 SCS	macrophages	 are	 critical	 for	 the	 survival	 of	mice	 during	 neurotropic	 viral	 infection	 like	vesicular	stomatitis	virus,	a	member	of	rabies	family,	which	is	fatal	in	the	absence	of	SCS	
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macrophages.	 In	 this	 model,	 the	 SCS	 macrophages	 function	 by	 capturing	 virions,	protecting	peripheral	nerves	from	neuroinvasion	by	producing	IFN-I,	as	well	as	recruiting	IFN-I-producing	 plasmacytoid	 DC	 (pDC)	 (Iannacone	 et	 al.	 2010).	 Moreover,	 SCS	macrophages	 can	 capture	 antigen	 on	 their	 surface,	 subsequently	 presenting	 antigen	 to	naïve	migratory	follicular	B	cells	and	inducing	humoral	immunity	(Junt	et	al.	2007;	Phan	et	al.	2007).			Although	 both	 SCS	 and	 medullary	 macrophages	 can	 present	 antigen	 to	 B	 cells	 in	 the	follicles,	they	are	not	necessarily	required	to	activate	the	humoral	response	in	all	types	of	viral	 infection.	 Depletion,	 using	 clodronate-encapsulated	 liposomes	 to	 eliminate	 these	resident	phagocytic	cells	subsets,	did	not	affect	humoral	immunity	against	influenza	virus	(Gonzalez	et	al.	2010).	SCS	macrophages	are	also	capable	of	cross-presentation	of	antigen	to	 CD8+	 T	 cells	 and	 subsequent	 induction	 of	 specific	 cytotoxic	 T	 lymphocyte	 (CTL)	responses	to	dying	tumour	cells	(Asano	et	al.	2011).	Despite	this,	they	were	not	required	for	the	activation	of	specific	CD8+	T	cell	responses	to	peripheral	WNV	infection	but	their	role	as	gatekeeper	in	preventing	systemic	spread	of	WNV	was	of	importance	(Winkelmann	et	 al.	 2014).	 Interestingly,	 viral	 and	 bacterial	 infection	 leads	 to	 the	 disruption	 of	 the	anatomical	 disposition	 of	 SCS	 macrophages	 due	 to	 the	 migration	 of	 mature	 DC	 and	neutrophils	 to	 SCS.	 This	 leads	 to	 cell	 loss	 and	 redistribution	 of	 SCS	macrophages	 to	 the	inner	 follicular	 area	 where	 antigen	 presentation	 occurs.	 Although	 this	 likely	maximises	lymph	 node	 immune	 responses	 to	 primary	 infection	 by	 enhancing	 entry	 of	 afferent	immune	cells,	relay	of	antigen	to	follicular	DC	and	maximisation	of	antigen	presentation	to	B	cells,	it	also	renders	the	lymph	node	temporarily	unable	to	respond	effectively	infection	by	another	organism	(Chtanova	et	al.	2008;	Braun	et	al.	2011;	Gaya	et	al.	2015).	
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Dendritic	cells	
DC	 occur	 at	 extremely	 low	 frequencies	 compared	 to	 other	mononuclear	 cells	 and	 are	 a	highly	 complex	 group	 of	 leukocytes	 with	 extremely	 variable	 cell	 surface	 protein	expression	 and	 multifarious	 functions,	 making	 them	 difficult	 to	 characterise	comprehensively.	The	primary	basic	characterisation	of	DC	in	the	spleen	and	lymph	node	is	based	on	CD11c	and	MHC-II	expression,	with	the	spleen	generally	possessing	lower	DC	heterogeneity	 than	 the	 lymph	node.	 In	 the	 lymph	node,	DC	populations	are	divided	 into	“lymphoid	tissue	resident	DC”,	expressing	CD11chiMHCIIint	and	“peripheral	 tissue-derived	migratory	 DC”,	 which	 are	 CD11cintMHCIIhi.	 The	 CD11chiMHCIIint	 resident	 population	 is	further	 subdivided	 into	 a	 CD8+	subset,	mainly	 situated	 in	 the	 T	 cell	 zone,	 and	 a	 CD11b+	population.	 Migratory/CD11cintMHCIIhi	 DC	 can	 also	 be	 subdivided	 into	 distinct	populations.	 These	 include	 the	 CD11b+	 migratory	 dermal	 DC,	 largely	 inhabiting	 the	interfollicular	 and	 outer	 paracortical	 regions	 once	 they	 enter	 the	 lymph	 node,	 and	 the	CD207+CD103-	 LC	 and	 CD207+CD103+	 dermal	 DC,	 localised	 in	 the	 deeper	 T	 cell	 zone	(Gerner	et	al.	2012;	Elpek	et	al.	2011).	The	main	function	of	migratory	DC	is	to	transport	antigen	from	the	site	of	infection	to	the	DLN,	where	antigen	presentation	to	T	and	B	cells	occur,	whereas	resident	DC	sample	antigen	within	the	lymph	(Kaplan	2010).	Free	antigen	can	be	 recognised	 in	 the	 lymph	node	by	 immature	DC,	which	 then	mature	 in	 the	 lymph	node	in	order	to	present	antigen	to	T	cells	(von	Andrian	and	Mempel	2003).	DC	subtypes	in	 the	 subcutaneous	 and	 mesenteric	 lymph	 nodes	 include	 two	 additional	 populations	based	 on	 CD8	 and	 DEC205	 expression	 and	 are	 characterised	 as	 CD4+8-DEC205-,	 CD4-8+DEC205+	 and	 CD4-8+DEC205+(Henri	 et	 al.	 2001).	 Other	 markers	 used	 to	 classify	 DC	include	CD4,	CD8α,	CD11b,	CD11c,	CD205,	B220,	MHC	II	and	GR1,	with	plasmacytoid	DC	expressing	B220	and	lymphoid	DC	expressing	CD8	(von	Andrian	and	Mempel	2003).		
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While	DC	 in	 the	 lymph	node	are	crucial	 for	 the	activation	of	 specific	T	cell	 responses	by	presenting	antigen	to	cognate	T	cells,	they	can	also	be	involved	in	the	humoral	response.	Medullary	DC	used	SIGN-R1	to	capture	lymph-borne	antigen,	such	as	influenza	virus,	and	subsequently	 migrated	 from	 the	 medulla	 to	 the	 B	 cell	 follicle,	 promoting	 the	 humoral	response	 (Gonzalez	 et	 al.	 2010).	 Indeed,	 Influenza	 A	 is	 similar	 to	 WNV,	 insofar	 as	pathology	 being	mainly	 immune-driven	 but,	 unlike	 the	 CNS	where	 these	 issues	 are	 just	beginning	to	be	elucidated,	the	lung	has	a	well-described	lymphatic	system,	and	DC	from	the	 lung	 clearly	migrate	 to	 the	mediastinal	 lymph	 node	 during	 infection.	 In	 this	model,	CD103+CD11b+	 DC	 populations	 increased	 in	 the	 lymph	 node	 by	 20%	within	 24h.	 These	migrating	 DC	 served	 both	 an	 antigen-distributing	 and	 T	 cell	 activation	 role,	 as	 antigen	transfer	 can	 occur	 between	 migrating	 and	 resident	 DC	 prior	 to	 T	 cell	 priming.	 Once	activated	by	DC,	T	cell	populations	expanded	from	d3	p.i.	and	mature	effector	T	cells	were	present	 in	 lung	6-8	days	p.i.,	 correlating	with	decreased	 lymph	node	T	cell	numbers	and	viral	clearance.	In	this	model,	antigen	delivery	by	DC	was	crucial	for	T	cell	activation	and	proliferation,	 as	 administration	 of	 sphingosine-1	 phosphate	 (S1P)	 agonist,	 which	interferes	with	 DC	 antigen	 delivery	 to	 the	 node,	 significantly	 impacted	 T	 cell	 responses	(Matheu	et	al.	2013).	Since	 the	 brain	 may	 not	 possess	 a	 comprehensive	 parenchymal	 lymphatic	 drainage	system,	 the	 process	 of	 local	 antigen	 presentation	 in	 a	 secondary	 lymphoid	 organ	 is	currently	largely	undefined.		However,	DC	in	the	CSF	have	been	shown	to	exhibit	targeted	migration	to	CLN	during	EAE,	a	process	that	will	be	discussed	in	section	1.3.2	(Hatterer	et	al.	 2008)	 Furthermore,	 as	 the	 primary	 source	 of	 antibody-secreting	 cells	 for	 the	 CNS	during	 viral	 infection,	 the	 cervical	 lymph	 node	 (CLN)	 is	 crucial	 for	 the	 development	 of	humoral	response	to	CNS	infection	(Metcalf	and	Griffin	2011).	
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NK,	NKT	cells	and	neutrophils	
Although	these	cells	are	classically	present	in	low	numbers,	their	anatomical	location	and	distribution	in	the	lymph	node	indicates	the	potential	of	these	subsets	to	play	specialised	roles	 during	 inflammation.	 Indeed,	 the	 obvious	 recruitment	 of	 these	 populations	 during	bacterial,	parasitic	and	viral	infections	to	the	DLN	indicates	a	likely	role	in	facilitating	host	defence.	In	naïve	mice,	innate	effector	NK	cells	are	located	in	the	medulla	and	paracortex	in	 close	 association	with	 DC.	 Parasitic	 infection	 recruits	 NK	 cells	 from	 the	 blood	 to	 the	lymph	 nodes,	 especially	 the	 paracortex,	 where	 they	 colocalise	 with	 DC	 and	 CD4+T	 cells	(Bajenoff	et	al.	2006).	The	recruitment	of	NK	cells	to	the	lymph	node	is	mediated	by	CXCR1	and	 the	 subsequent	 production	 of	 IFN-γ	 by	NK	 cells	 plays	 a	 crucial	 role	 in	 the	 adaptive	immune	response	by	 inducing	Th1	cell	 responses	(Martin-Fontecha	et	al.	2004).	The	NK	cells	present	in	human	lymph	nodes	are	mainly	CD56bright	and	reside	in	the	paracortex.	NK	cells	can	be	induced	to	secrete	IFN-γ	and	proliferate	through	the	action	of	DC-derived	IL-12	 and	 IL-15,	 respectively.	 T	 cell-derived	 IL-2	 also	 stimulates	 IFN-γ	 production	 by	 NK	cells,	 indicating	 interplay	 between	 adaptive	 and	 innate	 systems	 (Fehniger	 et	 al.	 2003;	Ferlazzo	et	al.	2004).	 IFN-γ-producing	NK	and	NKT	cells	were	 found	 in	close	association	with	SCS	macrophages,	resulting	in	the	activation	of	these	cells	with	IL-18	during	bacterial	and	parasitic	infections.	Furthermore,	depletion	of	NK	cells	resulted	in	increased	parasitic	burden	in	the	mesenteric	lymph	node	during	Toxoplasma	gondii	infection	(Coombes	et	al.	2012).	Indeed,	the	absence	of	NK	cells	in	the	lymph	node	may	be	detrimental	during	HIV	infection.	NK	cell	 recruitment	 in	HIV+	individuals	was	 impaired	due	 to	a	reduction	 in	 the	expression	of	the	NK	homing	receptor.	This	inhibited	innate	response	was	hypothesised	to	reduce	targeting	by	cytolytic	cells,	thus	allowing	virus	replication	(Luteijn	et	al.	2011).		Although	 naïve	 lymph	 nodes	 possess	 almost	 no	 neutrophils,	 bacterial	 infection	 induced	the	recruitment	of	neutrophils	 to	 the	 lymph	node	 in	 low	numbers,	 through	the	action	of	
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SCS	 macrophages,	 indicating	 that	 an	 innate	 response	 can	 be	 induced	 in	 rare	 innate	lymphoid	populations	by	the	scavenging	macrophages	of	the	lymph	node	(Kastenmuller	et	al.	2012).	 Indeed,	oral	 and	earflap	bacterial	 infection	with	Toxoplasma	gondii	resulted	 in	significant	recruitment	of	neutrophils	to	the	DLN.	Time-lapse	imaging	showed	neutrophils	forming	distinct	clusters	 in	 the	SCS	of	 the	DLN,	whilst	disrupting	 the	organisation	of	 the	SCS	 macrophage	 layer	 (Chtanova	 et	 al.	 2008).	 In	 addition,	 bacterial	 infection	 recruits	neutrophils	 that	 originate	 in	 the	 bone	marrow	 to	 the	DLN	 from	 the	 blood,	 entering	 the	lymph	node	through	the	HEV,	whereafter	they	migrate	deeper	to	the	medulla	and	between	the	 follicles.	Here,	 neutrophils	 form	 interactions	with	T	helper	 and	B	 cells	 at	 the	 follicle	border	and	act	by	supressing	 the	early	humoral	response	 through	the	release	of	TGF-β1	and	disruption	of	SCS	macrophages	(Kamenyeva	et	al.	2015).		
1.3.1.3. Leukocyte	homing	and	trafficking	to	the	lymph	node		
During	 homeostatic	 conditions,	 naïve	 lymphocytes	 are	 continuously	 circulating	 through	the	bloodstream	with	~5%	of	these	entering	the	secondary	lymphoid	organs	via	the	HEV	where	 they	 sample	 antigen	 and	 respond,	 or	 in	 the	 absence	 of	 cognate	 antigen,	 re-enter	circulation	(Ganusov	and	Auerbach	2014).	 In	addition,	memory	T	cells	generated	during	infection	 recirculate	 and	monitor	 peripheral	 tissues	 (Mackay	 et	 al.	 1990).	 Inflammatory	stimuli	 induce	the	recruitment	of	myeloid	and	 lymphoid	cells	 from	blood	and	peripheral	tissues	 to	 the	DLN,	 in	addition	 to	 the	proliferation	of	 resident	 lymph	node	 lymphocytes.	Much	debate	exists	as	 to	whether	 the	dramatic	 increase	 in	size	of	an	antigen-stimulated	lymph	node	is	due	to	the	significant	influx	of	lymphocytes	entering	the	lymph	node	or	due	to	 a	 decreased	 exit	 rate.	 In	 either	 case,	 the	 likelihood	 of	 specific	 T	 cells	 encountering	cognate	 antigen	 is	 improved	 (Ganusov	 and	 Auerbach	 2014;	 von	 Andrian	 and	 Mempel	2003).	Three	molecularly	distinct	steps	regulate	the	attachment	and	entry	of	lymphocytes	to	the	lymph	node.	Firstly,	leukocytes	bind	loosely	to	the	luminal	HEV	surface	as	they	are	
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pushed	 forward	by	 the	 bloodstream	 in	 a	 process	 known	as	 “tethering	 and	 rolling”.	 This	step	 is	mediated	by	L-selectin/CD62L,	 expressed	by	both	myeloid	 and	 lymphoid	 lineage	cells,	attaching	to	endothelial	ligands	or	peripheral	lymph	node	adressins	on	HEV	and	this	contact	is	likely	facilitated	by	the	turbulence	of	blood	caused	by	the	raised	physical	profile	of	the	HEV	themselves.		Next,	cellular	engagement	on	endothelium	occurs,	mediated	by	chemotactic	stimuli.	Arrest	of	T	cells	is	achieved	by	attachment	of	integrin	LFA-1	on	naïve	T	cells	and	ICAM-1	on	HEV.	Indeed,	 loss	of	LFA-1	 leads	 to	significantly	 reduced	homing	of	T	cells	 to	 the	 lymph	node	due	to	the	disruption	of	firm	arrest,	intravascular	crawling	and	transendothelial	migration	(Park	 et	 al.	 2010).	 In	 a	 skin	 transplantation	 model,	 LFA-1	 blockade	 resulted	 in	 the	selective	retention	of	effector	T	cells	in	the	lymph	node,	but	not	naïve	cells.	This	led	to	an	increase	 in	 antigen-specific	 T	 cells	 (CD62Llo)	 and	 regulatory	T	 cells	 (Treg)	 in	 the	 lymph	node	and	an	increase	in	naïve	T	cells	in	the	bloodstream.	Importantly,	LFA-1	blocking	did	not	 only	 affect	 T	 cell	 populations	 in	 the	 graft-draining	 lymph	 node,	 but	 also	 the	 non-draining	peripheral	nodes	(Reisman	et	al.	2011).	Integrin	activation	is	mediated	by	CCL21,	expressed	 on	 HEV,	 which	 binds	 to	 CCR7	 on	 T	 cells.	 In	 addition,	 CCL19	 and	mCLCA	 are	known	 to	 activate	 these	 integrins.	 However,	 evidence	 also	 exists	 for	 a	 chemokine-independent	 pathway	 of	 LFA-1	 activation,	 involving	 Ly6C,	 which	 in	 addition	 to	 being	 a	marker	of	inflammatory	monocytes	in	the	blood	(Geissmann	et	al.	2003),	is	also	found	on	activated	T	cells	(Peters	et	al.	2014).	Indeed,	Ly6C-crosslinking	was	shown	to	induce	LFA-1	clustering	on	CD8+	T	cells	and	increased	endothelial	adhesion	(Jaakkola	et	al.	2003).				B	and	memory	T	cell	attachment	is	governed	by	different	signals	from	naïve	T	cells,	with	B	cell	attachment	regulated	by	CXCL12-CXCR4	and	CCL21-CCR7	interaction,	although	this	is	strain-dependent.	Lastly,	activation-dependent	adhesion	and	emigration	of	leukocytes	into	the	HEV	is	governed	by	different	chemoattractants.	Once	leukocyte	attachment	and	rolling	occurs,	 cells	 need	 to	 arrest	 to	 emigrate	 from	 the	 intraluminal	 side	 of	 the	 HEV.	
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Granulocytes	 express	 L-selectin	 and	 LFA-1,	 allowing	 them	 to	 roll	 on	 the	 endothelial	surface	 but	 the	 absence	 of	 a	 CCR7/CXCR4	 interaction	 prevents	 subsequent	 arrest	 and	emigration	 of	 this	 subset.	 Currently,	 entry	 of	 B	 and	 T	 lymphocyte	 subsets	 into	 the	abluminal	 side	 of	 the	HEV	 is	 hypothesised	 to	 occur	 through	 transendothelial	 diapedesis	(von	Andrian	and	Mempel	2003;	Irjala	et	al.	2001).	The	interaction	of	mCLCA	with	Mac-1	on	granulocytes,	NK	cells	and	macrophages	may	facilitate	the	adhesion	of	these	subsets	to	lymphatic	 endothelium	 (Furuya	 et	 al.	 2010).	 Ultimately,	 entry	 into	 lymph	 nodes	 via	 the	HEV	 is	 limited	 to	naïve	B	and	T	cells	and	central	memory	T	cells,	with	other	 circulatory	subsets	entering	at	different	sites	and	by	different	means.		Thus,	 even	 if	 cells	 end	 up	 interacting	 with	 each	 other,	 they	 may	 get	 there	 by	 different	routes.	For	example,	 lymph-derived	T	 cell	 entry	occurs	mainly	via	 the	medulla,	whereas	DC	 enter	 through	 the	 SCS	 floor.	 Once	 in	 the	 parenchyma,	 the	 migration	 of	 both	 these	subsets	 into	 the	 deeper	 T	 cell	 zone	 was	 shown	 to	 be	 highly	 dependent	 on	 CCR7.	Interestingly,	DC	were	retained	in	the	first	lymph	node	encountered	whilst	some	naïve	T	cells	were	found	in	downstream	lymph	nodes,	indicating	a	constant	redistribution	of	naive	lymphocytes	throughout	the	lymphatic	system	in	the	quest	for	cognate	antigen	(Braun	et	al.	2011).			FRC,	 located	 in	 the	T	cell	 zone,	are	also	 involved	 in	homing	and	entry	of	 certain	subsets	into	 the	 lymph	node.	During	homeostatic	 conditions,	 these	 stromal	 cells	 produce	CCL21	and	 CCL19,	 which	 interact	 with	 CCR7	 on	 lymphocytes.	 Depletion	 of	 FRC	 reduced	 DC,	CD11b+,	 B,	 T	 and	NK	 cell	 numbers	 in	 the	 lymph	node.	Adoptive	 transfer	 of	 CD8+	T	 cells	showed	that	the	reduction	in	cell	numbers	was	due	to	decreased	homing	of	T	cells	to	the	lymph	node	as	a	direct	result	of	CCL21	loss.	Thus,	during	homeostatic	conditions,	homing	and	retention	of	T	cells	relied	on	CCL21	expression	by	FRC,	however,	during	inflammatory	conditions	 the	 loss	 of	 FRC	 did	 not	 affect	 egress	 of	 activated	 T	 cells	 from	 lymph	 node,	
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presumably	 due	 to	 the	 reacquisition	 of	 sphingosine-1	 phosphate	 receptor-1	 (S1P1),	 a	crucial	signal	for	T	cell	exit	(Denton	et	al.	2014).		After	 encountering	 an	 inflammatory	 stimulus,	DC	mature	 and	 express	CCR7,	 CXCR4	and	CCR4,	which	 facilitates	 the	access	of	DC	 into	 the	T	cell	area	of	 the	DLN.	 In	addition,	pDC	express	L-selectin	and	may	utilise	 this	 to	migrate	 into	 the	 lymph	node	via	 the	HEV	(von	Andrian	 and	Mempel	 2003).	 IRF4-dependent	 CCR7	 expression	 is	 a	major	 driver	 for	 DC	migration	and	positioning	in	the	lymph	node	(Randolph	et	al.	2005;	Bajana	et	al.	2012).	In	response	 to	 viral	 infection,	 pDC	 in	 the	 spleen	 and	 lymph	 nodes	 can	 produce	immunoregulatory	 cytokines	 IFN-α	 and	 IL-12,	 which	 may	 modulate	 T	 cell	 responses	(Asselin-Paturel	et	al.	2001).	
1.3.1.4. Leukocyte	exit	from	the	lymph	node	
Cellular	 turnover	 of	 a	 lymph	 node	 in	 steady	 state	 occurs	 rapidly,	 as	 recirculation	 of	lymphocytes	 is	 essential	 for	 immune	 surveillance.	 Indeed	within	 24h,	 70%	 of	 cells	 in	 a	lymph	 node	 will	 have	 been	 replaced.	 CD4+	 T	 cells	 exhibit	 the	 highest	 rate	 of	 turnover,	followed	by	CD8+	T	cells,	which	remain	 in	 the	 lymph	node	 for	up	to	~12h.	B	cells	spend	roughly	24h	in	the	lymph	node,	while	DC	show	the	lowest	rate	of	exit	(Tomura	et	al.	2008).	In	order	to	increase	the	likelihood	of	cells	meeting	their	cognate	antigen	during	infection,	the	 lymph	 node	 undergoes	 an	 acute	 inflammation-driven	 short-term	 “lymph	 node	shutdown”	 mediated	 in	 part	 by	 TNF	 and	 IL-6	 (Wee	 et	 al.	 2011).	 This	 phenomenon	 is	overcome	by	the	successful	exit	of	activated	cognate	lymphocytes	from	the	medulla	of	the	lymph	node	via	the	efferent	lymphatic	vessels,	and	their	subsequent	migration	to	effector	sites.	 In	 humans,	 the	mannose	 receptor	 on	 efferent	 lymphatics	 interacts	with	 CD62L	on	lymphocytes	to	facilitate	their	egress	(Irjala	et	al.	2001;	von	Andrian	and	Mempel	2003).	S1P1,	a	G-protein-coupled	receptor,	 is	key	 for	 the	efficient	attachment	and	exit	of	T	cells	and	to	some	extent	B	cells,	from	the	lymph	node.	In	the	absence	of	S1P1,	T	and	B	cells	fail	
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to	exit	the	secondary	lymphoid	organs.	Indeed,	during	inflammatory	conditions,	activated	T	cells	downregulate	S1P1,	 facilitating	T	cell	retention	and	antigen	 interaction	within	the	lymph	node	(Matloubian	et	al.	2004).	Furthermore,	inflammatory	mediators	such	as	IFN-α	and	-β	act	as	potent	 inducers	of	cell	surface	activation	markers	 like	CD69	on	 leukocytes.	CD69	negatively	regulates	the	S1P1	interaction	and	inhibits	lymphocyte	exit	by	forming	a	complex	with	the	S1P1.	This	complex	mimics	the	ligand	for	S1P1,	namely	S1P,	and	results	in	 the	 downregulation,	 internalisation	 and	 subsequent	 degradation	 of	 the	 receptor,	thereby	 promoting	 lymphocyte	 retention	 during	 the	 initial	 stages	 of	 inflammation	 i.e.,	lymph	node	shutdown	(Shiow	et	al.	2006;	Bankovich	et	al.	2010).			Lymphocytes	 from	 the	 lymph	 node	 exit	 back	 into	 the	 lymphatic	 circulation	 whereas	lymphocytes	from	the	spleen	exit	into	the	blood.	The	production	of	S1P	by	red	blood	cells	in	 the	 circulation	 indicates	 that	 the	 source	 of	 S1P	 likely	 varies	 between	 blood	 and	lymphatics	(Pappu	et	al.	2007).	The	intra-nodal	site	of	S1P1	receptor-ligand	interaction	is	the	 border	 between	 the	 lymph	node	parenchyma	 and	 the	 cortical	 or	medullary	 sinuses,	whereafter	directional	 lymph	flow	distributes	 lymphocytes	 to	 the	medullary	sinuses	and	SCS,	 where	 cells	 eventually	 exit	 the	 efferent	 lymphatics	 (Grigorova	 et	 al.	 2009).	 In	addition,	lymphocytes	can	rapidly	exit	the	node	after	entry	via	the	cortical	sinuses,	which	are	situated	close	to	the	HEV.	However,	during	inflammation	the	cortical	sinuses	collapse,	further	facilitating	lymphocyte	retention	during	inflammation,	resulting	in	the	node	vastly	increasing	in	size	(Grigorova	et	al.	2010).	
1.3.2. Antigen	presentation	in	the	CNS	
The	 structure	 of	 the	 CNS	 lymphatic	 system	 has	 historically	 been	 largely	 unknown.	Therefore,	the	process	of	antigen	presentation	and	subsequent	activation	of	the	adaptive	immune	system	in	this	organ	is	still	very	much	under	investigation.	Classically,	antigen	has	
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been	 thought	 to	 reach	 peripheral	 lymph	 nodes	 either	 via	 1)	 draining	 through	 nasal	lymphatics	 to	 CLN,	 2)	 transport	 through	 arachnoid	 villi,	 or	 3)	 draining	 through	 the	ventricular	 system	 via	 the	 choroid	 plexus.	 However,	 to	 induce	 an	 optimal	 immune	response,	 local	 draining	APC	 are	 still	 needed.	 Recent	 findings	 identified	 the	 presence	 of	functional	 lymphatic	 vessels	 in	 the	 meninges	 of	 mice	 draining	 directly	 into	 the	 CLN,	implying	 that	 the	 CNS	 might	 possess	 its	 own	 immune	 surveillance,	 in	 lieu	 of	 only	externally	derived	cells	(Louveau	et	al.	2015).		Even	 though	 the	 CNS	 is	 considered	 immune-privileged,	 certain	 CNS	 sites,	 such	 as	 the	circumventricular	organs	and	olfactory	nerve	projections	are	obvious	points	of	entry	 for	pathogens.	Additionally,	the	ability	of	resident	cells,	such	as	microglia,	to	function	as	DC	is	under	 investigation.	 Although	 microglia	 have	 poor	 antigen-presenting	 capacity	 the	 fact	that	 they	 are	 a	 heterogeneous	 population	 raises	 the	 possibility	 that	 a	 subpopulation	 of	these	cells	may	be	DC	precursors.	Studies	with	GFP	have	shown	CD11c+	cells	in	the	brain	co-expressing	 markers	 commonly	 found	 on	 microglia	 and	 macrophages.	 These	 DC-like	cells	were	 associated	with	 specific	 CNS	 structures	 and	 increased	 in	 response	 to	 trauma.	Studies	have	also	shown	the	presence	of	choroid	plexus	DC,	similar	to	classical	DC	in	the	spleen,	developing	 from	pre-DC	 in	 the	choroid	plexus,	 situated	along	sites	of	activated	T	cell	entry	(D'Agostino	et	al.	2012).		The	 use	 of	 EYFP-CD11c	 mice	 showed	 a	 CD11c+	 population	 in	 the	 naïve	 mouse,	 co-expressing	 CD45int/hi,	 potentially	 microglia.	 Indeed,	 microglia	 have	 been	 shown	 to	upregulate	 CD11c	 during	 inflammation.	 Upon	 stimulation	 with	 Flt3L,	 a	 potent	hematopoietin,	 this	 population	 expands,	 increasing	 their	 MHCII	 and	 CD11c	 expression.	This	DC-like	population	was	 located	 in	 the	 choroid	plexus	and	meninges	of	 animals	 and	exhibited	shared	gene	expression	profiles	with	splenic	CD8+	DC.	Adoptive	transfer	showed	that	 these	 DC	 likely	 arise	 from	 pre-DC	 in	 the	 bone	marrow	 rather	 than	monocytes	 and	relied	on	LFA-1	expression	to	migrate	into	the	CNS.		In	addition,	this	subset	was	able	to	act	
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as	 potent	 APC,	 inducing	 T	 cell	 activation	 and	 proliferation	 in	 vitro	 (John	 et	 al.	 2011;	Anandasabapathy	et	al.	2011).	 In	support	of	 this,	 i.c.	 injection	with	OVA	protein	 induced	the	 expansion	 of	 a	 CD11c+CD205+	 population	 at	 the	 site	 of	 injection.	 The	 subsequent	downregulation	 of	 MHC-II	 and	 increased	 expression	 of	 CCR7,	 a	 major	 driver	 of	 DC	migration	and	positioning	in	the	lymph	node,	suggests	that	this	population	was	maturing	and	potentially	preparing	to	migrate	to	a	DLN.	The	ability	of	these	cells	to	migrate	to	the	CLN	was	determined	by	injection	of	GFP-expressing	antigen-loaded	DC	into	the	CNS.	Apart	from	successful	migration	to	the	CLN,	these	DC	successfully	stimulated	an	antigen-specific	T	cell	response	and	subsequent	homing	of	antigen-specific	T	cells	to	the	CNS	(Karman	et	al.	2004).	
1.3.3. The	Spleen	
The	 spleen	 is	 the	 largest	 secondary	 lymphoid	 organ	 and	 is	 specialised	 for	 mounting	immune	 responses	 to	 blood-borne	 pathogens.	 It	 is	 divided	 into	 3	 functional	 and	anatomical	compartments,	namely	the	red	pulp,	white	pulp	and	marginal	zone.	Due	to	its	relationship	to	the	blood	stream,	vascularity	and	abundance	of	phagocytic	cells,	the	spleen	acts	as	an	ideal	filter	for	any	foreign	material	present	in	circulation.	The	first	compartment	to	 encounter	 the	 blood	 and	 its	 contents	 is	 the	 red	 pulp,	 which	 is	 highly	 adapted	 as	 a	phagocytic	 filter	with	a	multitude	of	macrophages,	 identified	by	the	expression	of	F4/80	and	CD11b.	Bordering	the	red	pulp	and	surrounding	the	white	pulp,	is	the	marginal	zone	(Sasou	et	al.	1982;	Batista	and	Harwood	2009).	Historically,	 the	marginal	zone	has	been	described	 as	 part	 of	 the	 white	 pulp,	 however,	 in	 reality	 it	 is	 functionally	 and	morphologically	distinct.	This	compartment	consists	of	 sinus-lining	reticular	cells	with	a	high	 concentration	 of	 non-circulating	 phagocytic	 leukocyte	 populations,	 including	marginal	zone	macrophages	(MZM),	marginal	metallophillic	macrophages,	marginal	zone	B	cells	and	DC.	The	MZM,	 located	on	 the	outer	rim	near	 the	red	pulp,	express	MARCO,	a	
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scavenger	receptor,	and	SIGN-R1,	a	C-type	 lectin,	and	are	hypothesised	 to	be	 the	splenic	counterpart	of	the	SCS	macrophages	(Hughes	et	al.	1995;	Kraal	and	Mebius	2006;	Kang	et	al.	 2003;	 Phan	 et	 al.	 2007).	 The	macrophages	 of	 the	marginal	 zone	 are	 also	 crucial	 for	trapping	 particulate	 antigen	 in	 the	 bloodstream	 and	 limiting	 the	 haematogenous	dissemination	of	pathogens.	They	are	able	to	phagocytose	apoptotic	material,	bacteria	and	nanoparticles	 (Demoy	 et	 al.	 1999).	 Although	 the	 depletion	 of	 these	 subsets	 significantly	affected	 the	 control	 of	 infection,	 they	 were	 not	 required	 for	 antigen	 presentation	 and	specific	T	cell	 immunity	against	Listeria	monocytogenes	 (Aichele	et	al.	2003).	 In	addition,	macrophages	of	the	splenic	marginal	zone	are	important	for	immune	regulatory	responses	to	endogenous	apoptotic	material.	Thus,	the	specific	depletion	of	MZM	severely	altered	the	maintenance	of	tolerance	in	CNS	and	systemic	autoimmune	diseases.	The	absence	of	MZM	resulted	 in	 increased	 uptake	 of	 apoptotic	 material	 by	 the	 red	 pulp	 macrophages	 and	presentation	to	the	T	cell	populations	of	the	white	pulp,	this	alteration	in	localisation	and	method	 of	 antigen	 presentation	 of	 apoptotic	material	 resulted	 in	 enhanced	 lymphocyte	responsiveness	 to	 self-antigen	 (Miyake	 et	 al.	 2007;	 McGaha	 et	 al.	 2011).	 The	 CCL22	production	 and	 subsequent	 recruitment	 of	 regulatory	 T	 cells	 by	 the	 CD169-expressing	marginal	metallophillic	macrophages,	situated	on	the	inner	rim	of	the	marginal	zone,	was	also	a	key	regulator	in	the	maintenance	of	tolerance	to	apoptotic	material	(Ravishankar	et	al.	2014).	 In	contrast	 to	what	occurs	 in	 the	 lymph	node,	neutrophils	 in	 the	spleen	act	as	marginal	 zone	 B	 cell	 helpers	 by	 promoting	 immunoglobulin	 production	 and	 class	switching	of	B	cells	(Puga	et	al.	2012).		The	 white	 pulp,	 surrounded	 by	 the	 marginal	 zone,	 contains	 the	 follicles	 and	 the	periarteriolar	 lymphoid	 sheath	 (PALS),	 which	 can	 be	 likened	 to	 the	 lymph	 node	 B	 cell	follicles	 and	paracortex	 respectively	 (Cesta	 2006).	 Although	 the	white	 pulp	 is	 similar	 in	structure	 to	 a	 lymph	 node	 (Nolte	 et	 al.	 2000),	 there	 are	 major	 differences	 in	 the	mechanism	 of	 antigen	 transport.	 The	 afferent	 lymphatics	 are	 the	 main	 entry	 point	 of	
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antigen	in	the	lymph	nodes,	whereas	the	spleen	receives	antigen	directly	from	blood,	as	it	possesses	 only	 efferent	 lymphatics.	 Indeed,	 antigen	 picked	 up	 from	 blood	 can	 be	presented	 to	white	pulp	B	and	T	 cells	by	 the	 cells	of	 the	marginal	 zone.	 In	 addition,	 the	white	pulp	has	its	own	conduit	system,	consisting	of	reticular	fibroblasts	and	is	connected	to	 the	marginal	 zone,	 allowing	 particles	 of	 low	molecular	weight	 to	 reach	 it	 directly.	 In	contrast	to	the	lymph	node,	the	white	pulp	conduit	system	has	no	direct	connection	to	the	lymphatic	system	and	is	only	supplied	by	the	blood	(Nolte	et	al.	2003).	During	homeostatic	conditions	 the	B	 and	T	 cell	 distribution	 in	 the	white	pulp	 is	 similar,	whilst	 the	 red	pulp	contains	more	B	cells.	 In	addition,	~1%	of	the	splenic	 leukocytes	consists	of	neutrophils,	mostly	situated	in	the	red	pulp	with	NK	cells,	which	are	also	present	in	very	low	numbers	(2-3%	 of	 splenic	 leukocytes)	 in	 both	 the	 white	 and	 red	 pulp	 (Nolte	 et	 al.	 2000).	 The	location	 of	 B	 cells	 in	 the	 spleen	 relates	 directly	 to	 their	 function,	 as	 follicular	 B	 cells	(CD21hiCD23hi)	 produce	 antibody	 in	 response	 to	 T	 cell-mediated	 stimulation,	 whereas	marginal	zone	B	cells	(CD21hiCD23lo)	can	promptly	respond	to	pathogens	independently	of	T	cell	stimulation	(Purtha	et	al.	2008).	
1.4. Immunomodulatory	treatment	of	flavivirus	infection	
1.4.1. Background	and	past	treatment	
There	are	currently	no	effective	vaccines	for	humans	against	WNV	and	treatment	remains	symptomatic.	Although	only	a	small	percentage	of	individuals	infected	with	WNV	develop	severe	 disease,	 the	 consequences	 can	 be	 life	 threatening	 and/or	 debilitating	 for	 the	remainder	 of	 life.	 As	 vectors	 for	 flaviviruses	 become	 more	 widespread	 the	 need	 for	 a	vaccine	or	successful	 treatment	becomes	critical.	Considering	 the	mounting	evidence	 for	WNV	being	an	 immunopathological	disease,	rather	than	one	caused	directly	by	the	virus	itself,	the	focus	needs	to	shift	towards	research	supporting	immune-modulating	therapies.	
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Importantly,	treatment	directed	at	reducing	the	overactive	immune	response	will	not	only	be	applicable	to	WNV	but	a	myriad	of	flaviviruses	and	potentially	other	viral	or	non-viral	immune-mediated	diseases.	
1.4.1.1. Vaccines	
Historically,	 the	 primary	 defence	 against	 mosquito-borne	 disease	 has	 been	 focused	 on	preventative	 measures,	 including	 vaccine	 development.	 However,	 few	 vaccines	 for	humans	 exist	 against	 flaviviral	 infections	 and	 commercially	 approved	 vaccines	 against	WNV	are	limited	to	the	treatment	of	horses.	Effective	live	flavivirus	vaccines	exist	for	both	JEV	and	yellow	fever	(Monath	2010;	Liu	et	al.	2011)	and	formalin-inactivated	whole	virus	vaccines	are	available	against	TBEV	(Barrett	et	al.	2003;	Heinz	et	al.	2007).	Unfortunately,	despite	 these	exhibiting	relatively	good	safety	records,	numerous	cases	of	 infection	with	these	 viruses	 still	 occur	 each	 year.	 Trials	 with	 formalin-inactivated	 WNV	 vaccines	 in	murine	 and	 non-human	 primate	 models	 showed	 some	 protective	 effect,	 with	 the	development	 of	 neutralising	 antibody	 after	 immunisation	 (Muraki	 et	 al.	 2015).	 Vaccines	synthesised	 to	mimic	virus,	but	 lacking	 the	 infectious	nucleus,	 called	virus-like	particles,	have	also	been	used	with	varying	success	in	animal	models	but	pose	the	risk	of	initiating	a	non-specific	immune	reaction	(Pijlman	2015).	Another	possibility	is	targeting	mosquitoes	and	ticks	directly	(vector	management)	with	anti-vector	vaccines	(Kortekaas	et	al.	2010).	A	 successful	 example	 being	 the	 stable	 infection	 of	 mosquitoes	 with	 the	 Wolbachia	bacterium,	which	limits	the	spread	of	dengue	by	shortening	the	mosquito	lifespan,	without	preventing	breeding	(McMeniman	et	al.	2009;	Bian	et	al.	2010).		A	different	approach	involves	the	activation	of	antigen-specific	CD8+	CTL	capable	of	lysing	WNV-infected	cells	 (Purtha	et	al.	2007).	Administration	of	a	chimeric	vaccine	containing	WNV-envelope	 antigen,	 produced	 antigen-specific	 CD8+	CTL	 persisting	 for	 up	 to	 a	 year	(Smith	 et	 al.	 2010).	Unfortunately,	 the	 short	 lifespan	of	 the	 vaccine	 and	 activation	of	 an	
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already	overactive	immune	response	makes	this	approach	a	less	desirable	option.	
	
1.4.1.2. Antiviral	therapies	
Initial	 in	 vitro	 studies	 into	 antiviral	 therapies	 appeared	 promising,	 with	 antiviral	treatment	 like	 ribavirin	effectively	 inhibiting	WNV	 infection	of	Vero	monkey	kidney	and	neural	cell	lines	(Jordan	et	al.	2000;	Anderson	and	Rahal	2002).	However,	clinical	studies	with	 ribavirin	 resulted	 in	 no	 improvement	 of	 WNV-infected	 patients	 (Chowers	 et	 al.	2001).	Minocycline	also	showed	promising	antiviral	effects	against	JEV	and	WNV	in	vitro,	as	 this	 tetracycline	 significantly	 reduced	 microglial	 and	 macrophage	 production	 of	inflammatory	cytokines,	chemokines	and	ROS	in	JEV	infection	(Dutta	et	al.	2010;	Das	et	al.	2011).	 Additional	 in	vitro	 studies	 show	minocycline	 effectively	 promoting	 neurogenesis	and	 inhibiting	apoptosis	of	 JEV-	 and	WNV-infected	neuronal	 cells	 (Michaelis	 et	 al.	 2007;	Mishra	and	Basu	2008;	Das	et	al.	2011).	Furthermore,	minocycline	has	successfully	been	used	 in	 the	 treatment	 of	 JEV-infected	 mice,	 reducing	 viral	 titre	 and	 promoting	neurogenesis.	 Besides	 the	 obvious	 antiviral	 effect	 of	 minocycline,	 the	 inhibition	 of	microgliosis	 and	 subsequent	 pro-inflammatory	 mediator	 release	 is	 likely	 the	 main	contributor	 of	 this	 therapeutic	 benefit	 (Mishra	 and	 Basu	 2008;	 Das	 et	 al.	 2011).	 Non-human	primate	studies	treating	SIV	infection	with	minocycline	also	resulted	in	improved	symptoms,	 which	 authors	 attributed	 to	 the	 reduction	 of	 the	 chemoattractant	 CCL2	 and	consequent	 decrease	 of	 inflammatory	 monocyte	 recruitment	 (Zink	 et	 al.	 2005).	 Direct	targeting	of	viral	 components,	 such	as	 the	viral	helicase,	with	 inhibitors	has	successfully	stunted	 viral	 replication	 of	 DENV	 and	 WNV	 in	 vitro	 (Sweeney	 et	 al.	 2015).	 Patients	suffering	 from	 TBEV	 showed	 improved	 recovery	 and	 reduced	 symptoms	 when	 treated	with	tetracycline	hydrochloride.	This	occurred	with	concurrent	serum	cytokine	reduction	(IL-6,	TNF,	IL-1β)	in	patients,	 indicating	that	the	clinical	effect	of	this	antibiotic	may	also	
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be	as	a	result	of	immune-modulation	(Atrasheuskaya	et	al.	2003).	The	 antiviral	 properties	 of	 interferons	 have	 identified	 these	 proteins	 as	 potential	candidates	for	immune-modulating	therapies.	IFN-α2b	was	established	as	being	protective	against	WNV	infection	in	vitro	(Anderson	and	Rahal	2002)	and	type-I	IFN	(α/β)	inhibited	viral	 spread	and	replication	 in	 the	periphery	and	CNS	of	WNV-infected	mice,	whilst	also	inhibiting	WNV-induced	neuronal	death	(Samuel	and	Diamond	2005).	ISG	expression	and	subsequent	protein	production	increased	during	viral	 infection	(Wacher	et	al.	2007)	and	inhibited	viral	replication	by	disrupting	multiple	steps	in	the	life	cycle	of	WNV	and	dengue	viruses.	 For	 example,	 IFN-induced	 transmembrane	 proteins-2	 and	 -3	 can	 inhibit	 viral	entry	of	host	cells	(Jiang	et	al.	2010).		However,	 as	 an	 overreactive	 immune	 response	 is	 characterised	 by	 the	 presence	 of	abundant	 cytotoxic	 immune	 components	 and	 minimal	 regulatory	 mechanisms,	 the	induction	 of	 inflammatory	mediators	with	 ISG-based	 treatments	 in	 infected	 individuals,	should	 be	 managed	 in	 a	 tailored	 and	 efficient	 manner	 in	 order	 to	 minimise	 cytotoxic	components	without	inhibiting	viral	clearance	and	resolution	of	disease.		
1.4.1.3. Neutralising	Antibody	treatment	
The	 components	 of	 the	 humoral	 immune	 response	 have	 also	 been	 highlighted	 as	candidates	for	treating	WNV	infection.	Although	the	production	of	numerous	antibodies	is	induced	 by	WNV	 infection,	 only	 a	 small	 proportion	 of	 these	 effectively	 neutralise	WNV,	limiting	their	therapeutic	application.	Protection	of	mice	against	lethal	WNV	infection	can	be	achieved	with	 the	use	of	humanised	antibodies	 targeting	 the	post-attachment	 step	of	the	 virus.	 Monoclonal	 antibody	 (mAb)	 against	 the	 envelope	 protein	 of	 the	 virus	 has	conferred	some	protection	in	murine	studies	by	preventing	the	conformational	change	of	the	 virus,	 critical	 for	 fusion	 with	 cellular	 membranes,	 thereby	 inhibiting	 entry	 into	 the	cells	 (Oliphant	 et	 al.	 2005;	 Throsby	 et	 al.	 2006;	Morrey	 et	 al.	 2007;	 Zhang	 et	 al.	 2009).	
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Further	examples	include	the	use	of	polyclonal	antibodies	to	promote	survival	in	B	and	T	cell-deficient	mice	and	 the	blocking	of	axonal	 spread	of	virus	with	neutralising	antibody	(Engle	and	Diamond	2003;	Samuel	et	al.	2007).	Additional	 limitations	 for	 the	 use	 of	 neutralising	 antibody	 therapies	 in	 the	 treatment	 of	WNV	infection	include	the	restricted	capacity	of	antibody	to	cross	the	intact	BBB	(Cheeran	et	al.	2005;	Morrey	et	al.	2007)	and	the	potential	development	of	antibody	escape-mutant	strains,	especially	considering	flaviviruses	in	general	form	quasispecies.	Although	strains	resistant	to	specific	mAb	are	currently	rare	it	needs	to	be	closely	monitored	as	mutations	on	viral	epitopes	can	abrogate	the	neutralising	effect	and	therefore	the	therapeutic	activity	of	 mAb	 against	 virus	 (Li	 et	 al.	 2005;	 Sanchez	 et	 al.	 2005;	 Zhang	 et	 al.	 2009).	 Antibody	treatment	of	flavivirus	infection	requires	epitope	binding	that	is	both	highly	specific	and	of	a	high	affinity	 (Sanchez	et	 al.	 2005).	 If	 these	 requirements	are	not	met,	 treatment	 could	result	 in	 exacerbation	 of	 the	 disease	 through	 antibody-dependent	 enhancement	 of	infection.	 This	 classically	 occurs	with	 recurrent	 infection	 of	 DENV	 in	 individuals	with	 a	different	 strain	 of	 DENV	 from	 the	 primary	 infection.	 Virus-specific	 antibody	 produced	against	 the	 initial	 DENV	 strain	 has	 a	 lower	 affinity	 for	 other	 serotypes	 and,	 upon	secondary	infection,	forms	a	complex	with	the	virus	instead	of	neutralising	it.	This	leads	to	increased	viral	entry	via	Fc	receptors	on	myeloid	lineage	cells,	such	as	macrophages,	and	consequently	higher	numbers	of	productively	infected	cells	(Halstead	and	O'Rourke	1977;	Boonnak	et	al.	2011).		Administration	 of	 intravenous	 immunoglobulin	 (pooled	 human	 IgG)	 has	 been	 used	 in	several	 clinical	 studies	 in	 the	 treatment	 of	 immunosupressed	 patients	 with	 severe	neuroinvasive	disease.	This	treatment	has	had	varied	success,	with	some	patients	making	complete	 recovery	 from	 severe	 neuroinvasive	 disease.	 However,	 whether	 improvement	was	 due	 to	 intravenous	 immunoglobulin	 treatment	was	 difficult	 to	 confirm	 and	 further	studies	are	needed	(Haley	et	al.	2003;	Shimoni	et	al.	2001;	Rhee	et	al.	2011).	Interestingly,	
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the	 therapeutic	 effect	 of	 intravenous	 immunoglobulin	 treatment	 is	 not	 due	 to	 the	neutralising	 activity	 of	 antibody,	 but	 a	 direct	 consequence	 of	 immune	modulation.	Mice	given	i.p.	 intravenous	immunoglobulin	treatment	survived	infection	with	a	 lethal	dose	of	WNV	 and	 neurotropic	 herpes	 simplex	 virus.	 This	 was	 directly	 attributed	 to	 the	 anti-inflammatory	 effect	 of	 intravenous	 immunoglobulin	 treatment,	 as	 there	were	 significant	reductions	 in	 pathogenic	 Ly6Chi	 macrophages	 and	 TipDC	 populations	 in	 the	 CNS	(Ramakrishna	et	 al.	 2011;	 Srivastava	et	 al.	 2015).	How	 the	 intravenous	 immunoglobulin	treatment	modulates	these	subsets	is	still	under	investigation.			The	 primary	 obstacle	 in	 the	 treatment	 of	WNV	 infection	 is	 the	 onset	 of	 immune-driven	clinical	symptoms	that	occur	once	there	is	an	established	neuronal	infection.	With	this	in	mind,	 a	 therapeutic	 approach	 combining	 the	 strategies	 discussed	 above,	 with	 targeted	treatment	of	the	pathogenic	immune	components	may	be	most	effective.	
1.4.2. Current	 effective	 treatments	 and	 Immune-modifying	
microparticles		
Considering	the	immune-driven	nature	of	WNV	encephalitis,	a	shift	in	focus	from	antiviral	to	 immunomodulatory	 therapies	 is	 more	 likely	 to	 be	 successful	 in	 unvaccinated	individuals.	Anti-inflammatory	compounds	could	have	significant	neuroprotective	effects	in	 a	 disease	 in	 which	 pathology	 is	 mediated	 by	 inflammation	 and	 apart	 from	 targeting	autoimmune	diseases,	 it	 is	clear	that	an	anti-inflammatory	treatment-based	design	could	be	beneficial	for	a	multitude	of	diseases,	 including	flaviviral	encephalitis.	Therapy	can	be	designed	 to	 target	 several	 aspects	 of	 the	 disease	 progression,	 starting	 with	 the	 initial	signals	 recruiting	 harmful	 cells.	 Intervention	 staged	 at	 this	 point,	 however,	 needs	 to	 be	highly	 controlled,	 as	 certain	 infiltrating	 subsets	 remain	 crucial	 for	 inhibiting	 viral	dissemination.	 Targeting	 and	 diverting	 pathogenic	 subsets	 from	 the	 CNS	 during	 later	stages	of	disease	may	enable	effective	viral	eradication	and	minimise	damage.	Lastly,	the	
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inflammatory	mediators	produced	by	infiltrating	as	well	as	resident	cells	can	be	reduced	or	 blocked	 by	 neutralising	 soluble	 mediators,	 such	 as	 NO,	 preventing	 direct	 oxidative	stress	 on	 the	 CNS.	 Ultimately,	 the	most	 likely	 scenario	 is	 the	 implementation	 of	 one	 or	more	 of	 these	 strategies	 tailored	 on	 a	 patient-by-patient	 basis,	with	 close	monitoring	 of	reaction	to	treatment.			Inhibition	 of	 ROS,	 Cox-2	 and	 iNOS	 has	 been	 effective	 in	 reducing	 neuronal	 apoptosis	during	JEV	infection	(Nazmi	et	al.	2011)	and	neutralising	antibody	against	TNF	and	IL-1β	during	 WNV	 infection	 has	 a	 protective	 effect	 on	 neuroblastoma	 cells,	 reducing	 the	apoptosis	 of	 infected	 cells	 (Kumar	 et	 al.	 2010).	 Inhibition	 of	 NO	 production	 with	aminoguanidine,	 was	 marginally	 protective	 in	 several	 models	 of	 flavivirus	 infection,	 as	mice	exhibited	longer	MST	but	not	increased	survival	rates	(Andrews	et	al.	1999;	Getts	et	al.	 2012).	 This	 indicates	 that	 it	 is	 likely	 the	 prolonged	 action	 of	 a	 combination	 of	inflammatory	 mediators	 produced	 by	 activated	 leukocytes	 that	 ultimately	 skew	 the	balance	 from	 a	 protective	 antiviral	 immune	 response	 to	 a	 pathogenic	 one.	 Ideally,	treatment	should	be	administered	before	this	balance	is	tipped	in	favour	of	a	pathogenic	response.	In	our	model	of	WNV	infection,	Ly6Chi	inflammatory	MDM	infiltration	in	the	CNS	correlated	 with	 weight	 loss	 and	 increased	 severity	 of	 clinical	 symptoms.	 Importantly,	preventing	Ly6Chi	inflammatory	MDM	from	migrating	to	the	infected	CNS	by	blocking	VLA-4	 does	 not	 improve	 survival	 when	 administered	 early	 in	 infection,	 prior	 to	 the	development	 of	 any	 clinical	 symptoms.	 However,	 administration	 of	 blocking	 treatment	when	 significant	 weight	 loss	 occurs	 (>5%)	 increases	 survival	 of	 mice	 that	 would	otherwise	succumb	to	disease	by	up	to	60%	(Getts	et	al.	2012).			A	recent	breakthrough	study	from	our	laboratory	targets	Ly6Chi	inflammatory	monocytes	in	 circulation,	 prior	 to	 entering	 their	 target	 organ,	 where	 they	 would	 otherwise	differentiate	 into	 either	 inflammatory	macrophages	or	DC	and	exert	 a	pathogenic	 effect.	
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Negatively	 charged,	 immune-modifying	 microparticles	 (IMP)	 are	 phagocytosed	 via	MARCO	expressed	at	high	 levels	on	Ly6Chi	monocytes	 in	 the	circulation	of	WNV-infected	animals	(figure	1.3).	As	a	result,	these	cells	are	mainly	diverted	to	the	spleen	where	they	become	 sequestered	 and	 likely	 undergo	 apoptosis.	 This	 action,	 whilst	 reducing	 the	immune	 response	 in	 the	 CNS,	 does	 not	 abrogate	 it,	 effectively	 allowing	 the	 virus	 to	 be	cleared	 from	 the	 CNS	 whilst	 minimising	 the	 potentially	 lethal	 immune-mediated	pathology.	 Intravenous	 infusion	 of	 IMP	 occurs	when	 animals	 have	 lost	 >5%	weight	 and	rescues	60-70%	of	animals	that	would	otherwise	succumb	to	disease,	with	sterilising	long-term	 immunity.	This	 therapy	has	proven	 to	be	 immensely	 successful	 in	 other	models	 of	disease	 where	 there	 is	 significant	 contribution	 of	 inflammatory	 monocytes	 to	 the	pathology,	 such	 as	 MI,	 EAE	 and	 inflammatory	 bowel	 disease	 (Getts	 et	 al.	 2014).	 This	highlights	 the	 fact	 that	 immunomodulatory	treatments	are	successful	 for	a	much	greater	range	 of	 therapies	 than	 just	 flaviviral	 encephalitis,	 if	 further	 trials	 prove	 successful	 this	line	of	treatment	may	redefine	how	treatment	is	approached.	
1.5. Objectives	of	this	research	
The	primary	objective	of	this	research	was	to	elucidate	the	role	of	the	secondary	lymphoid	organs	during	 lethal	WNV	encephalitis	and	subsequent	 immunomodulatory	treatment	of	this	disease.	In	particular,	we	focused	on	the	contribution	of	the	draining	and	non-draining	lymph	nodes	of	 the	CNS	to	the	 inflammatory	response	 in	WNV,	with	an	emphasis	on	the	lymphocyte	populations.	Furthermore,	we	aimed	establish	to	what	extent	the	spleen	and	its	resident	macrophages	are	required	for	the	efficacy	of	IMP	treatment	in	our	i.n.	model	of	WNV	infection.		
Figure	1.3	Immune-modifying	microparticle	treatment	of	WNV	encephalitis	
	Figure	1.3	illustrates	the	proposed	mechanism	of	action	of	IMP	for	the	treatment	of	WNV	encephalitis.	 IMP	 are	 injected	 as	 a	 bolus	 into	 the	 bloodstream	 (red	 section)	 and	subsequently	 phagocytosed	 by	 Ly6Chi	 inflammatory	 monocytes	 recruited	 by	 the	CCL2/CCR2	 axis	 from	 the	 bone	marrow	 (blue	 section).	 Ly6Chi	 inflammatory	monocytes	that	phagocytose	IMP	are	sequested	by	the	spleen	(yellow	section)	and	are	thus	prevented	from	migrating	to	the	CNS	(green	section).	 In	the	spleen	they	express	apoptosis	markers	caspase-3	and	Annexin	V.	
Figure 1.3 Immune-modifying microparticle treatment of WNV encephalitis
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2. Materials	and	methods	
2.1. Materials	
2.1.1. Virus	
Associate	 Professor	 Alison	 Kesson	 (The	 Children’s	 Hospital	 at	 Westmead,	 Sydney,	Australia)	kindly	provided	the	original	WNV	(Sarafend	strain)	stock.	
2.1.2. Mice	
Age	 matched	 8-12	 week	 old	 female	 WT	 C57BL/6	 (CD45.2)	 mice	 and	 congenic	B6.SJLPtprcaPep3b/BoyJ	(CD45.1)	mice	were	acquired	from	the	Animal	Resources	Centre	(Canning	 Vale,	 WA,	 Australia).	 Mice	 were	 housed	 in	 specific-pathogen	 free	 conditions	within	a	PC2	animal	 facility	 in	the	Charles	Perkins	center	and	offered	food	and	water	ad	
libitum.	 Mice	 were	 treated	 in	 accordance	with	 guidelines	 outlined	 by	 The	 University	 of	Sydney	 Animal	 Ethics	 Committee	 under	 Animal	 ethics	 protocol	 numbers:	 K20/8-2008/3/4863;	K20/8-2009/3/5127;	K20/11-2011/3/5660.		
2.1.3. 	Buffers,	solutions	and	anaesthetic	
Deoxyribonuclease	(DNase)	and	Collagenase	
DNase	 I	 and	 collagenase	 IV	 powders	 (Sigma	 Aldrich)	 were	 stored	 at	 -20°C	 until	 use.	Digestion	 of	 brain	 tissue	was	 performed	 at	 a	 concentration	 of	 0.005	 g/mL	DNase	 I	 and	
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collagenase	IV	0.05	g/mL	in	sterile	PBS.		Intracellular	BrdU	staining	was	done	with	DNase	at	a	concentration	of	300	µg/ml	in	sterile	PBS.	
Fluorescence-activated	cell	sorting	(FACS)	buffer	
FACS	 buffer	 was	 made	 up	 of	 5%	 FCS,	 10%	 (1	 mM)	 ethylenediaminetetraacetic	 acid		(EDTA;	Chem-Supply,	SA,	Australia)	and	sterile	PBS	and	stored	at	4°C	until	use.	
Foetal	calf	serum	(FCS)	
Foetal	calf	serum	(FCS;	Sigma-Aldrich,	MO,	USA)	was	stored	in	aliquots	at	-20°C	until	use.	FCS	used	was	not	heat	inactivated	before	use.	
Immune-	modifying	Microparticles	
Fluoresbrite®	 YG	 (yellow	 green)	 Carboxylate	 Microspheres	 0.50	 µm	 (Polysciences,	 Inc,	USA)	were	stored	at	4°C	until	use.	Stock	solution	(3.64x1011	particles/ml)	was	diluted	1:25	in	sterile	PBS	to	a	concentration	of	1.46x1010	particles/ml.	Each	mouse	was	given	300	µl	of	working	 solution	 (4.41x109	 particles)	 intravenously	 per	 dose,	 during	 once-daily	treatment.	
Minimum	Essential	Medium	(MEM)	
LPS-free	 Minimum	 Essential	 Medium	 containing	 L-glutamine	 and	 phenol	 red	 (Sigma-	Aldrich)	was	supplemented	with	20	mM	Hepes	(Invitrogen),	2.2	g/L	sodium	bicarbonate	(JRH	Bioscience),	 4	 g/L	 penicillin	 G	 and	 0.2	 g/L	 streptomycin	 sulphate	 (Sigma-Aldrich).	MEM	was	supplemented	with	either	2%	or	10%	FCS	as	required.	
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Paraformaldehyde	
A	4%	paraformaldehyde	(Sigma	Aldrich)	solution	was	prepared	in	PBS	and	stored	at	-20°C	until	required.	To	make	1	L	of	the	solution,	800	ml	of	1xPBS	was	heated	to	approximately	~60°C	 and	 40	 g	 of	 paraformaldehyde	 powder	 added	 to	 the	 heated	 PBS.	 Once	 the	paraformaldehyde	 had	 dissolved,	 the	 solution	 was	 cooled	 and	 filtered,	 and	 the	 volume	adjusted	to	1	L	by	adding	1xPBS.		
Percoll	
Percoll	(GE	Healthcare,	BKM,	UK)	was	stored	at	4°C.	Leukocyte	isolation	from	brain	tissue	was	performed	using	Percoll	solutions	of	80%	(to	make	100	ml	=	73.1	ml	Percoll	stock,	10	ml	1.5M	NaCl	and	16.9	ml	of	MilliQ	water)	and	30%	(to	make	100	ml	=	26.32ml	Percoll	stock,	 10	 ml	 of	 1.5M	 NaCl	 and	 63.7	 ml	 media).	 Leukocyte	 isolation	 from	 blood	 was	performed	using	70%	Percoll	solution	(to	make	100	ml	=	57	ml	of	Percoll	stock,	10ml	of	1.5M	NaCl,	and	33	ml	of	MilliQ	water).	
Phosphate	buffered	Saline	(PBS)	
PBS	powder	(Sigma-Aldrich)	was	dissolved	in	MilliQ	(9.57	g/L)	and	sterilised	using	a	0.22	µm	filter	(Corning	Incorporated,	NY,	USA).	
Red	blood	cell	(RBC)	lysis	buffer	
Stock	solution	of	10x	RBC	lysis	(BD	Pharm	LyseTM;	BD	Biosciences,	NJ,	USA)	was	stored	at	4°C	and	diluted	to	1x	working	solution	with	MilliQ	water.		
TAE	(Tris/acetate/EDTA)	electrophoresis	buffer	
Stock	solution	(50x)	was	prepared	by	dissolving	242	g	of	Tris	base	and	37.2	g	Na2EDTA	in	1l	MilliQ	water	and	adding	57.1	ml	glacial	acetic	acid	(all	from	Sigma	Aldrich).		
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Tribromoethanol	anaesthetic	(Avertin)	
Avertin	was	 prepared	 by	 dissolving	 1	 g	 of	 2,2,2-tribromoethanol	 in	 1	ml	 of	 2-methyl-2-butanol	(Sigma-Aldrich)	and	adding	50	ml	of	pre-boiled	tap	water.	This	solution	was	fully	dissolved	 by	mixing	 then	 sterilised	with	 a	 0.22	 filter	 (Corning).	 Aliquots	were	 stored	 at	4°C,	protected	from	light	until	required.	An	optimal	dose	0.012	ml/g	of	body	weight	was	used	 and	 administered	 i.p.	 to	 each	mouse.	 The	 amount	 to	 be	 used	 for	 each	mouse	was	determined	 based	 on	 mouse	 weight,	 from	 a	 precalculated	 nomogram,	 e.g.	 250	 µl/20	 g	mouse.	
Tris-buffered	saline	(TBS)	
TBS	buffer	was	prepared	as	a	10x	solution	and	stored	at	4°C	for	up	to	a	2	months.	To	make	1	L	TBS,	13.9	g	of	Tris	base	(Sigma	Aldrich),	60.6	g	Tris	HCL	(Sigma	Aldrich)	and	60.6	g	of	NaCl	 was	 dissolved	 in	 1	 L	 of	 MilliQ	 water,	 with	 5	 ml	 of	 Tween	 20.	 Stock	 solution	 was	diluted	to	1x	with	MilliQ	water	for	staining.	
2.1.4. 	TaqMan	primer	and	probe	sequences	
For	 real-time	 PCR	 of	 WNV	 NS5,	 the	 primers	 and	 probes	 were	 custom	 ordered	 from	Applied	 Biosystems	 (CA,	 USA).	 The	 sequences	 were	 obtained	 from	 published	 WNV	( T a n g 	 e t 	 a l . 	 2 0 0 6 ) 	 primer	 and	 probe	 sequences,	 as	 listed	 in	 Table	 2.1.	 WNV	primers	 targeted	 the	 WNV	 3’	 non-coding	region.	Primers	and	probes	were	reconstituted	or	 diluted	 to	 a	 final	 stock	 concentration	 of	 18	 and	 5µM	 respectively	with	 nuclease-free	water,	aliquoted	and	stored	at	-20°C	until	use.	
Target SequenceForward	  primer AAG	  TTG	  AGT	  AGA	  CGG	  TGC	  TGReverse	  Primer AGA	  CGG	  TTC	  TGA	  GGG	  CTT	  AC	  CTC	  GProbe AAC	  CCC	  AGG	  AGG	  ACT	  G
WNV
Table	  2.1	  Primer	  and	  probe	  sequences	  for	  WNV	  RNA	  amplification	  and	  detection	  by	  TaqMan	  PCR
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2.2. Methods	
2.2.1. West	Nile	virus	propagation	
Stock	WNV	was	 propagated	 by	 injecting	 suckling	 C57BL/6	mice	 intracranially	 (i.c.)	 and	collecting	 brains	 of	 mice	 at	 the	 first	 sign	 of	 illness.	 Brains	 were	 homogenised	 in	DMEM+10%FCS	 and	 clarified	 by	 centrifugation.	 The	 resulting	 supernatant	 was	 used	 to	infect	 Vero	 cells	 in	 Complete	 Medium	 (CM)	 i.e.	 Dulbecco’s	 modified	 Eagle’s	 medium	(DMEM;	 Gibco,	 NY,	 USA)	 and	 10%	 foetal	 calf	 serum	 (FCS;	 JRH	 Biosciences,	 KS,	 USA).	 A	multiplicity	 of	 infection	 of	 5	 plaque	 forming	 units	 (PFU)/cell	 was	 used.	 Cells	 were	propagated	 in	 a	 37°C	 incubator,	 in	 a	 humidified	 atmosphere	 with	 5%	 CO2.	 Virus	 was	allowed	 to	 adsorb	 to	 Vero	 cells	 for	 1	 h,	 with	 rocking	 every	 15	 min	 to	 allow	 even	distribution	of	virus,	after	which	infected	cells	were	incubated	for	a	further	40	h	at	37°C,	then	frozen	at	–80°C.	Flasks	were	then	thawed	and	the	virus-rich	supernatant	clarified	by	centrifugation.	Cell-free	supernatant	was	stored	in	aliquots	at	–80°C	until	use.	A	final	viral	titre	of	the	stock	used	in	this	project	1.7x109	PFU/ml	was	determined	by	plaque	assay.	For	100%	lethal	dose	infections	(LD100),	stock	virus	was	diluted	to	6x106	PFU/ml	in	10	µl	(i.e.	6x104	 PFU/mouse).	 For	 the	 50%	 sublethal	 dose	 of	 infection	 (LD50),	 stock	 virus	 was	diluted	a	further	10-fold	to	6x105		PFU/ml	or	6x103		PFU/mouse	in	10	µl.	
2.2.2. West	Nile	virus	Plaque	assay	
Baby	hamster	kidney	cells	 (BHK)	were	 taken	out	of	 liquid	nitrogen	storage	and	 thawed.	Cells	were	washed	3	times	with	CM	and	seeded	 in	cell	culture	 flasks	(Corning,	NY,	USA).	Cells	 were	 passaged	 until	 the	 required	 number	 of	 cells	 was	 obtained.	 Cells	 were	 then	plated	in	6-well	plates	at	1x106	cells/well	with	2	ml	CM	and	incubated	at	37°C	for	24	h	in	humidified	atmosphere	with	5%	CO2.	Once	 cells	 reached	an	even	monolayer	of	80-90%	
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confluence,	 the	medium	was	removed	and	150	µl	of	diluted	virus	carefully	added.	Serial	dilutions	of	virus	were	prepared	with	sterile	PBS.	Cells	were	then	incubated	at	37°C	with	virus	for	60	min	in	a	humidified	atmosphere	with	5%CO2,	rotating	every	15	min	to	ensure	infection	occurred	evenly.	Agarose	overlay	was	prepared	by	mixing	3%	(w/v)	low	gelling	molten	 agarose	 II	 (Amresco,	 OH,	 USA)	 with	 2xMEM+10%	 FCS	 in	 a	 1:1	 ratio.	 After	incubation	 of	 60	min	 the	 virus	was	 aspirated	 off	 and	 2	ml	 of	 agarose	mixture	 added	 to	each	 well	 and	 allowed	 to	 solidify	 before	 returning	 to	 the	 incubator	 for	 3-5	 days	 until	plaques	were	visible.	In	order	to	fix	cells	and	harden	the	agarose	for	easy	removal,	3	ml	of	10%	Formalin	(Lomb	Scientific)	 was	 added	 to	 each	 well	 for	 2-4	 hours.	 Formalin	 was	 then	 removed	 and	 the	agarose	plug	gently	removed	from	the	cell	monolayers.	Fixed	cells	were	stained	with	1	ml	of	3%	(w/v)	of	crystal	violet	solution	in	20%	(w/v)	of	methanol	(Fronine)	for	1	min	and	then	washed	with	water.	Well-isolated	plaques	were	counted	and	the	viral	titre	calculated	as	 PFU/ml	 or	 PFU/mg	 of	 tissue	 by	 the	 following	 formula:	
!"#$%&	()	*+,-"%.	/!	01%	2%++3/+"0/(!	),40(&	5	6(+"#%	3/+"0%3	7/&".	,33%3	/!	#+			
2.2.3. WNV	infection	
As	mentioned	 above,	 two	 doses	 of	 virus	were	 used	 for	 intranasal	 infection.	 These	were	6x104	 PFU/mouse,	 as	 the	 LD100	 dose	 or	 6x103	PFU/mouse	 for	 LD50	 survival	 studies.	Stock	virus	was	 thawed	on	 ice	and	diluted	 to	 the	appropriate	 concentration	with	 sterile	PBS.	 Prior	 to	 infection,	 mice	 were	 weighed	 and	 anaesthetised	 by	 intraperitoneal	 (i.p.)	injection	of	Avertin	at	a	concentration	of	0.012	ml/g	of	body	weight.	Unconsciousness	was	confirmed	by	squeezing	the	hind	foot	of	each	mouse	to	ensure	that	no	withdrawal	reflex	was	 observed.	 Once	 unconsciousness	 was	 established	mice	were	 given	 10	 µl	 of	 diluted	virus	or	PBS	for	mock-infected	controls,	5	µl	per	nostril	was	given	intranasally	(i.n.)	Mice	were	 placed	 on	 a	 heatpad	 in	 a	 supine	 position	 to	 prevent	 inoculum	 leaking	 out	 and	
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monitored	 until	 consciousness	was	 regained.	 The	 time-course	 experiments	 described	 in	chapter	3	and	4	were	set	up	as	follows.	Infections	were	timed	and	performed	on	separate	days,	thus,	mice	were	sacrificed	and	organs	collected,	processed,	stained	and	acquired	on	the	 same	 day	 for	 each	 time-point.	 In	 order	 to	 test	 for	 immunity	 mice	 were	 re-infected	intranasally	with	6x104	PFU	 (LD100),	 at	 least	3-months	 following	primary	 infection,	 and	monitored	for	any	symptoms	of	disease.		
2.2.4. Animal	monitoring	and	clinical	scoring	
Following	 infection,	 mice	 were	 weighed	 twice	 daily	 and	 monitored	 for	 any	 signs	 of	discomfort.	 	Mice	were	euthanised	when	≥5%	weight	 loss	was	 reached,	 compared	 to	d0	p.i.	The	disease	score	of	mice	was	determined	according	 to	 the	criteria	outlined	 in	 table	2.2.	
2.2.5. Tissue	dissection,	collection	and	processing	
2.2.5.1. Leukocyte	isolation	
In	 any	 sequence	 of	 isolation	 and	 cell	 surface	 of	 intracellular	 antibody	 staining,	 all	 cells,	alive	 or	 fixed	 were	 washed	 in	 order	 to	 remove	 the	 previous	 reagents	 used.	 Unless	otherwise	 stated,	 this	 entailed	 a	 uniform	 approach	 as	 follows:	 Cells	were	 centrifuged	 at	534	x	g,	for	5	min	at	4°C,	in	an	Allegra	X-14	Beckman	Coulter	centrifuge.	The	supernatant	was	 discarded	 and	 the	 resultant	 cell	 pellet	 gently	 resuspended.	 In	 addition,	 unless	otherwise	stated,	the	Allegra	X-12R	Beckman	Coulter	centrifuge	was	used	for	the	majority	of	steps	requiring	centrifugation.	
0 No	  weight	  loss
1 Weight	  loss	  of	  <5%.	  Minimal	  signs	  of	  disease.
2 Weight	  loss	  of	  >5%.	  Reduction	  in	  movement
3
Weight	  loss	  >5%.	  Significant	  reduction	  in	  movement,	  slightly	  hunched	  posture,	  face	  washing
4
Weight	  loss	  >5%,	  significant	  reduction	  in	  movement,	  hunched	  posture,	  ruffled	  fur	  and	  seizure	  development
5 Immobile	  but	  still	  alive
Table	  2.2	  Clinical	  scoring	  of	  WNV-­‐infected	  mice
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2.2.5.1.1. Blood	
Blood	 was	 collected	 with	 a	 single	 cardiac	 puncture	 using	 a	 27G	 needle	 and	 syringe	containing	 200	 µl	 of	 heparin.	 Blood	 was	 then	 transferred	 to	 heparinised	 tubes.	 The	solution	was	subsequently	diluted	to	2	ml	in	sterile	PBS	and	layered	on	top	of	3	ml	Ficoll-Paque	Plus	or	70%	Percoll	(GE	Healthcare).	Samples	were	centrifuged	at	1455	x	g	for	25	min	 at	 room	 temperature	 (RT)	 The	 purified	 layer	 of	 leukocytes	was	 collected	 from	 the	interface,	 washed	 twice	 with	 FACS	 buffer	 as	 described	 above.	 The	 cell	 pellet	 was	subsequently	resuspended	in	FACS	buffer	for	cell	counting	and	antibody	staining.	
2.2.5.1.2. Brain		
Perfusion	of	mice	was	performed	prior	to	collection	of	brain	tissue	by	cutting	the	inferior	vena	cava	and	flushing	the	vascular	system	via	the	left	ventricle	with	30ml	cold	PBS,	using	a	27G	needle.	Brains	were	placed	 in	petri	 dishes	 containing	 cold,	 sterile	PBS	 and	 gently	mashed	 through	 a	 coarse	 metal	 sieve	 and	 resuspended	 in	 30	 ml	 of	 cold	 PBS	 and	centrifuged	 for	20	min	at	524	x	g.	The	pellet	was	subsequently	resuspended	 in	20	ml	of	collagenase	and	DNase	solution	(described	in	materials)	and	incubated	at	37°C	for	60	min,	with	gentle	agitation	every	15	min.	Digestion	was	stopped	by	adding	25	ml	of	FACS	buffer	containing	10%	FCS	and	the	dispersed	tissue	centrifuged	for	20	min	at	524	x	g.	To	isolate	leukocytes,	 the	 pellet	 was	 resuspended	 in	 7	 ml	 of	 a	 30%	 Percoll	 solution	 and	 gently	layered	over	3	ml	of	80%	Percoll	and	centrifuged	 for	25	min	at	1455	x	g	at	RT	with	 the	brake	 off.	 Following	 collection	 of	 leukocytes	 from	 the	 interface,	 cells	 were	 washed	 and	resuspended	in	FACS	buffer	for	cell	counting	and	antibody	staining.	
2.2.5.1.3. Bone	marrow	
Whole	 femurs	were	dissected	and	rinsed	 in	ethanol	and	sterile	PBS.	 	After	removing	 the	head	and	 lower	extremity	of	 the	 femur,	 the	 femurs	were	 flushed	with	10	ml	cold,	sterile	
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PBS	using	a	30G	needle.	The	resultant	cell	 suspension	was	centrifuged	at	524	x	g	 for	10	min	and	the	pellet	subsequently	resuspended	in	2	ml	of	1x	RBC	lysis	and	incubated	at	RT	for	5	min.	 10	ml	 of	 FACS	buffer	was	 added	 to	 stop	 the	 reaction	 and	 the	 cell	 suspension	centrifuged	for	10	min	at	524	x	g.	The	cell	pellet	was	subsequently	resuspended	in	FACS	buffer	for	cell	counting	and	antibody	staining.	
2.2.5.1.4. Spleen	
Spleens	were	collected	in	cold,	sterile	PBS	and	gently	mashed	through	a	70	µm	nylon	sieve.	Cells	were	resuspended	in	10	ml	PBS	and	centrifuged	for	10	min	at	524	x	g.	RBC	lysis	was	performed	by	resuspending	the	pellet	in	4	ml	1x	RBC	lysis	buffer,	followed	by	incubation	for	10	min	at	RT.	FACS	buffer	was	added	to	stop	the	reaction	and	cells	were	centrifuged	for	 10	min	 at	 524	 x	 g.	 The	 pellet	was	 resuspended	 in	 FACS	buffer	 for	 cell	 counting	 and	antibody	staining.	
2.2.5.1.5. 	Lymph	nodes	
Lymph	nodes	were	removed,	placed	in	cold,	sterile	PBS	and	gently	mashed	through	70	µm	sieve.	Cells	were	washed	with	10	ml	FACS	buffer	and	centrifuged	for	10min	at	524	x	g.	The	cell	 pellet	 was	 resuspended	 in	 FACS	 buffer	 for	 cell	 counting	 and	 antibody	 staining.	Dissection	 and	 removal	 of	mouse	 lymph	nodes	was	performed	based	on	 the	 anatomical	distribution	described	by	Dunn	(Dunn	1954).	
2.2.5.2. Organ	collection	for	PCR	
Mice	were	perfused	as	described	above	and	the	brain	and	lymph	nodes	collected.	Organs	were	place	in	1	ml	(whole	brain)	and	200	µl	(for	2	lymph	nodes)	of	RNAlater®	stabilising	agent	(Life	Technologies,	CA,	USA)	and	stored	in	-80°C	until	required.	
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2.2.5.3. 	Organ	collection	for	immunohistochemistry	(IHC)	
Once	mice	were	anaesthetised	and	perfused	as	described	above,	the	relevant	organs	were	dissected	and	placed	in	Tissue-Tek	cryomolds	(Sakura,	Netherlands)	containing	Optimum	Cutting	 Temperature	 Compound	 (OCT;	 Sakura,	 Netherlands).	 Moulds	 containing	 organs	were	slowly	immersed	in	liquid	nitrogen	and	stored	at	-80°C	until	required.	
2.2.6. Administration	 of	 immune-modifying	 microparticles,	 Enalapril	
and	BrdU	
2.2.6.1. IMP		
A	stock	solution	of	IMP	was	kept	at	4°C	protected	from	light.	The	stock	solution	of	0.025	g/ml	or	3.64x1011	particles/ml	was	diluted	to	the	working	IMP	solution	to	deliver	a	dose	of	1.4	mg/kg.	For	an	adult	mouse	this	is	~0.3	mg/mouse	or	4.41x109	particles	per	mouse.	This	 required	 a	 1:25	 dilution	 (200	 µl	 of	 stock	 IMP	 into	 4800	 µl	 sterile	 PBS)=	 1.46x1010	particles/ml	in	sterile	PBS.	This	working	solution	was	kept	for	a	maximum	of	2-3days	at	4°C.	Mice	were	weighed	daily	and	received	a	single	dose	of	 IMP	as	a	300	µl	 intravenous	injection	in	the	morning,	depending	on	the	treatment	criteria	(i.e.	>5%	Weight	 loss,	time	point	 in	 disease	 etc.).	 To	 perform	 the	 intravenous	 injection	we	 dilated	 the	 tail	 veins	 in	mice,	 either	 by	 placing	 them	 in	 a	 warmer	 environment	 (e.g.	 at	 28-30	 ºC)	 for	 up	 to	 30	minutes,	or	by	placing	the	tail	in	warm	(30-35	ºC)	water.	After	removing	any	air	bubbles	present	 in	 the	 syringe,	 an	 appropriate	 restraining	 device	 was	 used	 and	 IMP	 were	administered	with	a	27-30G	needle.	Once	the	vein	was	located,	the	injection	was	begun	at	mid-length	or	slightly	distal	on	 the	 tail.	 Injection	of	a	300	µl	volume	was	performed	at	a	very	 slow	 rate	 to	 minimise	 any	 discomfort	 to	 the	 animal.	 Successful	 injection	 was	determined	 by	 lack	 of	 resistance	 when	 pressure	 was	 placed	 on	 plunger	 and	 when	
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blanching	of	the	vein	was	observed.	If	any	bubbles	formed	around	the	site	of	injection	or	resistance	 was	 felt,	 the	 needle	 was	 removed	 and	 reinserted	 above	 the	 initial	 injection.	After	 successful	 injection,	 the	 needle	 was	 removed	 slowly	 and	 pressure	 immediately	placed	on	the	injection	site	for	up	to	1	min	to	prevent	bleeding.	Mice	were	monitored	daily	for	any	discomfort.	Those	requiring	daily	treatment,	received	injections	on	alternate	sides	of	 the	 tail	 to	 give	 the	 tail	 maximum	 time	 to	 recover	 between	 injections,	 which	 in	 turn	maximised	the	success	of	the	injections.	
2.2.6.2. Clodronate	liposomes	
Clodronate,	a	bisphosphonate,	clinically	used	 in	osteoporosis	 to	 inhibit	osteoclast	action,	does	not	cross	the	cell	membrane,	but	enters	cells	through	phagocytosis	and	possibly	fluid	phase	pinocytosis.	High	intracellular	concentration	of	clodronate	induces	cell	death,	likely	as	a	 result	of	 interference	with	protein	kinase	C	and	other	pathways.	This	 results	 in	 the	depletion	 of	 phagocytic	 subsets,	 in	 particular	 circulatory	monocytes,	 as	well	 as	 resident	macrophages,	 including	 red	pulp	and	marginal	 zone	macrophages	of	 the	 spleen,	Kupffer	cells	in	the	liver	and	macrophages	in	the	lymph	nodes,	but	fails	to	deplete	others,	such	as	microglia	 (van	 Rooijen	 and	 van	 Nieuwmegen	 1984)	 (Getts	 et	 al.	 2008).	 	 Clodronate	 or	control	 PBS-encapsulated	 liposomes	 (Nico	 van	 Rooijen,	 Amsterdam,	 Netherlands)	 were	administered	 i.v.	 to	mock-infected	 or	 LD50	 (6x103	 PFU	 i.n.)	 or	 LD100	 (6x104	 PFU	 i.n.)	WNV-infected	mice	at	 a	volume	of	200μl	per	mouse	on	d5	p.i.	 as	per	 the	manufacturers	instructions.	
2.2.6.3. 	Bromodeoxyuridine	(BrdU)	administration	
BrdU	(BD,	USA),	2	mg	in	200	µl	sterile	PBS	per	mouse,	was	thawed	and	administered	i.p.	3	hours	prior	to	sacrificing	animals.		
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2.2.6.4. Enalapril	administration	
Enalapril	(Sigma-Aldrich)	was	administered	i.p.	in	200	µl	to	mock-infected	or	LD50	(6x103	PFU	 i.n.)	 or	LD100	 (6x104	PFU	 i.n.)	WNV-infected	mice.	Enalapril	was	 given	at	 a	dose	of	100	mg/kg/day,	i.e.	2	mg	for	a	20	g	mouse	(Gard	et	al.	1999;	Leuschner	et	al.	2010).	Mice	were	weighed	daily	and	monitored	for	any	signs	of	discomfort.	
2.2.7. Surgery	and	adoptive	transfer	
2.2.7.1. 	Surgical	removal	of	the	spleen	
Prior	to	surgery,	each	animal	was	given	an	i.p.	injection	of	the	analgesic	anti-inflammatory	drug,	 meloxicam	 (4.4	 mg/kg)	 (Loxicom,	 Norbrook	 Laboratories,	 UK)	 and	 tramadol	 (0.7	mg/kg)	(bioCSL,	Victoria).	Mice	were	sedated	in	a	gas	induction	chamber	with	isoflurane.	Once	 sedated,	 mice	 were	 fully	 anaesthetised	 under	 a	 general	 inhalational	 anaesthetic	(Isoflurane,	 Veterinary	 Companies	 of	 Australia,	 NSW,	 Australia)	 with	 a	 facemask	 for	surgery.	 	 Anaesthetised	mice	were	placed	on	 their	 right	 side,	 shaved	 and	 swabbed	with	70%	 ethanol	 above	 their	 left	 kidney.	 A	 small	 vertical	 10-15	 mm	 incision	 was	 made	through	 the	 skin	 and	 abdominal	 wall	 layers.	 The	 spleen	 was	 identified	 and	 carefully	exteriorised	through	the	incision.	The	splenic	arteries	and	veins	were	ligated	using	a	4-0	synthetic	 silk	 suture	 (Dynek,	 SA,	 Australia),	 the	 distal	 tissue	 sectioned	 and	 the	 spleen	removed.	The	abdominal	muscle	wall	and	skin	 incision	was	 then	sutured	separately	and	treated	with	iodine.	Mice	were	placed	on	a	heatpad	and	monitored	every	30	min	until	they	recovered	(Reeves	et	al.	2001).	On	d1	and	d2	post-surgery,	mice	were	given	tramadol	and	meloxicam	 orally,	 administered	 per	 drop	with	 a	 syringe.	Mice	were	 then	 checked	 twice	daily	for	a	2-week	period	for	any	signs	of	infection	or	discomfort	prior	to	commencing	any	experimental	procedures.	
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2.2.7.2. Dye	injection	and	Adoptive	transfer	experiments	
2.2.7.2.1. Footpad	injection	of	PKH26	
Mock-and	WNV-infected	mice	 (i.n.,	 6x104	PFU)	were	 sedated	 in	a	 gas	 induction	 chamber	with	isoflurane.	Once	sedated,	mice	were	fully	anaesthetised	under	a	general	inhalational	anaesthetic	 (Isoflurane,	 Veterinary	 Companies	 of	 Australia,	 NSW,	 Australia)	 with	 a	facemask	 for	 footpad	 injection.	 Once	 unconsciousness	was	 confirmed	 by	 testing	 for	 the	absence	 of	 the	 withdrawal	 reflex,	 mice	 were	 given	 a	 50	 µl	 injection	 of	 PKH26	 (Sigma	Aldrich)	via	the	footpad	on	d0	p.i.	Mice	were	sacrificed	at	24	h	p.i.	and	on	d7	p.i.,	and	the	draining	 lymph	 node	 of	 the	 foot,	 the	 popliteal	 lymph	 node,	 along	with	 the	 cervical	 and	inguinal	 lymph	nodes,	 brain	 and	 spleen	were	 collected	 and	placed	 in	 cold	PBS.	 Samples	were	subsequently	processed	for	flow	cytometry	as	described	in	section	2.2.4.1.	
2.2.7.2.2. Adoptive	transfer	of	leukocytes	
For	adoptive	transfer	experiments,	leukocytes	were	isolated	under	sterile	conditions	from	the	 bone	 marrow	 and	 lymph	 nodes	 of	 donor	 (CD45.1	 or	 CD45.2)	 mice	 as	 described	 in	section	 2.2.4.1.	 Cells	 were	 counted	 and	 cell	 membranes	 labelled	 according	 to	manufacturers’	 instructions	 with	 PKH26	 red	 fluorescent	 cell	 linker	 kit	 (Sigma	 Aldrich)	and/or	carboxyfluorescein	succinimidy	ester	(CFSE)	(Sigma	Aldrich).	PKH26	 staining:	 2x107	leukocytes	 were	 re-suspended	 in	 1	 ml	 of	 Diluent	 C,	 followed	 by	addition	of	1ml	of	2x	dye	suspension,	made	up	with	1	ml	Diluent	C	and	4	µl	PKH26.	Cells	were	incubated	for	1-2	min	and	the	reaction	terminated	with	2	ml	FCS.	The	samples	were	washed	three	times	with	cold,	sterile	PBS.	CFSE	 staining:	up	 to	1x108	cells/ml	were	 resuspended	 in	a	 solution	 containing	10	µM	of	CFSE	and	incubated	for	5	min.	FCS	was	added	to	the	cell	mixture,	which	was	subsequently	washed	three	times	with	sterile	PBS.	The	cells	were	subsequently	filtered	through	a	sterile	
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70	µm	cell	strainer	(Corning	Incorporate,	NY,	USA)	and	injected	into	recipient	animal.	For	the	footpad	injection	of	cells,	each	recipient	animal	was	given	2x106	cells	in	50	µl	of	sterile	PBS.	Intravenous	injection	of	cells	was	performed	as	described	in	section	2.2.6.1	with	each	animal	receiving	~2x106	cells	in	150-200	µl	sterile	PBS.	
2.2.8. 	Flow	cytometry	
2.2.8.1. Cell	surface	staining	
Once	total	live	cell	counts	were	determined,	1.5x106	cells/sample	were	transferred	to	a	96	well	U-bottom	plate	 (BD	Falcon)	 along	with	 aliquots	 for	 fluorescence	minus-one	 (FMO),	single-stain	 and	 isotype	 controls.	 To	 determine	 optimal	 voltage	 parameters	 bead	compensation	controls	(BD	CompBeads,	BD)	were	included	for	each	experiment.	Samples	in	 the	 96-well	 plates	 were	 centrifuged	 for	 5	 min	 at	 462	 x	 g	 at	 4°C	 and	 supernatant	discarded.	The	cell	pellets	were	re-suspended	in	50	µl	of	Fc	block	(anti-mouse	CD16/32)	(Biolegend)	and	0.1	µl/sample	fixable	blue,	dead	cell	staining	kit	(Life	Technologies)	and	incubated	on	 ice,	protected	 from	light.	After	30	min,	samples	were	raised	 in	FACS	buffer	and	washed.	Samples	were	then	re-suspended	in	50	µl	of	prepared	antibody-	and	isotype-cocktails,	 as	 well	 as	 single	 stain	 and	 FMO	 controls	 and	 incubated	 for	 40	 min	 at	 4°C,	protected	from	light.	Detailed	information	on	the	antibodies	used	can	be	found	in	table	2.3.	Cells	 were	 washed	 3x	 in	 FACS	 buffer	 and	 either	 acquired	 the	 same	 day	 on	 the	 flow	cytometer	or	fixed	with	40	µl	of	 fixation	buffer	(Biolegend)	for	20	min	at	RT.	Once	fixed,	the	cells	were	washed	3x	with	FACS	buffer.	Cells	were	re-suspended	in	200	µl	FACS	buffer,	sealed	and	stored	at	4°C	until	acquisition	(no	longer	than	1-2days).	
Antibody Isotype Clone Dilution Conjugate Application Source
CD45 Rat(IgG2b 30F111 1:200 PerCP FC Biolegend
CD45.1 Mouse((A.SW)(IgG2a A20 1:100 APC FC Biolegend
CD45.2 Mouse((SJL)(IgG2a 104 5:100 PerCP FC Biolegend
CD3ε Armenian(Hamster(IgG 14512C11 1:200(((((((((((((((1:100 Pe1CF594,(APC,(Af700 FC,((((((((((((((IHC BD(Biosciences
CD4 Rat(IgG2a RM415 1:400 AF700 FC Biolegend
CD8α Rat(IgG2a 53#6.7 1:100 BV711 FC Biolegend
B220 Rat(IgG2a RA3#6B2 1:100 Pe(,(B220((((((((((BV785,(PeCF594 FC,((((((((((((((IHC BiolegendCD19 Rat(IgG2a ID3 1:200,((((((2:100 Pe1CF594,(BV785 FC BD,(Biolegend
CD11b Rat(IgG2b M1/70 1:200,(((((1:100 BV650,BV605,PeCy7,(BUV395(((((((((((((((((FC BiolegendCD11c Armenian(Hamster(IgG N418 1:100 Pe,((APC((((((Pe/Cy7,((((FITC FC BiolegendMHCII((I1A/I1E) Rat(IgG2b M5/114.15.2 1:300 BV510 FC Biolegend
Ly6G((CD45R) Rat(IgG2a 1A8 1:100 APC/Cy7,(Pe,(PeCy7 FC Biolegend
Ly6C Rat(IgG2c HK1.4 1:100 BV421 FC Biolegend
NK1.1 Mouse(IgG2a PK136 5:100 BV510,(BV605,(BV711 FC BiolegendF4/80 Rat(IgG2a BM8 1:100 Pe FC,(((((((((((((IHC Biolegend
Annexin(V 1 1 5:100 PeCy7 FC eBioscience(
BrDU 1 1 5:100 APC FC BD;(Biolegend
Biotinylated1MARCO Rat(IgG1 ED31 5:100 Af594 FC,((((((((((((((((((((((IHC R&D(systems
Table82.38Antigen8specificity,8isotype,8clone,8dilution,8conjugate,8application8and8source8for8each8
antibody8used.8All8are8specific8for8mouse8antigens8unless8specified.8WB8=8Western8blotting,8FC8=8flow8
cytometry,8IF8=8immunofluorescence.8The8antibody8source8legend8is8listed8below.
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2.2.8.2. 	Intracellular	staining		
Organs	 were	 collected	 and	 leukocytes	 isolated	 as	 described.	 Following	 cell	 surface	staining,	 as	 described	 in	 the	 previous	 section,	 the	 samples	 were	 washed	 2x	 with	 FACS	buffer.	 After	 discarding	 the	 supernatant,	 samples	 were	 fixed	 and	 permeabilised	 by	resuspending	 cells	 in	 100	 µl	 of	 BD	 Cytofix/Cytoperm	 Buffer,	 followed	 by	 30	 min	incubation	 on	 ice.	 Samples	 were	 then	 washed	 with	 1xBD	 Perm/Wash	 buffer,	 and	resuspended	in	100	µl	of	BD	Cytoperm	Buffer	Plus,	with	10	min	incubation	on	ice.	Samples	were	then	washed	with	1x	BDPerm/Wash	Buffer,	the	supernatant	was	discarded	and	the	pellet	 resuspended	 in	100	µl	of	BD	Cytofix/Cytoperm	Buffer,	with	30	min	 incubation	on	ice.	Samples	were	washed	again	with	1xBD	Perm/Wash.	To	expose	incorporated	BrdU,	the	samples	were	treated	with	100	µl	of	DNase	(300	µg/ml	in	sterile	PBS	i.e.	30	µg	of	DNase	per	 106	 cells)	 and	 incubated	 for	 1	 hour	 at	 37°C.	 Samples	 were	 washed	 with	 1x	 BD	Perm/Wash	Buffer	and	intracellular	BrdU	staining	was	performed	as	follows.	Supernatant	was	 removed	 and	 the	 pellet	 resuspended	 in	 50	 µl	 of	 BD	 Perm/Wash	 Buffer	 containing	diluted	 fluorescent	anti-BrdU.	Following	a	20	min	 incubation	at	RT	protected	 from	 light,	samples	were	washed	3x	with	1x	BD	Perm/Wash	Buffer,	and	finally	resuspended	in	200	µl	of	FACS	buffer	and	stored	at	4°C	until	acquisition.	
2.2.8.3. Sample	acquisition	and	analysis	
Fixed	samples	were	stored	at	4°C	protected	from	light	until	acquisition	(no	longer	than	1-2days).	 Non-fixed	 samples	 were	 acquired	 with	 the	 flow	 cytometer	 on	 the	 same	 day	 as	processing.	 Prior	 to	 acquisition,	 samples	 were	 filtered	 through	 a	 70	 µm	 nytex	 filter	 to	remove	debris	and	prevent	potential	blockage	of	instruments.	Samples	were	acquired	on	either	a	BD	FACS	Canto	or	FACS	LSR-II,	running	FACS	Diva	software	(BD	Biosciences).	Data	files	 (.fcs)	 were	 analysed	 with	 FlowJo	 software	 (FlowJo,	 OR,	 USA)	 after	 which	 flow	
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cytometry	percentages	and	absolute	cell	counts	were	used	to	calculated	cell	populations	of	interest	in	Microsoft	Excel.		
2.2.9. 	RT	PCR		
2.2.9.1. RNA	extraction	
Tubes	were	thawed;	 tissue	removed	 from	RNAlater®	and	placed	 in	Trizol	 (1	ml/50-100	mg	tissue)	(Life	Technologies,	CA,	USA)	with	0.25	ml	Zircon	beads	(Biospec	Products,	USA)	in	microcentrifuge	tubes.	Tissue	was	homogenised	using	a	Fastprep	FP120	cell	disruptor	(ThermoElectron	Corporation,	MA,	USA)	(brain=	20	s	at	speed	5;	LN=	2x	20	s	at	speed	6).		Tubes	were	then	centrifuged	at	12	000	x	g	for	10	min	at	4°C	in	a	Microcentrifuge	5415R	(Eppendorf),	 after	 which	 the	 fatty	 layer	 was	 removed	 and	 the	 clear	 supernatant	transferred	 to	a	new	1.5	mL	microcentrifuge	 tube.	Note	 that	all	 further	centrifugation	 in	this	 section	was	 performed	with	 the	Eppendorf	microcentrifuge	 described	 above.	 Phase	separation	was	performed	by	adding	chloroform	(0.2	ml	per	1	ml	Trizol)	and	shaking	the	tube	vigorously	for	15	s	by	hand.	Samples	were	centrifuged	at	12	000	x	g	for	10	min	at	4°C,	followed	by	removal	of	the	aqueous	phase	of	the	sample	which	was	transferred	to	a	new	tube	 for	RNA	 isolation.	Next,	one	volume	of	70%	molecular-biology	grade	ethanol,	made	up	in	nuclease-free	water,	was	added	to	the	sample.	The	sample	was	then	transferred	to	a	RNA	binding	 column	 (RNeasy	Mini	 kit,	Qiagen,	Netherlands)	with	 a	2	ml	 collection	 tube	and	centrifuged	at	10	000	x	g	for	15	s	at	4°C	and	the	flow-through	liquid	discarded.	Next	700	µl	of	RW1	buffer	was	added	and	the	sample	centrifuged	again	at	10	000	x	g	for	15	s	and	the	flow-through	liquid	discarded.	This	step	was	repeated	2x	with	500	µl	RPE	buffer,	centrifuged	 for	 15	 s	 to	 dry	 the	 membrane	 and	 the	 flow-through	 liquid	 discarded.	 To	ensure	removal	of	the	flow-through	liquid	and	RPE	buffer,	the	column	was	transferred	to	a	
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new	2	ml	collection	 tube	and	centrifuged	 for	1	min	at	16	000	x	g.	The	column	was	 then	transferred	to	a	1.5	ml	microcentrifuge	tube	and	30	µl	of	nuclease-free	water	was	added	directly	 onto	 the	 column	membrane,	 which	was	 centrifuged	 for	 1	min	 at	 9000	 x	g.	The	eluted	RNA	was	collected	in	the	microcentrifuge	tube	and	tested	for	purity	and	yield.	The	NanoDrop	ND-1000	spectrophotometer	(Thermo	Fisher	Scientific,	MA,	USA)	was	used	to	measure	light	absorbance	at	230,	260	and	280	nm.	Protein	contamination	was	determined	by	A260:A280	ratio	and	ethanol	contamination	by	A260:A230	ratio.		
2.2.9.2. 	cDNA	
The	 SensiFAST	 cDNA	 Synthesis	 kit	 (Bioline,	 USA)	was	 used	 for	 cDNA	 synthesis	 and	 the	manufacturers	 protocol	 was	 followed.	 For	 the	 synthesis	 of	 cDNA,	 1	 µg	 of	 RNA	 was	diluted	 to	 a	 total	 volume	 of	13	µl	with	 nuclease-free	 water,	 1	µl	 of	250	ng/ul	hexamer	and	1	µl	of	reverse	transcriptase	with	4	µl	of	TransAmp	buffer.	This	was	gently	mixed	by	pipetting	 and	 the	 following	 program	 set	 up	 in	 the	 thermal	 cycler	 (Mastercycler	 Nexus,	Eppendorf,	 USA):	 25°C	 for	 10	 min	 (primer	 annealing),	 42°C	 for	 15	 min	 (reverse	transcription),	85°C	for	5	min	(inactivation)	and	4°C	for	any	hold	time.	
2.2.9.3. Taqman	PCR	
The	 RT	 reaction	was	 performed	 by	 using	 the	MyTaq	 Red	 DNA	 Polymerase	 kit	 (Bioline,	UK).	 The	 setup	 included	mixing	 2	 µl	 of	 template	with	 10	 µl	 of	 5x	MyTaq	 Red	 Reaction	buffer,	 0.25	µl	 of	MyTaq	Red	Polymerase,	 1	 µl	 of	 each	 reverse	 and	 forward	primer,	 and	raising	 the	 solution	up	 to	50	µl	 in	water.	 PCR	 cycling	 conditions	were	 as	 follows:	 Initial	denaturation	 at	 95°C	 for	 1	min,	 followed	 by	 30	 cycles	 of	 denaturation	 for	 15	 s	 at	 95°C;	Annealing	 for	 15	 s	 at	 60°C	 and	 extension	 for	 30	 s	 at	 72°C.	 This	 was	 performed	 on	 the	Mastercycler	Nexus	(Eppendorf,	USA).	
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2.2.9.4. Gel	electrophoresis	and	quantitative	PCR	
Visualisation	 of	 PCR	 and	 identification	 of	 virus	 was	 performed	 with	 agarose	electrophoresis.	 Agarose	 (Bioline,	 USA)	was	made	 up	 to	 2%	with	 TAE.	 Agarose	mixture	was	transferred	to	a	gel	tray	in	a	casting	chamber	and	left	to	cool.	PCR	product	was	then	loaded	into	each	well.	This	included	a	DNA	ladder,	as	well	as	a	positive	(RNA	isolated	from	virus	 stock)	and	negative	 control	 (media).	The	gel	was	 run	 for	45	min	at	100	volts.	The	resultant	gel	was	imaged	using	the	Gel	Doc	EZ	System	(BioRad,	CA,	USA).		For	 quantitative	 PCR,	 each assay for the gene of interest was multiplexed with the 
housekeeping gene, GAPDH. Each reaction was carried out in duplicate or triplicate. 
Amplification was performed using the ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). Quantitative	PCR	was	performed	and	the	relative	RNA	expression	in	 each	 organ	was	 normalised	 to	mock-infected	mice	 (d0)	 in	 terms	 of	 2000	 ng/µl	 total	RNA	and	analysed	using	the	2-ΔΔCT	method.	
2.2.10. Immunohistochemistry	
Sections	for	fluorescence	IHC	were	prepared	by	bringing	cryomolds	to	temperature	(-15-20°C)	 in	 the	 cryostat	microtome	 and	 cutting	 6	 to	 8-micron	 tissue	 sections.	 Slides	 were	allowed	to	air	dry	and	subsequently	stored	at	-80°C	until	required.		To	stain	samples,	 slides	were	removed	 from	-80°C	and	 thawed	at	RT	 for	~20	min.	Once	thawed,	sections	were	circled	with	a	DAKO	pen	(DAKO,	Denmark)	and	washed	once	 in	a	Copeland	jar	with	1x	TBS.	Sections	were	fixed	with	4%	PFA	in	PBS	and	incubated	for	10	min	 at	RT,	 after	which	 the	washing	 step	with	TBS	was	 repeated.	Avidin/Biotin	blocking	was	 performed	 in	 any	 scenario	 in	 which	 the	 antibody	 of	 interest	 was	 not	 directly	conjugated	 to	 a	 fluorophore.	 This	 blocked	 all	 endogenous	 biotin,	 biotin	 receptors	 and	avidin	 binding	 sites.	When	 required,	 Avidin	 block	 (100-150	 µl)	 (Vector)	 was	 placed	 on	
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each	 section	 and	 incubated	 for	 10	min	 at	 RT.	 Slides	 were	 washed	 for	 3	min	 with	 TBS.	Excess	 liquid	 was	 removed	 and	 100-150	 µl	 biotin	 block	 placed	 on	 each	 section	 and	incubated	for	10	min	at	RT,	after	which	slides	were	washed	for	3	min	in	TBS.	Slides	were	then	 blocked	 with	 TNB	 (Tris-NaCl-blocking	 buffer)	 with	 10%	 serum	 for	 30	 min	 at	 RT.	Excess	TNB	was	removed	and	100-150	µl	primary	antibody	or	isotype	control	in	antibody-staining	 buffer	 (45%	 TBS,	 45%	 TNB,	 10%	 FCS)	 was	 added	 to	 each	 section.	 This	 was	incubated	for	either	2	hours	at	RT	or	overnight	at	4°C	and	then	washed	3x	for	3	min/wash	in	TBS	buffer.	Sections	were	then	incubated	for	one	hour	at	RT	with	secondary	antibody,	diluted	in	antibody-	staining	buffer.	After	washing	sections	3x	for	3	min	with	TBS	buffer,	excess	liquid	was	removed	and	one	drop	of	DAPI	with	Prolong	Gold	added	to	each	section.	A	 coverslip	 was	 applied	 to	 each	 section,	 allowed	 to	 dry	 for	 ~20	min	 at	 RT	 and	 sealed.	Images	were	acquired	on	an	Olympus	BX-51	microscope	(Olympus,	Tokyo,	Japan),	using	a	DP-70	camera	and	DP	manager	software	(Olympus).		
2.2.11. Whole	blood	phagocytosis	assay	
WNV-infected	mice	 (6x104	PFU)	were	CLO-depleted	 at	 d5p.i.	 and	blood	was	 collected	 as	described	 in	 section	 2.2.5.1.	 at	 d6p.i.	 100µl	 of	 WNV-infected	 control	 and	WNV-infected	CLO-depleted	 blood	 was	 added	 to	 100	 µl	 of	 10%	 heat	 inactivated	 FCS	 and	 mixed	thoroughly.	10	µl	of	undiluted	IMP	(neat)	i.e.	3.64x109	IMP	and	serially	diluted	1:3	and	1:9	(with	sterile	PBS)	IMP	at	50	µl	of	resultant	stock	added	to	tubes	of	blood.	Tubes	containing	neat	and	diluted	IMP	with	blood	were	mixed	thoroughly	and	placed	in	a	37°C	waterbath	for	15	min,	whilst	 constantly	being	 agitated.	After	15	min	1	ml	 of	 cold	FACS	buffer	was	added	to	each	tube	to	stop	phagocytosis.	Samples	were	then	centrifuged	for	5	min	at	4°C	at	340	x	g	after	which	the	supernatant	was	removed	and	samples	resuspended	in	100	µl	of	FACS	buffer.	Cell	surface	staining	was	then	performed	as	described	in	section	2.2.8.1.	After	cell	surface	staining	was	performed	cells	were	fixed/lysed	by	adding	100	µl	of	Optilyse	to	
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each	sample	and	mixing.	Samples	were	incubated	for	10	min	at	RT	in	the	dark.	Cells	were	washed	twice	and	resuspended	in	FACS	buffer	for	acquisition.		
2.3. Statistical	analysis	
Raw	data	was	first	analysed	using	Microsoft	Excel.	Graphs	were	generated	and	statistical	analysis	 performed	 with	 GraphPad	 Prism	 4	 (GraphPad	 Software	 Inc.,	 CA,	 USA).	 For	comparison	of	2	samples	an	unpaired,	two-tailed	Student’s	t	test	was	used.	Comparison	of	3	or	more	samples	was	done	using	a	one-way	ANOVA	with	Tukey-Kramer	(each	column	to	the	other)	or	Dunnet’s	post-test	(each	column	to	a	control	column,	usually	mock-infected),	as	 appropriate.	 Survival	 data	 were	 analysed	 using	 Mantel-Haenszel	 logrank	 test.	Significance	 was	 determined	 as	 follows:	 	 p≤0.5	 was	 deemed	 statistically	 significant	 (*),	p≤0.1	very	significant	(**)	and	p≤0.001	extremely	significant	(***).					
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3. Chapter	 3	 The	 role	 of	 the	 draining	 and	 non-draining	
lymph	nodes	following	lethal	WNV	infection	
3.1. Introduction	
The	 critical	 role	 of	 the	 local	 draining	 lymph	 nodes	 in	 mounting	 an	 effective	 adaptive	immune	response	during	viral	infection	has	long	been	recognised.	In	addition	to	inhibiting	the	spread	of	pathogens,	the	draining	lymph	nodes	are	crucial	for	the	activation	of	cellular	immunity	and	the	development	of	humoral	immunity	through	the	presentation	of	antigen	to	T	and	B	cells,	respectively.	Although	the	exact	lymph	drainage	pathways	of	the	CNS	are	relatively	unknown,	several	publications	have	implicated	the	deep	and	superficial	cervical	lymph	nodes	(CLN)	in	the	lymphatic	drainage	of	the	CNS	(Yamada	et	al.	1991;	Karman	et	al.	 2004).	 The	 recent	 discovery	 of	 lymphatic	 vasculature	 in	 the	 CNS,	 connected	 to	 the	superficial	 and	deep	CLN,	has	cemented	a	 long-held	belief	 that	 the	CLN	are	 the	draining	nodes	of	the	CNS	(Louveau	et	al.	2015).	However,	the	extent	to	which	these	lymph	nodes	form	 part	 of	 the	 immune	 response	 to	 CNS	 inflammation,	 in	 particular	 during	 viral	encephalitis,	 has	 not	 been	 studied.	 During	 lethal	 WNV	 encephalitis,	 there	 is	 significant	infiltration	 of	 various	 leukocyte	 subsets	 (including	 lymphocytes)	 into	 the	 CNS.	 Previous	work	 from	 our	 lab	 has	 shown	 that	 the	 bone	marrow	 is	 a	 potent	 source	 of	 the	myeloid	lineage	 cells	 infiltrating	 the	 brain	 in	 this	 i.n.	 model	 of	 infection	 (Getts	 et	 al.	 2008).	However,	 the	 specific	 origin	of	 lymphoid	 lineage	 cells	 in	 the	 inflamed	CNS	has	not	 been	elucidated.	Considering	the	intimate	association	between	the	brain	and	CLN,	these	nodes	would	seem	likely	to	supply	the	humoral	and	cellular	immune	components	against	WNV.	Nevertheless,	 the	 lymphatic	 system	 is	 not	 an	 isolated	 organ	 and	 its	 constituents	 are	distributed	 throughout	 the	body,	all	of	which	are	connected	 to	some	degree	 through	the	
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lymphatic	and	blood	vessels.	Moreover,	there	is	some	evidence	that	not	only	the	draining	lymph	 nodes,	 but	 also	 the	 peripheral	 non-draining	 nodes	 may	 be	 involved	 during	 the	inflammatory	response	(Reisman	et	al.	2011;	Ciabattini	et	al.	2010).	With	this	in	mind,	the	aim	 of	 this	 chapter	 is	 to	 investigate	 the	 response	 of	 the	 CNS-draining	 and	 non-draining	lymph	nodes	during	lethal	WNV	encephalitis,	with	a	particular	focus	on	lymphoid	lineage	cells.		
3.2. Results	
3.2.1. Leukocyte	 population	 dynamics	 in	 the	 cervical,	 inguinal	 and	
mesenteric	lymph	nodes	following	lethal	WNV	infection	
In	 order	 to	 investigate	 the	 kinetics	 of	 the	 lymph	 node	 response	 during	WNV	 infection,	female	 C57BL/6	mice,	 8-12	weeks	 old,	 were	 infected	 i.n.	 with	 a	 lethal	 dose	 (LD100)	 of	WNV	 (6x104	 PFU).	 The	 intranasal	 model	 of	 infection	 was	 used	 throughout	 the	 project	reported	in	this	thesis,	as	it	has	been	extremely	well	characterised	in	our	laboratory,	with	defined	 LD100	 and	 LD50	 disease	 curves.	 This	model	 allows	 us	 to	 specifically	 study	 the	effect	of	 immune	components	on	 the	CNS	and	also	develop	detailed	 treatment	protocols	based	on	a	well-established	model.	Virus	can	be	detected	 in	 the	olfactory	bulb	by	d3	p.i.	and	is	first	evident	in	the	neurons	at	d6	p.i.	(Getts	et	al.	2007;	Getts	et	al.	2008).While	live	virus	can	be	detected	 in	 the	heart,	 lung	spleen	and	bone	marrow,	 these	 levels	were	 less	than	0.001%	of	those	detected	in	the	brain	(Terry	2012).	In	this	model,	d7	represents	the	peak	 of	 infection,	 characterised	 by	 maximal	 leukocyte	 infiltration	 into	 the	 CNS,	 severe	clinical	symptoms	and,	without	intervention	mice	would	die	on	d7p.i.	(Terry	2012).	Mice	were	sacrificed	on	d0,	d3	d5,	d6	and	d7	post	infection	and	the	CNS-draining	cervical	lymph	nodes	 (CLN)	 were	 harvested	 for	 flow	 cytometric	 analysis,	 with	 the	 inguinal	 (ILN)	 and	mesenteric	lymph	nodes	(MLN)	serving	as	peripheral/non-draining	lymph	node	controls.	
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Note	 that	 infections	 were	 performed	 on	 different	 days;	 thus,	 the	 organs	 from	 all	 time-points	were	collected,	processed,	stained	and	acquired	on	the	same	day.	An	example	of	the	initial	gating	strategy	performed	for	leukocyte	isolation	from	the	lymph	node	can	be	seen	in	Figure	3.1.	In	addition,	a	more	detailed	gating	strategy	of	the	lymph	node,	with	isotype	and	 fluorescence	minus	one	controls,	 can	be	 found	 in	 the	Appendix,	Figure	1	and	2.	The	gating	 steps	 applied	 followed	 a	 standardized	 protocol	 for	 flow	 cytometric	 data	 quality	control,	in	order	to	ensure	that	all	events	analysed	were	comparable	and	representative.	A	time	 gate	 (Figure	 3.1A)	was	 implemented	 first	 to	 exclude	 any	 events	where	 an	 uneven	flow-rate	 compromised	 the	 signal	 of	 the	 data	 collected.	 Secondly,	 all	 doublets	 were	excluded	 (Figure	 3.1B)	 based	 on	 the	 forward	 scatter-area	 (FSC-A)	 and	 forward	 scatter-	height	 (FSC-H)	 parameters.	 All	 cellular	 and	 tissue	 debris	 was	 subsequently	 excluded,	based	on	size	and	granularity,	using	 the	side	scatter-area	(SSC-A)	and	FSC-A	parameters	(Figure	3.1C).	Next,	all	dead	or	dying	cells	were	removed	with	the	use	of	a	UV	dye,	which	attaches	to	amine	groups	on	the	cell	surface	and	intracellularly.	Thus,	dead	or	dying	cells	with	permeable	membranes	will	show	intensely	positive	staining,	allowing	the	“negative	selection”	of	live	cells	(Figure	3.1D).	Lastly,	leukocytes	were	gated	using	the	pan-leukocyte	marker	CD45	(Figure	3.1E).	These	steps	ensured	 that	only	 the	data	 from	 live,	 single	cell	populations	acquired	under	the	same	conditions	were	analysed.		Figure	3.1	(F)	demonstrates	the	kinetic	changes	in	the	total	leukocyte	population	number	during	a	time-course	of	WNV	infection	in	the	CLN,	MLN	and	ILN.	A	significant	increase	in	leukocyte	 number	 was	 evident	 in	 the	 CLN	 from	 as	 early	 as	 d3	 p.i.,	 with	 cell	 numbers	increasing	by	up	 to	6-fold,	 compared	 to	d0	p.i.	 In	contrast,	 the	 ILN	and	MLN	exhibited	a	decrease	 in	 total	 leukocyte	 numbers	 during	 the	 course	 of	 infection,	 with	 a	 statistically	significant	decrease	by	d7p.i.	to	50%	of	the	leukocyte	numbers	seen	at	d0p.i.	
Figure	 3.1.	 Cellularity	 of	 the	 draining	 (CLN)	 and	 non-draining	 lymph	nodes	 (MLN,	
ILN)	of	the	CNS	following	lethal	WNV	infection	
		(A-E)	 Representative	 flow	 cytometric	 dot	 plots	 illustrating	 the	 gating	 strategy	 for	leukocytes	 in	 the	 secondary	 lymphoid	 organs	 (CLN,	 ILN	 &	 MLN)	 of	 mice	 infected	 with	LD100	WNV	 (6x104	PFU).	 In	 order	 to	 obtain	 a	 live	 single	 cell	 leukocyte	 population	 the	following	steps	were	performed	during	analysis:	(A)	Uniform	events	within	a	time	period	were	gated,	followed	by	exclusion	of	doublets	with	the	FSC-H	vs	FSC-A	gate	(B).	(C)	Debris	was	then	removed	with	the	SSC-A	vs	FSC-A	gate.	(D)	“Negative	selection”	of	live	cells,	using	a	live/dead	discriminating	dye	was	made.	Final	positive	selection	positive	selection	(E)	of	leukocytes	based	on	the	pan-leukocyte	marker	(CD45)	was	then	made	by	 further	gating.	(F)	Numbers	of	CD45+cells	in	the	CLN	(red),	MLN	(green)	and	ILN	(blue)	of	mice	following	lethal	WNV	infection	(6x104	PFU)	are	shown	on	day	0,	3,	5,	6	and	7	p.i. Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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3.2.1.1. T	cells	
An	example	of	 the	gating	strategy	used	to	 identify	 the	T	cell	populations	 is	 illustrated	 in	Figure	3.2	A.	T	cells	 form	the	bulk	of	 the	 leukocyte	population	 in	 the	CLN,	MLN	and	 ILN	during	 homeostatic	 conditions,	 comprising	 roughly	 60%	 of	 the	 total	 leukocytes	 present	(Figure	3.2C).	A	significant	expansion	in	the	number	of	T	cells	in	the	CLN	was	evident	from	as	early	as	d3	p.i.	and,	despite	a	transient	reduction	in	cell	number	between	d3-d5,	by	d6	p.i.,	T	cell	numbers	had	increased	significantly	by	3-fold,	compared	to	d0	p.i.	Interestingly,	however,	 the	 total	number	of	T	 cells	 in	both	 the	MLN	and	 the	 ILN	decreased	during	 the	course	of	infection.	A	significant	reduction	of	T	cells	was	present	as	early	as	d3	p.i.	in	the	ILN	and	by	d7p.i.	numbers	had	reduced	to	30%	of	those	present	at	d0	p.i.	(Figure	3.2B).		Both	 CD4+	 and	CD8+	T	 cell	 subsets	 contributed	 to	 the	 significant	 increase	 in	 total	 T	 cell	number	 in	 the	CLN.	 Similarly,	 the	 reduced	T	 cell	 numbers	 in	 the	 ILN	and	MLN	could	be	attributed	to	similar	reductions	in	CD4+	and	CD8+	subset	number	(Figure	3.2D	and	F).	The	dynamic	shift	 in	populations	of	 the	draining	and	non-draining	 lymph	nodes	during	WNV	infection	 was	 also	 evident	 in	 the	 percentages	 of	 T	 cells	 (Figure	 3.2C),	 including	 CD4+	(Figure	3.2E)	and	CD8+	subsets	(Figure	3.2G),	which	decreased	from	d3	p.i.	onwards	in	all	three	nodes.	At	d0	p.i.,	CD4+	and	CD8+	T	cells	constituted	30-40%	and	20-30%	of	the	total	leukocyte	 population,	 respectively,	 in	 all	 of	 the	 lymph	 nodes	 examined.	 By	 d7	 p.i.	 the	percentage	of	T	 cells	 in	 the	CLN	had	 reduced	 to	 approximately	one	 third	of	 the	 starting	values,	 while	 the	 proportion	 of	 ILN	 and	 MLN	 T	 cells	 decreased	 by	 ~20%.	 The	 overall	increase	 in	 T	 cell	 numbers	 of	 the	 CLN,	 as	 compared	 to	 the	 gradual	 decline	 in	 their	percentages	suggests	 that	another	 leukocyte	population	was	expanding	at	a	greater	 rate	than	the	T	cells.		
Figure	3.2.	T	cell	populations	in	the	draining	(CLN)	and	non-draining	lymph	nodes	
(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Panel	 A	 demonstrates	 the	 representative	 flow	 cytometric	 gating	 of	 T	 cells	 in	 the	 lymph	node.	The	sequential	starting	gates	are	 listed	above	each	panel.	The	number	(B)	and	(C)	percentage	 of	 total	 T	 cells	 (CD45+CD3+NK1.1-)	 in	 the	 CLN	 (red),	 ILN	 (blue)	 and	 MLN	(green)	 of	mice	 following	 lethal	WNV	 infection	 (6x104	PFU)	 on	 d0,	 3,	 5,	 6	 and	 7	 p.i.	 are	shown.	 T	 cells	were	 further	 categorised	 according	 to	 CD4	and	 CD8	expression.	 Panels	 D	and	E	show	the	numbers	and	percentages	of	CD4+	T	cells	(CD3+CD4+CD8-)	with	graphs	F	and	G	representing	 the	numbers	and	percentages	of	CD8+	T	 (CD3+CD8+CD4-)	 cells	 in	 the	CLN,	MLN	and	ILN	of	WNV-infected	mice	on	d0,	3,	5,	6	and	7	p.i.	Values	for	CD3+,	CD4+	and	CD8+	T	cells	in	panels	C,	E	and	G	are	expressed	as	a	percentage	of	total	leukocytes	in	the	CLN,	 MLN	 and	 ILN.	 Data	 are	 shown	 as	 the	 mean	 ±SEM	 of	 values	 from	 3	 independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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3.2.1.2. B,	NK	and	NKT	cells	
B	cells	are	critical	components	in	the	development	of	humoral	immunity	and	as	such	form	the	 second	 largest	 population	 of	 leukocytes	 in	 lymph	 nodes	 during	 homeostatic	conditions.	 Figure	 3.3	 A	 illustrates	 the	 gating	 strategy	 for	 B	 cell	 identification.	 In	 this	model,	B	cells	comprised	up	to	20%	of	the	total	leukocyte	population	at	d0	p.i.	in	all	three	nodes	(Figure	3.3D).	In	a	similar	manner	to	T	cells,	there	was	a	rise	in	B	cell	numbers	of	the	CLN	during	the	course	of	infection,	reaching	a	~15-fold	increase	by	d7,	relative	to	d0	p.i.	 (Figure	3.2C).	Thus,	compared	to	the	 increase	 in	numbers	of	T	cells,	B	cell	expansion	was	markedly	greater	and	the	significant	increase	in	B	cell	number	is	mirrored	in	the	40%	elevation	of	B	cell	percentage	in	the	CLN	(Figure	3.3D).	Parallel	enumeration	of	MLN	and	ILN	 B	 cells	 (Figure	 3.3C)	 demonstrated	 a	 negligible	 change	 throughout	 the	 course	 of	infection	 however,	 the	 percentage	 contribution	 of	 ILN	 and	 MLN	 B	 cells	 to	 the	 total	leukocyte	population	increased	by	15-20%	during	this	time	and	was	significantly	different	from	d0p.i	(Figure	3.3D).		The	gating	strategy	used	to	identify	the	innate	lymphoid	NK	cell	and	heterogeneous	NKT	cell	 populations	 is	 illustrated	 in	 Figure	 3.3	 B.	 Both	 populations	 contribute	 to	 less	 than	0.5%	of	the	total	leukocyte	population	in	the	lymph	node	in	each	case	(Figure	3.3F	and	H).	Regardless,	these	cells	have	important	effector	functions	during	viral	infection.	NK	(Figure	3.3E)	and	NKT	cell	(Figure	3.3G)	numbers	in	the	CLN	showed	similar	kinetics	to	B	and	T	cells,	with	an	overall	increase,	relative	to	d0,	but	ILN	and	MLN	numbers	remained	more	or	less	constant	during	infection.	The	percentage	of	NK	cells	in	the	CLN	and	MLN	exhibited	a	marginal	 increase,	with	a	 significant	 rise	 in	 the	 ILN	by	d7	p.i.	 (Figure	3.3F).	Off	all	 three	nodes,	only	the	MLN	showed	a	significant	rise	in	the	percentage	of	NKT	cells	from	d5-7	p.i.	(Figure	 3.3H).	 In	 summary,	 both	 B	 and	 T	 cell	 populations	 in	 the	 CLN	 had	 increased	significantly,	 with	 the	 expansion	 of	 B	 cells	 much	 greater,	 therefore	 accounting	 for	 the	decrease	 in	 T	 cell	 percentage.	 In	 contrast	 to	 the	 CLN,	 an	 absolute	 reduction	 in	 T	 cell	
Figure	3.3.	B,	NK	and	NKT	cell	populations	 in	the	draining	(CLN)	and	non-draining	
lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Panels	A	and	B	demonstrate	 the	representative	 flow	cytometric	gating	of	B	cells	(A)	and	NK1.1+	 cells	 (B)	 in	 the	 lymph	 node.	 The	 sequential	 starting	 gates	 are	 listed	 above	 each	panel.	The	number	 (C)	and	percentage	 (D)	of	 total	B	cells	 (CD45+B220+CD19+CD11c+)	 in	the	CLN	(red),	ILN	(blue)	and	MLN	(green)	of	mice	following	lethal	WNV	infection	(6x104	PFU)	on	d0,	3,	5,	6	and	7	p.i.	 are	shown.	Please	note	 the	change	 in	y-axis	 from	graphs	C	(x106)	and	D	(100%),	to	figures	E	(x104)	and	F	(0.1%).	Graphs	E	and	F	show	the	numbers	and	 percentages	 of	 NK	 cells	 (CD45+NK1.1+CD3-)	 with	 graphs	 G	 and	 H	 representing	 the	numbers	 and	 percentages	 of	NKT	 (CD45+NK1.1+CD3+)	 cells	 in	 the	 CLN,	MLN	 and	 ILN	 of	WNV-infected	mice	on	d0,	3,	5,	6	and	7	p.i. Values	of	B,	NK	and	NKT	cells	in	panels	D,	F	and	H,	 are	 expressed	 as	 a	 percentage	 of	 total	 leukocytes	 in	 the	CLN,	MLN	and	 ILN.	Data	 are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	 each	 experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.	 	
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numbers	in	the	ILN	and	MLN,	rather	than	an	increase	in	B	cell	numbers,	likely	accounts	for	the	increase	in	B	cell	percentages	in	the	non-draining	nodes,	since	there	was	little,	 if	any	increase	in	B	cell	number	in	these	nodes.	
3.2.1.3. Monocytes	and	neutrophils	
Figures	A	and	B	show	the	respective	flow	cytometry	gating	of	neutrophils	and	monocytes.	Similar	 to	 NK1.1+	 subsets,	 monocyte	 and	 neutrophil	 numbers	 were	 very	 low	 in	 lymph	nodes	 during	 steady	 state	 (Figure	 3.4C	 and	 E).	 Combined,	 these	 CD11b+	 subsets	constituted	 less	 than	 one	percent	 of	 the	 total	 leukocyte	 population	 (Figure	 3.4D	 and	F).	Statistically,	 numbers	 of	 both	 remained	 largely	 unchanged	 in	 all	 three	 nodes	 over	 the	course	 of	 infection	 (Figure	 3.4C	 and	 E),	 notwithstanding	 increases	 seen	 on	 d7p.i.	 in	 the	CLN.	 Neutrophils	 showed	 an	 increase	 in	 percentage	 in	 both	MLN	 and	 ILN,	 with	 a	 non-significant	 reduction	 in	 the	CLN	 (Figure	3.4D).	 Considering	 their	 low	percentages	 in	 the	lymph	 node,	 this	 change	 in	 is	 likely	 a	 side	 effect	 of	 more	 substantial	 changes	 in	 other	leukocyte	 subsets.	 Statistically	 significant	 changes	 in	 the	 percentage	 of	 monocytes	 was	only	evident	in	the	CLN	at	d3,	5	and	7	p.i.	(Figure	3.4F).			
3.2.1.4. Dendritic	cell	populations	
The	 irreplaceable	 role	 of	 DC	 in	 the	 lymph	 node	 is	 remarkable,	 considering	 the	 low	frequency	of	this	subset	in	the	lymph	nodes,	compared	to	B	and	T	cells.	DC	are	crucial	for	antigen	 presentation	 and	 activation	 of	 B	 and	 T	 cells,	 and	 the	 generation	 of	 effective	immune	responses	are	significantly	 impaired	 in	 the	absence	of	DC.	The	DC	 in	 the	 lymph	node	were	grouped	according	to	their	differential	expression	of	CD11c,	CD11b,	B220	and	CD8α.	 	 Based	 on	 CD11b	 and	CD11c	 expression,	 there	were	 3	 distinct	 populations	 of	DC	identified,	 namely	CD11c+CD11b+,	 CD11chiCD11bint	 and	CD11c+CD11b-	(Figure	3.5A).	 The	
Figure	 3.4.	 Monocyte	 and	 neutrophil	 populations	 in	 the	 draining	 (CLN)	 and	 non-
draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Panels	A	and	B	demonstrate	the	representative	flow	cytometric	gating	of	neutrophils	(A)	and	monocytes	(B)	in	the	lymph	node.	The	sequential	starting	gates	are	listed	above	each	panel.	 Graphs	 C	 and	 D	 show	 the	 numbers	 and	 percentages	 of	 neutrophils	(CD45+CD11bhiLy6G+SSChi)	in	the	CLN	(red),	ILN	(blue)	and	MLN	(green)	of	WNV-infected	mice	 on	 d0,	 3,	 5,	 6	 and	 7	 p.i.	 The	 numbers	 (E)	 and	 (F)	 percentages	 of	 monocytes	(CD45+CD11b+	Ly6G-CD11c-)	in	the	CLN	(red),	ILN	(blue)	and	MLN	(green)	under	the	same	conditions	described	above.	Values	of	monocytes	and	neutrophils	 in	graphs	D	and	F	are	expressed	as	a	percentage	of	total	leukocytes	in	the	CLN,	MLN	and	ILN.	Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Figure	3.5.	Dendritic	cell	populations	in	the	draining	(CLN)	and	non-draining	lymph	
nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Panel	A	demonstrates	 the	 representative	 flow	 cytometric	 gating	of	 dendritic	 cells	 in	 the	above	 lymph	nodes.	The	 sequential	 starting	 gates	 are	 listed	 above	each	panel.	Dendritic	cell	 populations	 (CD11c+)	 were	 defined	 based	 on	 differential	 CD11c	 and	 CD11b	expression.	 The	 numbers	 and	 percentages	 of	 CD11c+CD11b+	 DC	 (B&C),	 CD11chiCD11bint	DC	(D&E)	and	CD11c+CD11b-	DC	(F&G)	 in	 the	CLN	(red),	 ILN	(blue)	and	MLN	(green)	of	mice	following	lethal	WNV	infection	(6x104PFU)	on	d0,	3,	5,	6	and	7	p.i.	was	shown.	Values	of	DC	populations	in	graphs	C,	E	and	G	are	expressed	as	a	percentage	of	total	leukocytes	in	the	CLN,	MLN	and	ILN.	Data	are	shown	as	the	mean	±SEM	of	values	from	3	 independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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number	of	CD11c+CD11b+	cells	in	the	CLN	increased	significantly	from	d5	p.i.,	after	which	it	 plateaued,	 remaining	 high	 throughout	 the	 course	 of	 infection	 (Figure	 3.5B),	 while	numbers	in	the	MLN	and	ILN	remained	at	baseline	levels	throughout	(Figure	3.5B).	On	the	other	hand,	numbers	of	both	the	CD11chiCD11bint	(Figure	3.5D)	and	CD11c+CD11b-	(Figure	3.5F)	 populations	 in	 the	 CLN	 continued	 expanding	 until	 the	 end	 of	 the	 disease	 course.	Indeed,	 the	 number	 of	 CD11chiCD11bint	 cells	 in	 the	 CLN	 (below	 500	 cells	 at	 d0)	 had	increased	significantly	by	~14-fold	at	d7	p.i.	There	was	a	transient	increase	of	this	subset	in	the	MLN	between	d3	and	6	p.i.,	which	returned	to	baseline	by	d7	p.i.	but	corresponding	numbers	in	the	ILN	remained	unchanged	(Figure	3.5D).	The	CD11c+CD11b-	subset	was	the	most	abundant	DC	population	present	in	all	three	lymph	nodes	of	mice	in	the	steady	state	and	this	number	underwent	a	7-fold	increase	in	the	CLN	by	d7,	relative	to	d0	p.i.	Similar	to	the	 CD11chiCD11bint	 subset,	 numbers	 of	 the	 CD11c+CD11b-	 population	 in	 the	 MLN	displayed	a	slight	increase	from	d3	p.i.,	which	then	returned	to	baseline	by	d7	p.i.,	with	ILN	numbers	 remaining	 constant	 throughout	 the	 course	of	 infection	 (Figure	3.5F).	These	DC	subsets	 represented	 a	 small	 proportion	 of	 the	 total	 leukocyte	 population	 (<2%)	 and,	except	for	a	short-lived	non-significant	increase	in	all	three	subsets	of	the	MLN	at	5-6p.i.,	percentages	 of	 all	 three	 lymph	 nodes	 remained	 unchanged	 throughout	 the	 course	 of	infection	(Figure	3.5C,	E	and	G).		Numbers	 of	 pDC	 (Figure	 3.6A)	 in	 the	 CLN	 expanded	 from	 d0-7	 p.i.,	 but	 this	 was	 not	significant	(Figure	3.6C)	and	the	percentage	remained	more	or	less	constant	over	this	time	(Figure	3.6D).	Numbers	of	pDC	in	the	ILN	and	MLN	remained	statistically	unchanged,	with	a	reduction	in	percentage	present	only	at	d3	and	7p.i.	in	the	MLN.		In	addition,	a	CD8α+	subset	could	be	distinguished	 in	 the	CD11c+CD11b-	DC	(Figure	3.6B)	and	showed	an	increase	in	number	of	13-fold	in	the	CLN	between	d5-7	p.i.,	with	ILN	and	MLN	numbers	 remaining	 stable	 during	 this	 time	 (Figure	 3.6E).	 This	 subset	 represented	
Figure	 3.6.	 Plasmacytoid	 and	 resident	 lymphoid	 DC	 populations	 in	 the	 draining	
(CLN)	 and	 non-draining	 lymph	 nodes	 (MLN,	 ILN)	 of	 the	 CNS	 following	 lethal	WNV	
infection	
		Panels	 A	 and	 B	 demonstrate	 the	 representative	 flow	 cytometric	 gating	 of	 pDC	 (A)	 and	CD8α+	 DC	 (B).	 The	 sequential	 starting	 gates	 are	 listed	 above	 each	 panel.	 Dendritic	 cell	populations	 (CD11c+)	were	defined	based	on	differential	CD11c,	CD8α,	B220	and	CD11b	expression.	The	numbers	and	percentages	of	plasmacytoid	DC	(CD11c+B220+)	(C&D)	and	lymphoid-resident	DC	(CD11c+CD8α+)(E&F)	in	the	CLN	(red),	ILN	(blue)	and	MLN	(green)	of	mice	 following	 lethal	WNV	 infection	 (6x104PFU)	 on	 d0,	 3,	 5,	 6	 and	 7	 p.i.	 are	 shown.	Values	 for	 pDC	 and	 CD8α+	 DC	 populations	 are	 expressed	 as	 a	 percentage	 of	 total	leukocytes	in	the	CLN,	MLN	and	ILN.	Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	 experiments,	 with	 3-4	 mice/group	 in	 each	 experiment.	 Statistical	 analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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less	than	0.2%	of	the	total	leukocyte	population	in	all	the	nodes	analysed	and	remained	so	throughout	 the	 course	 of	 infection,	 with	 no	 expansion	 in	 percentage	 (Figure	 3.6F).	Collectively,	 these	 data	 indicate	 that	 CNS	 inflammation	 does	 not	 only	 induce	 change	 in	various	 leukocyte	 subsets	 in	 the	draining	CLN,	but	 also	 the	peripheral	non-draining	 ILN	and	MLN.	
3.2.2. Changes	 in	 cell	 surface	 marker	 expression	 associated	 with	
inflammation	 in	 the	 draining	 and	 non-draining	 lymph	 nodes	 during	
WNV	encephalitis	
The	distinct	 changes	 associated	with	 inflammation,	 occurring	 in	 both	draining	 and	non-draining	lymph	nodes,	during	the	course	of	infection	prompted	us	to	further	examine	cell	surface	marker	 expression	 of	 leukocytes	 in	 these	 nodes.	 Of	 particular	 interest	were	 the	changes	we	 identified	 in	 the	 levels	 of	 Ly6C	expression	 in	 the	draining	 and	non-draining	lymph	nodes,	as	follows.		During	the	7-day	time-course	of	infection	with	an	LD100	dose	of	WNV	(6x104	PFU),	there	was	 a	 distinct	 shift	 in	 lymphocyte	 populations	 from	 the	 CLN,	 ILN	 and	MLN	 towards	 an	increased	 expression	 of	 Ly6C.	 Flow	 cytometry	 histograms	 illustrate	 the	 upregulation	 of	the	cell	surface	marker	Ly6C	in	the	B	(Figure	3.7A)	and	T	cell	(Fig3.7-B	and	C)	populations	of	 all	 3	 nodes.	 Increases	 in	 Ly6C	 expression	 in	 B	 (Figure	 3.7A),	 CD4+	 (Figure	 3.7B)	 and	CD8+	T	cells	(Figure	3.7C)	 in	the	CLN	could	be	observed	from	as	early	as	d3p.i.,	with	the	CD8+	T	cells	subset	showing	the	highest	Ly6C	expression	by	d7p.i.	Upregulation	of	Ly6C	in	the	B	and	T	cells	of	the	ILN	and	MLN	also	occurred,	however	this	was	only	evident	from	d5p.i.	 (i.e.	 2	 days	 after	 CLN).	 Similar	 to	 the	 Ly6C	 expression	 of	 the	 CLN,	 CD8+	T	 cells	isolated	 from	 the	 ILN	 and	 MLN	 also	 exhibited	 the	 highest	 Ly6C	 expression	 by	 d7p.i.,	compared	to	the	B	and	CD4+	T	cells.	Indeed,	WNV	infection	induced	a	significant	increase	in	the	mean	Ly6C	expression	of	most	of	the	leukocyte	subsets	at	various	time	points	in	the	
Figure	3.7.	 Ly6C	 expression	of	T	 and	B	 cell	 populations	 in	 the	draining	 (CLN)	 and	
non-draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Representative	flow	cytometric	histograms	(A-C)	illustrate	the	change	in	Ly6C	expression	of	(A)	B	cells	(B220+/CD19+),	(B)	CD4+	T	cells	and(C)	CD8+	T	cells	in	the	CLN,	ILN	and	MLN	on	d0,	3,	5,	6	and	7p.i.	following	lethal	WNV	infection	(6x104	PFU).	WNV-infected	samples	are	shown	in	red,	while	isotype	controls	are	shown	in	grey.		 	
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CLN,	ILN	and	MLN,	relative	to	baseline	(Figures	3	&	4).	However,	of	interest	here	was	the	observation	that	in	most	cases	an	increase	in	Ly6C	expression	was	first	seen	in	a	subset	of	cells,	already	expressing	Ly6C	at	 intermediate	 levels,	which	 increased	with	 time,	both	 in	level	 of	 expression	 (brightness)	 and	 number	 of	 cells	 contributing	 to	 this	 Ly6Chi	 subset.	This	initial	data,	demonstrating	a	shift	towards	higher	expression	of	Ly6C	in	all	the	major	populations	 of	 the	 lymph	 node,	 in	 particular	 B	 and	 T	 cells,	 prompted	 our	 further	investigation	into	the	differential	upregulation	of	Ly6C	expression	in	the	various	leukocyte	subsets	of	the	draining	and	non-draining	lymph	nodes	of	the	CNS.		Along	 the	 lines	 of	 work	 previously	 published	 by	 our	 laboratory	 (Terry	 et	 al.	 2015),	leukocytes	 were	 further	 characterised,	 based	 on	 Ly6C	 expression,	 as	 Ly6Chi,	 Ly6Cint	 or	Ly6C-,	and	each	subset	enumerated	(Figure	3.8A,	B,	C)	and	the	kinetics	of	Ly6C	expression	shown	 in	 representative	 flow	 cytometry	 profiles	 over	 the	 duration	 of	 infection	 (Figure	3.8D	&	E).	At	d0p.i.,	B	cells	in	the	CLN	were	mainly	Ly6C-,	(Figure	3.8D)	and	this	was	also	true	 for	 the	 ILN	and	MLN	on	d0p.i.	 (data	not	shown).	However,	by	d7p.i.	41%,	35%	and	22%	of	B	cells	 in	 the	CLN,	 ILN	and	MLN,	respectively,	had	become	Ly6Cint,	with	very	 few	Ly6Chi	 B	 cells	 present	 in	 these	 nodes.	 Enumeration	 of	 these	 events	 demonstrated	 a	significant	 increase	 in	 absolute	Ly6Chi,	 Ly6Cint	 and	Ly6C-	B	 cell	numbers	 (Figure	3.8A)	 in	the	CLN	by	d7	p.i.,	 however	 the	Ly6Cint	and	Ly6C-	cell	 numbers	 exceeded	 those	of	 Ly6Chi	subset,	despite	a	significant	increase	in	the	Ly6Chi	subset	on	d7p.i.	In	the	ILN	the	Ly6C-	B	cells	 had	 decreased	 significantly	 by	 d6p.i.,	 although	 both	 Ly6C-	 and	 Ly6Cint	 remained	 at	more	or	less	the	same	levels	throughout,	whereas	the	Ly6Chi	B	cell	numbers	had	increased	significantly	by	d7p.i.	In	contrast,	in	the	MLN,	while	the	Ly6Cint	had	increased	significantly	by	 d7p.i.,	 there	 was	 a	 no	 significant	 variation	 of	 other	 populations	 over	 the	 course	 of	disease.	 This	 suggests	 that,	 similar	 to	 the	 CNS-draining	 CLN,	 the	 non-draining	 ILN	 and	MLN	have	 increased	 numbers	 of	 B	 cells	 expressing	 Ly6C	 at	 intermediate	 or	 high	 levels.	
Figure	3.8	Differential	Ly6C	subsets	in	the	B	and	T	cell	populations	of	the	draining	
(CLN)	 and	 non-draining	 lymph	 nodes	 (MLN,	 ILN)	 of	 the	 CNS	 following	 lethal	WNV	
infection	
	Leukocytes	 subsets	 in	 the	CLN,	 ILN	and	MLN	were	 further	 characterised	based	on	Ly6C	expression	 and	 subsequently	 classified	 as	 Ly6Chi	 (square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 Significance,	 compared	 to	 d0,	 for	 each	 subset	was	 defined	 as	 follows:	 ***Ly6Chi	+++Ly6Cint	and	ØØØLy6C-.	The	number	of	Ly6Chi/int/-	B	cells	(A)	(B220+/CD19+),	CD4+	(B)	and	CD8	 +	T	 (C)	 cells	 in	 the	CLN,	 ILN	and	MLN	on	d0,	3,	 5,	 6	 and	7p.i.	 following	 lethal	WNV	infection	 (6x104	PFU)	are	 shown.	Note	 the	change	 in	y-axis	 for	B	cells	 (x106)	and	T	cells	(x105).	 Flow	 cytometry	 contour	 plots	 D-E	 demonstrate	 the	 distributions	 of	 Ly6C	expression	 in	 the	 CLN,	 ILN	 and	 MLN	 of	 WNV-infected	 mice	 (6x104	 PFU)	 on	 d7p.i.,	compared	 to	d0.	Since	d0	p.i.	 for	CLN,	 ILN	and	MLN	were	similar,	only	d0	p.i.	 for	CLN	 is	shown.	 Figure	 D	 shows	 the	 change	 in	 Ly6C	 expression	 of	 B	 cells,	 with	 figure	 E	demonstrating	the	change	in	T	cells,	including	total	T	cells	(CD3+),	CD4+	and	CD8+	T	cells.	Note	the	data	in	panels	A-C	are	averaged	from	3	experiments,	while	those	in	D	and	E	are	representative	of	single	animals	at	single	time	points.	Thus	there	will	 inevitably	be	some	disparity	between	these	sets	of	data.	Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.	 	
Figure 3.8
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The	increase	in	Ly6Chi	and	Ly6Cint	B	cell	numbers	in	the	ILN	and	MLN,	respectively,	were	mirrored	by	a	similar	relative	decrease	in	Ly6C-	cells,	with	the	total	B	cell	number	in	these	nodes	remaining	stable	throughout	the	disease	course.	In	the	CLN,	despite	a	small	increase	in	Ly6Chi	cells	on	d7p.i.,	 it	was	clearly	 the	progressive	 increase	 in	Ly6Cint	and	Ly6C-	cells	that	were	responsible	for	the	increase	in	total	B	cell	number	over	the	course	of	infection.		Even	at	d0p.i.,	the	overall	level	of	Ly6C	expression	in	T	cells	was	higher	than	that	of	B	cells	in	 the	 lymph	nodes	 (Figure	3.8E).	 This	was	 contributed	 in	 the	 case	 of	 CD4+	T	 cells,	 by	 a	subpopulation	 that	 was	 Ly6Cint	 at	 this	 time-point,	 and	 in	 the	 case	 of	 CD8+	 T	 cells	 by	substantial	Ly6Cint	and	Ly6Chi	populations.	As	a	result	of	CNS	infection,	there	were	higher	numbers	of	T	cells	expressing	increased	Ly6C	in	both	CD4+	and	CD8+	T	cells	populations.	However,	 like	 the	 B	 cells,	 CD4+	 T	 cells	 showed	 an	 increase	 primarily	 in	 the	 numbers	 of	Ly6Cint	cells,	while	CD8+	T	cells	showed	an	increase	in	cell	numbers	in	both	the	Ly6Cint	and	Ly6Chi	compartments	over	the	course	of	 infection.	Numbers	of	Ly6Cint	and	Ly6Chi	CD4+	T	cells	 increased	significantly	(Figure	3.8B)	by	d6	and	d7p.i.,	 respectively,	 in	the	CLN,	with	no	appreciable	change	in	Ly6C-	CD4+	T	cell	number	over	the	disease	course.	In	the	ILN	and	MLN,	there	was	a	general	trend	towards	reduced	Ly6Cint	and	Ly6C-	CD4+	T	cells	numbers	by	d7p.i.,	 compared	 to	mock-infected	controls	 (Figure	3.8E).	This	suggests	 that,	with	 the	total	 number	 of	 T	 cells	 in	 the	 non-draining	 ILN	 and	 MLN	 decreasing,	 there	 was	 little	change	in	Ly6C	expression	in	the	cells	remaining	in	these	nodes.			Notably,	the	Ly6Chi	CD8+	T	cell	subset	had	increased	by	d7p.i.	(Figure	3.8E),	this	occurred	in	 parallel	 to	 the	 increase	 in	 Ly6ChiCD8+	 T	 cell	 numbers	 from	 d3p.i.	 onward,	 plateauing	until	 d7	 p.i.	 (Figure	 3.8C).	 In	 contrast,	 the	 ILN	 and	 MLN	 demonstrated	 a	 substantial	reduction	 in	 total	CD8+	T	cell	numbers	 in	response	to	 infection	(Figure	3.2F),	which	was	
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mirrored	 in	 the	 significant	 reduction	of	 Ly6C-	CD8+	T	 cells	 in	 these	nodes	 (Figure	3.8C),	relative	to	d0p.i.			NK	 and	 NKT	 cells	 in	 all	 three	 nodes	 showed	 distinct	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	subsets,	enumerated	in	Figure	3.9	A	and	B	and	shown	as	representative	contour	plots	in	panels	E	and	F.	Both	NK	and	NKT	cells,	in	all	three	nodes,	showed	a	reduction	in	the	percentage	of	Ly6C-	 cells	 and	 increase	 in	 the	 percentage	 of	 Ly6Chi	 cells	 by	 d7p.i.,	 compared	 to	 d0p.i.	Changes	in	numbers	of	Ly6Chi,	Ly6Cint	and	Ly6C-	NK	cells	in	the	CLN	were	not	statistically	significant,	but	appeared	to	increase	by	d3p.i.	and	plateau	thereafter	(Figure	3.9A),	while	numbers	 of	 these	 cells	 in	 the	 ILN	 and	 MLN	 remained	 relatively	 stable	 over	 this	 time.	Consistent	with	the	contour	plots	(Figure	3.9F),	numbers	of	Ly6Chi	NKT	cells	 in	the	CLN,	ILN	 and	MLN	 (Figure	 3.9B)	 all	 appeared	 to	 increase,	 compared	 to	 d0p.i.,	whereas	 there	was	a	significant	reduction	in	Ly6C-	NKT	cell	number	in	the	ILN	from	d3p.i.		Based	 on	 our	 gating	 strategy,	 neutrophils	 were	 mainly	 Ly6Chi	 and	 Ly6Cint,	 with	 almost	none	 of	 the	 neutrophils	 being	 Ly6C-	 (Figure	 3.9G).	 Nevertheless,	 despite	 possessing	relatively	 high	 baseline	 Ly6C	 expression,	 the	 neutrophils	 in	 all	 three	 nodes	 further	upregulated	Ly6C	expression	 in	 response	 to	 infection.	Enumeration	of	 these	neutrophils	showed	 that	Ly6Cint	 neutrophils	 increased	 significantly	by	d7p.i.,	 relative	 to	d0p.i.	 in	 the	CLN	(Figure	3.9C).	Both	Ly6Cint	and	Ly6Chi	neutrophils	 in	the	ILN	increased	substantially	by	d7	p.i.,	relative	to	d0,	whereas	only	Ly6Cint	neutrophils	in	the	MLN	increased	at	d5p.i.			At	d0p.i.,	 the	majority	of	monocytes	were	Ly6C-,	 however,	 by	d7p.i.	 the	monocytes	 from	the	 draining	 and	 non-draining	 nodes	 had	 upregulated	 their	 expression	 of	 Ly6C	 to	 form	three	 distinct	 populations	 (Figure	 3.9H).	 The	 number	 of	 Ly6Chi	 monocytes	 in	 the	 CLN	increased	significantly	by	d7,	compared	to	d0p.i.	(Figure	3.9D),	whereas	the	Ly6Chi,	Ly6Cint	
Figure	3.9	Differential	Ly6C	subsets	in	the	NK1.1+	and	CD11b+	cell	populations	of	the	
draining	(CLN)	and	non-draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	
WNV	infection	
		Leukocytes	 subsets	 in	 the	CLN,	 ILN	and	MLN	were	 further	 characterised	based	on	Ly6C	expression	 and	 subsequently	 classified	 as	 Ly6Chi	 (square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 Significance,	 compared	 to	d0,	 for	 each	 subset	was	defined	as	 follows:	 ***Ly6Chi;	+++Ly6Cint	and	ØØØLy6C-.	The	number	of	Ly6Chi/int/-	NK	cells	(A)	(NK1.1+CD3-),	NKT	cells	(B)	(NK1.1+CD3+),	Neutrophils	(C)	(CD11bhiLy6G+),	and	monocytes	(D)	(CD11b+CD11c-),	in	the	CLN,	ILN	and	MLN	on	d0,	3,	5,	6	and	7	p.i.	following	lethal	WNV	infection	(6x104PFU)	are	shown.	 Flow	 cytometry	 contour	 plots	 E-H	 demonstrate	 the	 distributions	 of	 Ly6C	expression	 in	 the	 CLN,	 ILN	 and	 MLN	 of	 WNV-infected	 mice	 (6x104	 PFU)	 on	 d7p.i.,	compared	 to	d0.	 	Since	d0	p.i.	 for	CLN,	 ILN	and	MLN	were	similar,	only	d0p.i.	 for	CLN	 is	shown.	 Figure	 E	 shows	 the	 change	 in	 Ly6C	 expression	 of	 NK	 cells,	 with	 figure	 F	demonstrating	 the	 change	 in	 NKT	 cells.	 Figures	 G	 and	 H	 are	 the	 representative	 flow	cytometry	plots	of	neutrophils	and	monocytes,	 respectively.	Note	 the	data	 in	panels	A-D	are	averaged	from	3	experiments,	while	those	in	E,	F,	G	and	H	are	representative	of	single	animals	at	single	time	points.	Thus	there	will	inevitably	be	some	disparity	between	these	sets	of	data.	Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.		 	
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and	Ly6C-	monocyte	numbers	 in	 the	 ILN	 and	MLN	did	not	 change	 significantly	 over	 the	disease	course.			The	 various	DC	 subsets,	 namely	 CD11c+CD11b+,	 CD11chiCD11bint	 and	 CD11c+CD11b-	also	displayed	 differential	 Ly6C	 expression	 (Figure	 3.10D,	 E,	 F),	 numbers	 of	which	 varied	 in	response	to	 infection	(Figure	3.10A,	B,	C).	Note	that	the	distribution	of	Ly6C	on	d0p.i.,	 in	the	ILN	and	MLN	was	similar	to	that	of	 the	CLN,	thus	only	the	CLN	d0p.i.	contour	plot	 is	shown.	 The	 numbers	 of	 Ly6Chi	 and	 Ly6Cint	 CD11c+CD11b+	 DC	 in	 the	 CLN	 increased	significantly	 from	 d3p.i.	 (Figure	 3.10A).	 In	 the	 MLN,	 a	 transient,	 statistically	 significant	increase	in	numbers	of	Ly6Chi,	Ly6Cint	and	Ly6C-	CD11c+CD11b+	cells	occurred	at	d5p.i.	but	decreased	on	d6-7	p.i.	The	number	of	Ly6Chi,	Ly6Cint	and	Ly6C-	CD11chiCD11bint	cells	in	the	CLN	all	increased	substantially	by	d7p.i.	(Figure	3.10B),	relative	to	d0,	whereas	these	cells	remained	unchanged	in	the	ILN,	with	a	short-lived,	but	significant,	 increase	in	Ly6Chi	and	Ly6Cint	cells	at	d5p.i.	in	the	MLN.	The	CD11c+CD11b-	DC	subset	(Figure	3.10F)	had	a	lower	percentages	 of	 Ly6Chi	cells	 in	 the	 CLN,	 ILN	 and	MLN	 at	 d7p.i.,	 compared	 to	 d0p.i.,	 with	higher	 the	 percentages	 of	 Ly6Cint.	However,	 the	 absolute	 numbers	 of	 Ly6Chi,	 Ly6Cint	 and	Ly6C-	 cells	 increased	 by	 d7p.i.	 in	 the	 CLN,	 with	 no	 response	 in	 the	 ILN	 and	 a	 variable	response	in	the	MLN	(Figure	3.10C).		The	 pDC	 subset	 (Figure	 3.11A	 and	 C)	 and	 CD8α+DC	 (Figure	 3.11B	 and	 D)	 had	 a	 lower	percentage	of	Ly6Chi	cells	 in	the	CLN,	ILN	and	MLN	at	d7p.i.,	compared	to	d0p.i.,	with	the	percentage	of	Ly6Cint	cells	increasing.	In	the	CLN	this	translated	to	significant	increases	in	Ly6Chi,	 Ly6Cint	 and	 Ly6C-	pDC,	 relative	 to	 d0p.i.	 (Figure	 3.11A),	 whereas	 ILN	 numbers	showed	 negligible	 changes	 and	 MLN	 Ly6Cint	 pDC	 had	 a	 short-lived	 increase	 at	 d5p.i.	Moreover,	while	there	were	significant	increases	in	the	Ly6Chi	and	Ly6Cint	CD8α+DC	in	the	CLN	at	d7p.i.	(Figure	3.11B),	relative	to	d0,	the	Ly6C-	population	remained	unchanged.	As	
Figure	 3.10	Differential	 Ly6C	 subsets	 in	 the	DC	 populations	 of	 the	 draining	 (CLN)	
and	non-draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Leukocytes	 subsets	 in	 the	CLN,	 ILN	and	MLN	were	 further	 characterised	based	on	Ly6C	expression	 and	 subsequently	 classified	 as	 Ly6Chi	 (square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 Significance,	 compared	 to	d0,	 for	 each	 subset	was	defined	as	 follows:	 ***Ly6Chi;	+++Ly6Cint	and	ØØØLy6C-.	The	number	of	Ly6Chi/int/-	CD11c+CD11b+	DC	(A),	CD11chiCD11bint	DC	(B)	and	CD11c+CD11b-	DC	(C)	in	the	CLN,	ILN	and	MLN	on	d0,	3,	5,	6	and	7p.i.	following	lethal	WNV	infection	(6x104PFU)	are	shown.	Note	the	change	in	y-axis	for	CD11c+CD11b+	(x103),	 CD11chiCD11bint	 (x103)	 and	 CD11c+CD11b-	 (x104)	 cells.	 Flow	 cytometry	 contour	plots	D-F	demonstrate	 the	distributions	of	 Ly6C	expression	 in	 the	CLN,	 ILN	and	MLN	of	WNV-infected	mice	(6x104PFU)	on	d7p.i.,	 compared	to	d0.	Since	d0	p.i.	 for	CLN,	 ILN	and	MLN	 were	 similar,	 only	 d0p.i.	 for	 CLN	 is	 shown.	 	 Figure	 D	 shows	 the	 change	 in	 Ly6C	expression	 of	 CD11c+CD11b+DC,	 with	 figure	 E	 demonstrating	 the	 change	 in	CD11chiCD11bint	DC	and	figure	F	illustrating	the	CD11c+CD11b-	DC.	Note	the	data	in	panels	A-C	 are	 averaged	 from	 3	 experiments,	 while	 those	 in	 D,	 E	 and	 F	 are	 representative	 of	single	animals	at	single	time	points.	Thus	there	will	inevitably	be	some	disparity	between	these	sets	of	data.	Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.	 	
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Figure	 3.11	Differential	 Ly6C	 subsets	 in	 the	DC	 populations	 of	 the	 draining	 (CLN)	
and	non-draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Leukocytes	 subsets	 in	 the	CLN,	 ILN	and	MLN	were	 further	 characterised	based	on	Ly6C	expression	 and	 subsequently	 classified	 as	 Ly6Chi	 (square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 Significance,	 compared	 to	d0,	 for	 each	 subset	was	defined	as	 follows:	 ***Ly6Chi;	+++Ly6Cint	 and	 ØØØLy6C-.	 The	 number	 of	 Ly6Chi/int/-	CD11c+B220+	 pDC	 (A),	 CD11c+CD11b-CD8α+	DC	 (B)	 in	 the	 CLN,	 ILN	 and	 MLN	 on	 d0,	 3,	 5,	 6	 and	 7p.i.	 following	 lethal	 WNV	infection	(6x104PFU)	are	shown.	Flow	cytometry	contour	plots	C	(CD11c+B220+	pDC)	&	D	(CD11c+CD11b-CD8α+)	 demonstrate	 the	 distribution	 of	 Ly6C	 expression	 in	 the	 CLN,	 ILN	and	MLN	 of	WNV-infected	mice	 (6x104PFU)	 on	 d7p.i.,	 compared	 to	 d0.	 Since	 d0	 p.i.	 for	CLN,	ILN	and	MLN	were	similar,	only	d0p.i.	for	CLN	is	shown.	Note	the	data	in	panels	A-B	are	 averaged	 from	 3	 experiments,	 while	 those	 in	 C	 and	 D	 are	 representative	 of	 single	animals	at	single	time	points.	Thus	there	will	inevitably	be	some	disparity	between	these	sets	of	data.		Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.
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for	the	other	DC	subset,	numbers	in	the	ILN	showed	no	appreciable	changes,	whereas	MLN	Ly6Chi	CD8α+DC	showed	a	transient,	but	significant	increase	at	d5p.i.		In	 summary,	 although	 the	 numbers	 of	 cells	 in	 the	 ILN	 and	 MLN	 did	 not	 necessarily	increase	significantly	in	response	to	CNS	infection,	there	were	still	various	increases	in	the	Ly6C	populations	in	these	nodes.	These	data	show	that	the	non-draining	peripheral	lymph	nodes	are	indeed	modulated	in	response	to	CNS	infection.	Whether	these	differential	Ly6C	populations	have	functional	significance	remains	to	be	seen.	Nevertheless,	similar	signals	modulating	 the	CNS-draining	node	may	be	 reaching	 the	peripheral	nodes	and	will	 likely	have	 additional	 consequences	 such	 as	 inhibiting	 or	 inducing	 activation	 and/or	proliferation	of	cells.	
3.2.3. Proliferation	 of	 leukocyte	 subsets	 in	 the	 draining	 and	 non-
draining	lymph	nodes	during	WNV	encephalitis	
It	is	clear	that	the	downstream	effects	of	CNS	inflammation	was	not	limited	to	the	draining	lymph	 node,	 but	 had	 a	 significant	 impact	 on	 the	 non-draining	 lymph	 nodes.	 We	hypothesised	that	the	signals	modulating	the	decrease	in	T	cell	numbers	and	upregulation	of	Ly6C,	potentially	denoting	activation,	 seen	 in	 the	MLN	and	 ILN,	may	be	 reflected	 in	a	change	in	replication	status	in	these	nodes.	Moreover,	to	what	extent	the	expansion	of	CLN	cell	number	was	due	to	infiltration	versus	proliferation,	remains	to	be	elucidated.	Here,	a	Bromodeoxyuridine	 (BrdU)	 incorporation	 assay	 was	 used	 to	 quantify	 leukocyte	proliferation	 in	 the	CLN,	 ILN	and	MLN	and	determine	 if	 the	signals	modulating	 the	non-draining	 lymph	 nodes	 was	 also	 associated	 with	 increased	 cell	 division.	 BrdU	 is	 an	analogue	 of	 thymidine	 that	 becomes	 incorporated	 into	 cellular	DNA	when	 a	 cell	 is	 in	 S-phase.	BrdU	was	administered	i.v.	3	hours	prior	to	sacrificing	mice,	thus,	BrdU+	cells	only	identify	the	leukocytes	that	were	in	S-phase	during	this	time-frame.		
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	As	shown	in	figure	3.12	A,	 leukocyte	proliferation	was	first	detectable	from	d3	p.i.	 in	the	CLN	 and	 reached	 a	 6-fold	 increase	 by	 d7	 p.i.,	 relative	 to	 d0.	 In	 contrast,	 there	 was	 no	evidence	 of	 increased	BrdU	 incorporation	 in	 the	 ILN	 at	 any	 time-point	 during	 infection.	However,	leukocyte	proliferation	in	the	MLN	showed	a	significant	increase	from	baseline	levels	 between	 d6-7	 p.i.	 (Figure	 3.12A).	 Substantial	 cell	 division	 occurred	 in	 the	 T	 cell	population	of	the	CLN	with	a	4-5-fold	rise	by	d7	p.i.	In	contrast,	the	proliferation	of	T	cells	in	 the	 ILN	was	 reduced	 to,	 30%	 of	 baseline	 levels	 by	 d7	 p.i.	 (Figure	 3.12B).	 Both	 CD4+	(Figure	 3.12C)	 and	 CD8+	 T	 cell	 (Figure	 3.12D)	 subsets	 in	 the	 CLN	 had	 increased	 BrdU	incorporation	from	d3	p.i.,	which	resulted	in	a	~4-	and	~5-fold	expansion,	respectively,	by	d7	p.i.	However,	replication	of	both	these	subsets	in	the	ILN	reduced	below	baseline	levels,	while	in	the	MLN	these	remained	stable,	apart	from	an	increase	seen	at	d7	p.i.		Increased	 proliferation	 of	 NK	 cells	 in	 the	 CLN	 plateaued	 by	 d5p.i.,	 remaining	 high	 until	d7p.i.	 Significant	 increases	 in	NK	cell	proliferation	were	also	 seen	 in	 the	MLN	at	d5	and	d7p.i.	(Figure	3.12E),	while	levels	of	NK	cell	proliferation	in	the	ILN	remained	unchanged	throughout	 infection.	 Interestingly,	 NKT	 cell	 replication	 remained	 at	 baseline	 level	throughout	the	disease	course	in	all	nodes,	with	a	sudden	significant	increase	at	d7	p.i.	in	the	CLN	(Figure	3.12F).		The	most	pronounced	increase	in	proliferation,	however,	was	seen	with	B	cells	in	the	CLN	(Figure	 3.12G).	 By	 d7	 p.i.	 CLN	 B	 cells	 had	 achieved	 a	 18-fold	 increase	 in	 BrdU	incorporation,	 compared	 to	 d0	 p.i.	 This	 impressive	 increase	 in	 B	 cell	 proliferation	substantiated	the	increases	seen	earlier	in	cell	numbers	in	the	CLN.	In	the	ILN	and	MLN	B	cell	 proliferation	 remained	 unchanged,	 apart	 from	 a	 relatively	 small	 but	 significant	increase	in	the	MLN	at	d7	p.i.	(Figure	3.12G).		Monocyte	proliferation	(Figure	3.13A)	increased	steadily	from	d3	p.i.	in	the	CLN	of	WNV-infected	mice,	reaching	a	10-fold	change	by	d7	p.i.,	relative	to	d0.	In	contrast,	the	levels	of	
Figure	 3.12	 Proliferation	 of	 leukocyte	 subsets	 in	 the	 draining	 (CLN)	 and	 non-
draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Proliferation	on	d0,	3,	5,	6	and	7	p.i.	following	lethal	WNV	infection	(6x104		PFU)	in	the	CLN	(red),	 ILN	(blue)	and	MLN	(green)	of:	 total	 leukocytes	(A),	 total	T	cells	 (B),	CD4+	(C)	and	CD8+	(D)	T	cells,	NK	(E)	and	NKT	(F)	cells	and	B	cells	(G).	Please	note	the	change	in	y-axis	from	 1000	 to	 2500	 in	 figure	 G.	 Proliferation	was	 quantified	 with	 a	 BrdU	 incorporation	assay	 and	 subsequent	 analysis	 of	 BrdU+	cells	 by	 flow	 cytometry.	 BrdU	 was	 given	 i.v.	 3	hours	before	 sacrifice.	Grouped	data	was	normalised	using	d0	as	 internal	 control	 and	 is	represented	as	percentage	change	of	BrdU+	cell	numbers	compared	to	day	0	(100%).		Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.		Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.	 	
Figure 3.12
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Figure	 3.13	 Proliferation	 of	 leukocyte	 subsets	 in	 the	 draining	 (CLN)	 and	 non-
draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Proliferation	on	d0,	3,	5,	6	and	7	p.i.	following	lethal	WNV	infection	(6x104PFU)	in	the	CLN	(red),	 ILN	 (blue)	 and	 MLN	 (green)	 of:	 monocytes	 (A),	 CD11c+CD11b+	 DC	 (B),	CD11chiCD11bint	 DC,	 (C)	 CD11c+CD11b-	 DC	 (D),	 CD11c+CD8α+	 DC	 (E)	 and	 pDC	 (F).	Proliferation	was	quantified	with	a	BrdU	incorporation	assay	and	subsequent	analysis	of	BrdU+	cells	by	flow	cytometry.	BrdU	was	given	i.v.	3	hours	before	sacrifice.	Grouped	data	was	normalised	using	d0	as	 internal	control	and	 is	 represented	as	percentage	change	of	BrdU+	cell	numbers	compared	to	day	0	(100%).	Data	is	shown	as	the	mean	±SEM	of	values	from	 3	 independent	 experiments,	 with	 2-4mice/group	 in	 each	 experiment.	 	 Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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A B
M
on
oc
yt
e 
pr
ol
ife
ra
tio
n 
(%
)
Day p.i. Day p.i.
C
D
11
c+
C
D
11
b+
 c
el
l 
pr
ol
ife
ra
tio
n 
(%
)
C
C
D
11
ch
i C
D
11
bi
nt
 c
el
l 
pr
ol
ife
ra
tio
n 
(%
)
Day p.i.
D
C
D
11
c+
 C
D
11
b-
 c
el
l
 p
ro
lif
er
at
io
n 
(%
)
Day p.i.
E
C
D
11
c+
D
8α
+  c
el
l 
pr
ol
ife
ra
tio
n 
(%
)
Day p.i.
F
C
D
11
c+
B
22
0+
 c
el
l
 p
ro
lif
er
at
io
n 
(%
)
Day p.i.
CLN ILN MLN
0 3 5 6 7
0
500
1000
1500
2000
* *
0 3 5 6 7
0
500
1000
1500
2000
*
**
0 3 5 6 7
0
500
1000
1500
2000
*
***
*
0 3 5 6 7
0
500
1000
1500
2000
*
***
0 3 5 6 7
0
500
1000
1500
2000
*
0 3 5 6 7
0
500
1000
1500
2000
*
**
		 90	
proliferation	 in	 monocytes	 of	 the	 MLN	 remain	 unchanged.	 Some	 elevation	 in	 BrdU	incorporation	occurred	in	the	ILN	monocytes,	with	a	statistically	significant	increase	seen	at	d6	p.i.	followed	by	a	subsequent	decrease	at	d7	p.i.	Proliferation	rose	by	5-fold	(d7p.i.)	in	the	CD11c+CD11b+	DC	subset	of	the	CLN	and	remained	at	baseline	levels	in	the	MLN	and	ILN	(Figure	3.13B).	Similarly,	replication	of	the	CD11chiCD11bint	DC	subset	in	the	CLN	rose	significantly	throughout	the	course	of	disease	(13-fold	by	d7	p.i.),	but	remained	at	baseline	fold	increase,	relative	to	d0	p.i.,	in	the	CLN	and	remained	unchanged	in	the	ILN	and	MLN,	apart	 from	 a	 relatively	 small	 increase	 at	 d7	 p.i.	 in	 the	 MLN	 (Figure	 3.13D).	 Moreover,	proliferation	of	the	CD8α+CD11c+	DC	(Figure	3.13E)	and	pDC	(Figure	3.13F)	populations	of	the	CLN	 increased	by	~13-fold	by	d7	p.i.,	 but	 showed	negligible	 changes	 in	 the	 ILN	and	MLN.		In	order	 to	determine	whether	 there	was	any	 correlation	between	Ly6C	expression	and	proliferation,	 we	 examined	 the	 Ly6C	 distribution	 of	 BrdU+	 cells	 (Figure	 3.14).	Interestingly,	 at	d0p.i.	 the	majority	of	BrdU+	 cells	 in	 the	CLN	 (Figure	3.14A)	were	Ly6C-,	whereas	 by	 d7p.i.	 this	 changed	 to	 Ly6C+(including	 Ly6Chi	 and	 Ly6Cint).	 However,	 this	increase	in	Ly6C	expression	of	BrdU+	cells	also	occurred	in	the	non-draining	ILN	and	MLN	(Figure	 3.14B	 and	 C).	 Furthermore,	 this	 trend	 was	 not	 only	 present	 in	 the	 total	 BrdU+	leukocyte	 population,	 but	 also	 applied	 to	 the	 individual	 leukocyte	 subsets	 analysed.	 As	there	was	 little	 evidence	 of	 increased	 proliferation	 in	 the	 ILN	 and	MLN	 it	 suggests	 that	Ly6C	upregulation	 and	proliferation	 is	 not	 necessarily	 biologically	 linked.	However,	 this	does	 suggests	 that,	 during	 infection,	 newly	 proliferated	 cells	 in	 the	 draining	 and	 non-draining	 lymph	nodes	 of	 the	 CNS	will	 be	 Ly6C+,	whereas	 during	 homeostatic	 conditions	they	 express	 lower	 levels	 of	 Ly6C.	 The	 functional	 significance	 of	 this	 will	 be	 of	 great	interest	for	future	studies.			
Figure	3.14	Ly6C	expression	of	BrdU+	proliferating	cells	 in	 the	draining	 (CLN)	and	
non-draining	lymph	nodes	(MLN,	ILN)	of	the	CNS	following	lethal	WNV	infection	
		Figure	 A-C	 are	 the	 representative	 flow	 cytometry	 plots	 illustrating	 the	 differential	expression	of	Ly6C	on	BrdU+	cells	 in	the	CLN	(A),	ILN	(B)	and	MLN	(C).	The	first	column	demonstrates	the	gating	of	 total	BrdU+	cells	 in	the	above	 lymph	node	at	d0	versus	d7p.i.,	following	 lethal	 WNV	 infection	 (6x104	 PFU).	 The	 second	 column	 demonstrates	 the	differential	Ly6C	expression	of	BrdU+	cells	in	the	above	LN	at	d0	versus	d7	p.i.	 	
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3.2.4. Viral	 presence	 in	 the	 CNS,	 draining	 and	 non-draining	 lymph	
nodes	
Cellular	 proliferation	 in	 lymph	 nodes	 is	 often	 triggered	 by	 the	 presence	 of	 pathogen	 or	pathogen-derived	 products.	 In	 order	 to	 establish	 whether	 or	 not	 the	 substantial	proliferation	induced	in	the	CLN	was	due	to	the	presence	of	virus,	we	processed	the	CNS,	CLN	and	ILN	of	WNV-	and	mock-infected	mice	for	viral	RNA	during	the	course	of	infection.	This	allowed	us	to	narrow	down	the	possible	factors	at	play	inducing	the	modification	of	the	non-draining	nodes	associated	with	inflammation.	Virus	was	detected	with	the	use	of	the	probes	and	primers	described	in	Table	2.1.			No	viral	RNA	could	be	detected	in	the	CNS	between	d0-3	p.i.	WNV	RNA	was	first	detected	in	the	CNS	at	d5	p.i.	and	remained	at	the	same	level	of	detection	until	 the	end	of	disease	course	 at	 d7	p.i.	 (Figure	3.15A	 columns	A2-15).	Next,	 the	 viral	RNA	 content	 of	 the	CNS-draining	 CLN	 was	 studied,	 yielding	 no	 appreciable	 difference	 between	 mock-infected	(Figure	3.15B	columns	B4-5)	and	d3-7p.i.	WNV-infected	groups	(Figure	3.15B	columns	6-18).	Similarly,	 the	non-draining	 ILN	showed	a	negligible	difference	 in	WNV	RNA	content	between	 mock-infected	 (Figure	 3.15A	 columns	 16-17)	 and	 WNV-infected	 cohorts	(Columns	A18-28	and	B2-3).	Compared	to	the	negative	control	(Figure	3.15	column	A29),	there	was	some	signal	present	in	all	the	lymph	nodes	(WNV-	and	mock-infected),	however,	this	was	very	similar	 in	both	mock-	and	WNV-infected	samples,	suggesting	 that	 this	was	most	likely	background	signal.		In	order	 to	confirm	 this	we	performed	quantitative	RT-PCR	(Figure	3.15C)	 to	determine	the	 relative	 levels	of	WNV	RNA	 in	 the	CNS,	 ILN	and	CLN,	 at	day	0,	1,	3,	5	 and	7	p.i.	The	relative	 RNA	 expression	 in	 each	 organ	 was	 normalised	 to	 mock-infected	 mice	 (d0)	 in	terms	 of	 2000ng/µl	 total	 RNA	 and	 analysed	 using	 the	 2-ΔΔCT	 method.	 There	 was	 a	
Figure	 3.15	 Viral	 RNA	 presence	 in	 the	 brain,	 draining	 and	 non-draining	 lymph	
nodes	
		Gel	electrophoresis	(panels	A	&	B)	of	total	viral	RNA	in	isolated	mouse	brain,	CLN	and	ILN	at	various	time	points	after	 infection	(Mock,	d1,	d3,	d5	and	d7	p.i.).	Neat	virus	stock	was	used	as	positive	control	and	uninfected	medium	as	negative	control.	Panel	C	demonstrates	the	results	of	the	RT-PCR	for	the	relative	quantity	of	WNV	RNA	in	the	CNS,	ILN	and	CLN	at	d1,	d3,	d5	and	d7	p.i.	with	 lethal	dose	of	WNV	(6x104	PFU).	The	relative	RNA	expression	levels	 were	 normalised	 to	 mock	 	 animal	 (d0)	 in	 terms	 of	 2000	 ng/µl	 total	 RNA	 and	analysed	using	the	2-ΔΔCT	method.			 	
Figure 3.15
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significant	increase	in	WNV	RNA	in	the	CNS	by	d7p.i.,	relative	to	d0.	In	contrast,	the	CLN	and	 ILN	both	showed	negligible	 change	 in	WNV	RNA	expression,	 relative	 to	d0p.i.,	 at	 all	time-points	 analysed.	 These	 results	 corroborated	 data	 from	 Figure	 3.15A	 and	 B,	confirming	 the	 absence	 of	 detectable	 levels	 of	WNV	RNA	 in	 both	 the	 draining	 and	 non-draining	 lymph	 nodes	 of	 the	 CNS.	 Therefore,	 it	 seems	 reasonable	 to	 conclude	 that	 no	detectable	viral	RNA	was	present	in	either	the	draining	lymph	node	(CLN)	or	non-draining	lymph	node	(ILN)	during	any	of	the	time	points	analysed,	including	the	peak	of	disease	at	d7	p.i.	and	that	virus-infection	was	limited	to	the	CNS	from	d5	p.i.	This	suggests	that	the	inflammation-associated	modulation	of	these	lymph	nodes	was	not	due	to	the	presence	of	virus	but	 likely	 inflammatory	mediators	originating	 in	 the	CNS	or	perhaps	 activation	by	APC	migrating	from	the	CNS.	
3.2.5. Distribution	of	cells	from	a	peripheral	node	to	the	draining	CLN	
following	lethal	WNV	infection	
3.2.5.1. Footpad	injection	and	subsequent	distribution	of	PKH26	
We	 have	 shown	 that	 the	 non-draining	 peripheral	 lymph	 nodes	 are	 undoubtedly	modulated	 by	 inflammatory	 signals	 during	 the	 course	 of	WNV-infection,	 as	 seen	 in	 the	reduction	of	T	cells	and	upregulation	of	Ly6C	 in	the	MLN	and	ILN.	Whether	or	not	 these	nodes	 function	 as	 a	 source	 of	 lymphoid	 cells	 to	 the	 upstream	 nodes,	 responsible	 for	draining	the	focus	of	inflammation,	remains	to	be	investigated.	Moreover,	these	nodes	may	bypass	the	draining	CLN	and	directly	supply	lymphoid	lineage	cells	to	the	CNS.	In	order	to	track	the	extent	of	 lymphatic	drainage	 from	a	peripheral	node	to	 the	CLN	or	CNS	during	the	course	of	WNV-infection,	we	performed	a	footpad	injection	of	a	highly	fluorescent	dye	PKH26	(protocol	outlined	by	Figure	3.16	A).	PKH26,	which	is	excited	at	551mn	and	has	a	bright	emission	at	567nm,	was	injected	on	d0	p.i.	into	the	footpad	of	mice	infected	i.n.	with	
Figure	3.16	Injection	of	PKH26	into	the	footpad	of	mock-	and	WNV-infected	mice	
	
	Diagram	A	outlines	 the	protocol	 followed	 for	 the	 injection	of	PKH26	 into	 the	 footpad	of	WNV-	and	mock-infected	mice.	Panels	B-E	are	the	representative	flow	cytometry	dot	plots	showing	the	distribution	of	PKH26+	leukocytes	(CD45+)	in	the	contra-	and	ipsilateral	PLN	(B),	 ILN	 (C),	 CLN	 (D)	 and	 spleen	 (E)	 of	 mock-	 and	 WNV-infected	 mice.	 The	 gating	 for	PKH26+	cells	was	based	on	the	control	mice	that	received	no	injection.	 	
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a	 lethal	dose	of	WNV	(6x104	PFU).	The	draining	node	of	 the	 footpad,	 the	popliteal	 lymph	node	(PLN),	was	subsequently	processed	on	d7p.i.	 (i.e.	7	days	after	PKH26	 injection	and	WNV	infection)	along	with	the	ILN,	CLN,	spleen	and	CNS	to	determine	the	extent	to	which	dye+	 cells	 become	 distributed	 in	 steady	 state	 versus	 inflammatory	 conditions.	Furthermore,	we	also	collected	control	PLN,	ILN	and	CLN,	24h	after	PKH26	injection	of	the	footpad	to	determine	baseline	PKH26	incorporation	within	24h	in	steady	state	conditions.	The	 steady-state	 distribution	 of	 dye	 throughout	 the	 lymphatic	 system	 within	 7	 days	 is	represented	 by	 mock-infected	 mice,	 which,	 in	 the	 absence	 of	 inflammatory	 signals,	allowed	 the	 homeostatic	 rate	 of	 lymphatic	 distribution	 throughout	 the	 body	 to	 be	determined.	In	addition	to	the	ipsilateral	nodes,	we	also	collected	the	contralateral	nodes	in	order	to	demonstrate	the	extent	to	which	dye-containing	cells	can	distribute	throughout	the	body.		Figures	 3.16	 B-D	 demonstrate	 the	 percentage	 of	 PKH+	 leukocytes	 in	 the	 contra-	 and	ipsilateral	 PLN,	 ILN	and	CLN	within	24h	 and	7	days	post-PKH26	 injection	 in	mock-	 and	WNV-infected	mice.	The	PLN,	draining	the	footpad,	was	the	first	node	to	encounter	the	dye	and	 within	 24h	 ~50%	 of	 the	 ipsilateral	 node	 was	 PKH26+,	 with	 very	 little	 dye	 in	 the	contralateral	PLN	(Figure	3.16B).	Within	7	days,	some	dye	had	spread	to	the	contralateral	PLN	in	both	mock-	and	WNV-infected	mice,	with	a	dramatic	reduction	in	dye+	cell	numbers	in	 the	 ipsilateral	 PLN,	 indicating	 that	 the	 dye	 or	 dye-containing	 cells	 had	 distributed	elsewhere.	Interestingly,	by	24h	the	dye	content	of	the	ipsilateral	ILN	(Figure	3.16C)	and	CLN	 (Figure	3.16D)	was	 comparable	 to	 that	 of	mock-infected	 ILN	and	CLN	after	 7	days,	indicating	that	24h	was	sufficient	 for	distribution	of	dye	or	dye-containing	cells	 to	reach	equilibrium	on	 the	 ipsilateral	side	of	 the	body.	However,	24h	was	not	sufficient	 time	 for	PKH26+	 leukocytes	 to	distribute	evenly	 to	 the	contralateral	nodes,	but	 this	had	occurred	after	 7	 days.	 Clearly,	 additional	 time-points	 are	 needed	 to	 estimate	 exactly	 how	 long	
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equilibration	took.	Notably,	the	contra-	and	ipsilateral	ILN	and	CLN	collected	from	WNV-infected	 mice	 had	 a	 higher	 percentage	 of	 PKH26+	leukocytes	 compared	 to	 their	 mock-infected	counterparts.			Similarly,	 the	 spleen	 from	 WNV-infected	 mice	 had	 a	 higher	 percentage	 of	 PKH26+	leukocytes,	 compared	 to	 mock-infected	 mice	 (Fig	 3.16E).	 Lastly,	 no	 dye+	 cells	 could	 be	detected	in	the	CNS	of	either	mock	or	WNV-infected	animals	(data	not	shown).	These	data	suggests	 that	 WNV	 infection	 of	 the	 CNS	 modulates	 the	 distribution	 of	 cells	 from	 a	peripheral	 node,	 potentially	 increasing	 recruitment	 of	 cells	 to	 the	 draining	 node	 of	 the	CNS.	
3.2.5.2. Number	 and	percentage	of	 PKH26+	 cells	 in	 the	 ispi-	 and	 contralateral	 PLN,	
ILN	and	CLN	of	mock-	versus	WNV-infected	mice	
One	of	the	perceived	problems	of	these	experiments	was	that	the	distribution	of	dye	into	the	upstream	lymph	nodes	and	spleen	could	occur	either	as	free	dye	or	incorporated	into	a	cell.	Therefore,	we	examined	the	dynamics	of	dye	distribution	in	the	ipsi-	and	contralateral	PLN,	ILN	and	CLN	in	more	detail.		There	was	a	clear	trend	for	the	total	number	of	PKH26+	 leukocytes	to	decrease	between	24h	and	7days	in	the	ipsilateral	PLN	(Figure	3.17A-i)	and	increase	in	both	the	contra-	and	ipsilateral	 CLN	 (Figure	 3.17A-v)	 by	 d7p.i.	 The	 percentage	 of	 PKH26+	 leukocytes	 in	 the	ipsilateral	PLN	(Figure	3.17A-ii)	also	 reduced	by	d7p.i.,	 suggesting	 that	 the	PKH26+	cells	had	left	the	node,	potentially	dispersing	to	the	CLN	or	ILN.	Indeed,	by	d7	p.i.,	the	number	of	PKH26+	leukocytes	in	the	contra-	and	ipsilateral	ILN	(Figure	3.17A-iii)	of	mock-infected	mice	had	increased	from	24h.	However,	the	number	of	PKH26+	leukocytes	in	the	ILN	from	WNV-infected	 mice	 had	 reduced,	 compared	 to	 mock-infected	 mice.	 In	 contrast,	 the	percentage	 of	 PKH26+	 leukocytes	 in	 the	 WNV-infected	 ILN	 (Figure	 3.17A-iv)	 was	
Figure	 3.17	 Number	 and	 percentage	 of	 PKH26+	 leukocytes,	 B	 and	 T	 cells	 in	 the	
contra-	and	ipsilateral	PLN,	ILN	and	CLN	of	mock-	and	WNV-infected	mice	
	
	Panel	A	demonstrates	the	number	(i,	iii,	v)	and	percentage	(ii,	iv,	vi)	of	PKH26+	leukocytes	in	 the	 contra-	 and	 ipsilateral	 PLN	 (i,ii),	 ILN	 (iii,	 iv)	 and	 CLN	 (v,	 vi)	 of	mock-	 and	WNV-infected	mice	 (6x104	PFU)	24h	and	7	days	after	PKH	 injection.	Cohorts	with	no	 injection	(light	 grey),	 24h	 after	 injection	 (dark	 grey),	 contralateral	 mock-infected	 (light	 blue),	ipsilateral	 mock-infected	 (dark	 blue),	 contralateral	 WNV-infected	 (light	 green)	 and	ipsilateral	WNV-infected	(dark	green)	are	shown.	Panel	B	demonstrates	the	number	(i,	iii,	v)	and	percentage	(ii,	 iv,	vi)	of	PKH26+	B	cells	in	the	contra-	and	ipsilateral	PLN	(i,ii),	ILN	(iii,	 iv)	 and	 CLN	 (v,	 vi)	 of	 mock-	 and	 WNV-infected	 mice	 24h	 and	 7	 days	 after	 PKH	injection.	Panel	C	shows	the	number	(i,	 iii,	v)	and	percentage	(ii,	 iv,	vi)	of	total	PKH26+	T	cells	in	the	contra-	and	ipsilateral	PLN	(i,ii),	ILN	(iii,	iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	 injection.	Data	are	 shown	as	 the	mean	±SEM	of	values	 from	 2	 independent	 experiments,	 with	 2-3	mice/group	 in	 each	 experiment.	 The	24h	time-point	was	from	one	experiment	and	was	not	included	in	the	statistical	analysis.	Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
Figure 3.17
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significantly	higher	than	in	mock-infected	ILN.	This	could	indicate	that	more	PKH26+	cells	were	being	recruited	from	the	PLN	during	infection,	or	that	more	cells	were	incorporating	dye	 during	 infectious	 circumstances	 than	 in	 steady-state.	 Either	 way,	 consistent	 with	earlier	data	showing	a	decrease	in	leukocyte	number	in	the	ILN,	this	increased	percentage	is	occurring	on	a	background	of	reduced	PKH26-	cell	numbers.	The	comparable	numbers	between	 contra-	 and	 ipsilateral	 sides	 suggests	 increased	 recruitment,	 rather	 than	incorporation	of	dye,	as	the	dye	would	have	had	to	enter	the	bloodstream	and	reach	the	contralateral	node	undiluted	and	in	similar	concentrations	to	the	ipsilateral	side	for	this	to	occur.	Furthermore,	 although	 the	 number	 of	 PKH26+	 leukocytes	 in	 the	 WNV-infected	 CLN		(Figure	3.17A-v)	was	significantly	higher	than	the	mock-infected	CLN,	the	percentages	of	PKH26+	leukocytes	(Figure	3.17A-vi)	were	comparable	between	mock-	and	WNV-infected.	Data	in	graph	3.1	F	showed	a	significant	increase	in	CLN	leukocyte	numbers	in	response	to	infection	and	taken	together	with	the	data	presented	here,	is	may	suggest	that	the	increase	in	PKH26+	leukocytes	occurred	in	a	similar	ratio	to	the	increase	in	total	leukocyte	number.		B	cells	accounted	for	the	highest	number	of	PKH26+	cells	in	the	ILN	(Figure	3.17B-iii)	and	CLN	(Figure	3.17B-v),	although	the	percentage	that	the	PKH26+	B	cells	contributed	to	the	total	 B	 cell	 population	 in	 both	 the	 ILN	 (Figure	 3.17B-iv)	 and	CLN	 (Figure	 3.17B-vi)	was	very	low,	both	24h	and	7	days	after	injection.	As	the	B	cell	population	in	the	ILN	and	CLN	is	so	large	by	d7	p.i.	the	PKH26+	B	cells	likely	became	quite	dilute.	Nevertheless,	the	trend	of	 PKH26+	B	 cell	 distribution	 throughout	 the	 lymph	 nodes	 mirrored	 that	 of	 the	 total	PKH26+	leukocyte	population,	in	particular	the	increase	of	PKH+	B	cells	in	the	contra-	and	ipsilateral	CLN	during	WNV	infection.	From	this	we	hypothesised	that	PKH26+	B	cells	leave	the	PLN	and	possibly	 the	 ILN,	preferentially	 trafficking	 to	 the	WNV-infected	contra-	and	ipsilateral	CLN.	Higher	numbers	of	PKH26+	B	cells	in	the	contra-	and	ipsilateral	ILN	(Figure	
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3.17B-iii)	 of	mock-infected	mice	 indicate	 that	 some	B	 cells	may	be	 retained	 there	 in	 the	absence	of	an	inflammatory	stimulus,	whereas,	during	infection	they	may	be	recruited	to	the	focus	of	inflammation	and	corresponding	draining	lymph	node	i.e.	the	CLN.	There	 was	 some	 incorporation	 of	 dye	 into	 PLN	 T	 cells	 (Figure	 3.17C-i),	 however	 the	reduction	in	numbers	of	PKH26+	T	cells	between	24h	and	7	days	was	less	than	in	B	cells.	Considering	the	large	numbers	of	T	cells	present	in	lymph	nodes,	very	few	of	these	were	PKH26+	in	the	ILN	(Figure	3.17C-iii)	and	CLN	(Figure	3.17C-v).	This	was	true	for	both	CD4+	(Figure	 3.18A	 i-vi)	 and	 CD8+	 T	 cells	 (Figure	 3.18B	 i-vi),	 with	 little	 difference	 between	mock-	and	WNV-infected	cohorts	 in	terms	of	PKH26+	T	cell	content.	This	suggests	that	T	cells	 account	 for	 a	 smaller	 proportion	 of	 the	 PKH26+	 population	 being	 distributed	throughout	steady-state	conditions	and	that	 inflammation	does	not	significantly	 increase	the	‘recruitment’	of	T	cells	from	a	peripheral	node	to	the	focus	of	infection	in	this	model	of	PKH26	injection.		Compared	to	B	and	T	cells,	monocytes	are	present	in	relatively	low	numbers	in	the	lymph	node,	however	~60%	of	monocytes	 in	 the	PLN	were	PKH26+	24h	after	 injection	 (Figure	3.18C-ii).	 Moreover,	 homeostatic	 conditions	 saw	 ~20%	 of	 monocytes	 being	 PKH26+	 in	both	 contra-	 and	 ipsilateral	 ILN	 after	 7	 days	 (Figure	 3.18C-iv),	 suggesting	 that	 a	 large	proportion	of	these	have	been	distributed	to	the	ILN	from	the	PLN.	Nevertheless,	infection	did	not	 have	 a	 significant	 effect	 on	 the	numbers	 or	percentage	of	 PKH26+	monocytes	 in	either	the	ILN	(Figure	3.18C-iii)	or	the	CLN	(Figure	3.18C-v).	Similarly,	although	present	in	low	numbers,	a	large	proportion	of	CD11b+	DC	(~70-80%)	in	both	the	contra-	and	ipsilateral	PLN	had	incorporated	PKH26.	In	addition,	the	20-40%	of	 the	 CD11b+	 DC	 in	 the	 contra-	 and	 ipsilateral	 ILN	 (Figure	 3.19A-iv)	 and	 CLN	 (Figure	3.19A-vi)	were	PKH26+.	This	suggests	that	a	large	proportion	of	this	population	in	the	CLN	and	 ILN	was	migratory	 and	may	be	 continually	 redistributed	 throughout	 the	body.	This	
Figure	3.18	Number	and	percentage	of	PKH26+	CD4+,	CD8+	T	cells	and	monocytes	in	
the	contra-	and	ipsilateral	PLN,	ILN	and	CLN	of	mock-	and	WNV-infected	mice	
	
	Panel	A	demonstrates	the	number	(i,	iii,	v)	and	percentage	(ii,	iv,	vi)	of	PKH26+	CD4+	T	cells	in	 the	 contra-	 and	 ipsilateral	 PLN	 (i,ii),	 ILN	 (iii,	 iv)	 and	 CLN	 (v,	 vi)	 of	mock-	 and	WNV-infected	mice	(6x104	PFU)	24h	and	7	days	after	PKH	injection.	Note	the	10-fold	change	in	y-axis	 from	x103	 (figure	3.17)	 to	 x102.	With	no	 injection	 (light	 grey),	 24h	after	 injection	(dark	grey),	contralateral	mock-infected	(light	blue),	ipsilateral	mock-infected	(dark	blue),	contralateral	 WNV-infected	 (light	 green)	 and	 ipsilateral	 WNV-infected	 (dark	 green)	 is	shown.	 Panel	 B	 demonstrates	 the	 number	 (i,	 iii,	 v)	 and	 percentage	 (ii,	 iv,	 vi)	 of	 PKH26+	CD8+	T	cells	 in	 the	contra-	and	 ipsilateral	PLN	(i,ii),	 ILN	(iii,	 iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	Panel	C	shows	the	number	(i,	iii,	v)	and	percentage	(ii,	iv,	vi)	of	PKH26+	monocytes	in	the	contra-	and	ipsilateral	PLN	(i,	ii),	ILN	(iii,	iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	Data	are	shown	as	 the	mean	±SEM	of	values	 from	2	 independent	experiments,	with	2-3	mice/group	 in	 each	 experiment.	 The	24h	 time-point	was	 from	one	 experiment	and	was	not	 included	 in	 the	 statistical	 analysis.	 Statistical	 analysis	was	 conducted	using	one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.		 	
Figure 3.18
WNVMock24hWNVMock24hNo injection# 
of
 P
K
H
+  C
D
4+
T 
ce
lls
 (x
10
2 )
PL
N
IL
N
C
LN
WNVMock24h
WNVMock24hNo
 injection
WNVMock24hWNVMock24hNo injection
PL
N
IL
N
C
LN
WNVMock24hWNVMock24hNo
 injection
WNVMock24hNo
 injection
WNVMock24h
PL
N
IL
N
C
LN
WNVMock24h
WNVMock
WNVMock24hNo
 injection
WNVMock24hNo
 injection
24h
PKH26+ Monocyte # PKH26+ Monocyte %
WNVMock24hNo
 injection# 
of
 P
K
H
+  M
on
oc
yt
es
 (x
10
2 )
0
5
10
15
# 
of
 P
K
H
+  M
on
oc
yt
es
 (x
10
2 )
0
5
10
15
# 
of
 P
K
H
+  M
on
oc
yt
es
 (x
10
2 )
0
5
10
15
A B C
WNVMock24hNo
 injection
PKH26+ CD4+T Cell # PKH26+ CD4+T Cell %
0
5
10
15
# 
of
 P
K
H
+  C
D
4+
T 
ce
lls
 (x
10
2 )
# 
of
 P
K
H
+  C
D
4+
T 
ce
lls
 (x
10
2 )
0
5
10
15
0
5
10
5
0
20
40
60
80
100
*
**
***
0
2
4
6
8
10
25
50
75
100
WNVMock24h
0
2
4
6
8
10
50
75
100
# 
of
 P
K
H
+  C
D
8+
T 
ce
lls
 (x
10
2 )
# 
of
 P
K
H
+  C
D
8+
T 
ce
lls
 (x
10
2 )
# 
of
 P
K
H
+  C
D
8+
T 
ce
lls
 (x
10
2 )
*
PKH26+ CD8+T Cell # PKH26+ CD8+T Cell %
0
5
10
15
0
20
40
60
80
100
*
0
5
10
15
0
5
10
15
0
2
4
6
8
10
50
75
100
WNVMock24h
0
2
4
6
8
10
25
50
75
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
No injection Contralateral d7p.i.
Ispilateral d7p.i.
Contralateral d7p.i.
Ipsilateral d7p.i.24h post-PKH26 injection W
N
V
M
oc
k
i ii
iii
vi
iv
v
i ii
iii
vi
iv
v
i ii
iii
vi
iv
v
CD4+ T cells CD8+ T cells Monocytes
%
 o
f P
K
H
+  C
D
4+
T 
ce
lls
%
 o
f P
K
H
+  C
D
4+
T 
ce
lls
%
 o
f P
K
H
+  C
D
4+
T 
ce
lls
%
 o
f P
K
H
+  C
D
8+
T 
ce
lls
%
 o
f P
K
H
+  C
D
8+
T 
ce
lls
%
 o
f P
K
H
+  C
D
8+
T 
ce
lls
%
 o
f P
K
H
+  m
on
oc
yt
es
%
 o
f P
K
H
+  m
on
oc
yt
es
%
 o
f P
K
H
+  m
on
oc
yt
es
Figure	 3.19	 Number	 and	 percentage	 of	 PKH26+	CD11c+CD11b+,	 CD11c+CD11b-	 and	
CD11c+CD8α+	DC	in	the	contra-	and	ipsilateral	PLN,	ILN	and	CLN	of	mock-	and	WNV-
infected	mice	
	
	Panel	 A	 demonstrates	 the	 number	 (i,	 iii,	 v)	 and	 percentage	 (ii,	 iv,	 vi)	 of	 PKH26+	CD11c+CD11b+	DC	 in	 the	 contra-	 and	 ipsilateral	PLN	 (i,ii),	 ILN	 (iii,	 iv)	 and	CLN	 (v,	 vi)	 of	mock-	 and	WNV-infected	mice	 (6x104	PFU)	24h	and	7	days	after	PKH	 injection.	With	no	injection	 (light	 grey),	 24h	 after	 injection	 (dark	 grey),	 contralateral	 mock-infected	 (light	blue),	 ipsilateral	mock-infected	(dark	blue),	contralateral	WNV-infected	(light	green)	and	ipsilateral	WNV-infected	(dark	green)	is	shown.	Panel	B	demonstrates	the	number	(i,	iii,	v)	and	percentage	 (ii,	 iv,	vi)	of	PKH26+	CD11c+CD11b-	DC	 in	 the	contra-	and	 ipsilateral	PLN	(i,ii),	ILN	(iii,	iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	 Panel	 C	 shows	 the	 number	 (i,	 iii,	 v)	 and	 percentage	 (ii,	 iv,	 vi)	 of	 PKH26+	CD11c+CD8α+	DC	 in	 the	 contra-	 and	 ipsilateral	 PLN	 (i,	 ii),	 ILN	 (iii,	 iv)	 and	CLN	 (v,	 vi)	 of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	Data	are	shown	as	the	mean	 ±SEM	 of	 values	 from	 2	 independent	 experiments,	 with	 2-3	 mice/group	 in	 each	experiment.	 The	 24h	 time-point	was	 from	 one	 experiment	 and	was	 not	 included	 in	 the	statistical	 analysis.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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notion	may	 be	 supported	 by	 the	 reduced	 numbers	 of	 these	 cells	 in	 the	 ILN	 of	 infected	mice,	compared	to	the	mock-infected	control,	although	this	difference	was	not	statistically	significant.	However,	as	was	the	case	with	monocytes,	infection	did	not	result	in	increased	numbers	 of	 PKH26+	 CD11b+DC	 in	 the	 CLN	 (Figure	 3.19A-v)	 and	 there	was	 a	 significant	decrease	in	the	percentage	(Figure	3.19A-vi)	of	CD11b+CD11c+	DC	that	were	PKH26+	in	the	CLN	by	d7p.i.,	presumably	due	to	the	fact	that	the	total	expansion	of	this	subset	in	the	CLN	occurred	at	a	much	greater	rate	than	the	recruitment	of	PKH26+	CD11b+CD11c+	DC.		Although	~30%	of	CD11b-	DC	 in	 the	PLN	had	 incorporated	dye	by	24h	(Figure	3.19B-ii),	relatively	low	distribution	of	these	cells	was	evident	in	the	ILN	(Figure	3.19B-iv)	and	CLN	(Figure	 3.19B-vi).	 Furthermore,	 there	 was	 little	 evidence	 for	 redistribution	 of	 PKH26+	CD8α+	DC	 (Figure	 3.19C	 i-vi)	 to	 the	 ILN	 and	CLN.	 The	CD8α+	DC	 of	 the	 lymph	node	 are	classically	regarded	as	the	lymphoid	tissue	resident	DC,	which	do	not	migrate,	explaining	the	absence	of	PKH26+CD8α+	DC	in	the	upstream	nodes.		Similar	to	the	CD11b+	DC	in	figure	3.19	A,	there	were	very	low	numbers,	but	relatively	high	percentage	of	PKH26+CD11chiCD11bint	DC	present	 in	both	 the	contra-	and	 ipsilateral	 ILN	and	CLN	of	mock-	and	WNV-infected	mice.	Indeed,	PKH26+CD11chiCD11bint	DC	contributed	to	~20%	of	the	total	CD11chiCD11bint	population	in	the	steady-state	ILN	and	CLN	(Figure	3.20A	i-vi).	Although	the	percentage	of	PKH26+CD11chiCD11bint	DC	in	the	CLN	was	slightly	lower	 in	 the	WNV-infected	 cohort,	 compared	 to	mock-infected,	 this	was	 not	 significant.	Therefore,	WNV	infection	of	the	CNS	did	not	significantly	modulate	the	PKH26+CD11b+	or	CD11b-	 DC	 response	 in	 the	 CLN	 or	 ILN.	 However,	 the	 large	 proportion	 of	 myeloid	 or	CD11b+	 DC	 that	 were	 PKH26+	 suggests	 that	 these	 cells	 likely	 possessed	 a	 migratory	phenotype,	in	contrast	to	the	lymphoid	resident	CD8α+	DC.		
Figure	 3.20	 Number	 and	 percentage	 of	 PKH26+	 pDC	 CD11chiCD11bint	 DC	 and	
neutrophils	 in	 the	 contra-	 and	 ipsilateral	 PLN,	 ILN	 and	 CLN	 of	 mock-	 and	 WNV-
infected	mice	
	
	Panel	 A	 demonstrates	 the	 number	 (i,	 iii,	 v)	 and	 percentage	 (ii,	 iv,	 vi)	 of	 PKH26+	CD11chiCD11bint	DC	in	the	contra-	and	ipsilateral	PLN	(i,	ii),	ILN	(iii,	iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	Figure	B	demonstrates	the	number	(i,	iii,	v)	and	percentage	(ii,	iv,	vi)	of	PKH26+	pDC	in	the	contra-	and	ipsilateral	PLN	(i,ii),	ILN	(iii,	iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	(6x104	PFU)	24h	and	7	days	after	PKH	injection.	With	no	injection	(light	grey),	24h	after	injection	(dark	grey),	contralateral	 mock-infected	 (light	 blue),	 ipsilateral	 mock-infected	 (dark	 blue),	contralateral	 WNV-infected	 (light	 green)	 and	 ipsilateral	 WNV-infected	 (dark	 green)	 is	shown.	 Panel	 C	 demonstrates	 the	 number	 (i,	 iii,	 v)	 and	 percentage	 (ii,	 iv,	 vi)	 of	 PKH26+	neutrophils	 in	 the	contra-	and	 ipsilateral	PLN	(i,	 ii),	 ILN	(iii,	 iv)	and	CLN	(v,	vi)	of	mock-	and	WNV-infected	mice	24h	and	7	days	after	PKH	injection.	Data	are	shown	as	the	mean	±SEM	 of	 values	 from	 2	 independent	 experiments,	 with	 2-3	 mice/group	 in	 each	experiment.	 The	 24h	 time-point	was	 from	 one	 experiment	 and	was	 not	 included	 in	 the	statistical	 analysis.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
Figure 3.20
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Interestingly,	the	distribution	of	PKH26+	pDC	was	clearly	influenced	by	WNV	infection,	as	there	was	a	significant	 increase	 in	PKH26+	pDC	(Figure	3.20B-v)	 in	 the	 ipsilateral	CLN	of	WNV-infected	 mice	 compared	 to	 mock-infected.	 Indeed,	 the	 PKH26+	 pDC	 exhibited	 a	similar	pattern	of	distribution	throughout	the	PLN,	ILN	and	CLN	to	PKH26+	B	cells	(Figure	3.17B)	suggesting	that	these	subsets	may	be	modulated	by	similar	signals.	The	number	of	PKH26+	neutrophils	in	the	PLN	(Figure	3.20C-i),	ILN	(Figure	3.20C-iii)	and	CLN	 (Figure	 3.20C-v)	 was	 extremely	 low	 (<100).	 However,	 in	 the	 CLN,	 >10%	 of	neutrophils	in	mock-and	WNV-infected	mice	were	PKH26+	suggesting	that	they	originated	elsewhere.	There	were	negligible	numbers	of	PKH26+	NK	and	NKT	cells	incorporating	dye	in	all	3	nodes	examined	(Data	not	shown).		There	are	two	ways	in	which	leukocytes	from	the	ipsilateral	ILN	could	become	PKH26+	:	1)	Free	dye,	which	distributed	throughout	the	lymph	and	entered	the	upstream	ILN	and	was	subsequently	incorporated	into	leukocytes	or	2)	Leukocytes	that	incorporated	dye	in	the	PLN	and	migrated	to	the	ipsilateral	ILN.	However,	there	is	no	direct	lymphatic	connection	from	the	ipsilateral	PLN	and	ILN	to	the	contralateral	PLN	and	ILN,	or	for	that	matter,	to	the	contra-	and	ipsilateral	CLN.	Therefore,	it	is	unlikely	that	free	dye	spread	undiluted	to	the	contralateral	 node	 in	 high	 enough	 concentrations	 to	 stain	 cells	 there.	 It	 is	 much	 more	likely	that	cells,	which	have	incorporated	dye	in	the	ipsilateral	ILN	or	PLN,	have	travelled	via	the	lymphatics	to	the	bloodstream,	and	thence	to	the	contralateral	ILN	and	PLN,	as	well	as	CLN.	If	true,	then	the	numbers	and	percentages	of	PKH26+	cells	in	the	contralateral	ILN	and	 contra-	 and	 ipsilateral	 CLN	 from	 mock-infected	 mice	 represents	 the	 steady-state	distribution	of	cells	throughout	the	body,	rather	than	free	dye.	Therefore,	any	changes	in	this	 number	 in	 the	 CLN	 of	 WNV-infected	 mice	 compared	 to	 mock-infected,	 suggests	increased	recruitment	of	cells	as	a	result	of	infectious	stimuli.	This	was	mainly	evident	in	the	B220+	populations	 i.e.	B	cells	and	pDC,	possibly	 indicating	that	 these	two	subsets	are	
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being	 recruited	 to	 the	 CLN	 by	 the	 similar	 signals.	 Moreover,	 the	 high	 percentage	 of	CD11b+DC	in	the	CLN	highlights	the	migratory	nature	of	these	cells.	There	 was	 a	 substantial	 presence	 of	 dye+	 cells	 in	 the	 mock-	 and	WNV-infected	 spleen,	seven	 days	 following	 PKH26	 footpad	 injection	 (Figure	 3.21B	 and	 C).	 Notably,	 in	 both	cohorts,	 the	 CD11c+CD11b-	 subset	 had	 incorporated	 the	majority	 of	 PKH26	with	 85.8%	(mock)	and	85%	(WNV)	of	 the	PKH26+	population	 identified	as	CD11c+CD11b-	cells.	The	remainder	of	the	PKH26+	population	in	the	spleen	from	mock-infected	mice	consisted	of	B	cells	 (~9%),	 T	 cells	 (~1%)	 and	 CD11b+	 cells	 (~5%).	 The	 ratio	 of	 various	 leukocytes	present	in	the	PKH26+	population	in	the	spleen	of	WNV-infected	cohort	differed	somewhat	to	the	spleen	from	mock-infected	mice,	as	the	remainder	of	cells	occupied	less	than	10%	of	the	PKH+	population.	Indeed,	when	enumerated	(Figure	3.21A)	there	were	fewer	PKH26+	B	cells,	T	cells	and	monocytes	in	the	spleen	from	WNV-infected	mice,	compared	to	mock-infected	 cohort,	 although	 this	 was	 not	 statistically	 significant.	 Interestingly,	 there	 were	significantly	more	PKH26+	neutrophils	 in	 the	spleen	 from	WNV-infected	mice,	compared	to	the	mock-infected	cohort.		
3.2.5.3. 	Adoptive	transfer	of	CD45.1	and	CFSE	stained	lymph	node	cells	
Although	 unlikely,	 the	 PKH26+	 could	 have	 spread	 through	 the	 lymphatic	 or	 circulatory	system	as	free	dye	and/or	incorporated	into	cells	migrating	to	the	spleen	and	lymph	nodes	during	homeostatic	and	 inflammatory	conditions.	 In	order	 to	confirm	that	cells	 from	the	peripheral	nodes,	and	not	 free	dye,	 can	migrate	 to	 the	draining	CLN	during	 infection	we	designed	 an	 experiment	 using	 adoptively-transferred	 cells.	 The	 adoptive	 transfer	 of	CD45.1+	and	CFSE-stained	cells	from	mock-infected	peripheral	nodes,	into	the	footpad	and	subsequent	 examination	 of	 PLN,	 ILN,	 CLN,	 spleen	 and	 CNS	 in	mock-	 and	WNV-infected	mice	(CD45.2+),	sought	to	clarify	this	issue.		
Figure	 3.21	 Number	 and	 percentage	 of	 PKH26+	cells	 in	 the	 spleen	 of	 mock-	 and	
WNV-infected	mice	
	
	Panel	A	demonstrates	the	number	of	PKH26+	leukocytes	in	the	spleen	of	mock-(blue)	and	WNV	(green)–infected	mice	7	days	after	PKH26	footpad	 injection	and	 i.n.	WNV	infection	(6x104	PFU).	 Panels	 B	 and	 C	 are	 the	 representative	 flow	 cytometry	 plots	 of	 PKH26+	leukocyte	subsets	of	mock	(B)-	and	WNV	(C)	–infected	mice.	Data	are	shown	as	the	mean	±SEM	of	values	from	1	experiment,	with	3	mice/group.	Statistical	analysis	was	conducted	using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	 P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Seven	 days	 following	 footpad	 injection,	 the	 majority	 of	 transferred	 cells	 in	 the	 PLN	 of	mock-	 and	WNV-infected	mice	were	 CD3+	 T	 cells	 (Figure	 3.22A).	 Interestingly,	 this	was	also	true	for	transferred	cells	migrating	into	the	ILN	of	mock-infected	mice	(Figure	3.22B).	Very	few	CD45.1+/CFSE+	cells	could	be	detected	in	the	ILN	of	WNV-infected	mice	at	d7	p.i.	However,	transferred	cells	could	be	identified	in	the	CLN	of	both	WNV-	and	mock-infected	mice	 and	 these	 were	 also	 identified	 as	 being	 mainly	 CD3+	 T	 cells	 (Figure	 3.22C).	 No	transferred	cells	 could	be	detected	 in	 the	CNS	or	 spleen	of	mock-	or	WNV-infected	mice	(Data	 not	 shown).	When	 enumerated	 (Figure	 3.22D),	 there	 were	 increased	 numbers	 of	transferred	cells	present	 in	the	mock-infected	mice	of	all	 the	nodes	examined,	compared	to	 the	WNV-infected	 counterpart.	 The	 highest	 number	 of	 transferred	 cells	 was	 isolated	from	 the	 PLN	 and	 there	 was	 a	 2-fold	 difference	 between	 the	 mock-	 and	WNV-infected	cohorts,	 although	 this	 was	 not	 significantly	 significant.	 On	 the	 other	 hand,	 the	 ILN	 had	significantly	more	 (7-fold)	 CD45.1+/CFSE+	cells	 in	 the	mock-infected	 than	WNV-infected	node.	In	contrast,	a	comparable	number	of	transferred	cells	were	present	in	the	mock-	and	WNV-infected	CLN.		
3.3. Discussion	
The	 results	 from	 this	 chapter	 describe,	 for	 the	 first	 time,	 the	 manner	 in	 which	 CNS	inflammation	 impacts	 on	 the	 cellularity	 of	 the	 draining	 as	 well	 as	 non-draining	 lymph	nodes	 of	 the	 CNS	 during	 WNV	 encephalitis.	 Furthermore,	 these	 data	 corroborate	published	data	supporting	a	role	for	the	CLN	in	the	lymphatic	drainage	of	the	CNS	(Stern	et	al.	2014;	Louveau	et	al.	2015).	The	dramatic	expansion	of	cell	numbers	 in	 the	CLN	early	during	 the	 course	 of	 infection	 indicates	 that	 a	 level	 of	 “lymph	 node	 shutdown”	 is	 likely	occurring.	 Furthermore,	 it	 seems	 that	 the	 rate	 of	 cellular	 recruitment,	 containment	 and	proliferation	in	the	CLN	far	exceeds	the	cells	emigrating	to	the	area	of	inflammation,	as	no	reduction	was	seen	in	any	of	the	leukocyte	subsets	analysed,	except	for	T	cells	on	d7	p.i.	
Figure	3.22	Adoptive	transfer	of	CD45.1+	and	CFSE+	cells	 into	the	footpad	of	mock-	
and	WNV-infected	mice	
	
	Representative	flow	cytometry	dot	plots	of	leukocytes	isolated	from	the	PLN	(A),	ILN	(B)	and	 CLN	 (C)	 of	 mock-	 and	WNV-infected	 (6x104	PFU)	 mice	 on	 d7	 p.i.	 and	 7	 days	 after	adoptive	transfer.	In	panel	A,	the	PLN	of	mice	receiving	adoptive	transfer	of	cells	(blue)	is	overlayed	onto	control	non-injected	(red)	to	illustrate	the	presence	of	CD45.1+	and	CFSE+	adoptively	 transferred	 cells	 in	 the	 PLN.	 Graph	 D	 shows	 the	 number	 of	 adoptively	transferred	cells	 in	 the	mock	(blue)	and	WNV-	(red)	 infected	PLN,	 ILN	and	CLN.	Control	nodes	 receiving	 no	 cells	 are	 represented	 by	 the	 light	 blue	 (mock)	 and	 orange	 (WNV)	columns.	Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	2	 independent	 experiments,	with	2-3	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.						
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Considering	 the	 immune-mediated	 nature	 of	 disease,	 in	 particular	 the	 contribution	 of	bone	marrow-derived	Ly6Chi	monocytes,	we	hypothesise	that	the	intensity	of	the	disease	and	 immunopathology	 present,	 overtakes	 the	 ability	 of	 the	 CLN	 to	 provide	 a	 sufficient	adaptive	response	to	resolve	infection	(Getts	et	al.	2008),	except	where	the	immigration	of	these	Ly6Chi	 inflammatory	monocytes	 into	 the	CNS	can	be	prevented	 (Getts	et	al.	2014).	However,	 it	 is	 also	 possible	 for	 the	 CLN	 B	 and	 T	 cell	 response	 to	 add	 to	 the	immunopathology	 and	 subsequent	mortality	 present	 in	WNV	 infection,	 as	RAG	KO	mice	(deficient	 in	 B	 and	 T	 cells)	 have	 longer	 MST	 as	 a	 result	 of	 reduced	 Ly6Chi	 monocyte	recruitment	 (Terry	 2012).	 Furthermore,	 T	 cell-derived	 IFN	 plays	 a	 crucial	 role	 in	 the	development	 of	 seizures	 during	 WNV	 encephalitis	 (Getts	 et	 al.	 2007).	 Thus,	 the	 CLN	response	 may	 contribute	 to	 the	 intensity	 of	 the	 pathological	 immune	 response	 during	WNV	encephalitis.		The	significant	expansion	of	CLN	leukocytes	likely	occurred	as	a	result	of	several	variables,	namely:	APC	draining	from	the	CNS	to	the	CLN;	subsequent	proliferation	of	resident	cells	in	 response	 to	 antigen	 presentation	 and	 the	 recruitment	 of	 additional	 cells,	 particularly	naïve	T	cells,	from	the	periphery.	This	study	further	examined	the	primary	source	of	B	and	T	cells	in	the	CLN	and	CNS	in	this	model	of	WNV	encephalitis.			In	addition	to	the	inflammation-related	changes	occurring	in	the	CLN,	it	was	also	evident	that	CNS	infection	and	inflammation	had	an	impact	on	the	leukocyte	composition	of	non-draining/peripheral	 lymph	nodes.	This	was	demonstrated	by	the	significant	reduction	 in	the	T	 cell	 numbers,	 as	well	 as	 shifts	 in	 total	 leukocyte	 composition	 of	 the	 ILN	 and	MLN	during	 the	course	of	 infection.	A	 few	studies	have	 identified	changes	 in	cell	number	and	specificity	of	 cells	 in	 the	 lymph	nodes,	not	 associated	with	drainage	of	 the	 infected	area	(Ciabattini	et	al.	2010;	Ciabattini	et	al.	2011).	The	i.v.	adoptive	transfer	of	CD8+	T	cells	into	naïve	 mice	 prior	 to	 i.p.	 infection	 with	 lymphocytic	 choriomeningitis	 virus	 resulted	 in	 a	
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significant	reduction	in	the	number	and	frequency	of	transferred	cells	in	the	non-draining	ILN.	This	occurred	in	contrast	to	a	significant	increase	in	the	draining	mediastinal	lymph	node.	However,	it	should	be	noted	that	viral	antigen	was	likely	acquired	in	the	ILN	due	to	the	systemic	spread	of	virus	(Olson	et	al.	2012).		Ciabattini	et	al.	discovered	the	presence	of	primed	and	proliferative	CD8+	and	CD4+	T	cells	in	 the	 non-draining	 mesenteric	 and	 iliac	 nodes	 following	 i.n.	 immunisation	 with	
Streptococcus	gordonii	(Ciabattini	 et	al.	2010).	However,	no	evidence	of	 clonal	expansion	could	 be	 detected	 in	 the	 non-draining	 lymph	 nodes	 in	 our	model	 of	 i.n.	WNV	 infection,	whereas	the	draining	CLN	showed	a	marked	increase	in	cellular	replication.	The	extent	to	which	cellular	expansion	in	the	CLN	could	be	attributed	to	proliferation	was	studied	with	a	BrdU	 incorporation	 assay,	 to	 determine	whether	DNA	 replication	was	 occurring.	 The	 6-fold	expansion	in	leukocyte	numbers	of	the	CLN	occurred	in	parallel	to	a	6-fold	increase	in	proliferation,	 relative	 to	 baseline.	 This	 was	 also	 true	 for	 B	 cells,	 which	 had	 a	 ~15-fold	increase	 in	 cell	 numbers	 and	 BrdU	 incorporation	 alike,	 compared	 to	 d0	 p.i.	 T	 cell	proliferation	increased	by	5-fold,	relative	to	baseline	levels,	whilst	cell	numbers	showed	a	~50%	 increase,	 relative	 to	 d0	 p.i.	 It	 may	 be	 that,	 although	 CLN	 T	 cell	 numbers	 do	 not	reduce	during	infection,	cells	which	are	being	supplied	to	the	CNS	are	rapidly	replaced	by	proliferating	cells.		It	is	likely	that	an	early	rise	in	APC	numbers	in	the	CLN	was	due	to	cells	draining	from	the	focus	 of	 inflammation.	 Furthermore,	 it	 was	 clear	 that	 inflammatory	 signals	 modulating	changes	 in	 the	 CLN	 differed	 from	 the	 signals	 present	 in	 the	 peripheral	 nodes	 (ILN	 and	MLN),	 as	 no	 increased	 BrdU	 incorporation	 occurred	 in	 these	 nodes	 in	 response	 to	 CNS	infection.	Although	there	was	a	reduction	in	T	cell	proliferation	in	the	ILN,	this	may	have	been	a	 reflection	of	 the	 significant	 reduction	 in	T	 cell	numbers	 in	 these	nodes	by	d7	p.i.	Whether	the	increased	BrdU	incorporation	present	in	some	of	the	leukocyte	subsets	in	the	MLN	between	d6-7p.i.	was	due	to	“real	proliferation”	remains	unclear	as	this	occurred	at	
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the	 height	 of	 disease	 when	 peripheral	 organ	 failure	 and	 high	 rates	 of	 cell	 death	 were	potentially	underway.	Although	this	was	not	directly	measured,	it	seems	unlikely	that	the	MLN	harboured	live	virus,	as	this	was	not	seen	in	either	the	ILN	or,	more	importantly,	the	CLN.		Further	 evidence	 for	 the	 impact	 of	 inflammation	 on	 the	 non-draining	 lymph	 nodes	was	identified	 in	 the	 dramatic	 alteration	 in	 levels	 of	 Ly6C	 expression	 in	 various	 leukocyte	subsets	during	the	course	of	 infection,	 in	both	the	draining	and	non-draining	nodes.	The	role	for	Ly6C,	a	cell	surface	glycoprotein,	is	still	being	investigated	and	high	expression	of	this	 marker	 is	 used	 in	 the	 identification	 of	 inflammatory	monocytes	 (Getts	 et	 al.	 2008;	Sunderkotter	et	al.	2004).	However,	 it	 is	also	expressed	on	B,	CD8+	and	CD4+	T	cells	and	increased	 expression	 has	 been	 associated	 with	 the	 stimulation	 of	 T	 cell	 proliferation	(Walunas	 et	 al.	 1995;	Yamanouchi	 et	 al.	 1998;	Dumont	1987;	Wrammert	 et	 al.	 2002).	 It	has	also	been	 implicated	as	an	accessory	molecule	 for	 the	CTL	response,	as	mAb	against	Ly6C	inhibited	adhesion	between	effector	and	target	cells,	as	well	as	IFN-γ	production	and	subsequent	lysis	of	target	cells	(Johnson	et	al.	1993).	Moreover,	Ly6C	has	been	shown	to	increase	T	cell	proliferation	and	IL-2	secretion.	As	opposed	to	the	stimulatory	role	of	Ly6C	in	CD8+	T	cells,	it	inhibits	IL-2	secretion	from	Th1	CD4+	T	cells	(Yamanouchi	et	al.	1998).	In	addition,	Ly6C	has	been	identified	as	a	regulator	of	endothelial	adhesion	of	CD8+	T	cells,	as	it	induced	the	clustering	of	LFA-1.	Evidently,	Ly6C	is	important	for	the	homing	of	T	cells	to	the	lymph	node	(Hanninen	et	al.	1997;	Jaakkola	et	al.	2003).	A	study	by	Wrammert	et	al.	demonstrated	that	B	cell	expression	of	Ly6C	was	restricted	to	plasma	cells	during	steady	state	conditions	and	may	be	used	as	an	additional	criterion	for	plasma	cell	 identification	(Wrammert	et	al.	2002).			
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We	performed	a	detailed	analysis	of	the	Ly6C	expression	on	the	various	leukocyte	subsets	present	in	the	CLN,	ILN	and	MLN	following	lethal	WNV	infection.	The	characterisation	of	lymph	 node	 leukocyte	 subsets	 into	 Ly6C-,	 Ly6Cint	 or	 Ly6Chi	 yielded	 some	 interesting	results.	 Although	 the	 majority	 of	 leukocyte	 populations	 in	 the	 CLN	 upregulated	 Ly6C	expression	in	response	to	infection,	certain	subsets	were	clearly	restricted	in	the	extent	to	which	they	could	express	Ly6C.	For	example,	CD4+	T	cells	were	mainly	Ly6Cint,	even	at	the	height	of	infection	and	level	of	Ly6C	upregulation,	whereas	CD8+	T	cells	clearly	possessed	a	 distinct	 Ly6Chi	 subset.	 Similarly,	 although	 B	 cells	 had	 significantly	 upregulated	 Ly6C	expression,	 the	majority	of	Ly6C+	cells	were	Ly6Cint,	 rather	 than	Ly6Chi.	Furthermore,	all	other	 leukocyte	 subsets	 analysed,	 including	 DC	 and	 myeloid	 subsets,	 increased	 their	expression	 of	 Ly6C,	 obtaining	 a	 Ly6Chi	 phenotype.	 Notably,	 the	 response	 of	 the	 non-draining	ILN	and	MLN	was	only	evident	1-3	days	after	the	CNS-draining	CLN.	This	implies	that	some	of	the	inflammatory	signals	modulating	the	CLN	environment	likely	reached	the	non-draining	 nodes	 over	 time;	 however,	 the	 exact	 signals	 regulating	 the	 expression	 of	Ly6C	 remains	 to	 be	 determined.	 The	 functional	 significance	 of	 this	 is	 still	 under	investigation	and	could	potentially	yield	valuable	 information	 in	 terms	of	understanding	the	 impact	 of	 inflammation	 on	 the	 immune	 system	 as	 a	 whole.	 It	 is	 unlikely	 that	 Ly6C	solely	plays	a	role	in	cellular	adhesion	and	migration	processes,	as	lymphoid	resident	cells	such	as	CD8α+	DC	also	showed	increased	expression	of	Ly6C.		A	possibility	for	the	disparity	in	Ly6C	expression	between	B	and	CD8+	T	cells,	may	be	the	differences	in	size	versus	the	density	of	Ly6C	on	the	surface	of	these	cells.	Nevertheless,	in	our	 model	 of	 i.n.	 WNV	 infection,	 the	 upregulation	 of	 Ly6C	 was	 a	 clear	 indicator	 of	inflammation	and,	albeit	CNS-infection-driven,	may	induce	a	certain	level	of	activation	in	leukocytes	throughout	the	lymphatic	system	in	preparation	for	potential	systemic	spread	of	infection.			
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The	presence	of	pathogen	is	known	to	trigger	an	inflammatory	response	in	lymph	nodes	and	considering	the	close	anatomical	relationship	between	the	CNS	and	CLN	it	is	possible	for	virus	to	reach	the	CLN	and	elicit	an	immune	response.	Furthermore,	as	the	lymphatic	system	is	a	continuous	network	of	vessels	and	nodes,	it	is	also	possible	for	virus	to	reach	peripheral	nodes	via	 the	circulatory	or	 lymphatic	system	eliciting	a	response.	Therefore,	we	analysed	the	viral	RNA	content	in	the	CNS,	CLN	and	ILN	in	order	to	establish	whether	any	detectable	virus	was	present.	However,	no	virus	could	be	detected	in	the	draining	CLN	and	 it	 is	 likely	 that	 APC,	 draining	 from	 the	 local	 site	 of	 infection	 (CNS)	 to	 the	 CLN,	presented	processed	antigen	only,	subsequently	inducing	proliferation	of	leukocytes	in	the	CLN.	 The	 absence	 of	 virus	 in	 the	 ILN	 indicates	 that	 viral	 presence	was	 not	 the	 primary	signal	 stimulating	 the	 changes	 seen	 during	 inflammation.	 Interestingly,	 detectable	 virus	was	 only	 identified	 in	 the	 CNS	 from	 d5	 p.i.,	 whereas	 obvious	 changes	 associated	 with	inflammation	 occurred	 by	 d3	 p.i.	 in	 the	 draining	 and	 non-draining	 lymph	 nodes.	 It	 is	possible	that	low	levels	of	viral	replication	or	distribution	of	antigen-primed	APC	from	the	CNS	or	olfactory	bulb,	to	the	draining	and	non-draining	nodes	occurred.	Previous	studies	from	 our	 lab	 have	 shown	 that	 viral	 levels	 in	 the	 peripheral	 organ	 such	 as,	 heart,	 lungs,	kidneys	 etc.	 are	 present	 in	 levels	 less	 than	 0.001%	 of	 those	 found	 in	 the	 brain	 (Terry	2012),	 during	 i.n.	 WNV	 infection,	 reducing	 the	 likelihood	 that	 APC	 cells	 draining	 from	peripheral	organs	could	account	for	the	alteration	in	cellular	composition	and	cell	surface	marker	 expression	 in	 the	 non-draining	 nodes.	 A	 more	 probable	 explanation	 is	 the	transmission	and	circulation	of	a	stimulus	from	the	draining	CLN	or	CNS	to	the	peripheral	nodes	 via	 the	 lymphatic	 and/or	 circulatory	 system.	 Inflammatory	 stimuli	 such	 as	cytokines	or	chemokines	produced	by	the	infected	CNS	and	released	into	the	bloodstream	clearly	 reach	 the	 bone	 marrow	 and,	 by	 inference,	 the	 peripheral	 lymph	 nodes	 via	 the	circulatory	system.	Irrespective,	this	indicates	the	extent	to	which	the	immune	system	acts	
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as	 a	 large	 interconnected	 network,	 including	 the	 bone	 marrow,	 spleen	 and	 lymphatic	system.		The	 significant	 reduction	 seen	 in	 the	 numbers	 of	 T	 cells	 in	 the	 ILN	 and	MLN	 led	 to	 the	hypothesis	 that	T	cells	 from	peripheral	nodes	could	traffic	 to	 the	CLN	and	even	the	CNS,	adding	to	the	lymphocyte	infiltrate.	In	an	attempt	to	elucidate	the	ultimate	destination	of	these	peripheral	T	 cells	 emigrating	 from	 the	non-draining	nodes,	we	attempted	 to	 track	cells	from	the	ILN	and	PLN,	following	lethal	WNV	infection.	Firstly,	we	established	the	extent	to	which	cells,	originating	from	a	completely	peripheral	node	 distributed	 throughout	 the	 lymphatic	 system	 during	 homeostatic	 conditions.	Secondly,	we	analysed	in	detail	how	this	distribution	changed	during	infection.	A	period	of	seven	days	was	sufficient	for	PKH26	and/or	cells	labelled	with	PKH26,	to	move	from	the	draining	PLN	 to	 the	 contralateral	 PLN.	Due	 to	 the	 small	 volume	of	 dye	 injected	 and	 the	anatomy	of	the	lymphatic	system,	it	was	unlikely	that	this	occurred	through	spread	of	free	dye	 via	 the	 lymphatics,	 further	 than	 the	 PLN.	 In	 addition,	 the	 constant	 circulation	 of	leukocytes	 throughout	 the	 lymphatic	 system	 during	 homeostatic	 conditions	 is	 a	 well-known	phenomenon	and	is	necessary	for	the	continuous	sampling	of	antigen	in	the	body.	Different	lymphocyte	subsets	exhibit	different	rates	of	recirculation.	CD4+	T	cells,	followed	by	CD8+T	cells,	 exhibit	 the	highest	 rate	of	 turnover	 (~12h),	which	 is	 turn	 followed	by	B	cells,	which	are	replaced	within	24h.	 Indeed,	~70%	of	steady-state	 lymph	node	cells	are	replaced	within	 24	 h	 and	 after	 3	 days	 equilibrium	 is	 reached	 throughout	 the	 lymphatic	system	 (Tomura	 et	 al.	 2008).	 Although,	 there	were	 still	 PKH26+	 cells	 in	 the	PLN	 after	 7	days	 in	 our	 model,	 these	 were	 likely	 cells	 that	 incorporated	 the	 dye	 and	 did	 not	recirculate.			
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The	CLN	had	significantly	more	PKH26+	leukocytes	in	WNV-	than	mock-infected	mice.	We	hypothesised	 that	 this	occurred	as	a	direct	 result	of	 increased	recruitment	of	peripheral	lymphocytes	 from	 non-draining	 nodes	 to	 the	 draining	 CLN	 during	 CNS	 infection.	Nevertheless,	this	increased	PKH26+	cell	number	in	the	CLN	was	essentially	limited	to	the	B	 cell	 and	 pDC	 subsets,	 indicating	 that	 they	may	 be	 recruited	 by	 similar	 signals.	 TLR-9	stimulation	activates	both	B	 cells	 and	pDC,	however,	 this	would	 require	 the	presence	of	virus	or	pathogen-associated	molecular	patterns	(Jiang	et	al.	2007;	Montoya	et	al.	2006).	Interestingly,	the	opposite	was	true	for	the	ILN	with	fewer	PKH26+	B	cells	and	pDC	in	the	WNV-	 than	mock-infected	 cohort,	perhaps	 suggesting	 that	 these	 cells	were	bypassing	or	rapidly	 leaving	 the	 ILN	 during	 infectious	 circumstances,	 trafficking	 to	 the	 CLN.	 The	PKH26+	content	of	CD11b+	DC	and	monocytes	was	relatively	high	in	both	the	ILN	and	CLN,	however	this	ratio	did	not	 increase	as	a	result	of	 infection.	This	highlights	the	migratory	capacity	of	these	subsets	during	homeostatic	conditions	throughout	the	lymphatic	system.	Interestingly,	 the	 contralateral	PLN	did	not	 obtain	 the	 same	numbers	of	 PKH26+	cells	 as	the	contralateral	ILN	or	CLN	in	either	mock-	or	WNV-infected	cohorts,	suggesting	that	the	extent	 to	 which	 these	 cells	 are	 able	 to	 spread	 throughout	 the	 lymphatic	 system	 was	somewhat	limited.		Unfortunately,	performing	dye	injection	alone	could	not	ultimately	verify	the	migration	of	cells,	rather	than	dye,	from	the	PLN	to	the	CLN	and	we	were	unable	to	prove	that	injection	of	dye	did	not	impair	migratory	capacity	of	these	cells.	Furthermore,	dye	injection	into	the	footpad	raises	the	possibility	that	there	may	be	increased	cell	death	of	dye+	cells,	however,	we	did	not	find	any	significant	differences	in	numbers	or	percentage	of	dead	cells	in	PLN	that	 received	 dye	 and	 control	 PLN	 to	 support	 this.	 Thus,	 we	 designed	 a	 preliminary	adoptive	 transfer	 experiment	 with	 cells	 obtained	 from	mock-infected	 peripheral	 lymph	nodes	in	order	to	clarify	this	 issue.	In	both	mock-	and	WNV-infected	mice	the	adoptively	
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transferred	 cells	 in	 the	PLN,	 ILN	and	CLN	were	 identified	 as	T	 cells,	 including	CD8+	 and	CD4+	 subsets.	 The	 only	 consistent	 finding	 with	 previous	 results	 was	 the	 fact	 that	 the	number	 of	 adoptively	 transferred	 cells	 was	 reduced	 in	 the	 ILN	 of	 WNV-infected	 mice,	compared	 to	 the	 mock-infected	 counterpart.	 Nevertheless,	 this	 study	 confirms	 the	migration	of	cells	from	a	peripheral	node	such	as	the	PLN	to	the	CLN	is	possible.	However,	it	 is	 likely	 that	 we	 transferred	 too	 few	 cells	 for	 detection	 in	 the	 CNS	 and	 follow	 up	experiments	are	needed	to	conclusively	say	whether	or	not	peripheral	nodes	can	supply	lymphocytes	to	the	CNS.	Interestingly,	no	B	cells	could	be	identified	in	the	transferred	cells	from	any	of	the	lymph	nodes,	suggesting	that	B	cells	may	not	so	easily	migrate	but	prefer	to	proliferate	in	situ.	In	contrast,	T	cells	likely	migrate	to	the	CLN	rather	than	proliferate	at	the	site	of	injection.	Even	so,	these	data	provide	evidence	that	the	nature	of	the	lymphatic	system,	 associated	 with	 the	 CNS,	 is	 not	 limited	 to	 the	 draining	 CLN	 and	 that	 CNS	inflammation	can	influence	lymph	nodes	as	far	removed	as	the	PLN,	MLN	and	ILN.				 	
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4. CHAPTER	4	Spleen,	WNV	infection	and	IMP	treatment	
4.1. Introduction	
The	spleen	is	the	largest	secondary	lymphoid	organ	and	acts	as	a	crucial	phagocytic	filter	for	the	circulatory	system,	protecting	the	body	from	invading	pathogens	and	disposing	of	apoptotic	 cells	 (Aichele	 et	 al.	 2003;	 Miyake	 et	 al.	 2007).	 This	 organ	 not	 only	 captures	particulate	 antigen,	 including	 bacteria,	 but	 also	 removes	 non-biological	 nanoparticles	present	 in	 circulation,	 in	 the	 marginal	 zone,	 the	 location	 of	 the	 MARCO+	marginal	 zone	macrophages	(Demoy	et	al.	1997;	Demoy	et	al.	1999).	Previous	work	from	our	laboratory	has	 shown	 that	Ly6Chi	 inflammatory	monocytes,	 recruited	 from	 the	bone	marrow	 to	 the	CNS	 during	 WNV	 infection,	 significantly	 contribute	 to	 the	 immunopathology	 of	 WNV	encephalitis	 (Getts	 et	 al.	 2008;	 Getts	 et	 al.	 2012).	 However,	 several	 studies	 have	 also	implicated	the	spleen	as	a	possible	reservoir	for	these	pathogenic	Ly6Chi	monocytes	(Bao	et	al.	2010;	Leuschner	et	al.	2010).		This	laboratory	recently	developed	a	treatment,	the	efficacy	of	which	is	primarily	based	on	reducing	 Ly6Chi	 inflammatory	 monocytes	 infiltrating	 into	 the	 CNS.	 The	 distribution	 of	Ly6Chi	 inflammatory	 monocyte	 numbers	 in	 the	 CNS	 occurred	 in	 conjunction	 with	 an	increase	of	this	subset	in	the	spleen.	This	strongly	suggests	that	these	cells	are	diverted	to	and/or	detained	 in	 the	spleen,	preventing	 their	migration	 to	 the	CNS,	where	 they	would	otherwise	have	exerted	their	pathogenic	action.	This	was	supported	by	the	distribution	of	IMP	within	 the	mouse	 as	 substantial	 numbers	 of	 IMP	were	 found	 in	 the	 spleen,	 located	primarily	in	the	MZM,	as	well	as	in	Ly6Chi	monocytes	in	the	red	pulp	(Terry	2012;	Getts	et	al.	2014).	Thus,	considering	its	prominent	role	as	a	filter	for	the	blood,	the	spleen	may	be	an	 ideal	 site	 for	 disposing	 of	 IMP,	 or	 cells	 that	 have	 phagocytosed	 IMP,	 and	 have	subsequently	travelled	to	the	spleen,	where	they	may	be	destroyed.	
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	Therefore,	 to	 further	 expand	 our	 understanding	 of	 the	 role	 of	 the	 secondary	 lymphoid	organs	 in	 CNS	 infection,	 we	 dissected	 the	 splenic	 response	 to	 WNV	 encephalitis.	 This	included	 looking	 at	 changes	 in	 cellularity	 of	 the	 spleen,	 leukocyte	 composition	 and	whether	 CNS	 infection	 could	 induce	 any	 proliferative	 changes	 in	 the	 spleen.	We	 further	investigated	the	potential	role	of	the	spleen	as	an	additional	source	to	the	bone	marrow,	of	the	 pathogenic	 Ly6Chi	 inflammatory	 monocytes	 infiltrating	 the	 CNS.	 In	 addition,	 we	examined	the	reaction	to	primary	WNV	infection	in	the	absence	of	the	spleen	and	looked	at	 the	 subsequent	 development	 of	 immunity	 in	 splenectomised	mice.	 Lastly,	we	 further	explore	the	role	of	the	spleen	in	the	efficacy	of	IMP	treatment.	
4.2. Results	
4.2.1. Leukocyte	dynamics	in	the	spleen	following	lethal	WNV	infection	
Chapter	3	demonstrated	the	significant	impact	of	CNS	infection	on	the	draining	and	non-draining	 lymph	nodes	of	 the	CNS	 following	 lethal	WNV	 infection.	 In	order	 to	 investigate	whether	 or	 not	 this	 holds	 true	 for	 the	 spleen,	 we	 examined	 the	 changes	 in	 leukocyte	number	and	composition	 in	the	spleen	following	 lethal	 i.n.	WNV	infection	(6x104	PFU)	of	female	 C57BL/6	mice.	 Note	 that	 a	 detailed	 flow	 cytometry	 gating	 strategy	 used	 for	 the	spleen	with	isotype	and	fluorescence	minus	one	controls,	can	be	found	in	Appendix	Figure	5	and	6.	.			Total	 leukocyte	 (CD45+)	and	B	cell	 (B220+/CD19+)	numbers	remained	stable	 throughout	the	7-day	course	of	infection	and	there	was	a	slight,	but	non-significant,	decrease	in	total	T	cell	numbers	 (CD3+)	 (Figure	4.1A).	Furthermore,	50%	of	 the	 spleen	was	 comprised	of	B	cells	and	this	remained	unchanged	throughout	the	course	of	infection.	However,	there	was	
	Figure	4.1	Cellularity	of	the	spleen	following	lethal	WNV	infection-	Total	leukocyte,	
B,	T	cell	and	DC	populations	
			Graph	 A	 shows	 the	 number	 of	 total	 leukocytes	 (CD45+)	(circle),	 B	 cells	 (CD19+/B220+)	(triangle)	 and	 total	 T	 cells	 (CD3+)	 (square)	 in	 the	 spleens	 of	mice	 following	 lethal	WNV	infection	(6x104	PFU)	on	day	0,	3,	5,	6	and	7	p.i.	The	percentage	of	B	cells	(CD19+/B220+)	(triangle)	 and	 total	 T	 cells	 (CD3+)	 (square)	 in	 the	 spleen	 of	 mice	 following	 lethal	WNV	infection	(6x104	PFU)	is	represented	by	graph	B.	T	cells	were	further	classified	into	CD4+	and	CD8+	 subsets,	with	 the	 number	 (C)	 and	percentage	 (D)	 of	 CD4+	 (circle)	 and	CD8+	T	(upside-down	 triangle)	 cells	 in	 the	 spleen	 following	 WNV	 infection.	 DC	 subsets	 were	classified	 according	 to	 their	 differential	 CD11c	 and	 CD11b	 expression	 to	 give	 three	subsets,	 namely	 CD11c+CD11b+	 (square),	 CD11c+CD11b-	 (circle)	 and	 CD11chiCD11bint	(triangle).	 Graphs	 E	 and	 F	 shows	 the	 number	 and	 percentage	 change	 of	 these	 DC	populations,	 respectively,	 following	 lethal	WNV	 infection.	 Values	 of	 the	 above	 leukocyte	subsets	are	expressed	as	a	percentage	of	total	leukocytes	in	the	spleen	of	each	cohort.	Data	are	 shown	 as	 the	 mean	 ±SEM	 of	 values	 from	 3	 independent	 experiments,	 with	 3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.	 	
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a	 5%	 decrease	 in	 the	 percentage	 of	 CD3+	T	 cells	 in	 the	 spleen	 by	 d7	 p.i.,	 relative	 to	 d0,	which	was	statistically	significant	(Figure	4.1B).	This	was	comprised	of	a	decrease	in	the	numbers	 of	 both	 CD4+	 and	 CD8+	 T	 cells,	 although	 not	 significant,	 these	 subsets	 had	reduced	by	30%	and	40%,	respectively,	of	 the	baseline	value.	 Indeed,	 this	accounted	 for	the	percentage	decrease	 seen	 in	 the	 total	T	 cell	populations	and	was	also	evident	 in	 the	reduction	in	percentage	of	both	T	cell	subsets	by	d7	p.i.,	compared	to	d0	(Figure	4.1D).		The	DC	in	the	spleen	were	gated	according	to	the	same	principles	used	for	lymph	node	DC	gating	 (Figure	 3.5).	 The	 CD11chiCD11bint	 subset	 remained	 stable	 throughout	 the	 disease	course,	with	no	change	in	the	numbers	(Figure	4.1E)	and	percentages	(Figure	4.1F)	of	this	population.	 However,	 CD11c+CD11b-	 numbers	 (Figure	 4.1E)	 had	 doubled	 by	 d7	 p.i.,	although,	 the	 proportion	 of	 this	 subset	 remained	 unchanged	 (Figure	 4.1F).	 In	 contrast,	numbers	 of	 the	 CD11c+CD11b-	 DC	 (Figure	 4.1E)	 subset	 had	 halved	 by	 d7p.i.,	 with	 a	significant	reduction	in	percentage		(Figure	4.1F)	seen	on	d7p.i.		The	 CD11b+	 populations,	 namely	 monocytes	 (CD11b+CD11c-Ly6G-)	 and	 neutrophils	(CD11bhiLy6G+),	 showed	 opposite	 responses	 in	 the	 spleen,	 following	 WNV	 infection.	Monocyte	numbers	reduced	by	50%,	whereas	neutrophil	numbers	doubled	(Figure	4.2A)	by	 d7	 p.i.,	 relative	 to	 d0.	 Moreover,	 the	 percentages	 (Figure	 4.2B)	 of	 these	 subsets	mirrored	 their	 changes	 in	 cell	 number,	 with	 percentage	 of	 monocytes	 in	 the	 spleen	reducing	by	half	and	the	percentage	of	neutrophils	increasing	significantly,	from	1	to	2.7%,	by	d7	p.i.	Neither	 the	number	 (Figure	4.2C)	 nor	 the	percentage	 (Figure	4.2D)	 of	NK1.1+	subsets,	namely	NK	(NK1.1+CD3-)	and	NKT	(NK1.1+CD3+)	cells,	showed	significant	change	during	the	disease	course.	
Figure	 4.2	 Cellularity	 of	 the	 spleen	 following	 lethal	 WNV	 infection	 -	 CD11b+	 and	
NK1.1+	populations	
		The	 number	 (A)	 and	 percentage	 (B)	 of	 monocytes	 (CD11b+CD11c-)	 (circle)	 and	neutrophils	(CD11bhiLy6G+)	(square)	in	the	spleen,	following	lethal	WNV	infection	(6x104	PFU)	 are	 shown	 on	 day	 0,	 3,	 5,	 6	 and	 7	 p.i.	 Graphs	 C	 and	 D	 show	 the	 number	 (C)	 and	percentage	(D)	change	in	NK1.1+	subsets,	including	NK	(NK1.1+CD3-)	cells	(circle)	and	NKT	cells	 (NK1.1+CD3+)	 (square)	 in	 the	 spleen	of	WNV-infected	mice	on	d0,	3,	 5,	 6	 and	7	p.i.	Values	of	CD11b+	and	NK1.1+	subsets	are	expressed	as	a	percentage	of	total	leukocytes	in	the	spleen	in	each	cohort.	Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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4.2.2. Changes	 in	 cell-surface	marker	expression	 in	various	 leukocyte	
subsets	of	the	spleen	following	lethal	WNV	infection	
Significant	 upregulation	 of	 the	 cell-surface	 glycoprotein,	 Ly6C,	 was	 demonstrated	 in	several	of	the	leukocyte	populations	in	the	lymph	nodes,	following	WNV	infection.	Review	of	the	literature	also	indicated	that	Ly6C	might	play	an	important	role	in	the	mobilisation	and	 activation	 of	 lymphocytes.	 Therefore,	 we	 analysed	 the	 expression	 of	 Ly6C	 in	 the	various	splenic	leukocyte	subsets	to	determine	whether	a	similar	pattern	might	be	present	here.	Indeed,	similar	to	lymph	node	data	presented	in	the	previous	chapter,	upregulation	of	 Ly6C	 occurred	 in	 most	 of	 the	 leukocyte	 subsets	 analysed	 in	 the	 spleen	 by	 d7p.i.	(Appendix	 figure	7),	 relative	 to	baseline	(d0),	prompting	us	 to	 investigate	 this	 in	 further	detail.		Flow	cytometry	histograms	demonstrated	the	expression	of	Ly6C	on	B	(Figure	4.3A),	CD4+	(Figure	4.3D)	and	CD8+	T	cells	(Figure	4.3G)	on	d0,	3,	5,	6	and	7	p.i.	As	previously	seen	in	the	lymph	nodes,	Ly6C	expression	marker	upregulation	was	evident	in	subsets	as	early	as	d3p.i.	As	with	the	lymph	nodes,	we	characterised	these	populations	into	Ly6C-,	Ly6Cint	and	Ly6Chi,	based	on	FMO	and	isotype	controls.	The	majority	of	the	B	(Figure	4.3C)	cells	were	Ly6C-	 at	 d0p.i.,	 with	 ~55%	 becoming	 Ly6Cint	 by	 d7p.i.,	 as	 reflected	 in	 the	 significant	increase	in	Ly6Cint	B	cell	numbers	(Figure	4.3B)	from	d5p.i.	onwards,	relative	to	d0p.i.		As	in	the	lymph	nodes,	the	CD4+	subset	(Figure	4.3F)	consisted	mainly	of	Ly6C-	and	Ly6Cint	populations,	 while	 the	 CD8+	 T	 cells	 were	 dispersed	 between	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	populations	 (Figure	 4.3I).	 In	 both	 CD4+	 (Figure	 4.3E)	 and	 CD8+	 T	 cell	 (Figure	 4.3H)	subsets,	the	number	of	Ly6C-cells	reduced	significantly,	from	d3	p.i.	onwards	in	the	course	of	infection.	The	upregulation	of	Ly6C	in	DC	subsets	in	the	spleen	was	evident	from	d3	p.i.	(Figure	4.4A,	D	 and	 G).	 Both	 the	 CD11c+CD11b+	 (Figure	 4.4C)	 and	 CD11c+CD11b-	 (Figure	 4.4I)	 DC	
Figure	4.3	Differential	Ly6C	subsets	in	the	B	and	T	cell	populations	of	the	spleen	of	
following	lethal	WNV	infection	
		Representative	 flow	 cytometric	 histograms	 (A,	 D,	 G)	 illustrate	 the	 change	 in	 Ly6C	expression	of	(A)	B	cells	(B220+/CD19+),	CD4+	T	cells	(D)	and	CD8+	T	cells	(G)	in	the	spleen	on	 d0,	 3,	 5,	 6	 and	 7p.i.	 following	 lethal	WNV	 infection	 (6x104	PFU)	with	 isotype	 control	(grey)	 and	 WNV	 infected	 sample	 (red).	 Flow	 cytometry	 contour	 plots	 C,	 F	 and	 I	demonstrate	the	expression	of	Ly6C	in	these	subsets	in	the	spleen	of	WNV-infected	mice	(6x104	PFU)	on	d7p.i.,	compared	to	d0.	Leukocyte	 subsets	 in	 the	 spleen	 were	 thus	 characterised	 based	 on	 Ly6C	 expression	 as	Ly6Chi	(square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 The	 number	 of	 Ly6Chi/int/-	B	 cells	 (B)	(B220+/CD19+),	 CD4+	 (E)	 and	 CD8	 +	 T	 (H)	 cells	 in	 the	 spleen	 on	 d0,	 3,	 5,	 6	 and	 7p.i.	following	 lethal	WNV	 infection	 (6x104	PFU)	are	 shown.	Significance,	 compared	 to	d0,	 for	each	subset	was	defined	as	follows:	***Ly6Chi-;	+++Ly6Cint	and	ØØØLy6C-.		Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.	 	
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Figure	4.4	Differential	Ly6C	subsets	in	the	DC	populations	of	the	spleen	of	following	
lethal	WNV	infection	
		Representative	 flow	 cytometric	 histograms	 (A,	 D,	 G)	 illustrate	 the	 change	 in	 Ly6C	expression	of	(A)	CD11c+CD11b+	DC,	CD11chiCD11bint	DC	(D)	and	CD11c+CD11b-	DC	(G)	in	the	spleen	on	d0,	3,	5,	6	and	7p.i.	following	lethal	WNV	infection	(6x104	PFU)	with	isotype	control	 (grey)	 and	WNV	 infected	 sample	 (red).	 Flow	 cytometry	 contour	 plots	 C,	 F	 and	 I	demonstrate	 the	 expression	of	Ly6C	 in	 the	 spleen	of	WNV-infected	mice	 (6x104	PFU)	on	d7p.i.,	compared	to	d0	in	CD11c+CD11b+	DC	(C),	CD11chiCD11bint	DC	(F)	CD11c+CD11b-	DC	and	(I).		Leukocytes	subsets	in	the	spleen	were	further	characterised	based	on	Ly6C	expression	as	Ly6Chi	 (square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	 (circle).	 The	 number	 of	 Ly6Chi/int/-	CD11c+CD11b+	DC	(B),	CD11chiCD11bint	DC	(E)	and	CD11c+CD11b-	DC	(H)	in	the	spleen	on	d0,	 3,	 5,	 6	 and	7p.i.	 following	 lethal	WNV	 infection	 (6x104	PFU)	 are	 shown.	 Significance,	compared	to	d0,	for	each	subset	was	defined	as	follows:	***Ly6Chi-;	+++Ly6Cint	and	ØØØLy6C-.		Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.	 	
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subsets	had	developed	distinct	Ly6C-,	Ly6Cint	and	Ly6Chi	populations	by	d7	p.i.,	while	 the	CD11chiCD11bint	DC	(Figure	4.4F)	mainly	showed	an	increase	in	Ly6Cint	cells.	The	numbers	of	Ly6C-	CD11c+CD11b+	cells	 (Figure	4.4B)	had	reduced	significantly	by	d6-7	p.i.,	 relative	to	d0.	Enumeration	of	the	CD11chiCD11bint	DC	subset	showed	a	significant	increase	in	the	number	 of	 Ly6Chi	 CD11chiCD11bint	DC	 (Figure	 4.4E)	 by	 d7p.i.,	 relative	 to	 d0.	 Moreover,	numbers	of	Ly6Chi	CD11c+CD11b-	cells	(Figure	4.4.H)	increased	significantly	by	d7	p.i.				The	 CD11b+	subsets	 in	 the	 spleen,	 including	 neutrophils	 (Figure	 4.5A)	 and	 monocytes	(Figure	4.5B),	expressed	relatively	high	levels	of	Ly6C,	at	d0,	remaining	Ly6Cint	and	Ly6Chi,	respectively,	 throughout	 the	 disease	 course.	 Numbers	 of	 Ly6C-	and	 Ly6Cint	 monocytes	(Figure	 4.5E)	 decreased	 significantly	 by	 d7p.i.,	 relative	 to	 day	 0.	 Similar	 to	 the	 CD11b+	subsets,	 the	 NK1.1+	 subsets,	 namely	 NK	 (Figure	 4.5G)	 and	 NKT	 cells	 (Figure	 4.5H),	expressed	 relatively	 high	 levels	 of	 Ly6C	 at	 d0p.i.,	 however,	 numbers	 of	 cells	 expressing	Ly6Cint	 and	 Ly6Chi	 increased	 during	 infection.	 This	 was	 more	 distinct	 in	 the	 NKT	 cell	subsets,	 with	 the	 majority	 of	 NKT	 cells	 becoming	 Ly6Chi	 or	 Ly6Cint	 by	 d7p.i.	Notwithstanding,	 changes	 in	 numbers	 of	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	 NK	 (Figure	 4.5I)	 and	NKT	cells	(Figure	4.5K)	were	non-significant.	
4.2.3. Proliferation	of	 leukocyte	subsets	 in	 the	spleen	 following	 lethal	
WNV	infection	
We	 hypothesised	 that,	 although	 changes	 in	 cell	 numbers	 in	 the	 spleen	 during	 infection	were	small,	 inflammation	may	have	an	 impact	on	the	rate	at	which	cells	replicate	 in	this	organ.	 The	 same	 BrdU	 incorporation	 assay,	 used	 to	 determine	 proliferation	 in	 lymph	nodes,	was	 applied	 to	 the	 spleen	 and	 results	 displayed	 as	percentage	 change	 relative	 to	baseline	 i.e.	 d0	 p.i.	 Supporting	 the	 stable	 cell	 numbers	 during	 infection,	 there	was	 little	
Figure	 4.5	 Differential	 Ly6C	 subsets	 in	 the	 CD11b+	 and	 NK1.1+	 populations	 of	 the	
spleen	of	following	lethal	WNV	infection	
		Representative	 flow	 cytometric	 histograms	 (A,	 B,	 G,	 H)	 illustrate	 the	 change	 in	 Ly6C	expression	of	(A)	neutrophils,	monocytes	(B),	NK	cells	G)	and	NKT	cells	(H)		in	the	spleen	on	 d0,	 3,	 5,	 6	 and	 7p.i.	 following	 lethal	WNV	 infection	 (6x104	PFU)	with	 isotype	 control	(grey)	 and	 WNV	 infected	 sample	 (red).	 Flow	 cytometry	 contour	 plots	 D,	 F,	 J	 and	 L	demonstrate	the	upregulation	of	Ly6C	in	the	spleen	of	WNV-infected	mice	(6x104	PFU)	on	d7p.i.,	compared	to	d0	in	neutrophils	(D),	monocytes	(F),	NK	cells	(J)	and	NKT	cells	(L).	Leukocytes	subsets	in	the	spleen	were	further	characterised	based	on	Ly6C	expression	as	Ly6Chi	(square),	 Ly6Cint	 (triangle)	 or	 Ly6C-	(circle).	 The	 number	 of	 Ly6Chi/int/-	neutrophil	(C),	monocytes	 (E),	 NK	 cells	 (I)	 and	NKT	 cells	 (K)	 in	 the	 spleen	 on	 d0,	 3,	 5,	 6	 and	 7p.i.	following	 lethal	WNV	 infection	 (6x104	PFU)	are	 shown.	Significance,	 compared	 to	d0,	 for	each	subset	was	defined	as	follows:	***Ly6Chi-;	+++Ly6Cint	and	ØØØLy6C-.		Data	 are	 shown	as	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	 a	 Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 Ly6Chi	 =P≤0.05*;	P≤0.01**;	P≤0.001***.	 Ly6Cint	 =P≤0.05+;	P≤0.01++;	P≤0.001+++.	 Ly6C-	=P≤0.05Ø;	P≤0.01ØØ;	P≤0.001ØØØ.		 	
Figure 4.5 Ly6C populations in the Spleen
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evidence	of	increased	BrdU	incorporation	in	any	of	the	cell	subsets	analysed	in	the	spleen	following	WNV	infection	(Figure	4.6A-E).	
4.2.4. WNV	infection	and	CNS	infiltration	in	the	absence	of	the	spleen	
4.2.4.1. Leukocyte	infiltration		
The	spleen	plays	a	crucial	role	in	mounting	an	effective	primary	immune	response	against	peripheral	bacterial	 and	parasitic.	However,	 there	 is	 little	 information	on	 the	 role	of	 the	spleen	in	immune	responses	against	a	CNS	viral	infection,	or	for	that	matter,	in	supplying	the	pathogenic	component	of	this	disease,	the	Ly6Chi	inflammatory	monocytes.	Thus,	with	a	view	to	establish	the	extent	to	which	the	spleen	may	be	involved	in	the	lethal	response	found	in	WNV	encephalitis,	we	used	the	i.n.	model	of	WNV	infection	in	mice	that	had	their	spleen	 surgically	 removed.	 Splenectomised	 female	 C57BL/6	 mice	 (7-week	 old)	 were	allowed	to	recuperate	for	2	weeks,	prior	to	 i.n.	 infection	with	WNV	at	9-11	weeks	of	age	(Reeves	 et	 al.	 2001).	 For	 a	 detailed	 gating	 strategy	 of	 the	 CNS	 with	 isotype	 and	fluorescence	minus	one	controls,	refer	to	Appendix	Figure	8	and	9.		The	 resultant	 changes	 in	 CNS	 cell	 numbers,	 following	WNV	 infection	 of	 splenectomised	mice	are	shown	in	Figure	4.7A	and	B.	There	was	a	distinct	trend	of	reduced	infiltration	of	leukocytes	into	the	CNS	of	splenectomised	mice	(green),	compared	to	mice	that	had	their	spleens	 intact	 i.e.,	 normal	 (blue)	 mice.	 Normal,	 WNV-infected	 mice	 had	 significant	infiltration	of	leukocytes	into	the	CNS,	compared	to	mock-infected	mice	(grey).	There	were	no	 differences	 in	 CNS	 leukocyte	 numbers	 between	 mock-infected,	 normal	 mice	 versus	splenectomised,	 mock-infected	 mice	 (data	 not	 shown),	 thus	 only	 normal	 mock-infected	cohort	 is	 presented.	 The	 largest	 infiltrating	 population	 in	 all	 WNV-infected	 cohorts	(splenectomised	and	normal)	consisted	of	 the	Ly6Chi	 inflammatory	macrophages	(Figure	
Figure	4.6	Proliferation	of	various	leukocyte	subsets	in	the	spleen,	following	lethal	
WNV	infection	
	
	Graph	A	represents	the	percentage	change,	relative	to	d0p.i.,	in	BrdU	incorporation	of	the	total	leukocyte	population	(CD45+)	(circle),	B	(B220+/CD19+)(triangle)	and	total	T	(CD3+)	(square)	cells,	with	graph	B	demonstrating	the	percentage	change	of	the	CD4+	(circle)	and	CD8+	 (upside-down	 triangle)	 T	 cell	 subsets.	 Proliferation	 of	 the	 various	 DC	 subsets,	namely:	CD11c+CD11b+	(square),	CD11chiCD11bint	 (triangle)	and	CD11c+CD11b-	(circle)	 is	demonstrated	 by	 figure	 C.	 The	 percentage	 change	 in	 BrdU	 incorporation	 of	 the	 CD11b+	CD11c-	 subsets,	 namely:	 monocytes	 (CD11b+Ly6G-)	 (circle)	 and	 neutrophils	 (CD11bhi	Ly6G+)	is	represented	by	graph	D,	with	the	proliferation	of	the	two	NK1.1+	subsets	namely:	NK	cells	(NK1.1+CD3-)	(circle)	and	NKT	cells	(NK1.1+CD3+)(square)	represented	by	graph	E.	Proliferation	was	quantified	with	a	BrdU	incorporation	assay	and	subsequent	analysis	of	 BrdU+	 cells.	 Grouped	 data	 were	 normalised	 using	 d0	 as	 internal	 control	 and	 is	represented	 as	 percentage	 change	 compared	 to	 baseline	 i.e.	 d0	 p.i.	 (100%).	 Data	 are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	 each	 experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.	 	
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Figure	4.7	Leukocyte	infiltration	into	the	CNS	of	normal	versus	splenectomised	mice	
following	lethal	WNV	infection	
		Panel	A	represents	 the	change	 in	number	of	 total	 leukocytes	(CD45+),	 including	resident	microglia	(CD11b+Ly6C-)	and	the	CD11b+Ly6C+	subset,	which	was	 further	phenotypically	characterised	as	inflammatory	macrophages	(CD11b+Ly6Chi)	and	an	immigrant/activated	microglia	 (CD11b+Ly6Cint)	 population	 in	mock-infected	 (grey),	WNV-infected	 (blue)	 and	WNV-infected,	splenectomised	mice	(green).	Panel	B	represents	the	change	in	number	of	neutrophils	(CD11bhiLy6G+)	and	lymphoid	cells,	including	T	cells	(CD3+),	NK	cells	(NK1.1+)	and	B	 (B220+)	 cells	 in	 the	 CNS	 of	mock-infected	 (grey),	WNV-infected	 (blue)	 and	WNV-infected+splenectomised	mice	(green).	Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	 experiments,	 with	 3-4	 mice/group	 in	 each	 experiment.	 Statistical	 analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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4.7A),	 followed	 by	 the	 CD11b+Ly6Cint	 immigrant/activated	 microglia	 population.	Compared	 to	 mock-infected	 mice,	 there	 was	 a	 reduction	 in	 Ly6C-	 resident	 microglia	following	 infection,	 as	 a	 proportion	 of	 these	 microglia	 likely	 upregulated	 their	 Ly6C	expression	 becoming	 Ly6Cint.	 Although	 a	 similar	 pattern	 of	myeloid	 cell	 infiltration	was	present	 in	 splenectomised	 animals,	 the	 numbers	 were	 reduced	 compared	 to	 normal,	WNV-infected	mice	and	not	significantly	increased	relative	to	mock-infected	mice.			Lymphoid	 lineage	 cell	 numbers	 were	 also	 affected	 in	 the	 absence	 of	 the	 spleen,	 as	splenectomised	 mice	 had	 fewer	 CD3+	 T	 cells	 than	 normal,	 WNV-infected	 mice	 (Figure	4.7B).	 In	 addition,	 neutrophil	 infiltration	 was	 also	 decreased.	 There	 were	 comparable	numbers	of	NK	cells	 in	 the	CNS	of	WNV-infected,	normal	and	splenectomised	mice,	with	both	 cohorts	 demonstrating	 significantly	 increased	 numbers	 of	 NK	 cells	 compared	 to	mock-infected	mice.	 B	 cells	 were	 present	 in	 relatively	 low	 numbers	 in	 the	 CNS	 of	 both	normal	and	splenectomised,	WNV-infected	mice	and	there	were	no	significant	differences	between	groups.	
4.2.4.2. Percentages	
As	 there	was	a	clear	 trend	 for	splenectomised	mice	 to	have	reduced	 infiltration	 into	 the	CNS,	we	examined	whether	this	affected	the	leukocyte	composition	of	cells	infiltrating	the	WNV-infected	 CNS.	 The	 percentages	 of	 various	 leukocyte	 subsets	 in	 the	 CNS	 of	 WNV-infected,	splenectomised	(green)	mice	were	compared	to	the	normal,	WNV-infected	cohort	(blue)	and	normal	mock-infected	cohort	(grey)	(Figure	4.8A	and	B).	There	were	negligible	differences	 in	 the	 percentages	 of	 CD11b+Ly6Chi,	 CD11b+Ly6Cint	 and	 CD11b+Ly6C-	 cells	between	WNV-infected,	normal	versus	splenectomised	mice.	This	indicates	that	the	spleen	did	 not	 significantly	 modulate	 the	 type	 of	 monocyte	 subset	 infiltrating	 the	 CNS	 in	 this	model	of	WNV	encephalitis.	As	expected	the,	CD45+	population	in	the	mock-infected	brain	
Figure	 4.8	 Percentage	 composition	 of	 leukocyte	 subsets	 infiltrating	 the	 CNS	 of	
normal	versus	splenectomised	mice,	following	lethal	WNV	infection	
		Panel	 A	 represents	 the	 percentage	 of	 resident	 microglia	 (CD11b+Ly6C-)	 and	 the	CD11b+Ly6C+	 subset,	 which	 was	 further	 phenotypically	 characterised	 as	 inflammatory	macrophages	 (CD11b+Ly6Chi)	 and	 an	 immigrant/activated	 microglia	 (CD11b+Ly6Cint)	population	 in	 mock-infected	 (grey),	 WNV-infected	 (blue)	 and	 WNV-infected,	splenectomised	 mice	 (green).	 Panel	 B	 represents	 the	 percentage	 of	 neutrophils	(CD11bhiLy6G+)	and	lymphoid	lineage	cells,	including	T	cells	(CD3+),	NK	cells	(NK1.1+)	and	B	 (B220+)	 cells	 in	 the	 CNS	 of	 mock-infected	 (grey),	 WNV-infected	 (blue)	 and	 WNV-infected,	splenectomised	mice	(green).	Percentages	of	various	subsets	are	expressed	as	a	percentage	 of	 total	 leukocytes	 in	 the	 CNS	 of	 each	 cohort.	 Data	 are	 shown	 as	 the	 mean	±SEM	 of	 values	 from	 3	 independent	 experiments,	 with	 3-4	 mice/group	 in	 each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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was	 comprised	 mainly	 of	 CD11b+Ly6C-	resident	 microglia.	 Both	 the	 CD11b+Ly6Chi	 and	CD11b+Ly6Cint	 subsets	 were	 increased	 significantly,	 compared	 to	 mock-infected,	 and	formed	30%	and	20%,	respectively,	of	 the	 total	 leukocyte	population	 in	 the	CNS	 in	both	normal	and	splenectomised	cohorts	(Figure	4.8A).			Lymphoid	lineage	cells,	such	as	T	and	NK	cells	were	distributed	in	similar	fractions	in	the	WNV-infected,	 normal	 and	 splenectomised	mice,	 and	were	 in	 both	 cohorts	 significantly	higher	 than	 mock-infected	 mice	 (Figure	 4.8B).	 Neutrophils	 contributed	 to	 a	 smaller	proportion	of	leukocytes	in	the	CNS	of	splenectomised	mice	than	normal	mice	during	WNV	encephalitis.	 Finally,	 a	 higher	 percentage	 of	 B	 cells	 was	 present	 in	 the	 inflamed	 CNS	 of	splenectomised	mice,	although	this	was	not	significant.	Both	splenectomised	and	normal,	WNV-infected	 mice	 had	 higher	 percentage	 of	 B	 cells	 and	 neutrophils	 present	 in	 the	leukocyte	population	of	the	CNS	than	the	mock-infected	cohort.	
4.2.4.3. Weight	 loss	 of	 normal	 and	 splenectomised	 mice	 following	 lethal	 WNV	
infection	
Average	weight	 loss,	 compared	 to	 original	weight,	was	 used	 as	 a	 further	 comparison	 of	disease	 model	 between	 normal	 and	 splenectomised	 animals	 (Figure	 4.9A).	 C57BL/6	female	 mice	 were	 infected	 with	 lethal	 dose	 WNV	 (6x104	PFU)	 and	 weighed	 daily	 from	d0p.i.	 until	 the	 end	 of	 disease	 course	 on	 d7	 p.i.	 Firstly,	 as	 expected,	mock-infected	mice	(grey)	had	no	significant	weight	loss	at	any	point	during	the	disease	course.	Furthermore,	both	 splenectomised	 and	 normal,	WNV-infected	mice	 started	 to	 have	 significant	weight	loss	 from	 d6p.i.,	 which	 continued	 to	 worsen	 until	 d7	 p.i.	 By	 d7p.i.,	 both	 normal	 and	splenectomised,	WNV-infected	cohorts	had	 lost	on	average	18%	of	 their	original	weight.	Therefore,	 the	 normal	 and	 splenectomised	 mice	 had	 developed	 comparable	 forms	 of	disease	following	both	lethal	dose	of	WNV	infection.	
Figure	4.9	Survival	and	average	weight	loss	of	naïve	normal	versus	splenectomised	
mice,	following	WNV	infection		
		Graph	A	represents	the	average	percentage	weight	loss,	compared	to	original	weight,	of	mock-	(grey)	and	WNV-infected	(blue)	versus	WNV-infected,	splenectomised	(green)	mice	following	lethal	WNV	infection	(6x104PFU),	from	d0-7	p.i.	Graph	B	demonstrates	the	survival	rate	of	WNV-infected	(blue)	versus	WNV-infected,	splenectomised	(green)	mice,	following	infection	with	LD50	dose	of	WNV	(6x103	PFU),	from	d0-d25	p.i.	Graphs	C	and	D	show	the	percentage	weight	loss	of	normal	and	splenectomised	mice,	respectively,	infected	with	LD50	dose	of	WNV	(6x103	PFU),	from	d0-17p.i.	Note	that	graphs	C	and	D	are	representative	of	4	independent	experiments,	thus,	the	percentage	survival	here,	may	not	reflect	the	average	of	all	four	experiments	combined,	seen	in	figure	B.	The	survival	study	(B)	was	performed	in	four	separate	experiments	with	18-25	mice/group.	Survival	data	were	graphed	in	a	Kaplan-Meier	survival	curve	and	a	Log-rank	test	was	used	to	determine	statistical	significance.	Weight	loss	data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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4.2.4.4. Survival	 of	 normal	 and	 splenectomised	 mice	 following	 infection	 with	 a	
sublethal	dose	of	WNV	
Considering	 the	 reduced	 cell	 numbers,	 in	 particular,	 the	 highly	 pathogenic	 Ly6Chi	inflammatory	macrophages,	infiltrating	the	CNS	of	WNV-infected,	splenectomised	animals	we	 hypothesised	 that	 this	 may	 impact	 on	 the	 MST	 and	mortality	 rate	 of	WNV-infected	mice.	 Thus,	 we	 infected	 normal	 (blue)	 and	 splenectomised	 (green)	 mice	 i.n.	 with	 a	sublethal	(LD50)	dose	of	WNV	(6x103	PFU)	(Figure	4.9B).	Both	WNV-infected,	normal	and	splenectomised	 animals	 started	 succumbing	 to	disease	 from	d7	p.i.	 onward.	 In	 addition,	infection	 of	 both	 cohorts	 resulted	 in	 ~60%	 mortality,	 with	 ~40%	 of	 mice	 surviving	infection,	without	 any	 signs	 of	 illness,	 such	 as	weight	 loss.	 The	 only	 difference	 between	normal	 and	 splenectomised	 mice	 was	 the	 slightly	 extended	 disease	 course	 in	splenectomised	mice,	as	the	last	animal	to	succumb	to	infection	in	this	cohort	occurred	on	d18	p.i.,	3	days	 later	than	normal	mice.	The	percentage	weight	 loss	of	 individual,	normal	(Figure	 4.9C)	 and	 splenectomised	 (Figure	 4.9D)	 animals	 in	 the	 LD50	 disease	 course	showed	no	significant	differences	between	these	cohorts.	However,	the	extended	disease	course	 and	 reduced	 infiltration	 of	 Ly6Chi	 inflammatory	macrophages	 in	 splenectomised	mice,	 raises	 the	 question	 of	 whether	 the	 splenic	 reservoir	 of	 monocytes	 potentially	contributes	to	the	pathology	in	this	model	of	WNV	encephalitis.	
4.2.5. The	development	of	immunity	in	splenectomised	mice	
Previous	work	 from	 our	 laboratory	 has	 shown	 that	mice	 that	 survive	 the	 LD50	 dose	 of	WNV	infection	(6x103	PFU)	develop	immunity	to	subsequent	lethal	dose	WNV	rechallenge.	Considering	 the	 evident	 role	 of	 the	 secondary	 lymphoid	 organs	 in	 the	 development	 of	immunity,	we	reinoculated	normal	and	splenectomised	mice	that	had	survived	the	LD50	dose	 of	WNV	 infection,	 90-days	 after	 primary	 infection	 to	 test	 for	 immunity.	Mice	were	
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reinoculated	 i.n.	with	 a	 lethal	 dose	 of	WNV	 (6x104	PFU)	 and	monitored	 for	 any	 signs	 of	disease.		All	 of	 the	 re-infected	 normal	mice	 (blue)	were	 immune	 to	WNV,	 as	 none	 of	 this	 cohort	succumbed	to	disease	(Figure	4.10A)	or	lost	any	significant	weight	(Figure	4.10B).	Two	of	the	 splenectomised	 animals	 developed	 signs	 of	 illness;	 one	 mouse	 lost	 a	 significant	amount	 of	 weight	 following	 infection	 but	 recovered	 fully	 (Figure	 4.10C-a),	 another	developed	significant	weight	loss	(Figure	4.10C-b)	and	ultimately	succumbed	to	infection	(Figure	4.10A).	While	 these	 two	mice	may	not	have	 received	 the	complete	dose	of	virus	during	 primary	 infection,	 due	 to	 poor	 technique	 or	 experimental	 variability,	 it	 was	 still	nevertheless	clear	that	~80%	of	reinoculated	splenectomised	mice	developed	no	signs	of	illness	and	could	be	considered	immune.		
4.2.6. Cellularity	of	the	bone	marrow	of	splenectomised	versus	normal	
mice	following	lethal	WNV	infection	
The	bone	marrow	of	WNV-infected	normal	and	splenectomised	animals	(6x104	PFU)	was	collected	on	d7	p.i.	and	processed	in	order	to	determine	how	WNV	infection	modulates	the	leukocyte	content	of	the	bone	marrow	in	the	absence	of	the	spleen.	As	the	bone	marrow	is	contained	within	a	rigid	structure	with	minimal	space	for	expansion,	dramatic	changes	in	cell	 number	 were	 not	 expected	 in	 normal	 mice,	 however,	 it	 was	 possible	 for	 the	composition	of	leukocytes	to	be	altered	during	infection	and	potentially	in	the	absence	of	the	spleen.	Additionally,	the	ability	of	the	bone	marrow	to	potentially	compensate	for	the	absence	of	a	spleen	was	of	interest.	There	were	no	differences	in	bone	marrow	leukocyte	numbers	between	mock-infected,	normal	mice	versus	splenectomised,	mock-infected	mice	(data	 not	 shown),	 thus	 only	 the	 normal	 mock-infected	 cohort	 is	 presented.	 A	 detailed	
Figure	4.10	Survival	and	average	weight	loss	of	splenectomised	versus	normal	mice,	
following	secondary	infection	with	a	lethal	dose	of	WNV			Following	primary	i.n.	infection	with	a	sublethal	dose	of	WNV	(6x103	PFU),	surviving	mice	were	 kept	 for	 3	 months	 p.i.,	 after	 which	 they	 were	 re-infected	 i.n.	 with	 a	 lethal	 dose	(LD100)	of	WNV	(6x104	PFU)	to	test	for	immunity.	Graph	A	demonstrates	the	survival	rate	of	normal	 (blue)	 and	 splenectomised	 (green)	mice,	 re-infected	with	 lethal	dose	of	WNV.	The	percentage	weight	loss	is	shown,	relative	to	original	weight	at	reinoculation,	of	WNV-infected	 (B-blue)	 versus	WNV-infected,	 splenectomised	 (C-green)	 mice	 following	 lethal	WNV	infection	(6x104	PFU).	The	survival	study	was	performed	in	one	experiment	with	7-14	mice/group.	Survival	data	were	graphed	 in	a	Kaplan-Meier	survival	curve	and	a	Log-rank	test	was	used	to	determine	statistical	significance.		 	
WNV-infected  WNV-infected+Splenectomised 
Figure 4.10
Day p.i.
Pe
rc
en
t s
ur
vi
va
l 
80 90 100 110 120
50
60
70
80
90
100
Reinoculation (6x104PFU)
Day p.i.
Pe
rc
en
ta
ge
 o
f
 in
iti
al
 w
ei
gh
t
90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106
60
80
100
120
Reinoculation (6x104PFU)
Pe
rc
en
ta
ge
 o
f
 in
iti
al
 w
ei
gh
t
Day p.i.
90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106
60
80
100
120
Reinoculation (6x104PFU)
A
B
C
a
b
		 119	
gating	strategy	for	the	bone	marrow	with	isotype	and	fluorescence	minus	one	controls	is	outlined	by	Appendix	Figure	10	and	11.		The	 myeloid	 lineage	 cell	 numbers	 in	 the	 bone	 marrow	 of	 WNV-infected	 mice	 did	 not	change	 appreciably	 compared	 to	 the	mock-infected	 cohort	 (Figure	4.11A).	 Furthermore,	comparable	numbers	of	myeloid	lineage	cells	were	present	in	the	bone	marrow	of	WNV-infected,	 normal	 and	WNV-infected,	 splenectomised	 bone	 marrow.	 Myeloid	 lineage	 cell	subsets	 analysed	 included	 neutrophils	 (CD11bhiLy6G+)	 and	 monocytes	 (CD11b+CD11c-Ly6G-),	 which	 were	 further	 classified	 as	 three	 separate	 populations	 based	 on	 Ly6C	expression	 namely:	 CD11b+Ly6Chi,	 CD11b+Ly6Cint	 and	 CD11b+Ly6C-.	 Despite	 a	 non-significant	increase	in	CD11b+Ly6Chi	number	of	the	WNV-infected	cohorts,	there	were	no	appreciable	differences	in	numbers	of	the	other	subsets	in	any	of	the	cohorts	analysed.	In	addition,	based	on	the	markers	available,	the	DC	populations	were	subdivided	into	pDC	(CD11c+B220+)	 and	 other	 DC	 (CD11c+B220-).	 However,	 neither	 of	 these	 populations	exhibited	 any	 difference	 between	 any	 of	 the	 cohorts	 compared.	 In	 parallel,	 there	 were	minor	 differences	 in	 the	 lymphoid	 lineage	 cells	 of	 WNV-infected,	 normal	 and	splenectomised,	and	mock-infected	mice	(Figure	4.11B).	Similar	numbers	of	B	cells	were	identified	 in	 the	 bone	 marrow	 of	 all	 three	 cohorts.	 WNV-infected,	 normal	 and	splenectomised	mice	had	higher	CD4+	and	CD8+	T	cell	numbers	in	the	bone	marrow	than	mock-infected	mice,	although	this	was	not	significant.	Furthermore,	normal	WNV-infected	mice	 had	 significantly	more	NKT	 cells	 present	 in	 the	 bone	marrow,	 compared	 to	mock-infected	mice.	This	trend	was	also	present	in	WNV-infected,	splenectomised	mice	but	was	not	significant.			In	parallel	to	the	cell	number	data,	the	percentage	composition	of	leukocytes	in	the	bone	marrow	changed	very	little	between	all	of	the	cohorts	(Figure	4.12A	and	B).	Of	the	myeloid	lineage	cells	analysed,	only	the	CD11b+Ly6Chi	subset	contributed	to	a	higher	fraction	of	the	
Figure	 4.11	 Number	 of	 leukocytes	 in	 the	 bone	 marrow	 of	 normal	 versus	
splenectomised	mice	following	lethal	WNV	infection	
		Panel	A	represents	 the	number	of	 total	 leukocytes	(CD45+)	 in	 the	bone	marrow	of	mock	(grey),	 WNV-infected	 (blue)	 and	 WNV-infected,	 splenectomised	 (green).	 This	 figure	includes	 neutrophils	 (CD11bhiLy6G+),	 monocytes	 (CD11b+CD11c-Ly6G-),	 pDC	(CD11c+B220+)	 and	 other	 DC	 (CD11c+B220-).	 The	 monocyte	 population	 was	 further	characterised	 based	 on	 Ly6C	 expression,	 namely:	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-.	 Panel	 B	represents	 the	number	of	B	 cells	 (B220+CD11c-),	 total	T	 cells	 (CD3+NK1.1-),	CD4+	T	 cells	(CD3+CD4+CD8-),	 CD8+	 T	 cells	 (CD3+CD8+CD4-),	 NK	 cells	 (NK1.1+CD3-)	 and	 NKT	 cells	(NK1.1+CD3+).	 Data	 are	 shown	 as	 the	 mean	 ±SEM	 of	 values	 from	 3	 independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	 P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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Figure	 4.12	 Percentage	 composition	 of	 leukocyte	 subsets	 in	 the	 bone	 marrow	 of	
normal	versus	splenectomised	mice	following	lethal	WNV	infection	
		Panel	A	represents	the	percentage	of	total	leukocytes	(CD45+)	in	the	bone	marrow	of	mock	(grey),	 WNV-infected	 (blue)	 and	 WNV-infected,	 splenectomised	 (green).	 This	 figure	includes	 the	 percentage	 of	 neutrophils	 (CD11bhiLy6G+),	 monocytes	 (CD11b+Ly6Chi;	CD11b+Ly6Cint;	 CD11b+Ly6C-),	 pDC	 (CD11c+B220+)	 and	 other	 DC	 (CD11c+B220-)	 in	 the	bone	 marrow.	 The	 monocyte	 population	 was	 further	 characterised	 based	 on	 Ly6C	expression,	namely:	Ly6Chi,	Ly6Cint	and	Ly6C-.	Panel	B	represents	the	percentage	of	B	cells	(B220+CD11c-),	 total	 T	 cells	 (CD3+NK1.1-),	 CD4+	 T	 cells	 (CD3+CD4+CD8-),	 CD8+	 T	 cells	(CD3+CD8+CD4-),	NK	cells	(NK1.1+CD3-)	and	NKT	cells	(NK1.1+CD3+)	in	the	bone	marrow.	Values	 of	 various	 subsets	 are	 expressed	 as	 a	 percentage	 of	 total	 leukocytes	 in	 the	 bone	marrow	of	each	cohort.	Data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	 P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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total	 leukocyte	population	 in	WNV-infected,	normal	and	splenectomised	mice,	 compared	to	mock-infected	mice,	 although	 this	 was	 not	 statistically	 significant.	 The	 percentage	 of	other	myeloid	 (CD11b+Ly6int,	CD11b+Ly6C-	cells	 and	neutrophils)	 and	DC	 subsets	present	in	the	bone	marrow	was	comparable	between	mock	and	WNV-infected.		The	 population	 of	 NKT	 cells	 expanded	 significantly	 in	 WNV-infected,	 normal	 mice,	compared	 to	mock-infected	mice	 (Figure	 4.12B).	 However,	 no	 appreciable	 difference	 in	percentage	of	T	cells,	including	CD4+	and	CD8+,	B	cells	and	NK	cells	was	present	between	mock-infected	and	WNV-infected,	normal	or	WNV-infected,	splenectomised	mice.	Thus	the	absence	 of	 the	 spleen	 produced	 very	 little	 change	 in	 the	 cell	 number	 or	 leukocyte	composition	of	the	bone	marrow	following	lethal	WNV	infection.	
4.2.7. Cellularity	of	 the	 lymph	nodes	of	splenectomised	versus	normal	
mice	following	lethal	WNV	infection	
As	 no	 significant	 differences	 were	 detected	 in	 the	 leukocyte	 composition	 of	 the	 bone	marrow	of	WNV-infected,	normal	versus	WNV-infected,	splenectomised	mice,	we	dissected	the	 leukocyte	 response	 of	 the	 other	 secondary	 lymphoid	 organ	 associated	 with	 WNV	encephalitis,	namely	the	CLN.	Results	from	chapter	3	clearly	established	a	role	for	the	CLN	as	 a	 draining	 lymph	 node	 of	 the	 infected	 CNS,	 and	 whether	 the	 removal	 of	 the	 largest	secondary	lymphoid	organ	would	affect	the	CLN	response	to	WNV	infection	was	of	great	interest.	 The	 expansion	 of	 leukocyte	 numbers,	 characteristic	 of	 the	 CLN	 during	 WNV	infection,	 was	 also	 evident	 in	 the	 CLN	 of	 WNV-infected,	 splenectomised	 mice	 (Figure	4.13A).	 However,	 this	 increase	 in	 leukocytes	 including,	 B	 and	 T	 cells,	 was	 significantly	higher	in	CLN	isolated	from	WNV-infected,	splenectomised	mice	than	their	normal,	WNV-infected	 counterparts.	 Similarly,	 significantly	 higher	 numbers	 of	 monocytes,	CD11c+CD11b+	 and	 CD11c+CD11b-	cells	 were	 identified	 in	 the	 CLN	 from	 WNV-infected	splenectomised	 mice,	 compared	 to	 WNV-infected	 normal	 mice	 (Figure	 4.13B).	 The	
Figure	4.13	Cell	number	and	percentage	of	various	leukocyte	subsets	in	the	CLN	and	
ILN	of	splenectomised	versus	normal	mice	following	lethal	WNV	infection	
		Panel	A	demonstrates	 the	number	of	 total	 leukocytes	(CD45+),	T	cells	 (CD3+)	and	B	cells	(CD19+/B220+)	 in	 the	 CLN	 mock	 (grey),	 WNV-infected	 normal	 (blue)	 and	 WNV-infected,splenectomised	 mice	 (green).	 The	 change	 in	 monocytes	 (CD11b+CD11c-),	neutrophil	 (CD11b+Ly6G+)	 and	DC	 subsets,	 including	 CD11c+CD11b+,	 CD11c+CD11b-	 and	CD11chiCD11bint,	 in	 the	 CLN	 is	 represented	 by	 panel	 B.	 The	 percentage	 of	 each	 of	 the	leukocyte	subsets,	in	the	CLN,	as	described	in	panel	A	and	B	is	demonstrated	by	figure	C.	Values	of	various	subsets	are	expressed	as	a	percentage	of	total	leukocytes	in	the	CLN	of	each	cohort.	Panel	D	shows	the	number	of	the	above	leukocytes	in	the	ILN	of	mock	(grey),	WNV-infected	 normal	 (blue)	 and	 WNV-infected	 splenectomised	 mice	 (green).	 Data	 for	panels	A-C	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Data	for	figure	D	is	shown	as	the	mean	±SEM	of	values	from	 2	 independent	 experiments,	 with	 3-4	 mice/group	 in	 each	 experiment.	 Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	 and	 P≤0.05*;	 P≤0.01**;	 P≤0.001***.
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CD11chiCD11bint	 subset	 and	 neutrophil	 numbers	 were	 also	 markedly	 higher	 in	 WNV-infected	splenectomised	mice,	however	this	was	not	significant.			The	 percentage	 composition	 of	 leukocytes	 in	 the	 CLN	 of	 the	 two	WNV-infected	 cohorts	were	 comparable,	 with	 negligible	 differences	 in	 any	 of	 the	 leukocyte	 subsets	 analysed	(Figure	4.13C).	Furthermore,	the	splenectomised	mice	demonstrated	similar	patterns	of	B	cell	expansion	and	reduction	in	percentage	of	T	cells	seen	in	normal	mice,	following	lethal	WNV	 infection.	 Levels	 of	 Ly6C	 expression	 between	 splenectomised	 and	 normal	 WNV-infected	mice	were	similar	(data	not	shown).	Collectively,	 the	DC	subsets	comprised	 less	than	4%	of	the	total	leukocyte	population	in	all	of	the	cohorts	studied,	with	WNV-infected,	normal	and	splenectomised	mice	both	exhibiting	higher	percentages	of	the	CD11c+CD11b+	and	 CD11c+CD11b-	 subsets,	 compared	 to	 mock-infected	 animals.	 Whether	 there	 were	detectable	 changes	 in	 peripheral	 non-draining	 nodes,	 such	 as	 the	 ILN,	 was	 also	investigated.	However,	while	 there	was	 a	 similar	 trend	 for	 leukocyte	 subset	numbers	 in	the	 ILN	 of	 WNV-infected,	 splenectomised	 mice	 to	 be	 higher	 than	 that	 of	 normal	WNV-infected	mice,	this	was	not	statistically	significant	(Figure	4.13D).	Thus	 it	 is	 evident	 that,	 although	 the	 leukocyte	 composition	 remained	 the	 same,	 the	CLN	leukocyte	numbers	are	impacted	significantly	by	the	absence	of	the	spleen	following	CNS	infection.	Whether	or	not	 the	 increased	cell	numbers	seen	 in	 the	CLN	of	 splenectomised	mice	 was	 due	 to	 proliferation	 or	 increased	 recruitment	 of	 cells	 is	 of	 great	 interest	 for	future	studies.	
4.2.8. Cellularity	 of	 the	 blood	 of	 splenectomised	 versus	 normal	 mice	
following	lethal	WNV	infection	
There	is	some	evidence	of	mice	becoming	leukopenic	after	the	spleen	has	been	removed.	If	this	 holds	 true	 for	 our	 model	 of	 infection,	 it	 may	 explain	 the	 reduction	 of	 leukocyte	
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infiltration	seen	in	the	CNS	of	splenectomised	mice	following	lethal	WNV	infection.	Blood	was	 collected	 from	 mock-normal,	 mock-splenectomised,	 WNV-normal	 and	 WNV-splenectomised	mice	on	d7p.i.,	in	order	to	establish	whether	there	were	any	deficiencies	in	circulatory	 leukocyte	 populations	 when	 the	 spleen	 is	 removed.	 On	 d7	 p.i.,	 both	 WNV-infected,	 normal	 and	 splenectomised	mice	 showed	 a	marked	 reduction	 in	monocytes,	 B	and	T	cells,	compared	to	their	mock-infected	counterparts.	However,	the	numbers	of	each	of	 the	 leukocyte	 subsets	 in	 the	 blood	were	 similar	 between	normal	 and	 splenectomised	mice	 in	 the	 mock-infected	 cohort	 and	 between	 these	 two	 groups	 in	 the	 WNV-infected	cohort	(Figure	4.14A).		In	 parallel	 to	 the	 cell	 number	 data,	 there	 were	 negligible	 differences	 in	 percentage	composition	 of	 these	 subsets	 in	 the	 blood	 of	mock-normal	 versus	mock-splenectomised,	and	WNV-normal	versus	WNV-splenectomised	mice	 (Figure	4.14B).	However,	both	 the	T	cell	 and	 monocyte	 subsets	 had	 halved	 at	 d7	 p.i.	 in	 splenectomised	 and	 normal	 WNV-infected	 mice,	 compared	 to	 their	 mock-infected	 counterparts,	 while	 the	 CD11c+CD11b-	subset	had	 increased	by	~2-fold.	This	was	presumably	due	 to	 the	recruitment	of	certain	leukocyte	subsets	from	the	blood	to	the	CNS	or	CLN	in	response	to	CNS	infection.			
4.2.9. IMP	 treatment	 of	 normal	 and	 splenectomised	 mice	 following	
lethal	WNV	infection		
4.2.9.1. Modulation	 of	 CNS	 leukocyte	 populations	 of	 normal	 mice	 following	 lethal	
WNV	infection	and	treatment	with	IMP	
Previous	work	 from	our	 laboratory	 has	 shown	 that	 IMP	 treatment	 significantly	 reduces	the	infiltration	of	pathogenic	Ly6Chi	monocyte	in	the	CNS.	This	occurred	with	a	concurrent	
Figure	4.14	Cell	number	and	percentage	composition	of	 leukocytes	 in	 the	blood	of	
mock-	 and	 WNV-infected	 normal	 and	 splenectomised	 mice	 following	 lethal	 WNV	
infection	
		The	absolute	number	(A)	and	percentage	(B)	of	leukocytes	(CD45+),	T	(CD3+)	and	B	cells	(B220+),	as	well	as	monocytes	(CD11b+CD11c-)	and	DC	(CD11c+)	per	millilitre	of	blood	in	mock-infected	normal	(dark	grey)	versus	mock-infected,	splenectomised	(light	grey),	and	WNV-infected	normal	(blue)	versus	WNV-infected,	splenectomised	(green).	Percentages	of	various	subsets	are	expressed	as	a	percentage	of	total	leukocytes	per	millilitre	of	blood	in	each	cohort.	Data	are	shown	as	the	mean	±SEM	of	values	from	2	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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increase	in	Ly6Chi	cell	numbers	in	the	spleen	and	liver	(Getts	et	al.	2014).	We	hypothesised	that,	since	the	spleen	was	one	of	the	organs	evidently	most	involved	in	sequestering	Ly6Chi	inflammatory	 macrophages,	 	 following	 lethal	 WNV	 infection,	 that	 the	 spleen	 may	 be	crucial	for	the	efficacy	of	IMP	treatment.	Figures	4.15	and	4.16	compare	the	modulation	of	leukocyte	subset	 infiltration	into	the	CNS	following	IMP	treatment	of	WNV-infected	mice	(6x104	PFU)	 in	 normal	 (Figure	 4.15A)	 and	 splenectomised	 (Figure	 4.15B)	 on	 d7p.i.	 The	significant	infiltration	of	leukocytes	in	WNV-infected	mice	(dark	blue),	compared	to	mock-infected	(grey),	was	dramatically	reduced	in	IMP-treated,	WNV-infected	mice	(light	blue)	(Figure	 4.15A).	 Furthermore,	 IMP	 treatment	 significantly	 reduced	 the	 pathogenic	 Ly6Chi	macrophage	subset	 in	normal	mice	with	 their	 spleens	 intact.	Although	 IMP	 treatment	of	splenectomised	 mice	 (light	 green)	 (Figure	 4.15B)	 somewhat	 reduced	 the	 number	 of	leukocytes	 infiltrating	 the	 CNS,	 compared	 to	 vehicle-treated,	 WNV-infected	splenectomised	mice	(dark	green),	this	was	not	significant.	Nevertheless,	compared	to	the	normal	 cohort	 presented	 in	 Figure	 4.15A,	 the	 absolute	 number	 of	 Ly6Chi	 inflammatory	macrophages,	was	at	least	50%	lower	in	IMP-treated,	splenectomised	animals,	due	to	the	already	reduced	numbers	as	a	result	of	splenectomy.	The	 infiltration	 of	 lymphoid	 lineage	 cells,	 such	 as	 T,	 NK	 and	 B	 cells,	was	 also	markedly	reduced	 in	 IMP-treated	 WNV-infected	 normal	 mice	 (Figure	 4.16A).	 There	 was	 also	 a	decrease	in	neutrophil	numbers	following	IMP	treatment	of	WNV-infected	mice,	however	this	was	not	significant.	Additionally,	 there	was	a	trend	of	reduction	in	 lymphoid	 lineage	cell	numbers	(T,	B	and	NK	cells)	in	the	CNS	of	IMP-treated,	WNV-infected	splenectomised	mice	 (Figure	 4.16B),	 relative	 to	 their	 vehicle-treated	 cohort.	 Similar	 to	 neutrophil	numbers	 of	 normal	mice	 (Figure	 4.16A),	 the	 numbers	 of	 neutrophils	 in	 splenectomised	animals	(Figure	4.16B)	had	a	slight,	but	non-significant	decrease,	compared	to	the	vehicle	treated	 cohort.	 	 Thus,	 compared	 to	 vehicle-treated	 splenectomised	mice,	 IMP	 treatment	does	not	 significantly	 reduce	 leukocyte	 infiltration	 into	 the	CNS	of	 splenectomised	mice.	
Figure	 4.15	 CNS	 leukocyte	 infiltration	 following	 IMP	 treatment	 of	 normal	 and	
splenectomised	mice	infected	with	a	lethal	dose	of	WNV	
	Panels	A	represents	the	change	in	number	of	total	leukocytes	(CD45+),	resident	microglia	(CD11b+Ly6C-)	 and	 the	 CD11b+Ly6C+	 subset,	 which	 can	 be	 further	 subdivided	 into	infiltrating	 macrophages	 (CD11b+Ly6Chi)	 and	 immigrant/activated	 microglia	(CD11b+Ly6Cint)	 populations	 in	 the	 CNS	 of	mock-infected	 (grey),	WNV-infected,	 vehicle-treated	 (dark	blue)	and	WNV-infected,	 IMP-treated	 (light	blue)	mice.	Panel	B	represents	the	change	 in	number	of	 total	 leukocytes	(CD45+),	resident	microglia	(CD11b+Ly6C-)	and	the	 CD11b+Ly6C+	 subset,	which	 can	 be	 further	 subdivided	 into	 infiltrating	macrophages	(CD11b+Ly6Chi)	and	immigrant	microglia	(CD11b+Ly6Cint)	populations	in	the	CNS	of	mock-infected	 (grey),	 WNV-infected,	 splenectomised,	 vehicle-treated	 (dark	 green)	 and	 WNV-infected,	 splenectomised,	 IMP-treated	 (light	 green)	 CNS.	 Data	 are	 shown	 as	 the	 mean	±SEM	 of	 values	 from	 3	 independent	 experiments,	 with	 3-4	 mice/group	 in	 each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	
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Figure	 4.16	 CNS	 leukocyte	 infiltration	 following	 IMP	 treatment	 of	 splenectomised	
mice	infected	with	a	lethal	dose	of	WNV	
	
	Panel	 A	 represents	 the	 change	 in	 number	 of	 neutrophils	 (CD11bhiLy6G+)	 and	 lymphoid	cells,	 including	T	cells	 (CD3+),	NK	cells	 (NK1.1+)	and	B	 (B220+)	 cells	 in	 the	CNS	of	mock-infected	(grey),	WNV-infected,	vehicle-treated	(dark	blue)	and	WNV-infected,	IMP-treated	(light	blue)	mice.	Panel	B	represents	the	change	in	number	of	neutrophils	(CD11bhiLy6G+)	and	 lymphoid	cells,	 including	T	cells	 (CD3+),	NK	cells	 (NK1.1+)	and	B	(B220+)	cells	 in	 the	CNS	of	mock-infected	(grey),	WNV-infected,	splenectomised,	vehicle-treated	(dark	green)	and	WNV-infected,	splenectomised,	IMP-treated	(light	green)	mice.	Panel	C	compares	the	percentage	 survival	 between	mice	 that	 did	 not	 lose	 significant	weight	 (black),	 i.e.	more	than	5%	of	original	weight,	to	mice	that	have	lost	more	than	5%	weight.	Normal	mice,	that	did	 lose	significant	weight,	were	given	either	vehicle	(dark	blue)	or	IMP	treatment	(light	blue).	Similarly,	splenectomised	mice,	 losing	significant	weight,	were	given	either	vehicle	(dark	 green)	 or	 IMP	 treatment	 (light	 green).	 The	 survival	 study	was	 performed	 in	 four	separate	 experiments	with	 18-25	mice/group.	 Survival	 data	were	 graphed	 in	 a	 Kaplan-Meier	 survival	 curve	 and	 a	 Log-rank	 test	was	 used	 to	 determine	 statistical	 significance.	Cell	number	data	are	shown	as	the	mean	±SEM	of	values	from	3	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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However,	 with	 the	 already	 reduced	 leukocyte	 numbers	 present	 in	 the	 CNS	 of	 WNV-infected	 splenectomised	 animals,	 any	 additional	 reduction	 in	 cell	 numbers,	 induced	 by	IMP	treatment,	may	improve	clinical	outcome	of	these	animals.	
4.2.9.2. Survival	 of	 splenectomised	 versus	 normal	 mice	 following	 infection	 with	
sublethal	dose	of	WNV	and	IMP	treatment	
As	shown	in	Figure	4.9,	splenectomised	and	normal	mice	develop	a	similar	disease	course	when	infected	with	a	sublethal	dose	of	WNV.	Therefore,	in	order	to	compare	the	efficacy	of	IMP	treatment	in	the	absence	of	the	spleen,	we	infected	normal	and	splenectomised	mice	with	the	LD50	dose	of	WNV	(6x103	PFU)	and	subsequently	treated	mice	displaying	clinical	symptoms	 (i.e.	 >5%	 of	 initial	 pre-infection	 weight)	 with	 IMP	 or	 vehicle	 treatment.	Previous	work	has	established	that	there	is	a	direct	correlation	between	weight	 loss	and	CNS	 involvement	of	disease,	 thus,	mice	 losing	more	 than	5%	of	 their	 initial	body	weight	were	assumed	to	have	CNS	infiltration	of	leukocytes.	WNV-infected	mice,	in	both	the	normal	and	splenectomised	cohorts	that	had	no	significant	weight	loss	or	showed	any	signs	of	illness	had	a	100%	survival	rate	(black)	(Figure	4.16C).	Normal	WNV-infected	 animals	 that	 received	 only	 vehicle	 treatment,	 upon	 losing	 5%	 or	more	of	their	original	weight,	had	the	worst	survival	outcome	compared	to	other	cohorts,	with	all	of	the	vehicle-treated,	normal	mice	succumbing	to	infection	(dark	blue).	However,	the	vehicle-treated,	splenectomised	cohort	exhibited	a	marginal	improvement	in	survival	rate,	with	10%	of	mice,	which	had	lost	significant	weight,	surviving	infection.	Interestingly,	although	 IMP	 treatment	 did	 not	 significantly	 reduce	 leukocyte	 infiltration	 in	splenectomised	 mice	 (light	 green),	 compared	 to	 their	 vehicle-treated,	 splenectomised	cohort	 (dark	 green),	 it	 did	 significantly	 improve	 survival	 outcome.	 Indeed,	 25%	 of	splenectomised	mice	 developing	 disease	 survived	 the	 infection,	when	 treated	with	 IMP.	Nevertheless,	normal,	WNV-infected	mice	given	IMP	treatment	(light	blue)	had	the	lowest	
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mortality	rate	of	all	the	cohorts	analysed.	IMP	treatment	of	these	mice,	saved	42%	of	mice	that	 would	 have	 otherwise	 succumbed	 to	 infection,	 suggesting	 that,	 although	 IMP	treatment	 works	 in	 the	 absence	 of	 the	 spleen,	 efficacy	 is	 reduced	 compared	 to	 normal	mice.	
4.2.9.3. The	location	of	IMP	and	IMP-containing	cells	in	the	absence	of	the	spleen	
As	 we	 know	 from	 previous	 studies	 in	 our	 lab,	 a	 significant	 proportion	 of	 IMP/IMP-associated	cells	are	destined	for	the	spleen	(Getts	et	al.	2014).	Indeed,	~4%	of	the	splenic	leukocytes	 are	 IMP+	by	 d7	p.i.	We	hypothesised	 that,	 in	 the	 absence	 of	 the	 spleen,	 these	IMP	or	IMP-containing	cells	may	be	more	abundant	in	other	lymphoid	and	non-lymphoid	organs,	 such	 as	 the	 liver,	 bone	marrow,	 CLN	 and	 in	 circulation.	However,	 unexpectedly,	there	was	no	indication	that	these	organs	compensated	for	the	absence	of	the	spleen,	with	regards	 to	 IMP	 uptake	 (Figure	 4.17).	 Indeed,	 there	 were	 negligible	 differences	 in	 the	absolute	 number	 of	 IMP+CD45+	cells	 identified	 in	 the	 liver,	 blood	 and	 bone	 marrow	 of	WNV-infected,	 normal	 (light	 blue)	 and	WNV-infected	 splenectomised	mice	 (light	 green)	(Figure	4.17A).	Furthermore,	brain	and	CLN	had	 fewer	 IMP+CD45+	cells	 in	WNV-infected	splenectomised	mice	than	the	normal	cohort.			The	 distribution	 of	 IMP+CD45+	cells	 contained	 within	 each	 organ	 was	 also	 comparable	between	 WNV-infected	 normal	 and	 WNV-infected	 splenectomised	 mice	 (Figure	 4.17B).	There	 was	 no	 appreciable	 difference	 in	 percentage	 of	 IMP+CD45+	cells	 in	 the	 either	 the	liver,	 blood,	 bone	 marrow	 or	 CNS.	 Moreover,	 the	 fraction	 of	 IMP+CD45+	cells	 contained	within	the	leukocyte	population	of	the	CLN	was	significantly	reduced.	Finally,	in	the	brain,	the	 percentage	 of	 IMP+	 Ly6C+	 monocytes	 in	 both	 normal	 and	 splenectomised	 WNV-infected	 mice	 remained	 similar	 at	 approximately	 0.25%	 of	 the	 total	 Ly6C+	 monocyte	population.		
Figure	4.17	IMP+	leukocytes	in	the	liver,	bone	marrow,	brain,	CLN	and	blood	of	WNV-
infected	normal	and	splenectomised	mice	following	IMP	treatment	
			Panels	 A	 and	 B	 respectively	 represents	 the	 number	 and	 percentage	 of	 each	 leukocyte	subset	 that	 is	 IMP+	in	 the	 liver,	 bone	 marrow,	 brain,	 CLN	 and	 blood	 (per	 ml)	 of	 WNV-infected,	normal	mice	(light	blue)	versus	WNV-infected,	splenectomised	mice	(light	green),	24h	after	IMP	treatment.	Data	for	the	brain,	bone	marrow	and	CLN	are	shown	as	the	mean	±SEM	 of	 values	 from	 3	 independent	 experiments,	 with	 2-4	 mice/group	 in	 each	experiment.	Data	for	the	blood	are	shown	as	the	mean	±SEM	of	values	from	2	independent	experiments,	 with	 3-4	 mice/group.	 Values	 of	 IMP+	 leukocytes	 are	 expressed	 as	 a	percentage	of	total	leukocytes	present	in	each	organ.	For	reference,	IMP+	subpopulations	in	 the	 spleen	 are	 shown	 in	 figure	 5.14.	 Data	 for	 the	 liver	 is	 shown	 as	 the	 ±SEM	 of	 3-4	mice/group	 and	 is	 representative	 of	 1	 experiment.	 Statistical	 analysis	 was	 conducted	using	an	unpaired,	two	tailed	T-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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4.2.10. The	potential	 role	of	 the	spleen	as	a	 splenic	 reservoir	 for	
monocytes	 infiltrating	 the	 WNV-infected	 CNS:	 the	 action	 of	 ACE	
inhibitors.	
4.2.10.1. Leukocyte	infiltration	into	the	CNS	following	Enalapril	treatment	
The	reduced	infiltration	of	leukocytes	into	the	CNS	of	WNV-infected,	splenectomised	mice	led	us	to	examine	the	possibility	of	a	splenic	reservoir	of	monocytes,	which	was	recently	identified	as	a	ready	source	of	undifferentiated	monocytes	(Swirski	et	al.	2009)	(Bao	et	al.	2010).	The	treatment	with	angiotensin-converting	enzyme	(ACE)	 inhibitor	Enalapril,	has	been	 used	with	 great	 success	 to	 inhibit	monocyte	 recruitment	 from	 the	 spleen	 in	 other	inflammatory	 disease	 models,	 such	 as	 MI	 (Leuschner	 et	 al.	 2010).	 Thus,	 we	 tested	 the	hypothesis	 that	 the	 spleen	 was	 acting	 in	 conjunction	 with	 the	 bone	 marrow,	 as	 an	additional	source	of	the	 leukocyte	 infiltrate	present	 in	the	CNS,	 following	WNV	infection.	Female	 C57BL/6	 mice	 were	 infected	 i.n.	 with	 a	 lethal	 dose	 WNV	 (6x104	 PFU)	 and	subsequently	 treated	daily	with	 i.p.	 injection	 of	 Enalapril	 administered	 at	 a	 dose	 of	 100	mg/kg/day,	from	d0	p.i.			A	pilot	study	was	initially	set	up	where	we	treated	mice	from	d5	p.i.	with	Enalapril,	as	this	is	 the	earliest	 time-point	 in	which	 leukocyte	 infiltration	 starts	 significantly	 increasing	 in	the	 CNS.	 However,	 intervention	 at	 this	 time-point	 did	 not	 result	 in	 any	 clinical	improvement,	decreased	mortality	or	reduction	in	monocyte	infiltration	(data	not	shown).	Intervention	 at	 this	 time-point	 may	 have	 been	 too	 late	 as	 the	 mobilisation	 of	 splenic	reservoir	monocyte	occurred	rapidly	after	inflammatory	stimulus	present	in	the	MI	model	(Leuschner	et	al.	2010)	(Swirski	et	al.	2009).	Therefore,	we	proceeded	to	prophylactically	treat	mice	with	the	ACE	inhibitor	from	d0	onwards	to	see	if	this	would	be	more	effective.		
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Enalapril	 treatment	 of	 mock-	 (light	 grey)	 or	 WNV-infected	 (purple),	 from	 the	 onset	 of	infection,	 did	 not	 decrease	 the	 numbers	 of	 leukocyte	 infiltrating	 the	 CNS,	 compared	 to	mock-infected+vehicle	(dark	grey)	and	WNV-infected+vehicle	(orange)	(Figure	4.18A).	In	addition,	comparable	numbers	of	Ly6Chi	inflammatory	macrophages	infiltrated	the	CNS	in	both	 Enalapril-	 and	 vehicle-treated	 WNV-infected	 cohorts.	 Similarly,	 prophylactic	Enalapril	treatment	had	no	impact	on	lymphoid	lineage	or	neutrophil	cell	numbers	in	the	CNS	following	WNV-infection	(Figure	4.18B).		
4.2.10.2. Leukocyte	numbers	of	the	spleen	following	Enalapril	treatment	
We	dissected	 the	spleen	 to	see	 if	any	retention	 in	 leukocyte	subsets,	 in	particular	Ly6Chi	monocytes,	 occurred	 as	 a	 result	 of	 Enalapril	 treatment	 (Swirski	 et	 al.	 2009).	 Firstly,	differences	 between	 mock-infected,	 vehicle-treated	 (dark	 grey)	 and	 mock-infected,	Enalapril-treated	(light	grey)	were	negligible	for	all	the	leukocyte	subsets	analysed	in	the	spleen	 (Figure	 4.19A	 and	 B).	 In	 particular,	 there	 was	 no	 notable	 retention	 of	 the	population	of	interest,	the	pathogenic	Ly6Chi	monocytes,	in	the	spleen,	following	Enalapril	treatment.	 Similarly,	 comparable	 numbers	 of	 DC	 subsets	 were	 present	 in	 the	 spleen	 of	both	 vehicle-	 and	 Enalapril-treated	 WNV-infected	 mice	 (Figure	 4.19A).	 Curiously,	neutrophil	numbers	were	slightly	 lower	 in	the	spleen	of	Enalapril-treated,	WNV-infected	mice,	compared	to	the	vehicle-treated	cohort,	but	this	was	not	significant.	None	of	the	lymphoid	lineage	subsets	(T,	B,	NK	and	NKT	cells)	in	the	spleen	demonstrated	any	 statistically	 significant	 changes	 in	 response	 to	 Enalapril	 treatment,	 following	 WNV	infection	(Figure	4.19B).		
Figure	4.18	 Leukocyte	number	 in	 the	CNS	of	mock-	 and	WNV-infected	 (6x104PFU)	
mice	following	treatment	with	Enalapril		Panel	 A	 represents	 the	 cell	 number	 of	 total	 leukocytes	 (CD45+),	 resident	 microglia	(CD11b+Ly6C-)	 and	 the	 CD11b+Ly6C+	 subset,	 which	 can	 further	 be	 subdivided	 into	infiltrating	 macrophages	 (CD11b+Ly6Chi)	 and	 immigrant/activated	 microglia	(CD11b+Ly6Cint)	 populations	 in	 the	 CNS	 of	 mock-infected,	 vehicle-treated	 (dark	 grey),	mock-infected,	Enalapril-treated	 (light	grey),	WNV-infected,	vehicle-treated	 (purple)	and	WNV-infected,	Enalapril-treated	(orange)	mice.	Panel	B	shows	the	number	of	neutrophils	(CD11bhiLy6G+)	 and	 lymphoid	 cells,	 including	 T	 cells	 (CD3+),	 NK	 cells	 (NK1.1+)	and	 B	(B220+)	cells	in	the	CNS	of	the	experimental	cohorts	described	for	panel	A.	Data	are	shown	as	the	mean	±SEM	of	values	from	2	independent	experiments,	with	3	mice/group	in	each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Figure	4.19	Leukocyte	number	in	the	spleen	of	mock-	and	WNV-infected	(6x104	PFU)	
mice	following	treatment	with	Enalapril	
			Figure	A	represents	the	number	of	the	following	leukocyte	subsets	present	in	the	spleen	of	mock-infected,	 vehicle-treated	 (dark	 grey),	mock-infected,	 Enalapril-treated	 (light	 grey),	WNV-infected,	 vehicle-treated	 (purple)	 and	 WNV-infected,	 Enalapril-treated	 (orange)	mice:	 total	 leukocytes	 (CD45+)	 (A),	 pDC	 (B220+CD11c+)	 and	 other	 DC	 (CD11c+B220-),	neutrophils	 (CD11bhiLy6G+)	 and	 monocytes,	 which	 were	 classified	 as	 CD11b+Ly6Chi,	CD11b+Ly6Cint,	 and	 CD11b+Ly6C-.	 The	 numbers	 of	 B	 (B220+CD11c-),	 T	 (CD3+NK1.1-),	 NK	(NK1.1+CD3-)	 and	 NKT	 (NK1.1+CD3+)	 cells	 are	 shown	 by	 panel	 B,	 for	 the	 same	experimental	 cohorts	described	 in	panel	A.	Data	are	 shown	as	 the	mean	±SEM	of	values	from	 2	 independent	 experiments,	 with	 3	 mice/group	 in	 each	 experiment.	 	 Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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4.2.10.3. Clinical	 symptoms	and	weight	 loss	of	mice	 following	 lethal	WNV	 infection	
and	Enalapril	treatment	
Even	 though	 Enalapril-treated	 mice	 had	 negligible	 differences	 in	 CNS	 and	 splenic	leukocyte	 number,	 compared	 to	 vehicle-treated	 cohorts,	we	 confirmed	 the	 absence	 of	 a	therapeutic	effect	by	closely	monitoring	clinical	symptoms.	The	classic	symptoms	of	WNV	encephalitis	 are	 outlined	 by	 table	 2.2	 and	 include	 progressive	 weight	 loss	 and	 seizure	development.	Although	mice	were	not	perceived	to	exhibit	any	adverse	effects	in	response	to	Enalapril	treatment,	treatment	did	not	produce	any	remarkable	improvement	in	clinical	symptoms	in	WNV-infected	Enalapril-treated	mice	(Figure	4.20A).	Furthermore,	both	the	Enalapril-	and	vehicle-treated	WNV-infected	cohorts	had	comparable	weight-loss	(Figure	4.20B),	with	both	cohorts	losing	significant	percentage	of	their	original	weight	from	d6p.i.	Mock-infected	 vehicle-	 and	 Enalapril-treated	 mice	 did	 not	 lose	 any	 significant	 weight	during	the	7-day	course	of	infection		
4.2.10.4. Survival	 outcome	 following	 Enalapril	 treatment	 of	 mice	 infected	 with	 a	
sublethal	dose	of	WNV		
Since	Enalapril	treatment	did	not	result	in	any	clinical	improvement	or	reduction	in	Ly6Chi	macrophage	infiltration	into	the	CNS	in	mice	that	had	been	infected	with	the	lethal	dose	of	WNV	(6x104	PFU),	we	 infected	mice	with	a	10-fold	 lower,	 sublethal	dose	of	WNV	(6x103	PFU)	 (Figure	4.20C).	However,	 despite	 the	 lower	dose	 of	 virus,	mice	 receiving	Enalapril	treatment	(orange)	did	not	have	improved	survival	outcomes	compared	to	vehicle-treated	mice	 (purple),	 nor	 was	 there	 any	 improvement	 in	 MST	 of	 animals	 given	 Enalapril	treatment.	These	experiments	provide	no	evidence	that	the	use	of	an	ACE	inhibitor,	widely	reported	 to	 inhibit	 the	 deployment	 of	 splenic	 reservoir	 monocytes,	 has	 any	 beneficial	action	in	our	i.n.	model	of	WNV	infection.	This	either	suggests	that	a	splenic	reservoir	does	
Figure	 4.20	 Clinical	 score,	 weight	 loss	 and	 survival	 of	WNV-infected	mice	 treated	
with	Enalapril		The	 comparative	 clinical	 scores	 (based	 on	 table	 2.2)	 for	 mock-infected,	 vehicle-treated	(dark	 grey),	mock-infected,	 Enalapril-treated	 (light	 grey)	 and	WNV-infected	 (6x104	PFU)	vehicle-treated	(purple)	and	Enalapril-treated	(orange)	mice	are	shown	in	by	panel	A.		The	average	percentage	weight	 loss	compared	 to	original	weight	of	mice	 infected	with	 lethal	dose	 of	 WNV	 (6x104	 PFU)	 and	 given	 either	 vehicle	 (purple)	 or	 Enalapril	 treatment	(orange)	 from	day	0-7	p.i.	 (B).	The	percentage	survival	of	mice	 infected	with	a	sublethal	dose	 of	 WNV	 (6x103	 PFU)	 and	 given	 either	 vehicle	 (purple)	 or	 Enalapril	 (orange)	treatment	is	represented	by	figure	C.	Data	for	the	clinical	score	(A)	are	shown	as	the	mean	±SEM	of	values	from2	independent	experiments,	with	3-4	mice/group	in	each	experiment.	Data	 for	 the	 weight	 loss	 graph	 (B)	 is	 shown	 as	 the	 mean	 ±SEM	 of	 values	 from	 2	independent	experiments,	with	3	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	P≤0.05*;	P≤0.01**;	P≤0.001***.	Survival	data	(C)	were	graphed	in	a	Kaplan-Meier	survival	curve	 and	 a	 Log-rank	 test	 was	 used	 to	 determine	 statistical	 significance.	 Survival	experiment	was	performed	once	and	is	representative	of	12-13	mice/group.	 	
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not	contribute	to	the	monocyte	infiltration	into	the	CNS	during	WNV	encephalitis	or	that	the	 infectious	 stimulus	 substantially	 overcomes	 the	 effect	 of	 this	 drug.	 Further	 studies	using	a	peripheral	model	of	infection	such	as	i.p.	or	s.c.,	as	a	possibly	lesser	inflammatory	stimulus,	 may	 produce	 a	 different	 outcome	 and,	 in	 light	 of	 the	 reduction	 in	 CNS	inflammation	seen	with	splenectomised	mice,	needs	to	be	investigated.	
4.2.11. Locating	 IMP+	 cells	 in	 the	 WNV-infected	 spleen-Adoptive	
transfer	of	spleen	cells,	MARCO	and	apoptosis	
In	order	to	track	the	fate	of	IMP	and	IMP-associated	cells,	we	adoptively	transferred	non-sorted	 spleen	 cells	 from	 C57BL/6	 mice	 i.v.,	 stained	 with	 PKH26,	 into	 C57BL/6	 WNV-infected	mice	and	subsequently	treated	them	with	IMP.	Previous	work	has	indicated	that	leukocytes	 phagocytosing	 IMP	 are	 sequestered	 by	 the	 spleen,	 localising	 in	 the	MARCO+	marginal	zone	macrophages,	known	for	the	phagocytic	uptake	of	apoptotic	material	from	circulation	(Getts	et	al.	2014).	Thus,	we	examined	the	dynamics	of	IMP-associated	myeloid	lineage	cells	within	the	mock-	and	WNV-infected	spleen	24h	following	IMP	treatment.	 In	particular,	 we	 focussed	 on	 the	 distribution	 of	 MARCO	 on	 IMP+	CD11b+	 cells,	 as	 well	 as	staining	 for	 annexin	 V.	 Annexin	 V	 has	 a	 strong	 affinity	 for	 phosphatidylserine	 residues,	found	on	 the	cell	 surface	during	 the	early	 stages	of	apoptosis	and	 is	 therefore	used	as	a	probe	in	the	detection	of	apoptosing	cells.		Almost	 all	 of	 the	 CD45+CD11b+IMP+	 transferred	 cells	 in	 the	 WNV-infected	 spleen	 were	positive	for	annexin	V	(Figure	4.21A-B).	It	was	also	clear	that	the	majority	of	transferred	CD45+CD11b+	 cells	 that	were	 annexin	V+	 (Figure	4.21C)	 and	 therefore	 likely	undergoing	apoptosis,	 were	 MARCO+	 (Figure	 4.21B)in	 both	 mock-	 and	 WNV-infected	 mice.	Furthermore,	 nearly	 all	 of	 the	 IMP+annexin	 V+	 transferred	 CD45+CD11b+	 cells	 were	MARCO+.	
Figure	 4.21	 Adoptive	 transfer	 of	 PKH+	 splenic	 leukocytes	 into	 mock-	 and	 WNV-
infected	mice	given	IMP	treatment	
			Representative	 flow	cytometric	dot	plots	of	adoptively	 transferred	splenic	 leukocytes	on	d6	p.i.,	 followed	by	i.v.	IMP	or	vehicle	treatment	in	mock-	and	WNV-infected	mice	(6x104	PFU).	Mice	were	sacrificed	on	d7	p.i.	and	isolated	leukocytes	stained	for	apoptosis	marker,	annexin	V,	and	scavenger	receptor	MARCO.	Panel	A	represents	 the	portion	of	adoptively	transferred	 PKH+	splenic	 total	 leukocytes	 identified	 in	 the	 spleen.	 Panel	 B	 demonstrates	the	portion	of	CD45+PKH+	cells	were	CD11b+.	Panel	C	demonstrates	which	of	these	CD45+	CD11b+PKH+	 splenic	 leukocytes	 stained	 positive	 for	 Annexin	 V	 (ii)	 and	 which	 were	Annexin	 V	 negative	 (i).	 Panel	 C,	 in	 turn	 indicates	 the	 MARCO	 distribution	 of	 both	 the	annexin	V+	(ii)	and	annexin	V-	(i)	PKH+	splenic	myeloid	lineage	cells.	 	
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We	 further	 quantified	 the	 percentage	 of	 total	 CD45+CD11b+PKH+	transferred	 cells	 that	were	 IMP+.	 It	was	 evident	 that	 the	 association	with	 or	 possibly	 phagocytosis	 of	 IMP,	 by	myeloid	lineage	cells	was	higher	in	the	WNV-infected	than	mock-infected	cohort,	although	this	 was	 not	 significant	 (Figure	 4.22A).	 Furthermore,	 ~90%	 of	 the	 IMP+	 CD11b+	transferred	cells	were	positive	for	annexin	V	in	WNV-infected	spleen,	in	contrast	to	50%	in	mock-infected	 spleen	 (Figure	 4.22B),	 indicating	 that	 a	 larger	 proportion	 of	 IMP+	 cells	likely	 undergo	 apoptosis	 under	 inflammatory	 conditions.	 Similarly,	 there	 were	significantly	more	 IMP+CD11b+	 transferred	 cells	 that	were	MARCO+	in	 the	WNV-infected	spleen	 (~85%)	 than	 mock-infected	 spleen	 (~60%)	 (Figure	 4.22C).	 Thus,	 CNS	 viral	infection	 promoted	 phagocytosis	 of	 particles	 by	myeloid	 lineage	 cells	 in	 the	 circulation	and	subsequent	transport	 to	the	spleen,	where	these	IMP-associated	cells	 likely	undergo	apoptosis.	However,	the	extent	to	which	MZM	take	up	IMP	and	undergo	apoptosis	needs	to	be	investigated.	
4.3. Discussion	
WNV	 infection	 of	 the	 CNS	did	 not	 induce	major	 changes	 in	 the	 cellularity	 of	 the	 spleen.	There	was	 little	 evidence	 of	 cell	 egress	 or	 proliferation	 from	 the	 spleen	 throughout	 the	course	 of	 infection,	 making	 it	 unlikely	 that	 the	 spleen	 contributes	 significantly	 to	 the	leukocyte	populations	infiltrating	the	CNS.	However,	the	significant	upregulation	of	Ly6C,	in	direct	correlation	with	disease	progression,	indicates	that	CNS	inflammation	does	have	some	impact	on	the	spleen.	Indeed,	CNS	inflammation	has	been	shown	to	modulate	splenic	mRNA	 profile	 of	 various	 pro-	 and	 anti-inflammatory	 mediators.	 For	 example,	 infection	with	JEV	induced	the	upregulation	of	various	genes	in	the	CNS	and	spleen,	associated	with	the	anti-viral	response.	These	included	pro-inflammatory	cytokines	and	chemokines,	such	as	 IFN-γ	 and	 CCL2,	 and	 also	 Ly6C,	 which	 was	 upregulated	 by	 4-fold.	 The	 authors	
Figure	4.22	Annexin	V	and	MARCO	distribution	of	IMP+	CD11b+	transferred	cells			Graph	 A	 represents	 the	 percentage	 of	 PKH+	 adoptively	 transferred	 CD11b+	 cells	 in	 the	mock-	 and	 WNV-infected	 cohorts	 that	 are	 IMP+.	 The	 percentage	 of	 CD45+	 PKH+	CD11b+IMP+	adoptively	 transferred	 cells	 that	were	positive	 for	 annexin	V	 is	 represented	by	graph	B.	Lastly,	the	fraction	of	CD45+PKH+CD11b+IMP+	adoptively	transferred	cells	that	were	positive	for	MARCO	is	represented	by	figure	C.	Data	are	shown	as	the	mean	±SEM	of	3-4	mice/group	and	is	representative	of	1	experiment.	Statistical	analysis	was	conducted	using	an	unpaired,	two	tailed	T-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	
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hypothesised	 that	 the	 increased	 expression	 of	 splenic	 factors	 may	 aid	 in	 the	 antiviral	response	or	contribute	to	the	pathogenic	response	(Yang	et	al.	2011).			It	may	be	possible	for	inflammatory	mediators	released	by	cells	of	the	infected	CNS,	such	as	 neurons	 or	 astrocytes,	 to	 enter	 the	 circulation	 and	 modulate	 the	 splenic	 immune	response.	 In	 addition,	 the	 influence	 of	 neuroimmunological	 connections	 should	 be	considered,	as	this	has	been	shown	to	directly	impact	the	spleen	and	vice	versa	following	traumatic	brain	injury.	Removal	of	the	spleen	immediately	after	traumatic	brain	injury	in	rats	directly	resulted	in	decreased	levels	of	pro-inflammatory	cytokines	in	the	blood	and	CNS,	suggesting	that	the	spleen	played	a	role	in	the	systemic	and	CNS	immune	response.	Consequently,	rats	had	improved	clinical	outcome,	which	was	attributed	to	the	decreased	IL-1β,	TNF	and	IL-6,	as	a	result	of	the	splenectomy	(Li	et	al.	2011).	Additionally,	the	spleen	was	demonstrated	to	be	a	potent	inducer	of	neuroinflammation	in	an	experimental	model	of	stroke	(Lee	et	al.	2008).	Another	 link	between	the	CNS	and	periphery	can	be	found	in	the	increased	risk	of	infection	that	is	frequently	seen	in	stroke	patients,	in	part	due	to	the	upregulation	 of	 anti-inflammatory	 signals	 occurring	 in	 reaction	 to	 ischemia-reperfusion	injury.	This	suggests	that	trauma	in	the	brain,	the	adverse	effect	of	which	is	also	associated	with	immunopathology,	influences	the	immunological	response,	although	whether	this	is	a	consequence	 of	 neuroimmunological	 crosstalk	 or	 release	 of	 pro-	 or	 anti-inflammatory	mediators	 into	 the	 circulation,	 remains	 to	 be	 elucidated.	 Even	 so,	 the	 rich	 sympathetic	nerve	 supply	 to	 the	 secondary	 lymphoid	 organs,	 such	 as	 the	 spleen,	 does	 highlight	 the	possibility	 of	 a	 neuroimmunological	 route	 of	 communication	 between	 the	 CNS	 and	peripheral	 organs,	 rather	 than	 solely	 through	 circulatory	 mediators	 (Chamorro	 et	 al.	2007),	although,	 the	exact	 signal/s	modulating	 the	expression	of	Ly6C	 in	 the	spleen	and	peripheral	lymph	nodes	remains	to	be	elucidated.		
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A	 link	 between	 CNS	 and	 the	 spleen	 is	 further	 emphasized	 by	 the	 dramatic	 reduction	 in	leukocyte	 infiltration	 into	 the	 WNV-infected	 CNS	 of	 splenectomised	 mice,	 compared	 to	normal	mice.	Notably,	the	reduction	in	cell	numbers	infiltrating	the	CNS	was	not	due	to	the	development	of	a	 leukopenic	state	 in	post-splenectomised	mice,	as	 there	were	negligible	differences	 in	 leukocyte	 numbers	 in	 the	 blood	 or	 bone	marrow	of	 normal,	 compared	 to	splenectomised	mice.	 These	 results	 suggest	 a	 potential	 role	 for	 the	 spleen	 in	 supplying	leukocyte	 subsets	 to	 the	 CNS,	 although	 the	 static	 nature	 of	 cell	 numbers	 in	 the	 spleen	during	 the	course	of	 infection	and	stable	 levels	of	proliferation	seem	antithetical	 to	 this.	Despite	this,	we	wanted	to	confirm	that	the	diminished	leukocyte	infiltration	in	the	WNV-infected	CNS	of	splenectomised	mice	was	not	due	to	the	spleen	acting	as	a	source	of	cells	for	the	inflamed	CNS.			Much	like	the	nervous	tissue	damage	present	in	WNV	encephalitis,	cardiac	fibrosis,	due	to	tissue	 remodelling	 and	decreased	 cardiac	 function	 following	MI	 can	be	 attributed	 to	 the	detrimental	 actions	 of	 an	 exaggerated	 immune	 response.	 The	 therapeutic	 action	 of	 ACE	inhibitors,	 such	 as	 Enalapril,	 following	 MI,	 has	 been	 well	 documented.	 However,	 the	cardioprotective	action	of	ACE	inhibitors	has,	 in	part,	been	attributed	to	the	inhibition	of	the	renin-angiotensin-aldosterone	system	and	subsequent	decrease	in	blood	pressure	(Xu	et	 al.	 2002).	 In	 addition,	 studies	 have	 demonstrated	 that	 the	 improved	 vascular	endothelial	function	and,	specifically	NO	release,	serves	as	an	important	mediator	of	ACE	inhibitor	function	(Liu	et	al.	2002).	However,	recent	studies	have	identified	the	spleen	as	a	reservoir	 of	 undifferentiated	 monocytes,	 residing	 in	 the	 red	 pulp,	 that	 can	 rapidly	 be	deployed	in	response	to	inflammatory	signals,	such	as	those	present	following	MI	(Swirski	et	al.	2009;	Goltz	et	al.	2015).	This	was	supported	by	post-mortem	studies,	demonstrating	diminished	CD14+	cell	numbers	in	the	spleen,	coinciding	with	an	accumulation	of	in	CD14+	cells	 in	 the	myocardium,	 following	 acute	MI	 (van	 der	 Laan	 et	 al.	 2014).	Moreover,	 ACE	
		 133	
inhibitors	were	 found	 to	abrogate	 the	 splenic	monocyte	 response,	 to	 the	same	extent	as	removal	of	the	spleen,	both	of	which	had	significant	cardioprotective	benefits	following	MI	(Leuschner	et	al.	2010).	The	immunopathogenic	action	of	splenic	monocytes	was	not	limited	to	peripheral	disease,	but	 also	 significantly	 contributed	 to	neuroinflammation	and	disease	 severity	 in	 the	CNS,	such	 as	 the	 pathology	 present	 in	 the	 post-ischemic	 brain	 following	 a	 stroke	 (Bao	 et	 al.	2010).	Removal	of	the	spleen	in	rats,	2	weeks	prior	to	stroke	induction	via	middle	cerebral	artery	 occlusion,	 resulted	 in	 significantly	 decreased	 infarct	 volume	 and	 infiltration	 of	leukocytes	(Ajmo	et	al.	2008).	Additionally,	 the	splenic	contribution	of	pathogenic	Ly6Chi	inflammatory	monocytes	to	the	spinal	cord	after	injury	far	outweighed	the	contribution	of	the	 bone	 marrow,	 with	 splenectomy	 significantly	 improving	 post-injury	 recovery	(Blomster	et	al.	2013).			Thus,	 we	 aimed	 to	 determine	 whether	 there	 was	 any	 evidence	 of	 deployment	 of	pathogenic	 Ly6Chi	 monocytes	 from	 this	 splenic	 reservoir,	 contributing	 to	 pathology	 in	response	 to	 a	 CNS	 viral	 infection.	 We	 treated	 mice	 with	 the	 ACE	 inhibitor,	 Enalapril,	prophylactically	 and	 at	 the	 onset	 of	 disease	 but	 found	 no	 appreciable	 differences	 in	leukocyte	infiltration	into	the	CNS.	There	was	no	reduction	in	Ly6Chi	macrophages	in	the	CNS,	nor	was	 there	any	 indication	 that	 these	 cells	were	 retained	 in	 the	 spleen	 following	Enalapril	 administration.	 Moreover,	 Enalapril	 treatment	 did	 not	 improve	 clinical	symptoms,	 and	 weight	 loss	 occurred	 at	 the	 same	 rate	 and	 extent	 in	 both	 vehicle	 and	Enalapril-treated	mice.			As	the	lethal	dose	of	WNV	is	severe	and	results	in	100%	mortality,	we	also	tested	Enalapril	treatment	 at	 the	 LD50	 dose,	 which	 is	 10-fold	 lower.	 As	 with	 the	 lethal	 dose	 of	 WNV,	however,	 Enalapril	 treatment	 of	mice	 infected	with	 the	 sublethal	 dose	 did	 not	 improve	
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survival	outcome	significantly.	Although	further	studies	into	titrating	the	dose	of	Enalapril	and	 testing	 different	 days	 of	 intervention	 may	 be	 warranted,	 these	 data	 undoubtedly	corroborate	 the	 previous	 studies	 from	our	 laboratory	 identifying	 the	 bone	marrow	as	 a	major	source	of	Ly6Chi	inflammatory	monocytes	during	WNV	encephalitis,	rather	than	the	spleen(Getts	et	al.	2008)	.	The	 nature	 of	 viral	 infection	 in	 the	 CNS	 is	 less	 rapid	 and	 immediately	 severe	 than	 an	ischemia	reperfusion	injury,	seen	in	MI	and	CNS	ischemia-reperfusion/stroke	injury.	It	 is	possible	 that	 the	 rapid	 deployment	 of	 splenic	monocytes	 is	 required	 for	 the	 immediate	response	to	ischemia-reperfusion	injury	whereas,	in	the	case	of	CNS	viral	infection,	signals	accumulating	in	an	incremental	manner,	over	a	period	of	several	days,	mobilises	the	bone	marrow,	 rather	 than	a	 splenic	 response.	Thus,	 the	 therapeutic	 efficacy	of	ACE	 inhibitors	may	 be	 limited	 to	 acute	 demand	 scenarios	 such	 as	 ischemia-reperfusion.	 Interestingly,	however,	the	IMP	treatment	developed	in	this	laboratory	was	successful	in	the	treatment	of	both	ischemia-reperfusion	injury,	such	as	cardiac	and	renal	reperfusion	injury,	as	well	as	CNS	viral	 infection	(Getts	et	al.	2014).	This	suggests	that,	 IMP	may	target	splenic-	and	bone	marrow-derived	monocytes,	released	into	circulation	in	response	to	various	types	of	inflammatory	disease	models.			The	absence	of	the	spleen	may	have	led	to	a	reduction	of	cell	numbers	infiltrating	the	CNS,	but	 it	did	not	alter	 the	distribution	of	 leukocyte	subsets	entering	 the	WNV-infected	CNS.	Despite	the	reduction	in	inflammatory	macrophage	subsets	in	the	CNS,	the	disease	was	not	exacerbated	 nor	 abrogated	 in	 splenectomised	 mice,	 as	 the	 MST	 and	 mortality	 rate	remained	comparable	 to	mice	with	 intact	 spleens.	 Indeed,	mice	without	 spleens	showed	very	similar	disease	progression	 to	normal	mice,	with	weight	 loss	occurring	at	 the	same	rate	 and	 intensity	 in	 both	 cohorts.	 The	 fact	 that	 splenectomised	 mice	 were	 able	 to	efficiently	clear	a	sublethal	dose	of	virus	to	the	same	extent	as	normal	mice,	indicates	that	
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the	primary	adaptive	immune	response	was	not	significantly	hampered	by	the	absence	of	the	 spleen.	 This	 suggests	 that	 the	 activation	 and	 priming	 of	 e.g.	 T	 cells	 occurring	 in	 the	lymph	 nodes	was	 sufficient	 to	 compensate	 for	 the	 absence	 of	 the	 spleen	 in	 primary	 i.n.	WNV	 infection.	 We	 hypothesised	 that	 a	 compensatory	 reaction	 may	 be	 induced	 in	 the	other	 organs	 involved	 in	 the	 immune	 response,	 such	 as	 the	 bone	 marrow	 and	 lymph	nodes.	However,	 the	 absence	of	 the	 spleen	did	not	 significantly	 alter	 the	 cell	 number	or	distribution	of	 leukocyte	subsets	 in	 the	bone	marrow	or	 the	blood.	Mice	did	not	become	leukopenic,	nor	was	there	any	sign	of	increased	haematopoiesis	and/or	leukocyte	release	into	circulation.	Thus,	a	compensatory	mechanism	for	the	absence	of	the	spleen	in	a	severe	CNS	infection	was	evidently	not	initiated	in	the	bone	marrow.			On	 the	 other	 hand,	 the	 absolute	 leukocyte	 numbers	 of	 all	 the	major	 subsets	 in	 the	 CLN	were	 nearly	 doubled	 in	 splenectomised	 mice,	 indicating	 a	 global	 compensation	 in	 the	absence	of	the	spleen.	Furthermore,	the	ratio	of	leukocyte	subsets	in	splenectomised	and	normal	mice	also	remained	unchanged.	Interestingly,	preliminary	data	suggested	that	this	also	occurred	in	peripheral	nodes,	such	as	the	ILN,	which	are	not	directly	involved	in	CNS	inflammatory	response.		Having	established	that	the	removal	of	the	spleen	had	no	effect	on	survival	and	severity	of	disease	 in	a	primary	 infection,	we	 investigated	 the	 impact	on	 the	memory	response	 to	a	secondary	 infection	 by	 rechallenging	 with	 a	 lethal	 dose	 of	 WNV.	 Both	 activation	 and	priming	of	naïve	T	 cells,	 and	development	of	memory	 cells	 are	highly	dependent	on	 the	environment	 of	 the	 secondary	 lymphoid	 organs,	 including	 the	 spleen.	 Splenectomised	mice	 have	 been	 shown	 to	 have	 severely	 impeded	 T	 cell	 responses	 to	 primary	 and	secondary	 infection	 with	 Listeria	monocytogenes	 (Kursar	 et	 al.	 2008).	 Furthermore,	 the	role	 of	 the	 spleen	 in	 the	 memory	 response	 and	 maintenance	 of	 peripheral	 B	 cell	
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homeostasis	 is	 highlighted	 by	 the	 decreased	 frequencies	 of	 IgM	 memory	 B	 cells	 in	splenectomised	individuals	(Martinez-Gamboa	et	al.	2009;	Cameron	et	al.	2011).	However,	 surprisingly,	 all	 but	 two	 splenectomised	 mice	 were	 able	 to	 successfully	eradicate	 a	 secondary	 i.n.	 infection	 with	 a	 lethal	 dose	 of	 WNV,	 without	 any	 signs	 of	developing	 illness.	 Of	 the	 two	 rechallenged	 splenectomised	 animals,	 the	 outcome	 was	lethal	 in	 one	 case,	with	 the	 remaining	mouse	 recovering	without	 any	 sequelae.	 There	 is	evidence	of	enhanced	homeostatic	proliferation	of	memory	T	cells	in	splenectomised	mice	(Kim	and	Harty	2014).	The	protective	capacity	of	these	memory	T	cells	was	unaltered	and	this	would	 explain	 the	 ability	 of	 splenectomised	mice	 to	maintain	 the	memory	 immune	responses.	 However,	 this	 raises	 the	 question	 of	 where	 the	 primary	 components	 of	 the	memory	response	reside,	in	the	lymph	nodes	or	the	spleen	and	to	what	extent	this	changes	in	 focussed	models	 of	 infection,	 such	 as	with	 i.n.	WNV	 in	 the	 CNS	 versus	perhaps	more	general	peripheral	models	of	 infection.	Future	studies,	 in	which	mice	with	 intact	spleens	are	 infected,	 resolve	 infection,	and	prior	 to	secondary	rechallenge	undergo	splenectomy,	may	 resolve	 this	 question.	 Furthermore,	whether	 splenectomised	mice	would	 retain	 the	ability	 to	 eradicate	 primary	 or	 secondary	WNV	 infection	 administered	 via	 a	 peripheral	route,	 i.e.	 i.p.	 or	 s.c.,	 is	 of	 interest	 but	 remains	 unknown.	 It	would	 seem	 logical	 that	 the	spleen	plays	a	critical	role	in	the	control	of	viral	dissemination,	priming	of	T	cells	and	the	development	 of	 memory	 responses	 in	 a	 peripheral	 rather	 than	 CNS	 infection.	Nevertheless,	 these	 data	 demonstrate	 that	 the	 spleen	 is	 not	 required	 in	 primary	 or	secondary	i.n.	WNV	infection,	limited	to	the	CNS.		Ly6Chi	 inflammatory	monocytes,	which	would	become	highly	pathogenic	macrophages	in	the	 CNS	 during	 WNV	 encephalitis,	 are	 reduced	 in	 the	 CNS	 by	 IMP	 treatment,	 which	 is	accompanied	by	a	concurrent	increase	in	this	subset	in	the	spleen.	Not	surprisingly,	after	IMP	treatment,	significant	numbers	of	IMP	localise	to	the	spleen.	We	hypothesised	that	the	
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spleen	 may	 play	 a	 crucial	 role	 in	 the	 efficacy	 of	 IMP	 treatment,	 and	 in	 testing	 IMP	treatment	in	splenectomised	mice,	we	found	that,	while	IMP	treatment	reduced	leukocyte	infiltration	 into	 the	WNV-infected	CNS,	 this	was	not	statistically	significant,	 compared	 to	WNV-infected,	 splenectomised,	 vehicle-treated	 controls.	 As	 shown	 in	 this	 chapter,	splenectomised	 animals	 infected	 with	 WNV	 had	 already	 diminished	 cell	 numbers	infiltrating	the	WNV-infected	CNS.	Thus,	further	reductions	in	Ly6Chi	macrophages	should	feasibly	 have	 translated	 into	 improved	 clinical	 outcome.	 Indeed,	 improved	 survival	followed	sublethal	WNV	i.n.	infection	of	splenectomised	mice,	treated	with	IMP.		Surprisingly,	 the	reduction	 in	 infiltrating	cell	numbers	evidently	due	to	splenectomy,	did	not	itself	improve	the	clinical	outcome,	to	the	same	extent	as	splenectomy	combined	with	IMP	 treatment	or	 IMP	 treatment	 in	normal	mice.	This	 indicates	a	disparity	between	cell	subsets	modulated	in	WNV-infected,	splenectomised	mice	and	normal	mice	receiving	IMP	treatment	 only.	 Nevertheless,	 the	 efficacy	 of	 IMP	 treatment	 remained	 maximal	 in	 mice	with	 intact	spleens,	strongly	suggesting	a	contribution	by	the	spleen	that	cannot	be	 fully	replicated	 by	 other	 organs	 where	 IMP+	 Ly6Chi	 monocytes	 may	 be	 sequestered,	 during	WNV	encephalitis	in	splenectomised	animals.		Notably,	however,	there	were	no	differences	in	the	numbers	of	IMP+leukocytes	in	the	liver,	blood,	bone	marrow	and	moreover,	splenectomised	mice	had	fewer	IMP+	leukocytes	in	the	brain	and	CLN,	compared	to	normal	mice.	Thus,	the	fate	of	IMP+	leukocytes	in	the	absence	of	the	spleen	is	currently	unclear	and	further	examination	will	be	necessary	to	resolve	the	kinetics,	distribution	and	excretion	of	IMP.		We	tried	to	determine	the	fate	of	cells	phagocytosing	and/or	associating	with	IMP	on	the	cell	 surface	 that	are	 subsequently	 sequestered	 in	 the	 spleen,	 following	 IMP	 treatment	of	WNV-infected	mice.	We	found	that	a	higher	percentage	of	adoptively	transferred	PKH26+	splenocytes	had	associated	with	 IMP	 in	 the	spleens	of	WNV-infected	 than	mock-infected	
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mice.	This	is	likely	to	be	due,	at	least	in	part,	to	the	fact	that	during	infection	cells	are	more	likely	 to	phagocytose	particulate	matter	 in	 the	blood	 (Getts	et	 al.	2014).	 In	addition,	 the	outcome	 of	 the	 annexin	 V	 staining	 suggested	 that	 WNV	 infection	 created	 a	 splenic	environment	 where	 IMP+	 myeloid	 lineage	 cells	 were	 more	 likely	 to	 undergo	 apoptosis	than	cells	in	a	mock-infected	mouse	spleen.	The	majority	of	annexin	V+	IMP+CD11b+	cells	were	 identified	 as	 being	 positive	 for	 the	 scavenger	 receptor	 MARCO.	 This	 may	 not	 be	surprising,	 as	 the	MARCO+	marginal	 zone	macrophages	 readily	phagocytose	 apoptotic	 or	negatively-charged	material	(McGaha	et	al.	2011).	Moreover,	WNV	infection	increases	the	expression	 of	 MARCO	 on	 peripheral	 blood	 monocytes	 and	 IMP	 are	 taken	 up	 by	 fewer	monocytes	when	MARCO	is	genetically	absent	(Getts	et	al.	2014).	Thus,	it	seems	to	confirm	that	 increased	numbers	of	MARCO+	monocytes	pick	up	 IMP	 in	 the	peripheral	 blood	 and	become	Annexin	V+	as	a	result,	subsequently	undergoing	apoptosis	in	the	marginal	zone	of	the	 spleen	 (Getts	 et	 al.	 2014).	 This	 would	 certainly	 reduce	 the	 number	 of	 Ly6Chi	inflammatory	monocytes	available	 to	migrate	 to	 the	CNS	 in	WNV	encephalitis.	However,	free	IMP	are	also	undoubtedly	picked	up	by	the	marginal	zone	macrophages	themselves.	Whether	monocytes	containing	IMP	expressing	phosphatidyl	serine	are	also	taken	up	by	the	 marginal	 zone	 macrophages,	 as	 part	 of	 clearance	 of	 “apoptotic	 cells”	 is	 not	demonstrated	 by	 these	 data.	 Moreover,	 whether	 the	 presence	 of	 marginal	 zone	macrophages	taking	up	IMP	or	apoptotic	cells	is	necessary	for	the	therapeutic	effect	of	IMP	is	not	resolved	by	these	data.	This	question	will	be	addressed	in	the	next	chapter.			 	
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5. Chapter	5	Depletion	of	circulatory	and	splenic	resident	
macrophages-WNV	infection	and	IMP	treatment	
5.1. Introduction	
The	 depletion	 of	 macrophages	 with	 clodronate-encapsulated	 liposomes	 has	 been	 well	documented	(Naito	et	al.	1996;	van	Rooijen	and	van	Nieuwmegen	1984).	These	liposomes	contain	 dichloromethylene-bisphosphonate	 (clodronate)	 and	 are	 designed	 to	 mediate	intracellular	delivery	of	 clodronate	via	phagocytosis.	Once	 inside	 the	phagocytic	cell,	 the	clodronate	 is	 released	 into	 the	 aqueous	 compartments	 and,	 after	 exceeding	 a	 threshold	concentration,	initiates	the	apoptosis	of	the	cells,	although	clodronate	itself	is	not	directly	toxic	 (van	 Rooijen	 and	 van	 Nieuwmegen	 1984).	 When	 administered	 intravenously,	clodronate	 liposomes	 deplete	 all	 the	 circulatory	 macrophages	 as	 well	 as	 the	 resident	macrophages	 of	 the	 spleen,	 such	 as	 the	 red	 pulp,	 marginal	 zone	 and	 marginal	metallophillic	 macrophages,	 and	 liver	 Kupfer	 cells	 (Naito	 et	 al.	 1996;	 Yamamoto	 et	 al.	1996;	van	Rooijen	et	al.	1989),	although	they	spare	the	microglia	in	the	CNS,	even	during	the	highly	inflammatory	pathogenesis	of	WNV	encephalitis.			As	the	modulation	of	Ly6Chi	monocytes	has	shown	great	therapeutic	promise	in	our	model	of	 i.n.	 WNV	 encephalitis	 (Getts	 et	 al.	 2014),	 we	 were	 interested	 to	 determine	 how	clodronate	depletion	would	affect	leukocyte	infiltration	and	in	particular	Ly6Chi	monocyte	content	 of	 the	 CNS	 during	 WNV	 infection.	 Indeed,	 cells	 of	 the	 myeloid	 lineage	 are	preferentially	 depleted	 by	 clodronate	 liposomes,	 with	 activated	 macrophages,	 such	 as	those	 present	 in	 circulation	 during	 WNV	 infection,	 exhibiting	 the	 highest	 degree	 of	liposome	 incorporation,	 compared	 to	 resting	 monocytes	 (Schmidt-Weber	 et	 al.	 1996).	Furthermore,	there	is	evidence	of	i.v.	clodronate	depletion	inducing	increased	production	
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and	release	of	monocytes	into	circulation	for	up	to	5	days	after	administration	(Yamamoto	et	 al.	 1996).	 As	WNV	 infection	 results	 in	 significant	 recruitment	 of	monocytes	 from	 the	bone	marrow,	 it	was	of	 interest	to	determine	how	the	disease	course	may	be	modulated	by	 the	 combined	 action	 of	 WNV	 and	 clodronate	 depletion	 on	 the	 bone	 marrow	 and	specifically	 the	 production	 of	 Ly6Chi	 monocytes.	 It	 is	 clear	 that	 both	 of	 these	 scenarios	place	 immense	 pressure	 on	 the	 bone	marrow	 to	 replace	monocytes.	 Our	 first	 objective	with	clodronate	depletion	was	 to	determine	how	the	depletion	of	circulatory	monocytes	would	affect	WNV	disease	course	and	mortality	rates.		Secondly,	 we	 wished	 to	 determine	 the	 therapeutic	 efficacy	 of	 IMP	 treatment	 following	clodronate	depletion,	after	ablation	of	MARCO+	marginal	zone	macrophages	in	the	spleen.	In	Chapter	4	our	 results	 illustrated	 that	 the	 spleen	not	only	has	 an	 impact	on	 leukocyte	trafficking	to	the	CNS,	but	also	contributes	significantly	to	the	efficacy	of	IMP	treatment..	Furthermore,	our	laboratory	has	shown	that	IMP	and/or	IMP-associated	cells	concentrate	in	 the	 MARCO+	 marginal	 zone	 macrophages	 (Terry	 2012).	 As	 these	 marginal	 zone	macrophages	are	known	to	 take	up	nanoparticles	and	apoptosing	cells,	we	hypothesised	that	 they	 likely	phagocytose	 IMP	and/or	 IMP-associated	cells,	which	may	be	undergoing	apoptosis.	Indeed,	the	marginal	zone	macrophages	may	provide	an	ideal	environment	for	interactions	to	take	place	that	are	crucial	to	the	therapeutic	efficacy	of	IMP	treatment.		
5.2. Results	
5.2.1. Clodronate	depletion	and	WNV	infection	
Previous	studies	indicate	that	24-48	h	is	sufficient	to	completely	deplete	the	marginal	zone	macrophages	 in	 the	 spleen,	 following	 i.v.	 administration	 of	 clodronate	 liposomes	 (CLO)	(Naito	et	al.	1996).	Therefore,	 the	splenic	 response	was	dissected	at	various	 time-points	
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after	i.v.	clodronate	depletion.	We	focussed	on	immunofluorescent	staining,	as	MARCO	is	a	particularly	difficult	antigen	to	detect	by	flow	cytometry.	Adult	C57BL/6	female	mice	were	given	 i.v.	 injection	of	CLO	and	 the	spleen	was	processed	 for	 IHC	14,	48	and	72h	 later,	 in	order	 to	 determine	 at	 what	 time-point	 the	 majority	 of	 MARCO+	 marginal	 zone	macrophages	were	 depleted.	 Figure	 5.1	 A	 shows	 the	 representative	 immunofluorescent	staining	 for	 the	 F4/80+	 red	 pulp	 macrophages	 (green),	 MARCO+	 marginal	 zone	macrophages	(red)	and	nuclei	(DAPI-blue)	of	CLO-	and	PBS-	 injected	spleen.	A	reduction	in	the	marginal	zone	macrophages	occurs	as	early	as	14h	post-injection	of	CLO,	and	these	cells	 are	 mostly	 depleted	 by	 48h.	 By	 72h	 after	 i.v.	 CLO	 administration,	 there	 was	 no	positive	 staining	 for	MARCO	 in	 the	 spleen.	 Furthermore,	 a	 distinct	 reduction	 in	 F4/80+	cells,	 i.e.	the	red	pulp	macrophages,	was	evident	by	48h	and	these	cells	were	also	largely	depleted	by	72h	after	CLO	administration.		Based	on	the	above,	we	used	a	single	i.v.	dose	of	CLO	liposomes	at	d5	p.i.	in	WNV-infected	(i.n.)	 mice,	 given	 either	 LD100	 (6x104	PFU)	 or	 LD50	 (6x103	PFU)	 dose	 of	 virus	 (Figure	5.1B).	In	the	LD100	model	of	infection,	CLO	was	administered	when	mice	first	start	losing	weight	 (d5p.i.)	 and	 showing	 signs	 of	 leukocyte	 infiltration	 into	 the	 CNS,	 i.e.,	 when	 the	pathogenic	 action	 of	 Ly6Chi	 monocytes	 starts	 and	 where	 any	 response	 to	 intervention	would	be	most	obvious.	
5.2.2. CNS	 leukocyte	 infiltration	 in	 the	 CNS	 of	 WNV-infected	 mice	
following	CLO	depletion	
Studies	suggest	 that	 i.v.	CLO	depletes	monocytes	 in	 the	circulation,	but	 these	are	rapidly	replaced	by	the	bone	marrow	in	higher	numbers	than	before	(Yamamoto	et	al.	1996).	This,	so-called	 ‘left	 shift’,	 induced	 in	 the	 bone	 marrow,	 is	 similar	 to	 that	 seen	 in	 WNV	encephalitis,	as	the	recruitment	of	monocytes	to	the	CNS	places	immense	pressure	on	the	
	Figure	 5.1	 Depletion	 of	 MARCO+	 marginal	 zone	 macrophages	 with	 clodronate	
liposomes	
		Panel	 A	 demonstrates	 the	 representative	 immunofluorescent	 staining	 for	MARCO+	 (red)	marginal	 zone	 macrophages	 and	 F4/80+	 (green)	 red	 pulp	 macrophages,	 with	 nuclei	stained	with	DAPI	(blue)	in	a	splenic	cross-section	of	naïve	mice	14,	48	and	72h	after	i.v.	clodronate	 (CLO)	depletion,	 compared	 to	 control	 spleen.	Panel	B	 illustrates	 the	protocol	followed	 for	 CLO	depletion	 of	WNV	and	mock-infected	mice.	Mice	were	mock-	 or	WNV-infected,	WNV	 infection	was	 administered	 at	 either	 LD50	 (6x103	PFU)	 or	 LD100	 (6x104	PFU)	dose	and	CLO	 liposomes	or	vehicle	 treatment	administered	at	d5	p.i.	Mice	 infected	with	the	LD100	dose	of	virus	were	culled	at	d7p.i.	and	tissue	collected	for	processing.		 	
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bone	 marrow	 for	 an	 increased	 supply	 of	 monocytes.	 Therefore,	 it	 was	 of	 interest	 to	determine	how	the	combined	actions	of	CNS	infection	and	CLO	depletion	affected	the	CNS	leukocyte	infiltration	and	immunopathology.		CLO	depletion	at	d5	p.i.	 in	mice	infected	with	lethal	dose	of	WNV	(6x104	PFU)	resulted	in	significantly	reduced	total	leukocyte	infiltration	into	the	CNS	at	d7p.i.,	compared	to	control	mice	(Figure	5.2	A	and	Figure	5.3	A).	Although	the	CLO-depleted	WNV-infected	cohort	still	had	 significant	 infiltration	 compared	 to	 mock-infected	 mice	 (grey),	 there	 was	 a	 stark	reduction	in	specific	leukocyte	subsets	relative	to	the	WNV-infected	control	group.	There	were	 negligible	 differences	 in	 the	 CNS	 leukocyte	 numbers	 of	 mock-infected	 mice	 given	CLO,	 compared	 to	 control	 mock-animals	 (data	 not	 shown),	 thus	 only	 control	 mock-infected	mice	are	included	in	these	graphs.		Notably,	 the	 Ly6Chi	 inflammatory	macrophages,	 as	 well	 as	 the	 Ly6C-	 resident	 microglia	were	 reduced	 in	 the	 CLO-depleted,	 WNV-infected	 cohort,	 whereas	 Ly6Cint	 cells	 were	comparable	 between	 control	 and	 CLO-depleted	 mice	 (Figure	 5.2A).	 The	 reduction	 in	Ly6Chi	 inflammatory	 macrophage	 numbers	 was	 likely	 due	 to	 the	 inability	 of	 the	 bone	marrow	to	keep	up	with	the	demand	for	these	cells	created	by	the	combined	action	of	CLO	depletion	 and	 WNV	 infection.	 The	 Ly6Cint	 microglial	 population	 in	 the	 CNS	 of	 WNV-infected	mice	 are	described	 as	 activated	microglia	 and	 are	 contributed	 to	 by	 infiltrating	Ly6Chi	monocytes,	which	downregulate	Ly6C	becoming	Ly6Cint	(Getts	et	al.	2008).	As	CLO	depletion	reduced	the	Ly6Chi	macrophage	population	in	the	CNS,	the	negligible	change	in	Ly6Cint	numbers	was	unexpected.	However,	it	may	be	that	a	higher	percentage	of	the	Ly6C-	resident	 microglia	 upregulated	 their	 Ly6C	 expression,	 becoming	 Ly6Cint,	 in	 order	 to	compensate	 for	the	dramatic	reduction	of	 infiltrating	monocytes.	This	would	account	 for	
Figure	5.2	Leukocyte	number	and	percentage	in	the	CNS	of	mock-	or	WNV-infected	
mice	following	single	or	daily	clodronate	depletion		Graph	A	shows	the	number	of	leukocytes	in	the	CNS	following	a	single	clodronate	(red)	or	control	 (blue)	 treatment	 at	d5p.i.	 of	WNV-infected	mice	 (6x104	PFU)	and	mock-(grey)	 at	d7	 p.i.	 Figure	 A	 demonstrates	 the	 total	 leukocyte	 number	 (CD45+)	 and	myeloid	 lineage	cells	 (CD11b+),	 including	 the	 resident	 microglia	 (CD45intCD11b+Ly6C-),	immigrant/activated	 microglia	 (CD45+CD11b+Ly6Cint)	 and	 inflammatory	 macrophages	(CD45+CD11b+Ly6Chi).	 Graph	 B	 demonstrates	 the	 percentage	 of	 myeloid	 lineage	 cells	(CD11b+),	 including	 the	 resident	 microglia	 (CD45intCD11b+Ly6C-),	 immigrant/activated	microglia	(CD45+CD11b+Ly6Cint)	and	inflammatory	macrophages	(CD45+CD11b+Ly6Chi)	in	the	CNS.	Data	 for	 figure	A	 and	B	 are	 the	mean	±SEM	of	 values	 from	3	 independent	 experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Figure	5.3	Leukocyte	number	and	percentage	in	the	of	mock-	or	WNV-infected	mice	
following	single-dose	(d5	p.i.)	and	daily	clodronate	depletion.	
	Graphs	A	and	B	show	the	numbers	and	percentages	of	cells	in	the	CNS	following	a	single	clodronate	(CLO)	(red)	or	vehicle	treatment	(blue)	at	d5p.i.	WNV-infected,	control	(6x104	PFU)	or	mock-infected	(grey)	mice	at	d7	p.i.	Graph	A	illustrates	the	number	of	neutrophils	(CD11bhiLy6G+Ly6Cint)	 and	 lymphoid	 lineage	 cells	 including	 T	 (CD3+),	 B	 (B220+/CD19+)	and	 NK	 (NK1.1+)	 cells	 in	 the	 CNS.	 Graph	 B	 illustrates	 the	 percentage	 of	 neutrophils	(CD11bhiLy6G+Ly6Cint)	 and	 lymphoid	 lineage	 cells,	 including	 T	 (CD3+),	 B	 (B220+/CD19+)	and	 NK	 (NK1.1+)	 cells	 in	 the	 CNS	 following	 CLO	 depletion	 at	 d5	 p.i.	 (expressed	 as	percentage	of	total	leukocytes).	Graph	 C	 demonstrates	 the	 number	 of	 leukocytes	 in	 the	 CNS	 following	 daily	 clodronate	depletion	 of	 mock-	 (grey)	 or	 CLO-depleted,	 WNV–infected	 (purple)	 and	 control,	 WNV-infected	(blue)	(6x104	PFU)	mice	at	d7	p.i.	Data	 for	 figures	A	and	B	are	 the	mean	±SEM	of	values	 from	3	 independent	experiments,	with	 2-4	 mice/group	 in	 each	 experiment.	 Data	 for	 figure	 C	 is	 the	 mean	 ±SEM	 of	 1	experiment	 with	 3-4	 mice/group.	 Statistical	 analysis	 was	 conducted	 using	 one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.			 	
Figure 5.3
# 
of
 L
eu
ko
cy
te
s/
br
ai
n 
(1
06
)
A
Mock WNV WNV + CLO
Total CD45+ CD3+  T 
cells
B220+ B
cells
NK1.1+ 
cells
Ly6G+
neutrophils
0
0.05
0.1
0.15
0.2
0.5
1.0
1.5
******
***
**
ns
******
***
******
***
*
B
Leukocyte number
Leukocyte percentage
0
5
10
15
20
25
50
75
100
***
***
***
*** ** ***
*
CD3+  T 
cells
B220+ B
cells
NK1.1+ 
cells
Ly6G+
neutrophils
%
 o
f L
eu
ko
cy
te
s/
br
ai
n
CNS leukocytes - CLO depletion (d5p.i. )
0
0.05
0.1
0.15
0.3
0.5
1.0
1.5 ***
**
*
*****
***
**
***
**
*
***
***
**
*
**
CNS leukocytes - CLO depletion (daily )
Ly6G+
neutrophils
CD3+  T 
cells
NK1.1+ 
cells
B220+ B
cells
Total CD45+ CD11b+
Ly6Chi
CD11b+
Ly6Cint
CD11b+
Ly6C-#
 o
f L
eu
ko
cy
te
s/
br
ai
n 
(1
06
)
C
Mock+CLO daily WNV+CLO dailyWNV
		 143	
the	reduction	in	Ly6C-	microglia	in	the	CNS	of	CLO-depleted	mice,	as	well	as	the	negligible	change	in	Ly6Cint	numbers	between	CLO-depleted	and	control	mice.			CLO	 depletion	 not	 only	 affected	 monocyte	 infiltration,	 but	 also	 significantly	 reduced	lymphoid	lineage	cell	infiltration	into	the	WNV-infected	CNS	at	d7p.i.	(Figure	5.3A).	These	included	 the	 number	 of	 total	 T,	 NK	 and	 B	 cells,	 however,	 except	 for	 the	 B	 cells,	 these	subsets	 were	 still	 present	 in	 significantly	 higher	 numbers	 compared	 to	 naïve	 mice.	Interestingly,	CLO	depletion	did	not	reduce	neutrophil	numbers	but	rather	increased	them	relative	to	WNV-infected	control,	but	this	was	not	significant.		The	 percentage	 distribution	 (Figure	 5.2B	 and	 Figure	 5.3B)	 of	 leukocytes	 infiltrating	 the	CNS	 of	 CLO-depleted,	WNV-infected	mice	was	 somewhat	modulated	 compared	 to	WNV-infected	 controls.	 Neutrophils	 were	 present	 in	 a	 significantly	 higher	 percentage	 in	 the	CLO-depleted	cohort	(Figure	5.3B),	whereas	the	percentage	of	NK	cells	(Figure	5.3B)	and	Ly6Chi	macrophages	(Figure	5.2B)	was	significantly	reduced,	relative	to	the	control	WNV-infected	 cohort.	 Nevertheless,	 the	 Ly6Chi	 macrophages	 remained	 the	 largest	 portion	 of	leukocyte	infiltrate	in	WNV-infected	mice	of	both	cohorts	(Figure	5.2B).		Although	the	number	and	percentage	of	Ly6Chi	inflammatory	macrophages	infiltrating	the	CNS	of	single-dose	CLO-depleted	mice,	was	markedly	reduced	compared	to	control	WNV-infected	 mice,	 it	 was	 still	 significantly	 high	 relative	 to	 the	 mock-infected	 cohort.	 We	reasoned	that,	if	a	single	dose	of	CLO	can	result	in	such	a	stark	reduction,	daily	injections	of	CLO	may	result	in	further	abrogation	of	the	Ly6Chi	macrophage	population	in	the	WNV-infected	 CNS	 (Figure	 5.3C).	 However,	 despite	 receiving	 daily	 injections	 of	 CLO,	 WNV-infected	mice	still	had	significant	infiltration	of	monocytes	into	the	CNS	at	d7	p.i.,	relative	to	naïve	mice.	Moreover,	 the	number	of	 cells	 infiltrating	 the	CNS	of	mice	 receiving	daily	
		 144	
CLO	injections	was	comparable	to	WNV-infected	mice	receiving	a	single	dose	of	CLO	at	d5	p.i.	This	indicates	that	the	bone	marrow	can	rapidly	replace	most	of	the	Ly6Chi	monocytes,	repeatedly	depleted	 from	circulation,	 for	an	extended	period	of	 time	 (i.e.	6	days)	during	infection	 of	 the	 CNS.	 The	 phenotypic	 markers	 we	 included	 in	 our	 analysis	(CD45+CD11b+Ly6Chi)	 indicated	 that	 the	 inflammatory	monocytes	produced	by	 the	bone	marrow	 after	 CLO	 depletion	were	 similar	 to	what	was	 being	 produced	 in	 control	mice.	However,	 future	additional	markers	may	specify	whether	or	not	 these	cells	vary	 in	 their	level	of	activation	or	maturity.	
5.2.3. Clinical	 outcome	 of	 WNV-infected	 mice	 following	 clodronate	
depletion	
Reduced	 numbers	 of	 pathogenic	 Ly6Chi	macrophages	 in	 the	WNV-infected	 CNS	has	 been	shown	to	correlate	with	 improved	disease	outcome	(Getts	et	al.	2012;	Getts	et	al.	2014).	Thus,	we	proceeded	to	establish	whether	the	significant	reduction	in	Ly6Chi	macrophages	in	 the	 CNS	 of	 CLO-depleted,	 WNV-infected	 mice	 might	 lead	 to	 an	 improved	 clinical	outcome.	 In	 contrast	 to	 what	 we	 have	 shown	 with	 IMP-induced	 reduction	 of	 Ly6Chi	inflammatory	 macrophages,	 the	 significant	 reduction	 in	 this	 subset	 following	 CLO-depletion	of	WNV-infected	mice	did	not	reduce	mortality	in	the	sublethal	dose	of	infection	(6x103	PFU)	 (Figure-5.4A).	 Indeed,	 in	 the	 lethal	 model	 of	 infection	 (6x104	PFU),	 CLO-depleted	mice	had	 similar	patterns	of	weight	 loss	 (Figure	5.4B)	 and	 comparable	 clinical	scores	(Figure	5.4C)	at	d7	p.i.	compared	to	their	WNV-infected	control	cohort.		Thus,	 although	 the	 absolute	 number	 of	 Ly6Chi	 inflammatory	macrophages	 in	 the	 CNS	 of	CLO-depleted	mice	reduced	significantly,	it	did	not	translate	to	improved	clinical	outcome.	This	 could	 indicate	 that	 the	 Ly6Chi	 inflammatory	 macrophages,	 induced	 from	 the	 bone	marrow	following	CLO	depletion,	differs	in	their	pathogenic	nature	i.e.	are	more	activated	
Figure	 5.4	 The	 clinical	 outcome	 of	 mock-	 or	WNV-infected	 mice	 following	 single-
dose	clodronate	depletion	at	d5	p.i.			Graph	 A	 demonstrates	 the	 percentage	 survival	 of	mock-infected	 (black);	mock-infected,	CLO-treated	 (grey);	WNV-infected,	 CLO-treated	 (red)	 and	WNV-infected,	 vehicle-treated	(blue)	 mice,	 following	 infection	 with	 a	 sublethal	 dose	 of	 WNV	 (6x103	PFU).	 Graph	 B	represents	 the	 average	 percentage	 weight	 loss,	 compared	 to	 original	 weight,	 of	 mock-	(grey)	 and	WNV-infected,	 control	 (blue)	 versus	WNV-infected,	 CLO-depleted	 (red)	 mice	following	lethal	WNV	infection	(6x104	PFU),	from	d0-7	p.i.	Graph	C	compares	the	average	clinical	 score	of	WNV-infected	 (6x104	PFU),	CLO-depleted	 (red)	or	 control	 (blue)	 treated	mice	at	d7	p.i.		The	 survival	 study	 was	 performed	 in	 3	 separate	 experiments	 with	 25-28	 mice/group.	Survival	data	(A)	was	grouped	and	graphed	 in	a	Kaplan-Meier	survival	curve	and	a	Log-rank	 test	was	used	 to	determine	statistical	significance.	The	weight	 loss	graph	(B)	 is	 the	mean	±SEM	of	3-4	mice/group	from	one	experiment.	Statistical	analysis	 for	graph	B	was	conducted	using	a	one-way	ANOVA	with	a	Dunnet’s	multiple	comparison	post-test	(d0	as	control).	 Clinical	 score	 data	 (C)	 is	 the	 mean	 ±SEM	 of	 values	 from	 3	 independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	for	figure	C	was	conducted	using	an	unpaired,	two	tailed	T-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	
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or	 immature	 than	 in	 control	mice.	 It	may	 be	 that	 CLO	 depletion	 exhausts	 the	 supply	 of	mature	monocytes	from	circulation,	inducing	the	release	of	highly	activated	and	immature	monocytes	 into	circulation	to	offset	the	effect	of	depletion	and	infection.	Therefore,	even	though	 there	 are	 decreased	 numbers	 of	 Ly6Chi	inflammatory	 macrophages	 in	 the	 CLO-depleted	WNV-infected	CNS,	the	Ly6Chi	cells	which	are	present	could	be	more	neuropathic,	abrogating	the	beneficial	effect	that	the	reduction	in	this	subset	may	otherwise	have	had.	
5.2.3.1. Leukocyte	numbers	 in	 the	spleen	 following	CLO-depletion	of	WNV-infected	
mice	
Intravenous	clodronate	depletion	is	characterised	by	distinct	changes	in	splenic	leukocyte	populations.	 Although	 macrophages,	 in	 particular	 the	 marginal	 zone	 and	 red	 pulp	macrophages,	are	the	primary	target	of	clodronate-encapsulated	liposomes,	other	splenic	leukocyte	subsets,	 such	as	 the	marginal	 zone	 lymphocytes	and	white	pulp	macrophages,	are	also	affected.	Although	these	subsets	are	not	completely	abolished,	they	do	reduce	in	number	and	phagocytic	activity	(van	Rooijen	and	van	Nieuwmegen	1984;	van	Rooijen	et	al.	1985;	van	Rooijen	et	al.	1989).	As	previous	work	from	our	lab	has	shown,	IMP	or	IMP+	cells	specifically	localise	in	the	marginal	zone	of	the	spleen	(Getts	et	al.	2014;	Terry	2012).	Therefore,	in	order	to	determine	how	CLO-depletion	would	affect	splenic	IMP	uptake,	we	needed	 to	 establish	 the	 baseline	 changes	 occurring	 in	 the	 splenic	 leukocyte	 populations	after	CLO	depletion	of	WNV-infected	mice	without	 IMP	treatment.	Since	single-dose	CLO	depletion	 produced	 similar	 outcomes	 to	 the	 daily	 CLO	 depletion	 regime,	 we	 used	 the	single-dose	depletion	approach	in	these	experiments,	as	shown	in	Figure	5.1	B.	As	 shown	 by	 the	 immunofluorescence	 staining	 in	 Figure	 5.1	 A,	 MARCO+	 cells	 were	completely	 abrogated	 by	 single-dose	 CLO	 depletion,	 within	 48h.	 Therefore,	 in	 these	experiments,	 FACS	 analysis	 focusing	 on	 changes	 in	 other	 leukocyte	 subsets	 was	
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conducted,	rather	than	trying	to	reconfirm	MARCO	expression,	considering	the	difficulties	in	identifying	MARCO	by	flow	cytometry.		As	mentioned	previously,	the	lymphocyte	populations	in	the	spleen	may	also	be	reduced	with	CLO	depletion	and	while	this	was	evident	in	our	data,	the	trend	for	B	and	T	cells	to	decrease,	 but	 this	 was	 not	 statistically	 significant,	 in	 CLO-depleted,	 mock-	 and	 WNV-infected	mice	(Figure	5.5A).	In	addition,	the	percentage	of	B	cells	in	the	spleen	significantly	increased	in	WNV-infected,	CLO-depleted	mice	as	a	consequence	of	the	depletion	of	other	cells	(Figure	5.5B).			As	expected,	single-dose	CLO	depletion	of	mock-	and	WNV-infected	mice	had	the	biggest	impact	on	the	F4/80+	red	pulp	macrophages.	Numbers	of	F4/80+	cells	were	reduced	to	less	than	3%	of	the	control	numbers		(Figure	5.6A),	with	the	percentage	reducing	to	<1%	of	the	total	 leukocyte	 population	 (Figure	 5.6B).	 In	 addition,	 the	DC	 subsets	 in	 the	 spleen	were	significantly	 decreased	 with	 CLO	 depletion.	 The	 CD11c+CD11b+	 subset	 of	 CLO-depleted	spleen	reduced	in	number	(Figure	5.6A)	and	percentage	(Figure	5.6B)	in	both	mock-	and	WNV-infected	mice,	 relative	 to	 their	 control-treated	 cohorts.	 Similarly,	 numbers	 (Figure	5.6A)	 of	 pDC	 in	 WNV-infected,	 CLO-treated	 mice	 decreased	 significantly.	 The	representative	 flow	 cytometry	 contour	 plots	 (Figure	 5.8B)	 demonstrate	 the	 stark	reduction	 in	 F4/80+	 and	 CD11c+	population	 in	 the	 WNV-infected,	 CLO-depleted	 spleen	compared	 to	 the	WNV-infected,	 control	 spleen.	 Additionally,	 Figure	 5.8	 A	 illustrates	 the	modulation	of	the	neutrophil	population	in	the	spleen	following	CLO	depletion.	Indeed,	the	percentage	 of	 neutrophils	 in	 the	 spleen	 increased	 significantly	 in	 WNV-infected,	 CLO-depleted	mice	(Figure	5.6B).	While,	this	is	 likely	to	be	due	to	the	decrease	in	numbers	of	other	 leukocyte	 subsets	 as	 a	 consequence	of	 depletion,	 it	 is	 also	possible	 that	 increased	neutrophil	 numbers	 are	 a	 result	 of	 bone	marrow	 responses	 in	 this	 cell	 lineage	 (Figure	5.6A).	
Figure	 5.5	 Leukocyte	 numbers	 in	 the	 spleen	 of	 mock-	 or	 WNV-infected	 mice	
following	clodronate	depletion	at	d5	p.i.	
	Graphs	 A	 and	 B	 represent	 the	 numbers	 and	 percentages	 of	 leukocytes	 in	 the	 spleen	 of	(6x104	PFU)	 WNV-infected,	 vehicle-treated	 (blue)	 or	 WNV-infected,	 CLO-depleted	 (red)	and	 mock-infected,	 vehicle-treated	 (dark	 grey)	 or	 mock-infected,	 CLO-depleted	 (light	grey)	mice	at	d7	p.i.	Figure	A	demonstrates	the	change	in	numbers	of	B	(B220+CD11c-),	T	(CD3+NK1.1-),	 NK	 (NK1.1+CD3-)	 and	 NKT	 (CD3+NK1.1+)	 cells	 following	 clodronate	depletion.	 Graph	 B	 demonstrates	 the	 change	 in	 percentage	 of	 B	 (B220+CD11c-),	 T	(CD3+NK1.1-),	 NK	 (NK1.1+CD3-)	 and	 NKT	 (CD3+NK1.1+)	 cells	 in	 the	 spleen	 following	clodronate	(CLO)	depletion.	Percentages	of	various	subsets	are	expressed	as	a	percentage	of	total	leukocytes	in	the	spleen	of	each	cohort.	Data	are	the	mean	±SEM	of	values	from	3	independent	 experiments,	 with	 2-4	 mice/group	 in	 each	 experiment.	 Statistical	 analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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Figure	 5.6	 Leukocyte	 distribution	 in	 the	 spleen	 of	 mock-	 or	 WNV-infected	 mice	
following	clodronate	depletion	at	d5	p.i.	
	
	Graphs	 A	 and	 B	 represent	 the	 numbers	 and	 percentages	 of	 various	 leukocytes	 in	 the	spleen	 of	 (6x104	 PFU)	 WNV-infected,	 vehicle-treated	 (blue)	 or	 WNV-infected,	 CLO-depleted	 (red)	 and	 mock-infected,	 vehicle-treated	 (dark	 grey)	 or	 mock-infected,	 CLO-depleted	 (light	 grey)	 mice	 at	 d7	 p.i.	 Graph	 A	 shows	 the	 depletion	 of	 the	 red	 pulp	macrophages	 (F4/80+CD11cint)	 and	 various	 DC	 subsets	 in	 the	 spleen	 including	CD11c+CD11b+,	 CD11c+CD11b-	and	 pDC	 (CD11c+B220-).	 It	 also	 illustrates	 the	 change	 in	neutrophil	numbers	(Ly6G+	CD11bhiLy6Cint).	Graph	B	shows	the	percentage	change	of	the	red	 pulp	macrophages	 (F4/80+CD11cint)	 and	 various	DC	 subsets	 in	 the	 spleen	 including	CD11c+CD11b+,	 CD11c+CD11b-,	 pDC	 (CD11c+B220-)	 and	 neutrophils	 (Ly6G+	CD11bhiLy6Cint)	 following	 clodronate	 depletion.	 Percentages	 of	 various	 subsets	 are	expressed	 as	 a	 percentage	 of	 total	 leukocytes	 in	 the	 spleen	of	 each	 cohort.	Data	 are	 the	mean	 ±SEM	 of	 values	 from	 3	 independent	 experiments,	 with	 2-4	 mice/group	 in	 each	experiment.	 Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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The	 monocyte	 populations	 in	 the	 spleen	 had	 no	 significant	 changes	 in	 number	 (Figure	5.7A)	or	percentage	(Figure	5.7B)	and	remained	more	or	 less	comparable	between	all	of	the	cohorts	analysed.	This	could	be	because	of	the	spread	of	replacement	of	these	subsets	by	the	bone	marrow,	over	the	time	from	ablation	to	analysis	in	this	model.		
5.2.4. Leukocyte	numbers	in	the	bone	marrow	following	CLO-depletion	
of	WNV-infected	mice	
Since	both	CLO	depletion	and	WNV	infection	likely	increases	bone	marrow	production	of	Ly6Chi	monocytes,	 the	 combined	 action	 of	 CLO	 and	 WNV	 on	 the	 bone	 marrow	 might	change	 the	 leukocyte	 content.	 However,	 although	 there	 was	 a	 slight	 increase	 in	 the	percentage	 of	 Ly6Chi	monocytes	 in	 the	 bone	marrow	 of	 CLO-depleted	mock-	 and	WNV-infected	 mice,	 this	 was	 not	 statistically	 significant	 (Figure	 5.9B).	 The	 only	 noticeable	change	 in	 the	 bone	 marrow,	 following	 CLO	 depletion	 of	 WNV-infected	 mice,	 was	 the	significant	reduction	in	F4/80+	stromal	macrophage	number	(Figure	5.9A)	and	percentage	(Figure	 5.9B	 and	 Figure	 5.9C).	 Therefore,	 despite	 the	 dramatic	 change	 found	within	 the	CNS	and	splenic	leukocyte	content,	CLO	depletion	had	little	effect	on	the	bone	marrow	cell	numbers,	other	than	depleting	the	stromal	macrophages.	Nevertheless,	these	data	do	not	allow	us	to	comment	on	any	proliferative	changes	or	modulation	of	precursor	populations,	which	may	occur	as	a	result	of	CLO	depletion.	
5.2.5. Therapeutic	 efficacy	 of	 IMP	 following	 clodronate	 depletion	 of	
WNV-infected	mice	
Having	determined	the	baseline	parameters	for	the	depletion	of	circulatory	macrophages	by	 CLO	 during	 WNV	 encephalitis,	 we	 wanted	 to	 test	 the	 therapeutic	 efficacy	 of	 IMP	
Figure	 5.7	 Leukocyte	 distribution	 in	 the	 spleen	 of	 mock-	 or	 WNV-infected	 mice	
following	clodronate	depletion	at	d5	p.i.	
	
	Graphs	 A	 and	 B	 represent	 the	 numbers	 and	 percentages	 of	 various	 leukocytes	 in	 the	spleen	 of	 (6x104	 PFU)	 WNV-infected,	 vehicle-treated	 (blue)	 or	 WNV-infected,	 CLO-depleted	 (red)	 and	 mock-infected,	 vehicle-treated	 (dark	 grey)	 or	 mock-infected,	 CLO-depleted	 (light	 grey)	 mice	 at	 d7	 p.i.	 Graph	 A	 demonstrates	 the	 number	 of	 monocytes	(CD11b+CD11c-),	 including	Ly6Chi,	Ly6Cint	and	Ly6C-	cells,	 following	clodronate	depletion.	Graph	 B	 demonstrates	 the	 percentage	 of	 monocytes	 (CD11b+CD11c-),	 including	 Ly6Chi,	Ly6Cint	and	Ly6C-	cells,	in	the	spleen	following	clodronate	depletion.	Percentages	 of	 various	 subsets	 are	 expressed	 as	 a	 percentage	 of	 total	 leukocytes	 in	 the	spleen	of	each	cohort.	Data	are	the	mean	±SEM	of	values	from	3	independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Figure	5.8	Clodronate	depletion	in	the	spleen	following	lethal	WNV	infection	
	Panels	 A	 and	 B	 are	 representative	 flow	 cytometry	 contour	 plots	 (10,	 000	 evts)	 of	 the	spleen	following	clodronate	depletion	(d5	p.i.)	of	WNV-infected	mice	(6x104	PFU)	at	d7p.i.	Panel	 A	 illustrates	 the	 percentage	 increase	 of	 splenic	 neutrophils	 following	 clodronate	depletion.	 Panel	 B	 demonstrates	 the	 depletion	 of	 the	 red	 pulp	 macrophages	(F4/80+CD11cint)	 and	 total	 DC	 population	 (CD11c+)	 in	 the	 spleen	 following	 clodronate	depletion	(d5	p.i.).	Both	panels	show	the	outliers	of	the	contour	plots	in	order	to	visualise	low	frequency	data,	such	as	 the	DC	and	macrophage	populations	described	 in	this	graph	(WNV+CLO).		 	
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Figure	 5.9	 Leukocyte	 numbers	 and	 percentage	 in	 the	 bone	 marrow	 of	 mock-	 or	
WNV-infected	mice	following	clodronate	depletion	at	d5	p.i.		Figure	 5.9	 represents	 the	 numbers	 (A)	 and	percentages	 change	 (B)	 of	 leukocytes	 in	 the	bone	marrow	of	(6x104	PFU)	WNV-infected,	vehicle-treated	(blue)	or	WNV-infected,	CLO-depleted	 (red)	 and	 mock-infected,	 vehicle-treated	 (dark	 grey)	 or	 mock-infected,	 CLO-depleted	(light	grey)	mice	at	d7	p.i.	Graph	A	demonstrates	the	change	in	numbers	of	B	cells	(B220+CD11c-),	 neutrophils	 (Ly6G+	CD11bhiLy6Cint),	 monocyte	 subsets	 (CD11b+CD11c-),	including	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	 cells,	 stromal	 macrophages	 (F4/80+CD11cint),	 DC	(CD11c+)	and	T	cells	(CD3+)	at	d7	p.i.	Graph	B	shows	the	percentage	of	these	cells	 in	the	bone	marrow.	 Panel	 C	 shows	 the	 representative	 flow	 cytometry	 contour	 plots	 (10,	 000	evts)	of	 the	bone	marrow	 following	 clodronate	depletion	 (d5	p.i.)	 of	WNV-infected	mice	(6x104	 PFU),	 demonstrating	 the	 depletion	 of	 stromal	 macrophages	 (F4/80+CD11cint).	Percentages	 of	 various	 subsets	 are	 expressed	 as	 a	 percentage	 of	 total	 leukocytes	 in	 the	bone	 marrow	 of	 each	 cohort.	 Data	 for	 figures	 A-B	 is	 the	 mean	 ±SEM	 of	 values	 from	 3	independent	 experiments,	 with	 2-4	 mice/group	 in	 each	 experiment.	 Statistical	 analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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following	the	depletion	of	the	MARCO+	marginal	zone	macrophages.	As	outlined	in	Figure	5.10A,	we	infected	adult	female	C57BL/6	mice	with	either	an	LD50	(6x103	PFU)	or	LD100	(6x104	PFU)	dose	of	WNV	and	gave	a	 single	 i.v.	dose	of	CLO	at	d5	p.i.	Thereafter,	LD100	mice	were	treated	i.v.	with	IMP	at	d6	p.i.,	whereas	mice	infected	with	the	sublethal	LD50	dose	 of	 WNV	 were	 treated	 with	 IMP	 once	 they	 had	 lost	 5%	 or	 more	 of	 their	 original	weight.		Figure	5.10	B	and	Figure	5.11	A	shows	the	number	of	leukocytes	infiltrating	the	CNS	on	d7	p.i.	 of	 mock-	 and	 WNV-infected,	 CLO-depleted	 given	 either	 vehicle	 or	 IMP	 treatment.	Figure	 5.10	C	 and	 Figure	 5.11	B	 demonstrates	 the	 number	 of	 leukocytes	 infiltrating	 the	CNS	 on	 d7	 p.i.	 of	 mock-	 and	 WNV-infected	 control	 mice	 given	 either	 vehicle	 or	 IMP	treatment.	 Interestingly,	 similar	 to	 control	 mice	 (Figure	 5.10C),	 IMP	 treatment	significantly	 reduced	 the	 pathogenic	 Ly6Chi	inflammatory	monocytes	 in	 the	 CNS	 of	 CLO-depleted	mice	 (Figure	5.10B),	 compared	 to	 the	 vehicle-treated	 cohort.	 The	number	 of	 T	cells	in	the	CNS	of	CLO-depleted	mice	was	also	reduced	by	IMP	treatment	(Figure	5.11A).	However,	 neutrophils,	 Ly6Cint,	 B	 and	 NK	 cells	 remained	 comparable	 between	 IMP-	 and	vehicle-treated,	WNV-infected,	CLO-depleted	mice	at	d7	p.i.			Considering	 the	 pre-existing	 reduction	 of	 Ly6Chi	 inflammatory	 macrophage	 numbers	 in	CLO-depleted	compared	to	control	mice,	we	hypothesised	that	the	additional	decrease	of	this	 subset,	 as	 a	 result	 of	 IMP	 treatment,	might	 improve	 survival	 of	WNV-infected	mice	given	 a	 sublethal	 dose	 of	 infection.	 CLO-depleted,	 WNV-infected	 and	 control,	 WNV-infected	 mice	 that	 did	 not	 lose	 a	 significant	 amount	 of	 weight	 did	 not	 receive	 any	treatment	 nor	 did	 any	 succumb	 from	 disease.	 Furthermore,	 CLO-depleted	 mice	 treated	with	 IMP	 had	 significantly	 improved	 survival	 outcome	 compared	 to	 their	 CLO-depleted,	vehicle-treated	 counterparts	 (Figure	 5.11C).	 Control	WNV-infected,	 IMP-treated	 animals	(non-CLO-depleted)	may	 have	 derived	more	 benefit	 from	 IMP	 treatment,	 as	 survival	 of	
Figure	 5.10	 IMP	 treatment	 of	 clodronate-depleted	 versus	 vehicle-treated	 mice	
following	WNV	infection		Panel	 A	 illustrates	 the	 protocol	 followed	 for	 IMP	 treatment	 (d6p.i-LD100	 or	 >5%WL-LD50)	 and	 clodronate	 depletion	 (d5	 p.i.)	 of	 WNV	 (LD50	 or	 LD100)	 and	 mock-infected	mice.	Graph	B	demonstrates	the	effect	of	IMP	treatment	on	leukocyte	numbers	in	the	CNS	of	mock-infected,	CLO-depleted	(grey),	WNV-infected,	CLO-depleted,	vehicle-treated	(red)	and	 WNV-infected,	 CLO-depleted,	 IMP-treated	 (orange)	 mice	 at	 d7	 p.i.,	 following	 WNV	LD100	 infection	 (6x104	 PFU).	 Graph	 C	 demonstrates	 the	 effect	 of	 IMP	 treatment	 on	leukocyte	numbers	in	the	CNS	of	mock-infected	control	(dark	grey),	WNV-infected	control,	vehicle-treated	(dark	blue)	and	WNV-infected	control,	IMP-treated	(light	blue)	mice	at	d7	p.i.,	following	WNV	LD100	infection	(6x104	PFU).	Graphs	B	and	C	show	the	myeloid	lineage	cells,	 including	 the	 resident	 microglia	 (CD45+CD11b+Ly6C-),	 immigrant/activated	microglia	(CD45+CD11b+Ly6Cint)	and	inflammatory	macrophages	(CD45+CD11b+Ly6Chi)	at	d7	p.i.	Data	for	graphs	B-C	are	the	mean	±SEM	of	values	from	3	independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.				 	
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Figure	 5.11	 IMP	 treatment	 of	 clodronate-depleted	 versus	 vehicle-treated	 mice	
following	WNV	infection		Graph	 A	 demonstrates	 the	 effect	 of	 IMP	 treatment	 on	 leukocyte	 numbers	 in	 the	 CNS	 of	mock-infected,	 CLO-depleted	 (grey),	 WNV-infected,	 CLO-depleted,	 vehicle-treated	 (red)	and	 WNV-infected,	 CLO-depleted,	 IMP-treated	 (orange)	 mice	 at	 d7	 p.i.,	 following	 WNV	LD100	 infection	 (6x104	 PFU).	 Graph	 B	 demonstrates	 the	 effect	 of	 IMP	 treatment	 on	leukocyte	numbers	in	the	CNS	of	mock-infected	control	(dark	grey),	WNV-infected	control	(dark	blue)	and	WNV-infected	 control,	 IMP-treated	 (light	blue)	mice	at	d7	p.i.,	 following	WNV	LD100	 infection	 (6x104	PFU).	Graphs	A	 and	B	 illustrate	 the	number	of	 neutrophils	(CD11bhiLy6G+Ly6Cint)	 and	 lymphoid	 lineage	 cells	 including	 T	 (CD3+),	 B	 (B220+/CD19+)	and	 NK	 (NK1.1+)	cells	 at	 d7p.i.	 Graph	 C	 compares	 the	 percentage	 survival	 of	 the	WNV-infected,	 CLO-depleted	 (red)	 and	 WNV-infected,	 vehicle-treated	 (dark	 blue)	 mice,	 with	their	 IMP-treated	 cohorts	 namely	 WNV-infected,	 IMP-treated	 (light	 blue)	 and	 WNV-infected,	CLO-depleted,	IMP-treated	(orange)	following	infection	with	a	sublethal	dose	of	WNV	(6x103	PFU).	The	graph	includes	a	no	weight	loss	(WL)	cohort	i.e.	weight	loss	of	<5%	(black)	that	received	no	treatment.	Data	for	graphs	A	and	B	are	the	mean	±SEM	of	values	from	 3	 independent	 experiments,	 with	 2-4	 mice/group	 in	 each	 experiment.	 Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	 and	 P≤0.05*;	 P≤0.01**;	 P≤0.001***.	 The	 survival	 study	 (C)	 was	 performed	 in	 3	separate	experiments	with	10-14	mice/group.	Survival	data	(C)	was	grouped	and	graphed	in	 a	 Kaplan-Meier	 survival	 curve	 and	 a	 Log-rank	 test	 was	 used	 to	 determine	 statistical	significance.		 	
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this	 cohort	 was	 slightly	 better	 than	 their	 WNV-infected,	 CLO-depleted,	 IMP-treated	counterparts.	Irrespective,	IMP	treatment	significantly	improved	survival	of	CLO-depleted	mice.	It	may	be,	in	the	absence	of	the	spleen,	that	other	organs,	such	as	the	liver,	with	high	numbers	of	replenished	macrophages	after	single-dose	CLO	depletion,	can	compensate	for	the	absence	of	the	marginal	zone	macrophages	in	the	spleen	as	an	environment	for	IMP-containing	 or	 IMP-associated	 cells	 undergoing	 apoptosis	 to	 be	 phagocytosed.	Nevertheless,	 this	 proves	 that	 the	 efficacy	 of	 IMP	 treatment	 is	 not	 solely	 reliant	 on	 the	presence	of	MARCO+	marginal	zone	macrophages	in	the	spleen.		
5.2.6. Distribution	of	IMP+	leukocytes	in	the	CNS	of	WNV-infected	mice	
following	clodronate	depletion	
Following	i.v.	IMP	treatment	of	control	mice	there	are	very	few,	if	any,	IMP+	leukocytes	in	the	 CNS	 of	 mock-	 or	 WNV-infected	 mice.	 Thus,	 it	 was	 of	 interest	 to	 discover	 that	 a	significant	 number	 of	 leukocytes	 infiltrating	 the	 CNS	 of	 CLO-depleted	 mice	 were	 IMP+	(Figure	 5.12A).	 These	 IMP+	leukocytes	 in	 the	 CNS	 of	 CLO-depleted,	 WNV-infected	 mice	consisted	 mainly	 of	 Ly6Chi	 inflammatory	 macrophages,	 Ly6Cint	 immigrant/activated	microglia	 and	 neutrophils.	 The	 representative	 flow	 cytometry	 plots	 in	 Figure	 5.12B	illustrate	 the	 presence	 of	 IMP+	cells,	 specifically	 in	 the	 IMP-treated,	WNV-infected,	 CLO-depleted	 cohort.	 Table	 5.1	 describes	 the	 percentage	 of	 each	 leukocyte	 subset	 that	 was	IMP+	 in	 the	CNS	of	mock-	and	WNV-infected	control	and	CLO-depleted	mice.	Of	 the	 total	leukocyte	population,	~10%	of	cells	were	IMP+	in	the	CLO-depleted,	WNV-infected	cohort,	compared	 to	 <1%	 in	 control,	WNV-infected	 and	 control-	 and	 CLO-treated	mock	 groups.	Furthermore,	~20%	of	neutrophils	and	~27%	of	Ly6Chi	inflammatory	macrophages	were	IMP+,	within	the	CLO-depleted,	WNV-infected,	IMP-treated	cohort	(Figure	5.12C	and	Table	5.1).	 This	 further	 indicates	 that	 clodronate-encapsulated	 liposomes	 not	 only	 remove	resident	and	circulatory	phagocytic	populations,	but	also	modulates	the	characteristics	of	
Figure	5.12	Number	and	distribution	of	 IMP+	 leukocytes	 in	 the	CNS	of	 clodronate-
depleted	versus	vehicle	treated	mice	following	lethal	WNV	infection	
		Graph	A	demonstrates	 the	number	of	 IMP+	 leukocytes	 in	 the	CNS	of	WNV-infected,	 IMP-treated	(light	blue)	and	WNV-infected,	CLO-depleted,	IMP-treated	mice	at	d7	p.i.	IMP+	cells	in	 the	 CNS	 of	 both	 cohorts	 were	 mainly	 found	 associated	 with	 myeloid	 lineage	 cells	namely:	 immigrant/activated	 microglia	 (CD45+CD11b+Ly6Cint),	 inflammatory	macrophages	 (CD45+CD11b+Ly6Chi)	 and	 neutrophils	 (CD11bhiLy6G+Ly6Cint).	 Panel	 B	shows	the	representative	flow	cytometry	contour	plots	of	mock	and	WNV-infected	(6x104	PFU)	 CNS	 from	 CLO-depleted	 or	 vehicle-treated	 mice	 receiving	 IMP	 treatment.	 Panel	 C	continues	on	demonstrating	 flow	cytometry	 contour	plots	of	 the	 IMP	distribution	 in	 the	CNS	 of	 CLO-depleted,	 WNV-infected	 mice.	 Table	 5.1	 contains	 the	 combined	 percentage	values	 of	 each	 major	 leukocyte	 population	 that	 was	 IMP+	at	 d7	 p.i.,	 i.e.,	 an	 average	 of	10.42%	 of	 the	 total	 leukocyte	 population	 in	 the	 CNS	 of	 clodronate-depleted	 and	WNV-infected	mice	was	positive	for	IMP.		Data	for	graph	A	are	the	mean	±SEM	of	values	from	3	independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	Data	for	table	 5.1	 are	 the	 average	 percentage	 from	 3	 independent	 experiments,	 with	 2-4	mice/group	in	each	experiment.		 	
Figure 5.12
0.8% 12%0.98%1.39%
Vehicle-treated CLO-treated
Mock+IMP Mock+IMPWNV+IMP WNV+IMP
C
D
45
C
D
45
IMP(FITC)
IMP(FITC)
Ly
6G
27%
0.14%
5.8%
26.3%
Ly
6C
hi
int
lo
WNV+CLO-treated
CD11b+Ly6Cint
Other 1.88
8.48
3.80
1.01
WNV+IMP  
Average percentage of each population in the CNS that is IMP+ 
Cell type Vehicle-treated CLO-treated Mock+IMP  WNV+IMP  Mock+IMP  
Total CD45+ cells
Neutrophils
CD11b+Ly6Chi
0.69
0.45
2.77
0.92
1.47
1.14
0.76
1.06
8.67
4.47
5.97
10.42
2.97
20.10
4.16
26.71
A
B
C
# 
of
 IM
P+
 L
eu
ko
cy
te
s/
br
ai
n 
(x
10
4 )
0
1
2
3
4
Total CD45+ CD11bhiLy6G+
Neutrophils
CD11b+Ly6Chi
 cells
CD11b+Ly6Cint
cells
WNV+CLO+IMPWNV+IMP
Other cells
*
*
*
Number of IMP+ Leukocytes/Brain
Table 5.1 IMP positivity in the leukocyte populations of the CNS
		 150	
the	Ly6Chi	inflammatory	macrophages,	as	well	as	neutrophils,	as	these	cells	preferentially	phagocytose	 IMP	 and	 traffic	 to	 the	 CNS	 during	 WNV	 infection,	 as	 a	 consequence	 of	clodronate	 depletion,	 a	 phenomenon	 which	 is	 not	 found	 in	 WNV-infected,	 IMP-treated	control	animals.		
5.2.7. Splenic	 IMP+	 leukocyte	 content	 of	WNV-infected	mice	 following	
clodronate	depletion	
As	 the	 spleen	 and	 in	 particular	 the	 MARCO+	 marginal	 zone	 macrophages,	 evidently	sequester	IMP	and	IMP-associated	cells,	we	wanted	to	determine	what	the	distribution	of	these	IMP+	cells	would	be	in	the	absence	of	the	marginal	zone	and	red	pulp	macrophages,	due	 to	 clodronate	 depletion.	 Notably,	 despite	 the	 clodronate-induced	 reduction	 in	 total	splenic	 leukocyte	 number,	 shown	 in	 figure	 5.5,	 there	was	 an	 increase	 in	 the	 number	 of	IMP+	leukocytes	in	the	spleen	of	CLO-depleted	mice	relative	to	their	control,	WNV-infected,	IMP-treated	 counterparts	 (Figure	 5.13A).	 Moreover,	 the	 percentage	 of	 IMP+	CD45+	cells	was	 significantly	 higher	 in	 WNV-infected,	 CLO-depleted	 mice	 compared	 to	 their	 WNV-infected	 counterparts	 (Figure	 5.14A).	 Therefore,	 although	 the	 numbers	 of	 splenic	leukocytes	 are	 diminished	 by	 CLO	 depletion,	 evidently	 their	 ability	 to	 sequester	 and/or	their	affinity	for	IMP	or	IMP+	cells	is	increased.	Compared	to	the	control	mice,	there	were	significantly	higher	numbers	of	IMP+	B	cells	(Figure	5.13A),	neutrophils,	CD11c+CD11b-	DC	(Figure	 5.13B)	 and	 Ly6ChiCD11b+	 monocytes	 (Figure	 5.13C)	 in	 the	 spleen	 of	 the	 CLO-depleted,	WNV-infected	cohort	at	d7	p.i.		Clodronate	depletion	also	significantly	increased	the	percentage	of	B	and	NK	cells	(Figure	5.14A	and	Figure	5.15B	and	G)	 that	were	evidently	positive	 for	 IMP.	This	may	be	due	 to	increased	 IMP	 uptake	 in	 the	 spleen	 and/or	 IMP+	 cell	 sequestration	 being	 greater	 in	
Figure	5.13	IMP+	leukocytes	in	the	spleen	of	mock-	or	WNV-infected	mice	following	
clodronate	depletion	(d5	p.i.)	and	IMP	treatment		
		Graphs	A-C	 represents	 the	number	 of	 leukocytes	 that	were	 IMP+	in	 the	 spleen	of	 (6x104	PFU)	 WNV-infected,	 IMP-treated	 (blue)	 or	 WNV-infected,	 CLO-depleted,	 IMP-treated	(orange)	 and	 mock-infected,	 IMP-treated	 (dark	 grey)	 or	 mock-infected,	 CLO-depleted,	IMP-treated	 (light	 grey)	 mice	 at	 d7	 p.i.	 Graph	 A	 demonstrates	 the	 number	 of	 B	(B220+CD11c-),	 T	 (CD3+NK1.1-),	 NK	 (NK1.1+CD3-)	 and	 NKT	 (CD3+NK1.1+)	 cells	 in	 the	spleen	that	are	IMP+	following	CLO	depletion.	Graph	B	shows	the	number	of	the	red	pulp	macrophages	 (F4/80+CD11cint),	 neutrophils	 (Ly6G+	 CD11bhiLy6Cint)	 and	 various	 DC	subsets,	including	CD11c+CD11b+,	CD11c+CD11b-	and	pDC	(CD11c+B220-)	that	are	IMP+	in	the	spleen	following	CLO	depletion.	Graph	C	demonstrates	the	number	of	IMP+	monocytes	(CD11b+CD11c-),	 including	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	 cells,	 in	 the	 spleen	 following	 CLO	depletion.	 Data	 for	 graphs	 A-C	 are	 the	 mean	 ±SEM	 of	 values	 from	 3	 independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	 one-way	 ANOVA	 with	 a	 Tukey’s	 multiple	 comparison	 post-test,	 and	 P≤0.05*;	P≤0.01**;	P≤0.001***.		 	
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Figure	5.14	Percentage	of	each	leukocyte	population	in	the	spleen	that	is	IMP+	in	of	
mock-	 or	 WNV-infected	 mice	 following	 clodronate	 depletion	 (d5	 p.i.)	 and	 IMP	
treatment	at	d6	p.i.	
		Graphs	 A-C	 represents	 the	 percentage	 of	 each	 subset	 of	 leukocytes	 that	 are	 IMP+	in	 the	spleen	of	 (6x104	PFU)	WNV-infected,	 IMP-treated	 (blue)	 or	WNV-infected,	 CLO-depleted,	IMP-treated	(orange)	and	mock-infected,	IMP-treated	(dark	grey)	or	mock-infected,	CLO-depleted,	IMP-treated	(light	grey)	mice	at	d7	p.i.	Graph	A	demonstrates	the	percentage	of	B	 (B220+CD11c-),	 T	 (CD3+NK1.1-),	 NK	 (NK1.1+CD3-)	 and	 NKT	 (CD3+NK1.1+)	 cells	 in	 the	spleen	 that	 are	 IMP+	 following	CLO	depletion.	 Graph	B	 shows	 the	 percentage	 of	 the	 red	pulp	macrophages	 (F4/80+CD11cint),	 neutrophils	 (Ly6G+	CD11bhiLy6Cint)	 and	 various	 DC	subsets,	including	CD11c+CD11b+,	CD11c+CD11b-	and	pDC	(CD11c+B220-)	that	are	IMP+	in	the	 spleen	 following	 CLO	 depletion.	 Graph	 C	 demonstrates	 the	 percentage	 of	 IMP+	monocytes	 (CD11b+CD11c-),	 including	 Ly6Chi,	 Ly6Cint	 and	 Ly6C-	 cells,	 in	 the	 spleen	following	 CLO	 depletion.	 Data	 for	 panels	 A-C	 are	 the	 mean	 ±SEM	 of	 values	 from	 3	independent	 experiments,	 with	 2-4	 mice/group	 in	 each	 experiment.	 Statistical	 analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	
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Figure	5.15	Distribution	of	IMP+	leukocytes	in	the	spleen	of	clodronate-depleted	
versus	vehicle	treated	mice	following	lethal	WNV	infection			Panels	A-H	are	the	representative	flow	cytometry	plots	of	IMP	distribution	in	the	various	leukocyte	populations	of	the	spleen	of	control	(left)	and	CLO-depleted	(right	)	WNV-infected	mice	on	d7	p.i.	These	include	the	IMP	distribution	of	(A)	total	leukocytes	(CD45+);	(B)	B	cells	(CD45+CD19+);	(C)	neutrophils	(Ly6G+CD11bhiLy6Cint	);	(D)	monocytes	(CD11b+CD11c-);	(E)	CD11b-DC	(CD11c+CD11b-);	(F)	CD11b+DC	(CD11c+CD11b-);	(G)	NK	cells	(NK1.1+)	and	(H)	red	pulp	macrophages	(F4/80+CD11cint).	 	
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proportion,	 compared	 to	 the	 IMP-	 cell	 numbers	 following	 CLO	 depletion.	 Furthermore,	there	 was	 a	 significantly	 larger	 percentage	 of	 F4/80+	 red	 pulp	 macrophages	 and	 other	myeloid	subsets	that	were	IMP+	in	the	CLO-depleted,	IMP-treated	cohorts	(both	mock-	and	WNV-infected)	 (Figure	 5.14B	 and	 C).	 Figure	 5.15	 shows	 the	 comparison	 of	 IMP-treated	mice	±CLO	at	the	individual	level,	showing	markedly	increased	IMP+	cell	numbers	in	CLO-treated,	WNV-infected	mice,	 compared	 to	CLO-untreated.	Although	a	 large	proportion	of	these	subsets	were	depleted	by	clodronate	administration	(Figure	5.6B),	the	fact	that	such	large	percentages	of	these	subsets	were	IMP+	suggests	that	the	cells	that	remained	of	these	subsets	after	CLO	depletion	had	a	significant	affinity	 for	 IMP.	Another	noteworthy	result	was	 the	 increased	 percentage	 of	 neutrophils	 in	 both	 mock-	 and	 WNV-infected,	 CLO-depleted	mice	 that	were	 IMP+	(Figure	 5.14B	 and	 Figure	 5.15C).	 As	 very	 few	neutrophils	associate	 with	 IMP	 in	 control	 mice	 this	 supports	 data	 from	 the	 CNS	 (Figure	 5.12)	suggesting	 that	clodronate	depletion	not	only	resulted	 in	macrophage	depletion	but	also	altered	 the	 phagocytic	 activity	 of	 other	 myeloid	 lineage	 cells	 such	 as	 neutrophils	 that	normally	do	not	pick	up	IMP.	Furthermore,	the	percentage	of	Ly6Chi	and	Ly6Cint	monocytes	that	were	positive	for	IMP	also	increased	in	CLO-depleted	mice	(Figure	5.14C	and	Figure	5.15D).	 However,	 it	 should	 be	 noted	 again	 that	 CLO	 depletion,	 without	 infection,	 also	increased	the	percentage	of	IMP+	neutrophils	and	myeloid	lineage	cells.	The	abrogation	of	resident	 phagocytic	 subsets	 in	 the	 spleen	 with	 CLO	 depletion	 not	 only	 leads	 to	 higher	availability	 of	 IMP	 for	 possible	 phagocytosis	 by	 other	 leukocyte	 populations,	 but	 also	impacts	on	the	structural	organisation	of	the	spleen,	allowing	access	of	IMP	to	areas	which	would	 normally	 be	 bordered	 by	 the	 marginal	 zone	 and	 red	 pulp	 macrophages.	 As	 a	significant	 proportion	 of	 the	 phagocytic	 cells	 in	 the	 marginal	 zone	 and	 red	 pulp	 are	abolished	 by	 CLO	 depletion,	 it	 follows	 that	 other	 leukocytes	 that	 would	 not	 normally	associate	 with/phagocytose	 IMP	may	 be	 able	 to	 do	 so	 after	 CLO	 depletion.	 Indeed,	 the	
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absence	of	marginal	zone	cells	also	allows	access	of	IMP	further	into	the	spleen	including	the	white	pulp	with	the	B	cell	follicles	and	PALS.		Immunofluorescence	staining	showed	IMP+	cells	and/or	IMP	concentrated	in	the	marginal	zone	of	the	spleen,	surrounding	the	B	cell	follicles	and	PALS	of	control	WNV-infected	mice	(Figure	5.16A-C).	Indeed,	there	were	very	few	IMP	in	the	white	pulp	of	the	spleen	and	the	association	of	IMP	with	B	cells	only	occurred	at	the	border	of	the	marginal	zone	and	the	B	cell	follicles	in	control	spleen	sections,	with	very	few	T	cells	colocalising	with	IMP.	There	were	 some	 IMP	 in	 the	 red	 pulp,	 likely	 phagocytosed	 by	 the	 red	 pulp	macrophages,	 but	these	were	 less	 clustered	 and	more	 dispersed	 than	 those	 present	 in	 the	marginal	 zone.	Following	clodronate	depletion	however,	 it	was	clear	that	the	anatomy	of	the	spleen	had	been	 severely	 disrupted,	 leading	 to	 IMP	 being	 distributed	 in	 a	 much	 less	 organised	manner	 throughout	 the	 spleen	 (Figure	 5.16A-C).	 The	 distinct	 pattern	 of	 T	 cells,	surrounded	 by	 B	 cell	 staining	 and	 IMP	 localised	 within	 the	 marginal	 zone	 is	 highly	disrupted	in	CLO-depleted	splenic	sections.	In	contrast	to	the	tight	ring-like	distribution	of	IMP	in	the	marginal	zone	of	control	spleen,	CLO-depleted	spleen	sections	show	the	spread	of	 IMP	 in	a	much	more	diffuse	distribution.	Additionally,	 the	clodronate-depleted	spleen	had	 fewer	 clusters	 of	 IMP	 and	 IMP	 were	 distributed	 in	 smaller	 groups.	 The	 ring-like	distribution	of	 IMP	was	occasionally	evident	 in	 the	clodronate-depleted	spleen,	however	as	both	B	and	T	 cell	 staining	was	 less	defined	 than	 in	 control	mice	 it	was	hard	 to	 judge	where	anatomically	IMP	or	IMP+	cells	were	located	and	whether	IMP	were	internalized	or	merely	 attached	 to	 the	 cell	 surface.	 Nevertheless,	 in	 parallel	with	 IMP+	cell	 number	 and	percentage	data,	 the	 immunofluorescent	staining	 indicates	that	CLO-depleted	spleen	had	more	IMP+	cells	in	the	spleen	compared	to	control	mice.	
Figure	5.16	A-C	Distribution	of	IMP+	in	the	spleen	of	clodronate-depleted	versus	
control	mice	following	lethal	WNV	infection	
	
	Panels	A-C	are	the	representative	immunofluorescent	staining	for	B220	(red)	and/or	CD3	and	IMP	(green),	with	nuclei	stained	with	DAPI	(blue)	in	a	splenic	cross-section	of	WNV-infected,	IMP-treated	and	WNV-infected,	CLO-depleted,	IMP-treated	mice.	Mice	were	infected	with	LD50	dose	of	WNV	(6x103	PFU)	and	clodronate	liposomes	or	vehicle	treatment	administered	at	d5	p.i.	followed	by	IMP	treatment	when	>5%	WL	was	reached.	Spleen	was	collected	24-48	h	after	IMP	administration.			 	
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5.2.8. IMP+	 leukocyte	 content	 in	 the	 bone	 marrow	 of	 WNV-infected	
mice	following	clodronate	depletion		
Chapter	4	figure	4.17	shows	that	there	were	negligible	differences	in	the	number	of	IMP+	cells	 in	 the	 bone	 marrow	 of	 mice	 that	 have	 had	 their	 spleens	 removed,	 compared	 to	control	 animals.	 However,	 there	 was	 a	 remarkable	 presence	 of	 IMP+	 leukocytes	 in	 the	bone	marrow	of	either	mock-	or	WNV-infected,	CLO-depleted	mice.	 Indeed,	compared	to	control	 mice,	 there	 were	 significantly	 higher	 numbers	 of	 IMP+	neutrophils	 and	 Ly6Chi	monocytes	 in	 the	 bone	marrow	of	 CLO-depleted,	mock-	 and	WNV-infected	mice	 (Figure	5.17A).	Clodronate	depletion	had	mostly	depleted	the	F4/80+	stromal	macrophages	in	the	bone	 marrow	 and,	 as	 a	 consequence,	 there	 were	 also	 significantly	 lower	 numbers	 of	IMP+F4/80+	 cells,	 compared	 to	 control	 cohorts	 (Figure	 5.17A).	 Nevertheless,	 the	percentage	 of	 the	 remaining	 F4/80+	stromal	 macrophages	 in	 the	 bone	 marrow	 of	 CLO-depleted	mice	 that	phagocytosed	 IMP	was	significantly	higher	 than	control	mice	 (Figure	5.17B	and	Figure	5.18D).	As	with	the	spleen,	except	for	the	CD11c+	and	T	cell	subsets,	most	of	 the	 leukocyte	 subsets	 analysed	 in	 the	 bone	 marrow	 contained	 significantly	 higher	percentages	of	IMP+	cells	than	the	control	animals	that	had	not	undergone	CLO	depletion	(Figure	5.17B),	including	neutrophils	(Figure	5.18B)	and	monocyte	subsets	(Figure	5.18C).	This	 further	 supports	 the	 notion	 that,	 although	 CLO	 depletion	 does	 not	 alter	 the	 bone	marrow	 distribution	 or	 number	 of	 leukocytes,	 it	 may	 change	 the	 activation	 status	 and	phagocytic	 and/or	 cell	 surface	 characteristics	 of	 certain	 leukocyte	 subsets,	 in	 particular	the	Ly6Chi	monocytes	and	neutrophils.	Indeed,	preliminary	data	obtained	from	an	ex	vivo	whole	 blood	 phagocytosis	 assay	 indicated	 that	 the	 Ly6Chi	 inflammatory	 monocytes,	isolated	 24h	 after	 CLO	 depletion	 of	 WNV-infected	 mice,	 are	 much	 more	 efficient	 in	phagocytosing	IMP	than	cells	 isolated	from	control	WNV-infected	mice	(Appendix	Figure	12).	
Figure	5.17	IMP+	leukocytes	in	the	bone	marrow	of	mock-	or	WNV-infected	mice	
following	clodronate	depletion	(d5	p.i.)	and	IMP	treatment		
	
	Graph	A	represents	the	number	of	leukocytes	that	are	IMP+	in	the	bone	marrow	of	(6x104	PFU)	WNV-infected,	IMP-treated	(blue)	or	WNV-infected,	CLO-depleted,	IMP-treated	(orange)	and	mock-infected,	IMP-treated	(dark	grey)	or	mock-infected,	CLO-depleted,	IMP-treated	(light	grey)	mice	at	d7p.i.	Graph	A	demonstrates	the	number	of	IMP+	total	leukocytes	(CD45+),	B	cells	(B220+CD11c-),	neutrophils	(Ly6G+	CD11bhiLy6Cint),	monocytes	(CD11b+CD11c-),	including	Ly6Chi,	Ly6Cint	and	Ly6C-	cells,	stromal	macrophages	(F4/80+CD11cint),	DC	(CD11c+)	and	T	cells	(CD3+).	Graph	B	represents	the	percentage	of	leukocytes	that	are	IMP+	including	total	leukocytes	(CD45+),	B	cells	(B220+CD11c-),	neutrophils	(Ly6G+	CD11bhiLy6Cint),	monocytes	(CD11b+CD11c-),	including	Ly6Chi,	Ly6Cint	and	Ly6C-	cells,	stromal	macrophages	(F4/80+CD11cint),	DC	(CD11c+)	and	T	cells	(CD3+)	that	are	IMP+.	Data	for	figures	A-B	are	the	mean	±SEM	of	values	from	3	independent	experiments,	with	2-4	mice/group	in	each	experiment.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Tukey’s	multiple	comparison	post-test,	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	.	 	
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Figure	5.18	IMP+	leukocytes	in	the	bone	marrow	of	mock-	or	WNV-infected	mice	
following	clodronate	depletion	(d5	p.i.)	and	IMP	treatment		
			Panels	A-D	are	the	representative	flow	cytometry	plots	of	IMP	distribution	in	the	various	leukocyte	populations	of	the	bone	marrow	of	control	(left)	and	CLO-depleted	(right	)	WNV-infected	(6x104	PFU)	mice	on	d7	p.i.	These	include	the	IMP	distribution	of	(A)	total	leukocytes	(CD45+);	(B)	neutrophils	(Ly6G+CD11bhiLy6Cint);	(C)	monocytes	(CD11b+CD11c-Ly6Chi/int/-);	(D)	stromal	macrophages	(F4/80+CD11cint).		 	
Figure 5.18 IMP+ cells in the bone marrow
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5.2.9. Long-term	outcome	 of	 clodronate	 depletion	 and	 IMP	 treatment	
of	WNV-infected	mice		
The	 spleens	 of	 mice	 surviving	 the	 LD50	 dose	 of	 WNV	 infection	 following	 clodronate	depletion	and	IMP	treatment	were	investigated	to	determine	the	fate	of	IMP	after	90	days.	By	this	time	the	splenic	leukocyte	numbers	of	CLO-depleted	mice	had	returned	to	that	of	control	mice,	with	negligible	differences	in	the	number	of	F4/80+	red	pulp	macrophages	in	WNV-infected	 control	 and	 CLO-depleted	 cohorts	 (Figure	 5.19A).	 Nevertheless,	 the	percentage	of	IMP+	F4/80+	red	pulp	macrophages	and	neutrophils	remained	higher	in	the	CLO-depleted	counterpart	(Figure	5.19C),	although	the	numbers	of	IMP+	splenic	leukocyte	subsets	were	similar	between	groups	(Figure	5.19B).	This	points	to	retention	of	the	IMP	in	the	spleen	over	time.	There	is	also	an	increase	in	the	percentage	of	these	cells,	containing	IMP.	This	may	suggest	 that	 cells	 taking	up	 IMP	have	a	 shorter	 lifespan	necessitating	 the	take	up	of	IMP	by	surrounding	macrophages,	eventually	leading	to	a	higher	percentage	of	IMP+	cells.	Alternatively,	there	is	evidently	a	redistribution	of	these	IMP.	For	example,	the	number	 of	 IMP+	 B	 cells	 reduced	 from	 3	 to	 1x106,	 while	 the	 number	 of	 IMP+F4/80	macrophages	increased	by	10-fold	from	0.1	to	1x106	over	90	days.	
5.3. Discussion	
Clodronate	depletion	has	been	associated	with	ameliorating	diseases	in	which	pathogenic	macrophages	 play	 a	 detrimental	 role.	 Indeed,	 the	 depletion	 of	 specific	 circulatory	macrophages	24	prior	to	injury,	significantly	improved	clinical	outcome	in	a	murine	model	of	renal	ischemia	(Ferenbach	et	al.	2012).	However,	diphtheria	toxin-induced	CD11b+	cell	depletion	resulted	in	a	worsened	disease	outcome	in	this	model,	which	authors	attributed	to	the	depletion	of	resident	renal	macrophages	by	diphtheria	toxin.	Due	to	the	inability	of	CLO	 liposomes	 injected	 i.v.	 to	reach	these	macrophages,	 they	are	not	depleted.	Thus,	 the	
Figure	5.19	Long-term	outcome	of	clodronate	depletion	and	IMP	treatment	in	the	
spleen	of	WNV-infected	mice		Graph	A	represents	the	cell	number	of	total	leukocytes	(CD45+)	in	the	spleen	90	days	p.i.	with	 the	 LD50	 dose	 (6x103	PFU)	 of	 WNV.	 Ninety	 days	 was	 sufficient	 for	 CLO-depleted	animals	(red)	 to	have	recovered	 leukocyte	number	to	 that	of	control	mice	(blue).	B	cells	(B220+CD11c-),	 T	 cells	 (CD3+),	 red	 pulp	 macrophages	 (F4/80+CD11cint),	 monocytes	(CD11b+CD11c-),	DC	 (CD11c+)	and	neutrophils	 (Ly6G+	CD11bhiLy6Cint)	have	all	 recovered	in	 cell	 number.	 Graphs	 B-C	 demonstrate	 the	 numbers	 (B)	 and	 percentages	 (C)	 of	 these	leukocytes	 described	 in	A	 that	 are	 IMP+	in	 vehicle-treated	 (light	 blue)	 and	CLO-depleted	mice	 (orange).	 Data	 are	 the	mean	 ±SEM	 of	 4	mice/group	 from	1	 experiment.	 Statistical	analysis	 was	 conducted	 using	 an	 unpaired,	 two	 tailed	 T-test,	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.			
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authors	 hypothesised	 that,	 in	 contrast	 to	 circulatory	 macrophages,	 these	 renal	macrophages	were	renoprotective,	highlighting	the	dual	pathogenic/protective	nature	of	macrophages	 (Ferenbach	 et	 al.	 2012).	 In	 contrast,	 CLO-depletion	 of	 circulatory	macrophages	resulted	in	increased	morbidity	and	mortality	in	a	vesicular	stomatitis	virus	infection,	which	 causes	 acute	 encephalitis	 (Steel	 et	 al.	 2010).	The	data	presented	 in	 this	chapter	emphasises	 that	both	 the	method	of	monocyte	depletion	and	 the	specific	 subset	targeted	are	crucial	determinants	of	whether	intervention	is	beneficial.		Clodronate	 depletion	 alone	 did	 not	 result	 in	 remarkable	 improvement	 or	 worsening	 of	disease	 in	 our	 i.n.	 model	 of	 WNV	 encephalitis,	 which	 was	 surprising,	 considering	 the	crucial	role	of	Ly6Chi	 inflammatory	macrophages	in	the	disease	pathogenesis.	Although	a	single	 administration	 of	 clodronate	 liposomes	 significantly	 altered	 the	 dynamics	 of	leukocyte	 infiltration	 into	 the	 WNV-infected	 CNS,	 in	 particular	 reducing	 Ly6Chi	inflammatory	 macrophages,	 this	 did	 not	 translate	 to	 an	 improved	 clinical	 outcome.	Furthermore,	daily	depletion	of	circulatory	macrophages	did	not	result	in	further	reduced	CNS	leukocyte	numbers	of	WNV-infected	mice,	demonstrating	the	remarkable	capacity	of	the	bone	marrow	to	produce	a	continuous	supply	of	this	Ly6Chi	macrophage	subset.		Interestingly,	the	significant	reduction	of	Ly6Chi	cells	occurring	in	the	CNS	with	clodronate	depletion	was	not	seen	in	the	Ly6Cint	immigrant	microglial	population,	but	CLO	depletion	did	 decrease	 the	 Ly6C-	 resident	 microglial	 population.	 The	 possibility	 that	 resident	microglia	 become	more	 activated	 to	 counterbalance	 the	 absence	 of	 infiltrating	 myeloid	cells	is	an	interesting	one,	which	needs	to	be	addressed	in	future	experiments.			Interestingly,	 clodronate	 depletion	 did	 not	 reduce	 neutrophil	 numbers	 in	 the	 CNS	 but	increased	 this	 subset.	 Taken	 together	 with	 data	 from	 the	 spleen,	 in	 which	 neutrophils	significantly	 increased	 following	CLO	depletion	of	WNV-infected	mice,	 this	 suggests	 that	
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the	combined	action	of	WNV	infection	and	CLO	depletion	may	alter	neutrophil	production	in	 the	 bone	 marrow.	 Indeed,	 as	 neutrophils	 and	 monocytes	 are	 both	 of	 the	 myeloid	lineage,	 the	 effect	 of	 CLO	 on	 the	 myeloid	 progenitor	 in	 the	 bone	 marrow	 needs	 to	 be	further	 investigated.	However,	no	obvious	changes	 in	neutrophil	numbers	or	percentage	were	present	in	the	bone	marrow,	with	the	only	subsets	significantly	altered	by	CLO	being	the	 reduction	 in	 F4/80+	stromal	 macrophages.	 Nevertheless,	 data	 from	 our	 laboratory	supports	the	notion	that	Ly6Chi	monocyte	production	is	increased	in	the	bone	marrow	of	WNV-infected	mice,	in	order	to	keep	up	with	the	demand	for	this	subset	during	infection	(Thomas	Ashhurst,	Unpublished).	As	 the	bone	marrow	 is	 a	 rigid	 structure	 limiting	 large	expansion	 in	cell	numbers,	 it	 is	 likely	 that	 the	Ly6Chi	monocytes	and	potentially	also	 the	neutrophils	are	 released	 into	 the	circulation	continuously.	Thus,	 it	 is	may	be	 that	Ly6Chi	monocyte	 and	 possibly	 neutrophil	 production	 is	 increased	 by	 the	 bone	 marrow	 in	response	to	the	joint	action	of	WNV	infection	and	clodronate	depletion	but	that	the	release	of	cells	into	the	circulation	matches	the	rate	of	proliferation.	Proliferation	assays,	such	as	the	 BrdU	 assay	 used	 in	 chapter	 3	 and	 4,	 will	 be	 useful	 in	 determining	 to	 what	 extent	clodronate	 depletion	 increases	 the	 rate	 of	 cellular	 proliferation	 in	 the	 bone	 marrow	 of	WNV-infected	mice.		Moreover,	 the	 remarkable	 presence	 of	 IMP+	cells	 in	 the	 CNS,	 in	 particular	 IMP+Ly6Chi	monocyte	and	IMP+	neutrophils,	could	be	a	consequence	of	the	intense	left-shift	produced	by	the	combined	action	of	WNV	infection	and	clodronate	depletion	on	the	bone	marrow.	It	may	 be	 that	 the	 overwhelming	 demand	 for	 these	 subsets	 results	 in	 a	 high	 output	 of	immature	 and	 possibly	 more	 activated	 cells	 from	 the	 bone	 marrow.	 Immature	 Ly6Chi	monocytes	and	neutrophils	may	be	more	likely	to	phagocytose	these	IMP,	but	still	traffic	to	the	CNS.	In	the	classic	model	of	IMP	treatment	of	WNV-infected	mice,	the	bone	marrow	supply	 of	mature	monocytes	 is	 likely	 released	 into	 circulation	making	 their	 way	 to	 the	
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CNS,	 whereas	 the	 immature	 monocytes	 are	 targeted	 by	 IMP	 treatment,	 which,	 once	sequestered	by	the	spleen,	undergo	apoptosis.		Clodronate	 liposomes	 deplete	 any	 mature	 (possibly	 less	 pathogenic)	 monocytes	 in	circulation,	 leaving	 an	 abundance	 of	 activated	 and	 immature	 Ly6Chi	 monocytes	 in	circulation,	 which	 are	 highly	 phagocytic	 and	 take	 up	 IMP.	 Studies	 show	 that	 the	 GR-1+	monocyte	 (i.e.	Ly6Chi)	populations	 in	circulation	completely	 recover	within	24h	after	 i.v.	clodronate	 depletion	 and	 reach	 levels	 higher	 than	 normal	 by	 48h,	 whereas	 the	 GR-1-	(Ly6C-)	subset	has	a	delayed	recovery.	Authors	excluded	neutrophils	from	these	monocyte	populations	 based	 on	 Ly6G	 expression	 and	 found	 that	 circulatory	 neutrophils	were	 not	depleted	by	clodronate	(Ferenbach	et	al.	2012).				An	 overwhelming	 presence	 of	 activated	 subsets	 in	 the	 blood	 may	 traffic	 to	 the	 CNS,	accounting	for	the	distinct	presence	of	IMP+	cells	in	the	CNS	of	clodronate-depleted	mice.	If	true,	this	may	explain	why	the	reduction	of	this	subset	as	a	result	of	clodronate	depletion	only,	 does	 not	 improve	 clinical	 outcome.	 The	 absence	 of	 mature	 monocytes	 and	abundance	 of	 activated	 immature	 Ly6Chi	 monocytes	 in	 the	 CNS,	 although	 reduced,	 are	potentially	 more	 pathogenic	 in	 nature.	 It	 is	 likely	 that	 the	 ratio	 of	 immature-activated	
versus	 mature	 monocytes	 is	 changed	 in	 clodronate-depleted	 mice,	 in	 favour	 of	 the	activated-immature	monocytes.	Thus	in	control	animals,	IMP	may	substantially	reduce	the	infiltration	of	 the	pathogenic	 subset	of	monocytes,	whilst	 allowing	 the	numbers	of	more	mature	neuroprotective	cells	of	this	lineage	migrating	into	the	CNS	to	supervene.			Importantly,	 IMP	 treatment	was	 still	 effective	 in	 clodronate-depleted	animals,	 indicating	that	 the	reduction	of	activated-immature	and	potentially	pathogenic	subset	mediated	by	IMP	 treatment	 of	 clodronate-depleted	 mice	 was	 sufficient	 to	 enable	 viral	 eradication	whilst	limiting	pathogenic	action	of	Ly6Chi	macrophages.	Irrespective,	these	data	indicate	
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that,	in	contrast	to	our	initial	hypothesis,	that	MARCO+	marginal	zone	macrophages	are	not	essential	for	the	therapeutic	efficacy	of	IMP	treatment.		Classically	the	action	of	clodronate-encapsulated	liposomes	is	 limited	to	phagocytic	cells,	in	particular	circulatory	and	resident	macrophages.	However,	 there	were	also	significant	reductions	in	lymphoid	lineage	cells	such	as	B,	T	and	NK	cells	in	the	CNS	of	WNV-infected	mice	 following	 clodronate	 depletion.	 Studies	 have	 shown	 the	 chemokine-dependent	recruitment	of	lymphoid	lineage	cells	to	be	mediated	by	inflammatory	cytokines	produced	by	 macrophages	 (Pak-Wittel	 et	 al.	 2013).	 Thus,	 it	 may	 be	 that	 lymphoid	 lineage	 cells	decrease	in	response	to	reduced	inflammatory	macrophages	in	the	CNS,	as	a	consequence	of	clodronate	depletion.		Dendritic	cells	in	the	spleen	are	also	susceptible	to	clodronate	depletion,	especially	the	DC	in	 the	 marginal	 zone,	 which	 make	 up	 the	 majority	 of	 the	 DC	 population	 in	 the	 spleen	(Leenen	et	al.	1998).	In	our	model,	there	was	significant	depletion	of	DC	in	the	spleen.			The	fact	that	clodronate	depletion	did	not	significantly	alter	disease	outcome	might	have	been	markedly	different	in	a	peripheral	model	of	infection,	as	the	resident	macrophages	of	the	spleen	(Seiler	et	al.	1997)	and	 lymph	node	are	crucial	 in	 limiting	viral	dissemination	and	 systemic	 spread.	 The	 extent	 to	 which	 the	 macrophages	 of	 the	 spleen	 may	 prevent	peripheral	infection	and	dissemination	of	WNV	warrants	further	study.	 	
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6. Chapter	6	General	discussion	
6.1. Role	of	 the	draining	and	non-draining	 lymph	nodes	during	
WNV	encephalitis	
The	data	in	chapter	3	corroborate	studies	identifying	the	CLN	as	the	draining	lymph	node	of	the	CNS	(Louveau	et	al.	2015;	Stern	et	al.	2014).	The	absence	of	detectable	virus,	paired	with	 the	 significant	 clonal	expansion	 in	 the	CLN,	but	not	 in	 the	peripheral	 ILN	and	MLN	suggests	 that	 antigen	 presentation	 is	 occurring	 in	 the	 CLN,	 rather	 than	 non-draining	lymph	nodes,	such	as	the	ILN	and	MLN.	Although	present	 in	very	 low	numbers,	DC	from	the	 CNS	 likely	 drain	 to	 the	 CLN,	 inducing	 the	 proliferation	 and	 activation	 of	 local	 CLN	leukocytes.	However,	whether	 the	 innate	 response	 generated	 by	 the	 CLN	 contributes	 to	the	lethal	immunopathology	present	in	WNV	encephalitis	remains	to	be	shown.		The	 results	 provided	 in	 chapter	 3	 and	 4	 clearly	 demonstrate	 that	 the	 response	 to	 CNS	inflammation	 is	not	 limited	 to	 the	CNS	draining	 lymph	nodes	but	 that	 this	 encompasses	the	peripheral	nodes,	as	well	as	the	spleen.	During	homeostatic	conditions	there	is	a	base	level	 of	 leukocyte	 movement	 throughout	 the	 lymphatic	 system	 (Tomura	 et	 al.	 2008).	However,	this	thesis	clearly	demonstrates	that	this	movement	of	leukocytes,	in	particular	B	 cells,	 from	 elsewhere	 to	 the	 local	 DLN	 is	 elevated	 during	 infection,	 as	 there	 was	increased	presence	of	PKH+B	cells	 in	 the	CLN	during	 infection,	 as	 shown	by	 the	 footpad	injection	of	PKH26.		In	 addition,	 the	 significant	 reduction	 of	 T	 cells	 in	 the	 ILN	 and	 MLN	 following	 WNV	infection	 suggests	 that	 these	 lymphocytes	 are	 recruited	 to	 the	 CNS	 or	 CLN,	 during	infection.	 In	 contrast	 to	 the	 footpad	 injection	 of	 PKH26,	 adoptive	 transfer	 of	 CD45.1+	leukocytes	 showed	 the	 migration	 of	 T	 cells,	 from	 the	 peripheral	 PLN	 to	 the	 CLN.	 This	migration	of	T	cells	from	a	peripheral	node	to	the	CLN	was	not	significantly	modulated	by	
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CNS	infection	and	we	could	not	conclusively	demonstrate	the	recruitment	of	lymphocytes	from	the	lymph	nodes	to	the	CNS.	These	experiments	need	to	be	refined	in	future	studies	and	will	 include	the	adoptive	transfer	of	higher	numbers	of	leukocytes	prior	to	infection,	as	well	as	potential	lymphadenectomy	procedures	to	shed	light	on	this	issue.		The	significant	upregulation	of	Ly6C	on	cells	seen	 in	both	the	draining	and	non-draining	lymph	nodes	may	have	a	biological	function	linked	to	migration	(Jaakkola	et	al.	2003)	or	it	could	indicate	that	these	leukocytes	are	in	the	preliminary	stages	of	activation,	but	need	a	secondary	 signal	 such	 as	 virus,	 which	 would	 complete	 this	 process,	 for	 a	 potential	onslaught	of	 virus,	 should	 it	 spread	 from	 the	CNS	 to	 the	peripheral	organs.	The	delayed	kinetics	of	increased	Ly6C	expression	in	the	ILN	and	MLN	(d5	p.i.),	compared	to	the	CLN	(d3	 p.i.),	 suggests	 that	 the	 signals	 modulating	 Ly6C	 likely	 originate	 elsewhere.	 Studies	have	 shown	Th1	 cytokines,	 specifically	 the	 IFN	 group,	 to	 directly	 upregulate	 Ly6C	 on	B	and	T	cells	(Schlueter	et	al.	2001,	2002).	IFNγ	production	is	significantly	increased	during	WNV	infection	and	is	also	associated	with	the	development	of	seizures	(Getts	et	al.	2007).	It	 is	 also	 reasonable	 to	 speculate	 that	 cytokines	 like	 type	 I	 IFN,	 could	 emanate	 from	 the	area	 of	 inflammation,	 reaching	 the	 local	 draining	 lymph	 node	 to	 induce	 upregulation	 of	Ly6C.	On	 the	other	hand,	 it	 could	also	be	 that,	 following	 initial	 infection	of	 the	CNS,	 low	levels	of	virus	spread	systemically	to	initiate	a	delayed	response	in	the	peripheral	lymph	nodes.	 However,	 levels	 of	 virus	 in	 the	 ILN	 and	 by	 inference	 the	 peripheral	 organs,	 are	undetectable	 in	 this	 model	 (Terry	 2012),	 making	 it	 unlikely	 that	 this	 is	 the	 case.	 In	addition,	previous	work	from	our	laboratory	has	shown	that	CCL2	production	by	infected	neurons	 and	 subsequent	 release	 into	 the	 circulation	 attracts	 inflammatory	 monocytes	from	 the	bone	marrow	 to	 the	CNS	 in	WNV	 infection	 (Getts	 et	 al.	 2008).	Considering	 the	crucial	 intimate	 relationship	 of	 the	 secondary	 lymphoid	 organs	 with	 the	 circulatory	system,	 it	 is	 reasonable	 to	 assume	 that	 inflammatory	 mediators	 emanating	 from	 the	
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infected	CNS	and	present	 in	circulation	 in	reaching	the	secondary	 lymphoid	organs,	may	initiate	 these	 changes.	 It	 is	 clear	 that	 changes	 in	 Ly6C,	 and	 leukocyte	 number	 and	composition	 in	 the	 peripheral	 nodes	 are	 modulated	 by	 infection	 of	 the	 CNS,	 however,	whether	these	leukocytes	contribute	to	the	immune	response,	and	if	so,	in	a	pathogenic	or	regulatory	manner,	remain	to	be	elucidated.	
6.2. Role	of	the	spleen	in	the	primary	immune	response	to	WNV	
encephalitis	
We	further	examined	the	role	of	the	secondary	lymphoid	organs	in	CNS	inflammation	by	examining	the	splenic	response	to	lethal	WNV	infection.	There	were	negligible	changes	in	cell	number	and	proliferation	of	leukocytes	in	the	spleen,	suggesting	that	the	spleen	is	not	the	primary	source	of	 lymphoid	 lineage	cells	 to	 the	 inflamed	CNS	during	WNV	 infection.	However,	 as	 with	 the	 CLN,	 ILN	 and	 MLN,	 splenic	 leukocytes	 showed	 significant	upregulation	 of	 Ly6C	 expression	 in	 response	 to	 WNV	 infection	 and	 the	 same	 distinct	Ly6Chi	 Ly6Cint	 or	 Ly6C-	 profiles	were	 also	 observed	 in	 the	 spleen	 following	 infection,	 in	various	 subsets.	 Thus,	 B	 cells	 in	 both	 the	 spleen	 and	 lymph	 nodes	 were	 Ly6C-	 during	homeostatic	conditions,	but	became	more	positive	as	disease	progressed,	until	they	were	Ly6Cint.			On	the	other	hand,	both	CD4+	and	CD8+	T	cells	possess	a	Ly6C+	subset	during	homeostatic	conditions,	with	CD8+	T	cells	clearly	showing	a	subset	of	Ly6Chi	cells.	This	pattern	of	Ly6C	distribution	on	CD8+	T	cells	seems	to	suggest	that	these	cells	become	Ly6Cint	transiently	on	their	way	to	become	Ly6Chi.	Interestingly,	apart	from	the	CD4+	T	cells	and	B	cells,	all	other	leukocyte	 subsets	 in	 the	 lymph	 nodes	 and	 spleen,	 including	DC,	monocytes,	 neutrophils	and	NK1.1+	cells	became	Ly6Chi	at	the	peak	of	infection	in	the	spleen.	Therefore,	the	classic	characterisation	of	monocytes	and	macrophages	(Geissmann	et	al.	2003),	based	on	Ly6C	
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expression	 could	 extend	 to	 classification	 of	 DC	 subtypes	 and	 even	 lymphocytes	 in	 the	future,	as	a	means	to	describe	 inflammatory	phenotypes.	Future	experiments	using	mAb	depletion	 or	 blockade	 of	 Ly6C	 during	 infection	 may	 prove	 useful	 in	 elucidating	 the	biological	significance	of	Ly6C	expression	on	these	subsets.		Whether	 these	 changes	 relate	 to	 migration,	 activation	 or	 maturation	 as	 previously	suggested,	will	be	the	aim	of	future	studies	(Wrammert	et	al.	2002).	Despite	initial	results	based	on	proliferation	and	splenic	leukocyte	numbers,	suggesting	that	the	spleen	did	not	play	 a	 role	 in	 supplying	 cells	 to	 the	 CNS	 during	 infection,	 splenectomy	 prior	 to	 WNV	infection	 suggested	 otherwise.	 The	 reduction	 in	 pathogenic	 Ly6Chi	 inflammatory	monocytes	 in	 the	 CNS	 of	 WNV-infected	 splenectomised	 mice	 led	 us	 to	 investigate	 the	possibility	of	 the	spleen	acting	as	a	splenic	 reservoir	of	monocytes	 (Swirski	et	al.	2009).	However,	 despite	 the	 success	 of	 ACE	 inhibitors	 in	 reducing	 the	 infiltration	 of	 Ly6Chi	inflammatory	 macrophages	 in	 other	 disease	 models,	 such	 as	 MI	 and	 stroke	 (Bao	 et	 al.	2010;	Leuschner	et	al.	2010),	 treatment	with	ACE	 inhibitor	Enalapril	did	not	 reduce	 the	numbers	 of	 Ly6Chi	 monocytes	 in	 our	 model	 of	 i.n.	 WNV	 infection,	 nor	 did	 it	 improve	survival.		It	should	be	noted	that	the	majority	of	studies	showing	successful	use	of	ACE	inhibitors	to	inhibit	 monocytes	 from	 the	 splenic	 reservoir,	 have	 been	 limited	 to	 acute	 ischemia-reperfusion	injuries.	This	type	of	inflammatory	insult	generally	occurs	over	an	acute	time-frame	compared	to	the	pathogenesis	of	viral	infection	of	the	CNS,	suggesting	that	a	more	chronic	 recruitment	 of	 monocytes	 may	 gradually	 deplete	 the	 splenic	 reservoir,	 while	simultaneously	 initiating	 significant	 alternative	 bone	 marrow	 production	 of	 Ly6Chi	monocytes,	which	quickly	overtakes	the	contribution	by	the	spleen.	Indeed,	CLO	depletion	experiments	demonstrated	the	immense	the	capacity	of	the	bone	marrow	to	continuously	supply	 these	 cells	 throughout	 the	 course	 of	 infection.	 Thus,	 these	 data	 verify	 the	
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importance	of	the	bone	marrow	as	the	primary	source	of	pathogenic	Ly6Chi	inflammatory	macrophages	during	WNV	encephalitis.	
6.3. The	 role	 of	 the	 spleen	 in	 the	 development	 of	 immunity	
against	lethal	WNV	infection	
Notably,	 in	 our	 i.n.	model	 of	WNV	 infection,	 splenectomised	mice	were	 able	 to	 develop	sterilising	 immunity	 to	 WNV,	 raising	 the	 issue	 of	 where	 immunity	 against	 CNS	 viral	infection	resides.	The	spleen	is	undoubtedly	 important	 for	the	development	of	 immunity	in	 certain	 diseases,	 although	 whether	 this	 applies	 to	 CNS	 infection,	 has	 not	 been	investigated	 in	 any	 depth.	 There	 is	 data	 implicating	 the	 spleen	 as	 a	major	 reservoir	 for	long-lived	 memory	 B	 cells	 specific	 to	 vaccinia	 virus	 (Mamani-Matsuda	 et	 al.	 2008).	 In	addition,	there	is	a	significant	reduction	in	memory	B	cells	against	pneumococcal	infection	in	 individuals	 after	 splenectomy	 (Rosado	 et	 al.	 2013).	We	 hypothesise	 that	 the	 relative	contribution	of	the	spleen	versus	 the	draining	lymph	nodes,	 likely	vary	depending	on	the	route	 of	 viral	 infection,	 with	 i.n.	 infection	 favouring	 a	 prominent	 role	 for	 the	 draining	lymph	 nodes	 in	 the	 development	 and	maintenance	 of	 immunity.	 However,	 the	 route	 of	primary	and	secondary	infection	in	all	of	these	experiments	were	i.n.,	therefore	the	effect	of	 splenectomy	 and	 subsequent	 development	 of	 immunity	 in	 a	 peripheral	 model	 of	infection	 was	 not	 investigated.	 Future	 studies	 will	 employ	 different	 routes	 of	 infection,	such	as	 i.p.	 or	 s.c.	 in	 combination	with	 splenectomy	after	primary	 infection,	 followed	by	lethal	dose	rechallenge	to	resolve	this	question.		
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6.4. Role	 of	 the	 spleen	 and	 the	marginal	 zone	macrophages	 in	
IMP	treatment	
Previous	 studies	 from	 this	 laboratory	 have	 implicated	 the	 spleen,	 and	 in	 particular	 the	marginal	zone	macrophages,	as	a	major	site	of	IMP	sequestration	(Terry	2012;	Getts	et	al.	2014).	 Thus,	 we	 hypothesised	 that	 the	 spleen	 may	 be	 crucial	 for	 the	 efficacy	 of	 IMP	treatment	 of	 WNV	 encephalitis.	 Although	 the	 IMP	 treatment	 of	 WNV-infected,	splenectomised	 mice	 did	 not	 result	 in	 a	 significant	 reduction	 of	 Ly6Chi	 inflammatory	macrophages	in	the	CNS	of	LD100	infected	mice,	it	did	improve	survival	outcomes	of	mice	infected	 with	 the	 LD50	 dose	 of	 virus.	 Indeed,	 the	 already	 reduced	 Ly6Chi	inflammatory	monocyte	numbers,	as	a	result	of	the	splenectomy,	may	have	contributed	to	the	improved	survival	 outcome	 following	 IMP	 treatment.	 Nevertheless,	 IMP	 treatment	 had	 the	 best	survival	outcome	in	mice	with	intact	spleens.	This	suggests	that;	although	the	absence	of	the	spleen	may	somewhat	impede	the	beneficial	outcome	of	IMP	treatment,	the	spleen	as	a	whole	 is	 not	 crucial	 for	 the	 efficacy	of	 IMP	 treatment	 and	 that	 other	organs	 such	 as	 the	liver,	 lungs	 or	 kidneys	may	 provide	 similar	 compensatory	 environments,	 promoting	 the	sequestration	and	phagocytosis	of	IMP+	cells.		We	therefore	focussed	on	the	role	of	the	marginal	zone	macrophages	in	the	efficacy	of	IMP	treatment,	by	depleting	these	macrophages	with	CLO-encapsulated	liposomes	prior	to	IMP	administration.	 Much	 like	 the	 splenectomised	 mice,	 CLO-depleted	 mice	 showed	 a	significant	 reduction	 in	 the	 number	 of	 leukocytes	 infiltrating	 the	 CNS	 during	 WNV	infection.	Nevertheless,	this	reduction	alone,	although	significant,	did	not	improve	survival	outcome.	 We	 hypothesise	 that	 this	 was	 likely	 due	 to	 the	 fact	 that	 CLO	 depletion	 also	modulated	 the	 maturation	 and	 activation	 profile	 of	 monocytes	 in	 circulation.	 Thus,	
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although	the	Ly6Chi	inflammatory	macrophages	infiltrating	the	CNS	of	CLO-depleted	mice	were	reduced,	those	that	did	get	into	the	CNS	may	have	been	more	pathogenic.	IMP	 treatment	 of	 CLO-depleted,	 WNV-infected	 mice	 further	 reduced	 the	 numbers	 of	infiltrating	 Ly6Chi	inflammatory	macrophages	 in	 the	 CNS	 and	 also	 resulted	 in	 significant	improvement	 in	 survival.	 However,	 similar	 to	 the	 splenectomy	 model	 of	 infection,	 the	maximal	benefit	of	IMP	treatment	was	achieved	in	mice	without	CLO-depletion,	albeit	only	marginally.	Despite	this,	these	results	show	that,	in	contrast	to	our	initial	hypothesis,	that	the	 spleen	 and	 splenic	 marginal	 zone	 macrophages	 are	 not	 critical	 for	 the	 therapeutic	efficacy	of	IMP	treatment	in	our	model	of	i.n.	WNV	infection.		
6.5. Modulation	of	circulatory	and	resident	macrophages	during	
WNV	encephalitis		
Clodronate	 depletion	 not	 only	 abrogated	 resident	 splenic	 macrophages	 and	 circulatory	monocytes,	 but	 also	 significantly	 altered	 the	 phagocytic	 capacity	 and	 distribution	 of	 the	myeloid	lineage	cells	in	the	spleen	and	CNS,	including	neutrophils	and	Ly6Chi	inflammatory	macrophages.	Daily	CLO	depletion	of	macrophages	demonstrated	the	remarkable	capacity	of	 the	 bone	 marrow	 to	 continuously	 and	 rapidly	 deploy	 new	 monocytes	 into	 the	circulation.	As	neutrophils	have	a	shared	lineage	with	monocytes,	it	is	not	surprising	that	this	 subset	was	 also	modulated	 by	 CLO	 depletion.	 Studies	 of	mice	with	 peritonitis	 have	shown	 increased	 neutrophil	 accumulation	 in	 the	 peritoneal	 exudate	 in	 mice	 that	 were	CLO-depleted.	 This	 increase	 in	 neutrophils	 was	 attributed	 to	 a	 reduction	 in	 monocyte-derived	 IL-10	 as	 a	 result	 of	 CLO	 depletion,	 as	 IL-10	 is	 known	 to	 inhibit	 neutrophil	accumulation	(Ajuebor	et	al.	1999;	Chadzinska	et	al.	2004).	In	our	model,	neutrophils	were	significantly	 increased	 in	 the	 spleen	 of	 CLO-depleted,	WNV-infected	mice	 and	were	 also	present	 in	 the	 WNV-infected	 CNS,	 containing	 IMP.	 IMP-containing	 Ly6Chi	inflammatory	macrophages	were	also	present	 in	high	numbers	 in	 the	WNV-infected	CNS,	which	 is	not	
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seen	in	the	classic	model	of	IMP	treatment.	These	results	suggest	that	the	combined	action	of	WNV-infection	and	CLO	depletion	amplifies	the	“left-shift”	in	the	bone	marrow,	inducing	a	response	which	results	in	the	production	and	release	of	immature	and	highly	activated	monocytes	 and	 neutrophils	 into	 circulation.	 Importantly,	 these	 results	 also	 show	 that	while	 these	 IMP+	 cells	 may	 change	 their	 phenotype	 to	 become	 apoptotic	 by	 expressing	phosphatidyl	 serine,	 to	 become	 sequestered	 in	 the	 spleen,	 they	 are	 still	 capable	 of	migrating	to	 the	CNS	and	diapedesing	across	 the	endothelium	into	 the	CNS	parenchyma.	The	 clinical	 impact	 of	 IMP	 on	 other	 flavivirus	 infection	 models,	 the	 elucidation	 of	 the	mechanism(s)	by	which	IMP	induce	apoptosis	markers	in	MZM	and	other	cell	subsets	and	the	subsequent	pathophysiological	impact	on	these	cells	will	be	of	great	interest	for	future	studies.	
6.6. Conclusion	
The	 results	 presented	 in	 this	 thesis,	 show	 for	 the	 first	 time,	 the	 manner	 in	 which	 CNS	inflammation	modulates	the	peripheral	secondary	lymphoid	organs.	The	distinct	patterns	of	 Ly6C	 upregulation	 occurring	 in	 the	 spleen	 and	 non-draining	 lymph	 nodes,	 not	 only	indicates	 that	 these	 organs	 are	 likely	 involved	 in	 the	 immune	 response,	 but	 may	 also	provide	 new	 methods	 of	 phenotypically	 characterising	 leukocyte	 subsets	 during	inflammation,	based	on	Ly6C	expression.	The	 data	 from	 splenectomy	 and	 CLO-depletion	 models	 highlight	 the	 issue	 that	 various	methods	of	depletion	or	abrogation	of	pathogenic	Ly6Chi	monocytes	can	result	in	different	clinical	 outcomes.	 Thus,	 although	modulation	 of	 pathogenic	 components	 of	 the	 immune	system	has	shown	great	promise	in	the	treatment	of	several	disease	models,	it	needs	to	be	done	with	care,	taking	into	account	the	nuanced	nature	of	monocytes.		Furthermore,	 although	 both	 splenectomy	 and	 CLO-depletion	 reduced	 the	 infiltration	 of	pathogenic	 Ly6Chi	 macrophages	 to	 the	 WNV-infected	 CNS,	 neither	 of	 these	 models	
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treatment.	Moreover,	although	the	efficacy	of	IMP	treatment	was	not	solely	reliant	on	the	spleen	or	splenic	marginal	zone	macrophages,	the	absence	of	these	components	impeded	the	therapeutic	action	of	IMP	as	maximum	benefit	from	IMP	treatment	was	demonstrated	in	non-CLO-depleted	mice,	which	had	their	spleens	intact.	
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8. Appendix	
	
Appendix	Figure	1	General	Leukocyte	gating	of	lymph	node	
		Representative	flow	cytometric	dot	plots	illustrating	the	gating	strategy	for	leukocytes	in	the	secondary	lymphoid	organs,	in	particular	the	lymph	node,	of	mice	infected	with	lethal	dose	 WNV	 (6x104	 PFU).	 In	 order	 to	 obtain	 a	 live	 single	 cell	 leukocyte	 population,	 the	following	steps	were	performed	during	analysis:	Time	gate	(A),	 followed	by	exclusion	of	doublets	with	the	FSC-H	vs	FSC-A	gate	(B).	Removal	of	debris	with	the	SSC-A	vs	FSC-A	gate	(C).	Negative	selection	of	live	cells	(D)	and	finally	positive	selection	of	leukocyte	(E),	based	on	pan-leukocyte	marker	(CD45).	Specific	leukocyte	subsets	were	then	identified	based	on	lineage	markers.	This	allowed	us	 to	 identify	 the	 following	 subsets:	 total	T	 cells	 (F)	 from	which	we	isolated	the	CD4+	T	cells	(G)	and	CD8+	T	cells	(G).	NK	cells	and	NKT	cells	(F).	B	cells	and	pDC	(H);	Neutrophils	(I);	Monocytes	(J),	CD11c+CD11c+	DC	(J),	CD11c+CD11b-	DC	(J),	 CD11chiCD11bint	 DC	 (J).	 Lastly	 the	 CD8α+	 DC	 subset	 (K)	 was	 isolated	 from	 the	CD11c+CD11b-	DC	gate.	Each	plot	represents	10,000	events.		 	
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Appendix	Figure	2	General	Leukocyte	gating	of	lymph	node-Fluorescence	minus-one	
and	isotype	controls	
		Representative	 flow	 cytometric	 dot	 plots	 illustrating	 the	 fluorescence	 minus-one	 and	isotype	controls	for	the	gating	strategy	of	leukocytes	in	the	secondary	lymphoid	organs,	in	particular	 the	 lymph	 node,	 of	 mice	 infected	 with	 lethal	 dose	 WNV	 (6x104	 PFU).	 Black	denotes	fluorescence	minus-one	and	red	denotes	isotype	control.	In	order	to	obtain	a	live	single	cell	leukocyte	population,	the	following	steps	were	performed	during	analysis:	Time	gate	(A),	followed	by	exclusion	of	doublets	with	the	FSC-H	vs	FSC-A	gate	(B).	Removal	of	debris	 with	 the	 SSC-A	 vs	 FSC-A	 gate	 (C).	 Negative	 selection	 of	 live	 cells	 (D)	 and	 finally	positive	 selection	 of	 leukocyte	 (E),	 based	 on	 pan-leukocyte	 marker	 (CD45).	 Specific	leukocyte	 subsets	 were	 then	 identified	 based	 on	 lineage	 markers.	 This	 allowed	 us	 to	identify	the	following	subsets:	total	T	cells	(F)	from	which	we	isolated	the	CD4+	T	cells	(G)	and	 CD8+	 T	 cells	 (G).	 NK	 cells	 and	 NKT	 cells	 (F).	 B	 cells	 and	 pDC	 (H);	 Neutrophils	 (I);	Monocytes	(J),	CD11c+CD11c+	DC	(J),	CD11c+CD11b-	DC	(J),	CD11chiCD11bint	DC	(J).	Lastly	the	 CD8α+	 DC	 subset	 (K)	 was	 isolated	 from	 the	 CD11c+CD11b-	 DC	 gate.	 Each	 plot	represents	5,000	events.		 	
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Figure 2
General lymph node leukocyte gating-FMO and Isotype controls
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Appendix	 Figure	 3	 Expression	 of	 Ly6C	 in	 leukocyte	 populations	 in	 the	 draining	
(CLN)	 and	 non-draining	 lymph	 nodes	 (MLN,	 ILN)	 of	 the	 CNS	 following	 lethal	WNV	
infection	
		Ly6C	 levels	 were	 quantified	 using	 the	 geometric	 mean	 of	 Ly6C	 expression	 of	 whole	populations.	Ly6C	expression	of	 the	 (A)	B	cells,	 (B)	CD4+	T,	 (C)	CD8+	T	cells,	 (D)	NK	cells	(E)	NKT	 cells,	 (F)	 neutrophils	 and	 (G)	monocytes	 in	 the	CLN	 (red),	 ILN	 (blue)	 and	MLN	(green)	 of	 mice	 following	 lethal	 WNV	 infection	 (6x104	PFU)	 on	 d0,	 3,	 5,	 6	 and	 7	 p.i.	Grouped	 data	 was	 normalised	 using	 d0	 as	 internal	 control,	 and	 is	 represented	 as	percentage	change	of	the	geometric	mean	of	cells	compared	to	day	0	(100%).	Data	are	the	mean	 ±SEM	 of	 3-4	 mice/group	 and	 is	 representative	 of	 3	 independent	 experiments.	Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Dunnet’s	 multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Appendix	 Figure	 4	 Expression	 of	 Ly6C	 in	 leukocyte	 populations	 in	 the	 draining	
(CLN)	 and	 non-draining	 lymph	 nodes	 (MLN,	 ILN)	 of	 the	 CNS	 following	 lethal	WNV	
infection	
		Ly6C	 levels	 were	 quantified	 using	 the	 geometric	 mean	 of	 Ly6C	 expression	 of	 whole	populations.	 Ly6C	 expression	 of	 (A)	 CD11c+CD11b+	 DC,	 (B)	 CD11chiCD11bint	 DC,	 (C)	CD11c+CD11b-	DC,	(D)	pDC	and	CD11c+CD8α+	DC	(E)	in	the	CLN	(red),	ILN	(blue)	and	MLN	(green)	 of	 mice	 following	 lethal	 WNV	 infection	 (6x104	PFU)	 on	 d0,	 3,	 5,	 6	 and	 7	 p.i.	Grouped	 data	 was	 normalised	 using	 d0	 as	 internal	 control,	 and	 is	 represented	 as	percentage	change	of	the	geometric	mean	of	cells	compared	to	day	0	(100%).	Data	are	the	mean	 ±SEM	 of	 3-4	 mice/group	 and	 is	 representative	 of	 3	 independent	 experiments.	Statistical	 analysis	 was	 conducted	 using	 one-way	 ANOVA	 with	 a	 Dunnet’s	 multiple	comparison	post-test	(d0	as	control),	and	P≤0.05*;	P≤0.01**;	P≤0.001***.	 	
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Appendix	Figure	5	General	Leukocyte	gating	of	spleen	
		Representative	flow	cytometric	dot	plots	illustrating	the	gating	strategy	for	leukocytes	in	the	spleen,	of	mice	 infected	with	 lethal	dose	WNV	(6x104	PFU).	 In	order	 to	obtain	a	 live	single	cell	leukocyte	population	the	following	steps	were	performed	during	analysis:	Time	gate	(A),	followed	by	exclusion	of	doublets	with	the	FSC-H	vs	FSC-A	gate	(B).	Removal	of	debris	 with	 the	 SSC-A	 vs	 FSC-A	 gate	 (C).	 Negative	 selection	 of	 live	 cells	 (D)	 and	 finally		positive	 selection	 of	 leukocyte	 (E)	 based	 on	 pan-leukocyte	 marker	 (CD45).	 Specific	leukocyte	 subsets	 were	 then	 identified	 based	 on	 lineage	 markers.	 This	 allowed	 us	 to	identify	the	following	subsets:	B220+	cells	(F)	from	which	we	isolated	the	B	cells	and	pDC	(G);	Neutrophils	(H);	NK1.1+	subsets	(I)	from	which	we	isolated	NK	cells	and	NKT	cells	(J).	Monocytes	 (K);	 CD11c+CD11c+	 DC	 (K);	 CD11c+CD11b-	 DC	 (K);	 CD11chiCD11bint	 DC	 (K).	Lastly	the	total	T	cell	subset	(L)	including	CD4	and	CD8	T	cell	(M).	Each	plot	represents	10,	000	events.	 	
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Appendix	Figure	6	General	Leukocyte	gating	of	spleen-Fluorescence	minus	one	and	
Isotype	controls	
		Representative	 flow	 cytometric	 dot	 plots	 illustrating	 the	 fluorescence	 minus-one	 and	isotype	controls	 for	the	gating	strategy	of	 leukocytes	 in	the	spleen,	of	mice	 infected	with	lethal	 dose	 WNV	 (6x104	 PFU).	 Black	 denotes	 fluorescence	 minus-one	 and	 red	 denotes	isotype	 control.	 In	 order	 to	 obtain	 a	 live	 single	 cell	 leukocyte	 population	 the	 following	steps	were	performed	during	 analysis:	 Time	gate	 (A),	 followed	by	 exclusion	of	 doublets	with	 the	 FSC-H	 vs	 FSC-A	 gate	 (B).	 Removal	 of	 debris	with	 the	 SSC-A	 vs	 FSC-A	 gate	 (C).	Negative	selection	of	live	cells	(D)	and	finally		positive	selection	of	leukocyte	(E)	based	on	pan-leukocyte	marker	 (CD45).	 Specific	 leukocyte	 subsets	were	 then	 identified	 based	 on	lineage	markers.	 This	 allowed	 us	 to	 identify	 the	 following	 subsets:	 B220+	 cells	 (F)	 from	which	we	isolated	the	B	cells	and	pDC	(G);	Neutrophils	(H);	NK1.1+	subsets	(I)	from	which	we	 isolated	 NK	 cells	 and	 NKT	 cells	 (J).	 Monocytes	 (K);	 CD11c+CD11c+	 DC	 (K);	CD11c+CD11b-	DC	(K);	CD11chiCD11bint	DC	(K).	Lastly	the	total	T	cell	subset	(L)	including	CD4	and	CD8	T	cell	(M).	Each	plot	represents	5,	000	events.		 	
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General spleen leukocyte gating-FMO and Isotype controls
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Appendix	 figure	 7	 Expression	 of	 Ly6C	 in	 the	 leukocyte	 populations	 of	 the	 spleen,	
following	lethal	WNV	infection	
	Graph	A	demonstrates	the	change	in	Ly6C	expression	between	d0-7,	following	lethal	WNV	infection	 (6x104	 PFU)	 of	 the	 total	 leukocyte	 population	 (CD45+)	 (circle),	 B	 cells	(B220+/CD19+)	(triangle)	and	total	T	(CD3+)	(square)	cells.	T	cells	were	further	classified	into	two	subsets	based	on	CD4	or	CD8	expression,	and	Ly6C	expression	analysed.	Figure	B	represents	 the	 change	 in	 Ly6C	 expression	 between	 d0-7p.i.	 of	 CD4+	 (circle)	 and	 CD8+	(upside-down	 triangle)	 T	 cells.	 Ly6C	 expression	 of	 the	 various	 DC	 subsets,	 namely:	CD11c+CD11b+	 (square),	 CD11c+CD11b-	 (circle)	 and	 CD11chiCD11bint	 (triangle)	 is	demonstrated	by	figure	C.	Furthermore,	the	change	in	Ly6C	expression	between	d0-7p.i.	of	the	 CD11b+	CD11c-	 subsets,	 namely:	 monocytes	 (CD11b+Ly6G-)	 (circle)	 and	 neutrophils	(CD11bhi	Ly6G+)	 (square)	 is	 represented	 by	 figure	 D,	 with	 the	 Ly6C	 expression	 of	 the	NK1.1+	 subsets	 namely:	 NK	 cells	 (NK1.1+CD3-)	 (circle)	 and	 NKT	 cells	 (NK1.1+CD3+)	(square)	represented	by	figure	E.	All	of	the	graphs	(A-E)	show	average	geometric	mean	of	Ly6C	 expression,	 of	 the	 relevant	 splenic	 leukocyte	 population,	 following	 lethal	 WNV	infection	(6x104	PFU)	on	d0,	3,	5,	6	and	7	p.i..	Ly6C	levels	were	quantified	by	averaging	the	geometric	mean	 of	 Ly6C	 expression	 of	whole	 population.	 Grouped	data	was	 normalised	using	d0	as	internal	control	and	is	represented	as	percentage	change	compared	to	baseline	i.e.	d0	p.i.	(100%).	Data	are	the	mean	±SEM	of	3-4	mice/group	and	is	representative	of	3	independent	experiments.	Statistical	analysis	was	conducted	using	one-way	ANOVA	with	a	Dunnet’s	 multiple	 comparison	 post-test	 (d0	 as	 control),	 and	 P≤0.05*;	 P≤0.01**;	P≤0.001***.	 	
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Appendix	Figure	8	General	Leukocyte	gating	of	the	WNV-infected	CNS	
		Representative	flow	cytometric	dot	plots	illustrating	the	gating	strategy	for	leukocytes	in	the	CNS,	of	mice	infected	with	lethal	dose	WNV	(6x104	PFU).	In	order	to	obtain	a	live	single	cell	 leukocyte	population	the	following	steps	were	performed	during	analysis:	Time	gate	(A),	followed	by	exclusion	of	doublets	with	the	FSC-H	vs	FSC-A	gate	(B).	Removal	of	debris	with	the	SSC-A	vs	FSC-A	gate	(C).	Negative	selection	of	 live	cells	(D)	and	finally	 	positive	selection	 of	 leukocyte	 (E)	 based	 on	 pan-leukocyte	 marker	 (CD45).	 Specific	 leukocyte	subsets	were	 then	 identified	 based	 on	 lineage	markers.	 Lymphoid	 lineage	 (CD11b-)	 and	myeloid	 lineage	 cells	 (CD11b+)	 were	 separated	 (F).	 Myeloid	 lineage	 cells	 were	 further	classified	as	neutrophils	(CD11bhiLy6G+)	(G)	and	resident	microglia	(CD11b+CD45intLy6C-),	immigrant	 microglia	 (CD11b+CD45-Ly6Cint)	 and	 inflammatory	 macrophages	(CD11b+CD45+Ly6Chi)	(H).	Lymphoid	 lineage	 cells	 were	 further	 characterised	 as	 T	 cells	 (CD3+NK1.1-),	 NKT	 cells	(CD3+NK1.1+)	and	NK	cells	(CD3-NK1.1+)	(I).	Lastly	B	cells	were	identified	based	on	B220	expression	 (J).	 Each	 plot	 represents	 10,	 000	 events.
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Appendix	Figure	9	General	Leukocyte	gating	of	the	WNV-infected	CNS-Fluorescence	
minus-one	and	Isotype	controls	
		Representative	 flow	 cytometric	 dot	 plots	 illustrating	 the	 fluorescence	 minus-one	 and	isotype	 controls	 for	 the	 gating	 strategy	 of	 leukocytes	 in	 the	 CNS,	 of	 mice	 infected	 with	lethal	 dose	 WNV	 (6x104	 PFU).	 Black	 denotes	 fluorescence	 minus-one	 and	 red	 denotes	isotype	 control.	 In	 order	 to	 obtain	 a	 live	 single	 cell	 leukocyte	 population	 the	 following	steps	were	performed	during	 analysis:	 Time	gate	 (A),	 followed	by	 exclusion	of	 doublets	with	 the	 FSC-H	 vs	 FSC-A	 gate	 (B).	 Removal	 of	 debris	with	 the	 SSC-A	 vs	 FSC-A	 gate	 (C).	Negative	selection	of	live	cells	(D)	and	finally		positive	selection	of	leukocyte	(E)	based	on	pan-leukocyte	marker	 (CD45).	 Specific	 leukocyte	 subsets	were	 then	 identified	 based	 on	lineage	 markers.	 Lymphoid	 lineage	 (CD11b-)	 and	 myeloid	 lineage	 cells	 (CD11b+)	 were	separated	(F).	Myeloid	lineage	cells	were	further	classified	as	neutrophils	(CD11bhiLy6G+)	(G)	 and	 resident	 microglia	 (CD11b+CD45intLy6C-),	 immigrant	 microglia	 (CD11b+CD45-Ly6Cint)	and	inflammatory	macrophages	(CD11b+CD45+Ly6Chi)	(H).	Lymphoid	 lineage	 cells	 were	 further	 characterised	 as	 T	 cells	 (CD3+NK1.1-),	 NKT	 cells	(CD3+NK1.1+)	and	NK	cells	(CD3-NK1.1+)	(I).	Lastly	B	cells	were	identified	based	on	B220	expression	(J).	Each	plot	represents	5,	000	events.		 	
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Appendix	Figure	10	General	Leukocyte	gating	of	the	bone	marrow	
		Representative	flow	cytometric	dot	plots	illustrating	the	gating	strategy	for	leukocytes	in	the	bone	marrow,	of	mice	infected	with	lethal	dose	WNV	(6x104	PFU).	In	order	to	obtain	a	live	single	cell	 leukocyte	population	the	following	steps	were	performed	during	analysis:	Time	 gate	 (A),	 followed	 by	 exclusion	 of	 doublets	 with	 the	 FSC-H	 vs	 FSC-A	 gate	 (B).	Removal	of	debris	with	the	SSC-A	vs	FSC-A	gate	(C).	Negative	selection	of	live	cells	(D)	and	finally		positive	selection	of	leukocyte	(E)	based	on	pan-leukocyte	marker	(CD45).	Specific	leukocyte	 subsets	 were	 then	 identified	 based	 on	 lineage	 markers.	 This	 allowed	 us	 to	identify	the	following	subsets:	neutrophils	(Ly6G+)	and	total	T	cells	(CD3+)	(F)	from	which	we	isolated	the	NKT	cells	(CD3+NK1.1+)	(G),	and	CD4+	(CD3+NK1.1-CD4+)	and	CD8+	T	cells	(CD3+NK1.1-CD8+)	 	 (H);	 Monocytes	 (CD11b+)	 and	 F4/80+	 stromal	 macrophages	 (I);	Monocyte	 subset	 were	 further	 classified	 as	 Ly6Chi,	 Ly6Cint	 or	 Ly6C-	 (J).We	 further	identified	 dendritic	 cells	 (CD11c+B220-),	 pDC	 (CD11c+B220+)	 and	 B	 cells	 (CD11c-B220+)	(K).	Lastly	NK	cells	were	gated	based	on	NK1.1	expression	(L)	Each	 plot	 represents	 10,	 000	 events.
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Appendix	 Figure	 11	 General	 Leukocyte	 gating	 of	 the	 bone	 marrow-Fluorescence	
minus-one	and	Isotype	controls	
		Representative	 flow	 cytometric	 dot	 plots	 illustrating	 the	 fluorescence	 minus-one	 and	isotype	controls	for	the	gating	strategy	of	leukocytes	in	the	bone	marrow,	of	mice	infected	with	lethal	dose	WNV	(6x104	PFU).	Black	denotes	fluorescence	minus-one	and	red	denotes	isotype	 control.	 In	 order	 to	 obtain	 a	 live	 single	 cell	 leukocyte	 population	 the	 following	steps	were	performed	during	 analysis:	 Time	gate	 (A),	 followed	by	 exclusion	of	 doublets	with	 the	 FSC-H	 vs	 FSC-A	 gate	 (B).	 Removal	 of	 debris	with	 the	 SSC-A	 vs	 FSC-A	 gate	 (C).	Negative	selection	of	live	cells	(D)	and	finally		positive	selection	of	leukocyte	(E)	based	on	pan-leukocyte	marker	 (CD45).	 Specific	 leukocyte	 subsets	were	 then	 identified	 based	 on	lineage	markers.	 This	 allowed	 us	 to	 identify	 the	 following	 subsets:	 neutrophils	 (Ly6G+)	and	 total	T	cells	 (CD3+)	 (F)	 from	which	we	 isolated	 the	NKT	cells	 (CD3+NK1.1+)	 (G),	and	CD4+	(CD3+NK1.1-CD4+)	and	CD8+	T	cells	(CD3+NK1.1-CD8+)		(H);	Monocytes	(CD11b+)	and	F4/80+	 stromal	 macrophages	 (I);	 Monocyte	 subset	 were	 further	 classified	 as	 Ly6Chi,	Ly6Cint	 or	 Ly6C-	 (J).We	 further	 identified	 dendritic	 cells	 (CD11c+B220-),	 pDC	(CD11c+B220+)	and	B	cells	(CD11c-B220+)	(K).	Lastly	NK	cells	were	gated	based	on	NK1.1	expression	(L)	Each	plot	represents	5,	000	events.		 	
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Appendix	 Figure	 12	Whole	 blood	 phagocytosis	 assay	 of	 blood	 from	 CLO-depleted	
mice	
	Graphs	A	and	B	show	the	number	(A)	and	percentage	(B)	of	cells	in	1ml	of	blood	that	have	taken	up	IMP	(undiluted/neat)	in	WNV-infected+IMP	(blue)	and	WNV-infected+CLO+IMP	mice.	Graphs	C	and	D	show	the	number	(C)	and	percentage	(D)	of	cells	in	1ml	of	blood	that	have	taken	 up	 IMP,	 which	 has	 been	 diluted	 3x,	 in	 WNV-infected+IMP	 (blue)	 and	 WNV-infected+CLO+IMP	mice.	Grapsh	E	and	F	show	the	number	(E)	and	percentage	(F)	of	cells	in	1ml	of	blood	that	have	taken	 up	 IMP,	 which	 has	 been	 diluted	 9x,	 in	 WNV-infected+IMP	 (blue)	 and	 WNV-infected+CLO+IMP	 mice.	 Data	 is	 representative	 of	 1	 sample	 per	 group	 from	 one	experiment.					
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